TW200524957A - Modified peptide YY and conjugates thereof - Google Patents

Abstract

A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

Description

200524957 IX. Description of the invention: The scope of the invention The invention relates to an improved therapeutic version. In particular, the present invention relates to the protection of the peptides from the effects of hypoglycemic activity by an improvement that selectively conjugates the peptides to a blood component. Therefore, the & The plate is free of the action of the plate bee activity and increases the period of action of the therapeutic peptide for treating various diseases.

BACKGROUND OF THE INVENTION Many endogenous peptides have been described as the main components of biological processes. Some of these peptides have been identified as the main therapeutic substances for treating various diseases. In general, endogenous peptides are more suitable as a therapeutic substance than a synthetic version with a non-natural sequence because these synthetic peptides cannot generate an immune response triggered by endogenous properties such as tritium. In addition, endogenous peptides are highly specific to their target receptors and are easy to synthesize and produce

Alas. However, the main difficulty in the delivery of these therapeutic peptides is their short plasma half-lives & ^ ^ ^ x work, which is mainly due to the rapid serum clearance and the protein through the action of version enzymes. Degradation by hydrolysis. It is said that by inserting a water molecule across the bond, the vicissitudes of vicissitudes are destroyed. Most of the peptides are produced by the action of peptidases in the human body in minutes or less. "Inside is degraded", some peptides with enzymes of ten hours have a specific life time, which makes their degradation more rapid. H Xin-Niu Chung as H impurities, then 200524957 when the peptide is in the body When the endogenous enzyme is rapidly degraded, its activity is generally reduced. One way to overcome this disadvantage is to administer a high dose of the desired therapeutic peptide to the patient, so that even partial peptides When degraded, there are still & enough therapeutic peptides to achieve the therapeutic effect. However, this method is quite uncomfortable for the patient. Because most of the therapeutic peptides cannot be administered orally, the therapeutic peptide The version must be administered continuously by intravenous injection or frequently, or frequently through the uncomfortable route of subcutaneous injection. The need for this frequent administration will also create a variety of possible individual treatments. Unacceptable input cost Peptide therapy. The presence of this large amount of degraded peptides can also cause unwanted side effects. The discomfort and high cost of administration are the two reasons why most therapeutic peptides with attractive bioactive properties cannot develop into drugs. Instead, these therapeutic peptides have been used as templates to mimic the development of peptides to replace the therapeutic peptides. Biotechnology and large pharmaceutical companies have generally begun long and expensive refinement programs to Attempts have been made to develop non-peptide, organic compounds that mimic the activity of the therapeutic peptide without producing an unacceptable side effect. For example, cyclic peptides, mimic peptides, and expensive SAR ( Structure-activity relationship), and molecular model research has reached the development of an unbelievable amount of peptide mimetics. However, these peptide mimics cannot reflect the correct original biological properties of the therapeutic peptide, And therefore it is inferior to this endogenous therapeutic peptide as a therapeutic substance. 200524957 The method used to replace the production of the tritium mimetic is blocking The role of the version to prevent the degradation of the therapeutic peptide or change the therapeutic cause, in the same method, their degradation will be slowed while still maintaining their biological activity. This method includes and A polymeric substance (such as dextran, polyvinylpyrrolidine, glycopeptide, polyethylene glycol and polyurethane), conjugated with adroitin sulfates, and polysaccharides _ Low-molecular-weight compounds such as amino lecithin, amino acids, Bi9, and glycosides are conjugated. However, these conjugates are generally still sensitive to protein peptidase activity. In addition, the peptides The therapeutic activity is usually reduced by the addition of the polymeric substance. Finally, when the substance is injected into the body, there are risk factors for an immune response due to the conjugate. Some methods include in vitro and in vivo The carrier proteins are conjugated, resulting in the production of this random conjugate. The conjugate is difficult to manufacture, and its benefits are limited by the commercial availability of the carrier and its poor pharmaceutical economy. The flake ore therefore has a need for a new financial method for improving pure peptides to prevent them from being affected by peptidase activity and provide longer effects in vivo. # Months, while maintaining low toxicity and retaining the improvement The therapeutic advantages of Peptide. Brief description of the present invention. The present invention relates to the door ears which overcome the degradation of peptides in the body by improving the therapeutic peptide, the X X, and the therapeutic peptide, and attaching it to a protein carrier. To avoid the effects or degradation of peptidase. In detail, the present invention # 右 Μ 5 You have about chemically reactive derivatives of novel therapeutic peptides, in particular, 葙, Λ j 疋 禋 cure · sex peptides-cisbutin-7- 200524957 Maleimide derivatives can form covalent bonds with effective functional groups on blood proteins. The invention also relates to: novel chemically reactive derivatives or analogs of therapeutic peptides. In addition, the invention also relates to the therapeutic use of these compounds. The present invention relates to the improvement and attachment of a therapeutic peptide through an in vivo or in vitro technique to a protein carrier (preferably albumin) to perform by the -residue to be excised- Synthetic modification to prevent the action of silk low peptidase. The N-terminus, c-terminus, or the middle of the peptide of the therapeutic peptide is often activated. The technique of the present invention is used to make the inactive position of the therapeutic peptide and some reactive groups Effect and improve it. These reactive groups can form covalent bonds with functional groups present on blood components. The anti-slave group is placed in the-position so that the peptide can retain the activity of a portion of the substance itself when the therapeutic step is bound to the blood component. ^. The improvement of the Xuan'α therapeutic peptide is performed by the chemical modification method used in the present invention. Under this method, regardless of whether it is attached to a blood component, all or most of the specificity of the victory can be Reserved. This therapeutic peptide_ complex of blood components can be delivered to various parts of the body without being degraded by peptidases' and the peptide still retains its therapeutic activity. The present invention is applicable to all known therapeutic peptides and is easily measured under physiological conditions by direct comparison with pharmacokinetic variables with or without the improved therapeutic peptide. The present invention relates to an improved therapeutic peptide, which can form a peptidase-stabilized therapeutic peptide, which is composed of 3-50 amino acids. The win 200524957

The peptide has a carboxy-terminated amino acid, a mono-amino-terminated amino acid, a therapeutically active regio-amino acid, and a poorly-treated reactive regio-amino acid. The peptide contains a reactive group that can react with amine, meridian, or thiol groups on blood components to form a stable covalent bond, and thereby form a stable enzyme therapy Sex wins. In the peptide of the present invention, the reactive group is selected from a reactive group composed of a succinimidy 1 and a cis butylene diimide group, and the reactive group is The cluster attaches to the amino acid position of the amino acid located in the less therapeutically active area. In a specific embodiment, the therapeutically active region of the peptide includes a carboxyl-terminated amino acid, and the reactive group is attached to the amino-terminated amino acid. In another specific embodiment, the therapeutically active region of the peptide includes the amino terminal amino acid, and the reactive group is attached to the carboxy terminal amino acid. In yet another embodiment, the therapeutically active region of the peptide includes the carboxyl-terminated amino acid, and the reactive group is attached to an amine located between the amine-terminated amino acid and the carboxy-terminated amino acid. Based acid. In yet another embodiment, the therapeutically active region of the peptide includes the amino-terminal amino acid and the reactive group is attached to an amine located between the amino-terminal amino acid and the carboxy-terminal amino acid. Based acid. The present invention also relates to a method for synthesizing the improved therapeutic treatment. The method includes the following steps. In the first step, if the therapeutic version does not contain cysteine ', the peptide is synthesized from the base of the enemy, and the reactive group is added to the carboxy-terminal amino acid. In addition, a terminal amine acid is added to the carboxyl terminal amino acid, and the reactive group is added to the terminal -9- 200524957

In the first step, if the therapeutic peptide contains only half of the amine i, before the reactive group is added to the poor therapeutic active region of the peptide & Cysteine reacts with a protective group. In the second step, if the therapeutic peptide contains two cysteine acids as a dithizone bridge, the dicysteine is oxidized and the reactive group is added to the therapeutic peptide. The amino terminal amino acid of the peptide is added to the amino terminal amino acid or added to an amino acid placed between the carboxy terminal amino acid and the amino terminal amino group. In the fourth step, if the therapeutic peptide contains more than two cysteine acids as a disulfide bridge, the cysteine in the disulfide bridge is sequentially oxidized, and the reactive The peptide is purified before the group is added to the carboxy-terminal amino acid. The present invention also relates to a method for protecting a therapeutic peptide from a peptidase 'tongue action' in vivo. The peptide is composed of 3-50 amino acids, and has a tertiary end and an amino group. End, and a carboxyl-terminated amino acid and a monoamino-terminated amino acid. The method includes the following steps: (a) by attaching a reactive group to the carboxy-terminated amino acid, the amino-terminated amino acid, or attached to an amino-terminated amino acid and Amino acids between carboxyl-terminated amino acids to modify the peptide 'so that the modified peptide can form a covalent bond with reactive functional groups on blood components in vivo; (b) in the reactive group A covalent bond is formed between the group and the reactive functional group on a blood component to form a peptide-blood component composition, thereby protecting the peptide from the action of peptidase activity; and-200524957 ( c) Analyze the stability of the peptide-blood component conjugate to assess the protection of the peptide from the effects of peptidase activity. These steps can be performed in vivo or in vitro. The present invention also relates to a method for protecting a therapeutic peptide from the enzyme-like action in vivo 'the winning version is composed of 3 and 50 amino acids' and has an amino group having a therapeutically active region Acid and an amino acid with a poor therapeutically active area. The method includes the following steps: (a) determining the amino acid of the therapeutically active region; (b) by attaching a reactive group to the amino acid, The peptide is changed at the amino acid position in the amino acid to form a modified peptide, so that the modified peptide has therapeutic activity and can form a reactive functional group on the blood component in vivo A covalent bond; '(c) forming a covalent bond between the reactive group and a reactive functional group on a blood component to form a peptide-blood component conjugate, thereby protecting the peptide Free from the effects of peptidase activity; and (d) Analyze the stability of the peptide-blood component conjugate to evaluate the protection of the peptide from the effects of peptidase activity. These steps can be performed in vivo or in vitro. The victory or defeat in the composition and method of the present invention includes, but is not limited to, peptides represented by SEQ ID NO ·· 1 to SEQ ID NO: 1617. -11-200524957 Detailed description of the invention Definition In order to determine a complete understanding of one of the invention, the following definitions are provided:

The reactive group in the reaction group is a group capable of forming a covalent bond. This reactive group is coupled or bonded to the desired therapeutic advantage. These reactive groups are generally stable in an aqueous environment, and are usually a carboxyl group, a phosphonium group, or a suitable fluorenyl group (the fluorenyl group may be an ester or a mixed anhydride), or a imidate Thus, a covalent bond can be formed with a functional group such as an amine group, a hydroxyl group, or a thiol at a target position on a moving blood component. For the most part, this ester involves a desired compound or is a thiol, alkyl, phosphate, and the like. Reactive groups include succinimidyl and maleimide groups. The functional group is a group on the blood component, which includes mobile and fixed proteins, which react with the reactive group on the modified therapeutic peptide, and the groups react with each other to form a covalent bond. . The functional group usually includes a hydroxyl group for bonding to an ester-like reactive group, a thiol group for bonding to a maleimide diimide group, an imine and a thioester group, and a bond for bonding As for the activated carboxyl group on the reactive radical diagram, the ethenyl group, or other amine groups. — ^ Blood components can be fixed or mobile. Fixed blood components are non-mobile blood components, and include tissues, membrane receptors, interstitial proteins, fibrin, collagen, platelets, endothelial cells, -12-200524957 and related cell membranes and membranes Receptors, somatic cells, flat muscle cells, nerve components, osteocytes and osteoclasts, as well as expected body tissues, especially those with circulatory and lymphatic systems. The moving blood component is included within a period of time, which generally does not exceed 5 minutes, and more often does not exceed 1 minute 'without having a fixed location of the blood component. Second-class blood components are not connected to the membrane and exist in the blood for a long time. They exist at a minimum concentration of at least 0 · ΐ μδ / ίη1. Moving blood components include serum albumin, transferrin, ferritin, and immunoglobulins (such as IgM and IgG). The half-life of the mobile blood component is at least 2 hours. Basket 1: Protective group: A protective group is a chemical moiety used to protect a peptide derivative from its interaction with itself. Various protective groups are disclosed here and in U.S. 5, 493, 007, which are hereby incorporated by reference. This protective group includes ethenyl, fluorenylmethoxycarbonyl ({^ 00 :), butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and the like. The specific protective amino acids are described in Table 1. Fengji: The linking group is a chemical site that connects or links a reactive group to / σ treatment. The linking group may include one or more alkyl 'alkoxy, alkenyl, alkenyl' alkynyl, or alkyl, cycloalkyl, polycyclic, aryl, polyaryl, substituted aryl , Heterocyclyl, and amine substituted with a substituted heterocyclyl. The linking group may also contain a polyethoxyamino acid such as AEA ((2-amino) ethoxyacetic acid) or a preferred linking group aeea -13- 200524957 ([2- (2-amino) Ethoxy)] ethoxyacetic acid). A preferred linking group is aminoethoxyethoxyacetic acid (AEEA). Sensitive Functional-A sensitive functional group is a group of atoms that exhibits possible reactive positions on the therapeutic version. If it were present, a sensitive functional group could be selected as the attachment point for the modification of the linking-reactive group. Sensitive functional groups include, but are not limited to, carboxyl, amine, thiol, and meridian. To _ Therapeutic Peptide-An improved therapeutic peptide is a therapeutic peptide that has been modified by attaching a reactive group, which can be conjugated to a blood component to form an enzyme Stable peptide. The reactive group may be attached to the therapeutic peptide by a linking group or optionally without using a linking group. One or more additional amino acids may also be added to the therapeutic peptide to facilitate attachment of the reactive group. The modified peptide can be supplied in vivo, so that its conjugation with blood components can be used in vivo.

Change to use. Peptidase stabilized therapeutic peptide

The enzyme-induced stability is a reactive group with or without good peptides. 200524957 A modified peptide conjugated to a blood component. Peptide release The mimetic therapeutic peptide is more stable in vivo in the presence of peptidase than a non-stable peptide. -Peptidase-stabilized therapeutic peptides are generally more similar in sequence than others: Definite victory: Yes-Increased half-life of at least 10-50¾. Peptidase stability is determined by comparing the half-life of an unmodified therapeutic peptide in blood or blood with the half-life of a modified therapeutic peptide in serum or blood. Half-life is determined by improving and After the unmodified peptide is supplied, the serum or blood is sampled and the activity of the peptide is determined. &Amp; In addition to determining the activity, the length of the therapeutic peptide can also be determined.-As in the present invention For the user, the therapeutic peptide is a therapeutically active amino acid chain between 2-50 amino acids, that is, as described above. Each therapeutic peptide has an amino terminal (also known as ^ Terminal or amino terminal amino acid), a carboxyl terminal (also known as 0-terminal or carboxyl terminal amino acid), and an intermediate amino acid disposed between the amino terminal and the carboxyl terminal. The amino terminal system is It is defined only by an amino acid within a therapeutic peptide bond having a free α-amino group. The carboxy terminus is defined only by an amino acid within a therapeutic peptide chain having a free α-amino group. The therapeutic peptide used in the present invention contains a therapeutically active region, and is generally placed at the amine end , Carboxy-terminus, or on an intermediate amino acid. The treatment of the lingual area can be identified by blindness or structural activity correlation (SAR) to drive generation, as defined in detail in this application. SAR This is an analysis of the correlation between the molecular structure of a series of compounds and their pharmacological activities. In addition, the therapeutically active area 15—200524957, which has been identified and can be obtained from the literature, can be specified by reference materials such as science Obtained in a magazine. Knowledge of the location of the therapeutically active area of the victory is important to improve the therapeutic peptide, as defined in detail below. The therapeutic peptide used in the present invention also contains a poorer treatment The active region is generally arranged at the amino end, at or near the carboxyl end, at or near an intermediate amino acid. The poor therapeutic active region is a region that does not coincide with the therapeutic active region Amino acid region. The poor therapeutically active region is generally configured away from the therapeutically active region so that the improvement of the poorer therapeutically active region is substantially Will affect the therapeutic activity of the therapeutic agent. For example, if the therapeutically active region is located at the amine end, the therapeutic agent will be modified at the carboxyl end or an intermediate amino acid. In addition, if the treatment When the active region is disposed at the base end, the therapeutic peptide is modified at the amino end or an intermediate amino acid. Finally, if the therapeutic active region is disposed at the middle end, it is at the amino end The therapeutic victory is improved at the base of the betrayal. "Therapeutic activity" refers to any activity related to curing or treating a patient's biological disease. Examples of this therapeutic victory include pituitary hormones, such as vasopressin, oxytocin, melanocyte st imu 1 at ing hormones, adrenocorticotropic hormones ), Growth hormone; ^ hypothalamic hormones (lower hypothalamic hormones), such as growth hormone releasing factor, corticotropin releasing factor, prolactin releasing hormone, gonadotropin releasing hormone and related peptides, Luteinizing hormone release hormones, thyroid-stimulating release-1 6 — 200524957 thyrotropin releasing hormone, orlexin, and soma tost at l η; sacral gland Hormones such as calcitonins, calcitonin predecessors, peptides related to the calcitonin gene; parathyroid hormone and its related proteins; pancreatic hormones such as insulin and insulin-like Peptides, glucagon, somatostatin, somatostatin, pancreatic peptide Amyl in, Gamma γγ, and neuropeptide Y; digestive hormones, such as gastric hormone (gastrin), gastric hormone releasing peptide, gastric hormone inhibiting peptide, gallbladder thinner ( cholecystokinin), secretin, motilin, and vasoactive intestinal peptide; natriuretic peptides, such as Fang Na urine win version, Zhibu Na urine win And C-type urination; neurokinins' such as neurokinin A, neurokinin B, substance p; angiotensinogenase (renin) -related peptides, such as blood vessels Tonicity protonase substrates and inhibitors, and angiotensins; endothelins, which include big endothelins, endothelin A receptor antagonists, and sarafotoxin ) Peptides; and other peptides, such as the adrenal medulla peptide, Aristostatin (311 & 1: 05131: [11) peptides, 0 amyloid fragments, antibiotics and antimicrobial tablets, Apoptosis-related victory pt〇sis related peptides), bag cell peptides, bombesin, bone Gla protein peptides, CART-like peptides, and 5k (chemotact ic peptides) ), Cortical Balancer 200524957

(Cort1Statin) Victory, fibronectin fragments and fibrin-related peptides, FMRF and similar peptides, gaianin and its related peptides, growth factor and its related peptides, G therapeutic peptide-binding Protein fragments, guany 1 in and uroguany 1 in, inhibin peptides, mesoprene and mesoprene receptor proteins, kubumic acid fragments, epteptin Fragments 肷, leukocyte kinase (1 euc 〇kinins), mast cell degranulation 1、1, pituitary adenylate% activating enzymes (a (jenyiafe cyclase activating polypeptides), pancreastatin, peptide T , Peptides, virus-related peptides, signaling substances, toxins, and other species, such as adjuvant pept i de analogs, alpha mating factor, antiarrhythmia Winning version, anti freeze polypeptide, anorectic peptide, bovine pineai antireproductive peptide, berberine, C3 peptide P16, tumor necrosis factor, adhesion factor (C adherin), chromogranin A fragment, contraceptive tetrapeptide, conetagin ((: 0 de 1 ^ 〇1 ^ 4) 〇, conetagin , Crustacean cardioactive peptide, C-telopeptide, cytochrome b588 peptide, decorsin, del icious peptide, △ -Sleep-induced peptides, benzodiazepine-binding inhibitor fragments, nitric oxide synthase blocking peptides, OVA-like, platelet cal pa in inhibi tor (PI), blood Plasminogen activator inhibitor 1, rigin, peptides related to schizophrenia, serum thymus factor, sodium — 18— 200524957

If A therapeutic peptide wasp inhibitor_ι, Speract, sperm-activating peptide, system in, thrombin receptor agonist 'thymic humoral gamma 2 factor), thymus-like element (Let) '111〇0 € 111: 丨 11), thymosin (11, thymus factor, tuftsin), adipokinetic hormone, uremia Fifth centipede and other therapeutic peptides. When considering these definitions, the focus of the present invention is to improve the therapeutic peptide to protect it from the effects of peptidase activity in vivo and thereby extend the therapeutic peptide Effective treatment period, the effective treatment period is the problem found when the drug itself is administered to the patient. 1. The therapeutic peptide used in the present invention is selected from a therapeutic peptide (from the attached The peptide fragment composition of the amino acid sequence determined by the sequence list (provided by SEqUENCE LISTING) includes the starting point containing the development of the present invention. The length of the peptide is in the range from 2 to 50 amino acids The interchangeable terms "peptide fragment" and " The meaning of "edition part" includes both synthetic and naturally-occurring amino acid sequences derived from a naturally-occurring amino acid sequence. In a specific embodiment, the peptide and the peptide fragment are formed by the traditional method σ 'It is synthesized by a bench-top method or by an automatic peptide synthesis machine, as described in detail below. However, it is also possible to use a proteolytic enzyme such as a naturally occurring amine to generate the naturally occurring amine The amino acid sequence is cut into fragments and then the winning fragment is obtained. In addition, it is also possible to use, for example, Man 丨 at is 丁 · # 人 in Molecular Biology: A Laboratory Manual, Cold 19-19200524957

Revealed in Spring Harbor, New York (1 982) ’through the use of recombined human & surgery to obtain the desired therapeutic victory fragment, this content is here v # for reference. Other new improvements and the use of existing methodologies can also be considered. The invention includes peptides derived from the sequence of naturally occurring therapeutic peptides. If a peptide can be obtained by cutting a naturally occurring sequence or based on a naturally occurring amino acid sequence or synthesized from knowledge of the genetic material (DNA or RNA) encoding the sequence, the peptide is said to be Is `` derived from a naturally occurring amino acid sequence, ''. Included within the scope of the present invention are molecules called "derivatives" of a peptide. This "derivative" has the following characteristics: (1) it is related to the therapeutic peptide or the peptide One of the similar size fragments of the peptide shares substantial homogeneity; and (2) it has the same therapeutic activity as the peptide. If the amino acid sequence of a derivative of a peptide is at least 80% And preferably at least 90% and most preferably at least 95% similar to the amino acid sequence of other peptides or a peptide fragment having the same number of amino acid residues, the derivative of the peptide is called In order to enjoy "substantially homogeneity" with the peptide. Derivatives of the present invention include dermatose fragments which, in addition to containing a sequence that is substantially homogeneous to naturally occurring / therapeutic derivates, may also contain one or more amine groups at their amine or / and carboxyl termini. The amino acids are described in detail below. Therefore, the present invention relates to polypeptide fragments of therapeutic peptides, which may contain one or more amino acids that are not present in the naturally occurring therapeutic peptide sequence provided, the The peptide fragment has a higher therapeutic activity than the therapeutic peptide. i 200524957 Likewise, the present invention includes polypeptide fragments, although they contain a substantially identical peptide. A naturally occurring therapeutic peptide sequence, but it may have one or more other amino acids deleted at its sarcosine end and / or carboxyl end. These amino acids are generally found naturally in the treatment Sex peptide. Therefore, the present invention relates to a polypeptide fragment of a therapeutic peptide, which may lack one or more amino acids, and these amino acids are generally present in the naturally-occurring sequence provided, and the polypeptide has a Higher therapeutic activity than this therapeutic peptide. The present invention also includes various different forms of the above-mentioned fragments that are obvious or unimportant, that have different amino acid substitutions before and after the provided sequence (and therefore have different amino acid sequences from the natural sequence), which are different The product of form A has the activity of the quaternary phase 4 compared with the above-mentioned derivative. Examples of obvious and unimportant substituents include: a test group substitute another test group (ie · Lys with Arg), a hydrophobic group with another hydrophobic group (ie. Leu with lie), Or one aromatic group is substituted for another aromatic group (i. As known in the art, this amino acid residue may exist in a protected or unprotected form, and the use of a suitable amine or carboxy protecting group is discussed in detail below. The peptides of various lengths may exist in the form of free amine groups (at the I-terminus) or their acid addition salts. The general acid addition salt is a hydrophilic acid salt, ^ H 讦, HI, or more preferably ΗΠ. The cations that can be used are alkali metal or alkaline earth metal cations (i.e. Na, K, U,

Ca, Ba, etc.), or amine cations (ie • tetraalkylamine, trialkylamine, where the alkyl group may be CrC ^). Any peptide having a therapeutic activity can be used in the present invention. The wins listed below 200524957 are examples of peptides that can be used in the present invention, but are not complete and not limited to the number and types of wins that can be used in the present invention. Both the therapeutic peptides and the fragments produced by the peptides can be improved according to the present invention and can be therapeutically incorporated in the human body. A. 雎 Sagging "hormones (SEQ ID NOS: 1 -72)

-Bao-xian on-line corticosteroids (ACTH_aka promotes sacrifice of Shangpa Guxi 1) (SEQ ID NOS: 1-22)-The endocrine function of the adrenal cortex is derived from an anterior pituitary hormone, ACTH, Regulation. ACTH is a 39-amino acid peptide that is produced in the cortical cells of the anterior pituitary gland under the control of the corticotropin-releasing factor. ACTH is derived from a translational modification of a $ 24 precursor of amino acid called pro-opiomeianocortin (POMC). The biological role of ACTH is to maintain the amount and viability of the adrenal cortex, and to stimulate the production of steroids such as corticosterone and corticosterone. The mechanism of ACTH's action involves its binding to ACTH receptor, and then activating the adenylate yamiyam, Nami 4 adenosine acid (cAMP) and increasing the activity of protein kinase A (PKA) in the adrenal cortex . The main role of these events is to increase the activity of the side chain cutting enzyme (Slde chain ~ cleaving enzyme), which can convert cholesterol to pregnenolide]. Because these enzymes are distributed in the subdivisions of the adrenal cortex, the important physiological role of ACTH is 22-200524957 for the production of glucocorticosteroids.

In addition to controlling adrenal cortex activity, ACTH has been shown to have different biological roles, including regulation of endocrine and exocrine glands, temperature regulation, and its effect on neural regeneration and differentiation. In addition, ACTH and its fragments affect movement, learning, and behavior. Therefore, the use of ACTH as a therapeutic substance can help control these functions. ACTH is released by the anterior lobe of the pituitary gland, which is regulated by corticotropin-releasing factor (CRF). SEQ ID NOS: 23-24, 45)-human placental lactogen (hPL), growth hormone and prolactin (Prl) are included in the growth hormone group. All of them have about 200 amino acids, two disulfide bonds, and have no saccharification effect. Although each has a specific receptor and unique characteristics relative to its activity ', all of its temples have activities that promote growth and lactation. Mature GH (22,000 ear swallows) is produced as a single polypeptide chain in eosinophilic pituitary somatic cells (s 细胞 atotropes). Because of alternative RNA splicing, a small number of smaller molecules are also secreted. There are most GG related genetic defects. g Η-Defective short humans lack the ability to synthesize or secrete GH, and these short height individuals respond quite well to ⑶ treatment. Pygmies lack IGF-1 in response to GH, rather than the lack of GH's metabolic results. Therefore, in pygmies, they inherently lack postreceptors. Finally, the short man of Laron has 200524957

Normal or excessive plasma GH, but it lacks liver GH receptors and has a lower amount of circulating IGF-1. The defect in these individuals is clearly related to their loss of GH response caused by IGF-1 production. Before the epiphyseal is closed, the production of excess GH will cause huge gigantism, and when the ⑶ becomes too much after the skull is closed, the growth of the extremity bone will lead to the feature of the extremity hypertrophy appear. The use of GH as a therapeutic shellfish will be used to help treat these diseases and stimulate the growth of other patients with short or normal cases of low or normal GH content. Melatonin- (MSH) (SEQ ID NOS ·· 25-39)-Melatonin (MSΗ) is produced in the middle pituitary gland under dopamine control. MSH may have important physiological roles in melanogenesis of spinal animals, melanogenesis, neural function related to learning and behavior, and fetal development. It can be found in the study of Sawyer, TK, et al., Published in Proc. Nat. Acad. Sci USA, 79, 1 751 (1 982). Oxytocin (SEQ ID NOS: -44)-Oxytocin is involved in promoting milk secretion, contraction of the uterus, and relaxation of the bone discs before delivery of the baby. The secretion of oxytocin in lactating women stimulates its secretion through the direct neurofeedback effect obtained from nipple stimulation during breastfeeding. Its physiological effects include the contraction of mammary epithelial cells (myoepi 丨 丨 a 1) (which includes the ejection of milk from the mammary glands) and the stimulation of the contraction of uterine smooth muscles born to babies. Oxytocin causes the contraction of myoepithelial cells around the secretory aclnl of the mammary glands, pushing milk through the catheter. In addition, it stimulates the release of prolactin, which acts on the breast and stimulates the formation of acinars in milk. Therefore, a conjugated oxytocin can be used to help milk -24-200524957 juice secretion and to help relax the disc before production. It can also be used to prevent uterine bleeding after childbirth. Hippocampal Leptin (ADH) (SEQ ID NOS: 46-72V Hippocampal pressure

Jin, also known as 4-diuretic hormone (ADH) 'because it is the main body fluid osmotic & weekly controller, it will cause antidiuresis (antidiuresis) and increase blood pressure. Posterior vasopressin binds to serosa membrane receptors and activates cyclic AMP / protein kinase A (cAMP / PKA) in the circulatory system through G-proteins. The secretion of vasopressin in the posterior lobe is regulated in the hypothalamus by osmotic receptors (〇SmoreCeptors), which will sense the concentration of water, and will stimulate the increased posterior lobe when the plasma osmotic pressure increases. Vasopressin secretion. The secreted posterior vasopressin will increase the rate of water reabsorption in renal tubular cells, which will cause the discharge of urine (concentration of Na + in urine) and thus produce a net decrease in the osmotic pressure of body fluids. Loss of vasopressin in the posterior lobe causes urination and thirst, a condition called diabetes insipidus. Therefore, the use of vasopressin or vasopressin fragments after conjugation will prevent these diseases and maintain the osmotic pressure of the human body normally. B · Hypothalamus hormone (Release factor) Corticotropin ggleasing F_g_ct〇r (CRF) ”μ μ meq τη π-1M1-Adrenocorticotropic hormone release factor (CRF) The 41 amino acid peptides play a very important role in coordinating the overall response of stress acting in both the brain and peripheral parts. In the brain, CRf? Is mainly produced and secreted by tiny cellular nerves of the paraventricular hypothalamic nucleus in the subventricular hypothalamus. · Since then, the nervous system containing 200524957 CRF extends to the portal microvascular area of the medial eminence and acts to stimulate the anterior pituitary hormone (ACTH), stone-endorphin and other morphine-like Like neuropeptide (POMC) -derived peptide is secreted from the pituitary gland. This subsequent AC-induced adrenal glucocorticoid system is the last step in the hypothalamus-pituitary-adrenal axis (HPA), which regulates the endocrine response to stress. In addition to its neuroendocrine role,

It can also be used as a neurotransmitter and a neuromodulator to trigger a wide range of autonomic, behavioral, and immune responses to physiological, pharmacological, and pathological stimuli. Clinical studies have shown that CRF hypersecretion is associated with various diseases, such as' most depression, anxiety-related conditions, anorexia, and inflammation symptoms. Low levels of CRF have been found in Alzheimer's disease, dementia, obesity, and many endocrine diseases. Therefore, the use of CRF as a therapeutic substance to counter high- or low-level CRF-related responses will provide a basis for treatment of diseases associated with abnormal CRF secretion. A variety of peptide antagonists and non-peptide antagonists have been discovered and extensively studied, including a-helix CRF (9-41), Astressin, D-PheCRF (12-41) (peptide Antagonists) and CP-1 54526 (non-peptide antagonists). These CRF antagonists can provide a novel drug for the treatment of depression, anxiety and other crf-related diseases. Therefore, conjugated CRF peptides can be used to maintain adrenal health and survival during prolonged steroid use or as an anti-inflammatory agent. Gonadotropin Releasing tel (GAP) (SEO ID NOS: 103-110)-GAP line 200524957 is contained in the precursor molecules of gonadotropin-releasing hormone (GnRH). GAP has the ability to inhibit prolactin Characteristics: Gn-RH is a hormone secreted by the hypothalamus, which stimulates the release of gonadotropins and luteinizing hormone (FS Η) and luteinizing hormone (LH). Low circulating sex Hormones reduce the feedback inhibition on GnRH synthesis, leading to an increase in FSH and LH levels. The latter's winning hormones bind to the gonads, causing sexual hormones to be regulated by cyclic AMP (cAMP) and protein kinase A (PKA) A combination of GnRM can be used to help fertility, or as a contraceptive for men or women. The substance can be used on animals as it is used on humans.

Growth hormone release factor "(GRF) (SEO ID NOS: 111 -GRF is a hypothalamus, which plays an important role in controlling the synthesis and secretion of growth hormones in the anterior lobe of the pituitary gland. Some structures Irrelevant short-chain peptides have also been published to trigger growth hormone secretion through different mechanisms. 'Under the influence of GRF, growth hormone is released into the systemic circulation, causing the tadpole tissue to secrete IGF -1. Growth hormone also has other more direct metabolic effects (both hyperglycemia and lipolytic metabolism). The main source of this systemic IGF-1 is in the liver, although most other tissues can help and secrete Systemic IGF-1. The liver's leaf- 丨 system is regarded as the main regulator of tissue growth. In particular, IGF-1 secreted by the liver is believed to synchronize the growth of the entire body, resulting in tissue size and volume Stable balance in the body. Secreted by surrounding tissues is generally regarded as autocrine or paracrine in its biological function. A conjugated GRF is used as a therapeutic substance. In order to increase the release of ⑶, it will help treat diseases related to the growth function regulated by GRF after 200524957. Luteinizing Hormone Releasing Hormone (LH-RH) (SEQ ID NOS: -161)-Luteinizing Hormone Releasing Hormone It is divided into gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH).

The main mediator of secreted neural regulation. LH-RH can improve sexual behavior by regulating the amount of plasma gonadotropins and sex steroids. See Vale, W. W. et al., Peptides, Structure and Biological Function, Proceedings of the Sixth American Peptide Symposium, Gross, E. and Meienhofer, M., eds., 781 (1 979). A conjugated LH-RH substance can be used to stimulate ovulation in the human or animal body as a fertility aid. Orexins (SEQ ID NOS: 162-164)-Orexins (Orex i ns) is a group of neurogenic wins derived from the hypothalamus, which has recently been discovered and characterized. Orexin (〇rexin ns) can stimulate appetite and food consumption. The other gene lines appear bilaterally and symmetrically in the lateral hypothalamus, and their early lines were determined to be the "feeding center" of the hypothalamus. Conversely, the general center's satiety center ) It is expressed in the ventral and median hypothalamus' and is regulated by the neuropeptide network regulated by Lepting. Therefore, ID NOS: 65-170) -prolactin; prognosis by a S Prolactin-producing cells (丨% 70S) are produced by the body. Prolactin-releasing peptides act on lactophils to release prolactin. PRL initiates and maintains lactation in mammals, but generally only in breast tissue It has been activated by the sex hormone of estrogen. PRP 200524957 can be used to increase human or animal lactation. Rabbit ·· Long hormone release inhibitor Somatostatin CSEQ ID N0 & —also known as growth Hormone release inhibitor

Hormone Release Inhibiting Factors (GIF), a 14-amino acid peptide, is composed of both the hypothalamus and pancreatic d cells (the pancreas is described below) secretion. Somatostatin release inhibitors have been reported to regulate physiological functions in many different locations including the pituitary gland, pancreas, digestive tract, and brain. It inhibits the release of growth factors, insulin and glucagon. It has many biological roles, including: inhibition of secretion of basal and stimulating hormones from endocrine and exocrine cells, effects on motor activity and cognitive function, and possible therapeutic value in microcellular lung cancer. See Reubi, c. Mai,

Endocrinology, 110, 1049 (198, 2). A conjugated growth hormone release inhibitor can be used to treat huge deformities in children or acromegaly in adults.

lil-THR stimulates the production of thyroid stimulating hormone (Ding Yi is also known as thyroid stimulating hormone) and the secretion of prolactin. In adults, tSH is responsible for improving the control of general protein production and inducing a state of positive nitrogen balance. At the embryonic stage, it is necessary for general normal development. Hypothyroidism in the embryo is manifested as stunting, which is characterized by most congenital defects and mental retardation. Therefore, Grade I HR can be used as a therapeutic substance to treat these diseases. It can also

200524957 Treatment of hypothyroidism caused by pituitary gland or diagnosis of human goiter. C. Thyroxine Biopsy ID NOS: 215-224) -Dorbintin (CT) is a peptide of -32-amino acid, which is secreted by the c-cells of the f-gland. Calcitonin can be used to treat the symptoms of osteoporosis, although the detailed mechanism of action is not clear. However, it has been found that c-butane induces the synthesis of parathyroxine in isolated cells, which results in an increase in the amount of plasma Ca2 + in vivo. In addition, CT has been shown to reduce the synthesis of osteoporosis factor (Osteoporin) (0pn), a protein made by bone germ cells and responsible for attaching bone germ cells to bone. Therefore, the use of a conjugated ct as a therapeutic peptide can increase the amount of Ca2 + in plasma through the induction of PTH, and reduce bone resorption by reducing the attachment of osteoblasts to bone. The chapferin gene phase M peptide (CGRP) (SE0 1 ^^: 225-Yu)-CGRP is a 37 amino acid peptide derived from the alternate cleavage of the transcription of the survivin gene. It exists in at least two forms: α-CGRp (or CGRP-I) and Θ-CGRP (or CGRP-Π). CGRP is very homogeneous in Amyl in and Adrenomedullin, and is widely and centrally and peripherally distributed in organs including skin, heart, viscera, lungs, and kidneys. CGRP has multiple biological roles, such as affecting the nervous and cardiovascular system, immune response, and metabolism. -30— 200524957 D_ Parathyroidisin and its related proteins Parathyroid hormone (PTH) is produced and secreted by the chief cells in the parathyroid gland to reflect the systemic amount of Ca2 +. It plays a major role in the regulation of blood calcium concentration, thereby affecting the physiological role of minerals and bone metabolism. The parathyroid Ca2 + receptor system responds to Ca2 + by increasing the amount of pKC, +, and IP3 in the cell. After a period of protein production, this step is followed by the secretion of PTH. The generation and behavior of ρΤίί in the main cells are basically present, but when the amount of blood 4 rises, + the amount of pa in the main cells is regulated by increasing the rate of PTH proteolysis And the secretion of PTH), when the amount of Ca2 + decreases, the amount of PTH in the main cell is controlled by reducing the rate of PTH proteolysis. The role of this pth is to regulate the concentration of Ca2 + in extracellular fluid. Therefore, the feedback pathway that regulates pth secretion involves the parathyroid, Ca2 +, and the following target tissues. PTH works by binding to cAMP-coupled serosa membrane receptors, which initiates a cascade of reactions that reach extremes in biological reactions. The body's response to PTH is complex, but it targets all tissues with an increased amount of extracellular ca2 +. PTH induces the breakdown of bones by stimulating the activity of osteoclasts, which leads to an increase in Ca2 + and phosphate in the plasma. In the kidney, PTH reduces renal Ca2 + clearance by stimulating renal Ca2 + reabsorption. At the same time, PTH decreases phosphoric acid reabsorption to increase phosphate clearance. Finally, PTH acts on the liver, kidneys, and intestines to stimulate the production of the steroid hormone 1,25-dicholesterol (1,25-dihydroxycholecalciferol (calcitriol)), which is responsible for the intestinal Ca2 + absorb. 200524957 A conjugated PTH can be used to regulate calcium homeostasis in patients with a parathyroid hormone deficiency state. Inhibitor antagonists can be used to block the effect of pa in renal failure or other patients with excessive PTH. Comfort_Thyroxine white (PTHrP) CSEO ID NOS ·· 2Q4-

Ml) A-parathyroid hormone-associated protein (PTHrP) has been noted as a physiological regulator to reduce chondrocyte differentiation (Chrondrocytic heart) [6 ^ 111: 31: 丨 0: 1) And prevent planned apoptosis. Just started? Le} _11 ^ is considered to be a tumor-derived secreted protein with a structure similar to parathyroid hormone (PTH). PTH is the main regulator of homeostasis. ? PTHrp binds to a general G protein-coupled cell surface receptor (ρτη / ΡΤΗγP or PTH-1 receptor), which recognizes the 1-terminal (1-34) site of these peptides. Therefore, when tumor-derived PTHrP enters the circulatory system, it activates in standard pTH-depleted organs (such as bones and kidneys), vocal volume, and triggers similar biological activity. By promoting bone resorption and controlling calcium excretion control, circulating PTHrP can cause symptoms of malignant tumors associated with malignant hypercalcemia associated with general body fluids. Although it was initially found in tumors, PTHrP was subsequently shown in most noteworthy normal tissues, including the bones of young children and j people, where it acts on the amine-based scoring associated with it ^ 1 On the receptor, it is used to regulate cell growth and differentiation. The anabolic effect on the intermittent ρτΗ supply of bones and its treatment possibilities for osteoporosis have been extensively studied. Due to the recognition that PTHrP is an endogenous ligand in the body of osteoblasts, its use as an anabolic agent has been studied. The improved PTHrP peptide can be used for indicators similar to PTH. 200524957 The main role of hormonal and pancreatic hormones is in the whole body energy metabolism control 1 ′, mainly by regulating the concentration and activity of various enzymes related to catabolism and anabolic metabolism provided by most cellular energy. -The cell hormone meridian (Amylln) is a 37-amino acid peptide, which is related to CGRP and blood-reducing substances. It is co-secreted with insulin originating from the cell of the aunt. Starch meridian is deficient in type 1 diabetes. The meridian has been shown to work with insulin to regulate the roll of water glucose in the bloodstream. It inhibits knife A of the glucagon hormone peptide after meals and inhibits @Empty speed. Patients with diabetes have a phenomenon of insufficient starch secretion, which is equivalent to insufficient insulin secretion, which causes excessive glucose to flow into the bloodstream during the postprandial period. Although Tengdaosu replacement therapy is one of the treatments for diabetes, the replacement of the functions of amyloid and amylin can allow for more complete recovery of normal physiological functions controlled by glucose. Type 2 diabetes is characterized by the deposition of island-shaped tertiary protein, which is mainly composed of the amyloid-producing human type of island amyloid polypeptide. A conjugated starch meridian can be used in the management of diabetes to limit postprandial hyperglycemia. (NOS: 336-376)-Glucagon is a hormone of 29 amino acids, which is synthesized by a cells of the Isle of Langerhans, and it is a large previously raised sugar Hormone molecule. Similar to insulin, glucagon lacks a plasma carrier protein, and similar to insulin, it has a circulating half-life of 200524957. minute. A series of features, such as the one described later, are mainly used in the liver, which is the first tissue perfused with blood from the pancreas. Glucagon is bound to the serosal receptor and is coupled to adenylate cyclase via g-protein. The amount of material obtained is increased. ‘Responds to ρκΑ, which reverses all the above-mentioned reactions of insulin on the liver. This increase also results in a marked rise in circulating glucose, which is produced by the liver's sugar production and liver glycolysis. _ Conjugated hyperglycein will be used for the treatment of dangerous diabetes with hyperglycemia that occurs on a weekly basis or for the prevention or treatment of iatrogenic hyperglycemia. (SEQ ID NOS: —These hormones were first regarded as insulin, a dipeptide of 2 and 30 amino acids bound by a disulfide bond, which is produced by the pancreas, and other major The functional system is to counteract the hormones produced by most hyperglycemia, and to maintain a low amount of glucose in the blood. Insulin is a molecular group with similar structures and functions, including IGF_2, and relaxin (re 1 ax 1 η). The secondary structure of these four knives is similar, and all of them have the function of promoting growth. The main role of rententin is metabolism, and the main role of IGFs and relaxin is cell growth and differentiation. Tengdaosu is synthesized in the form of a hormone in the b cells of the Langerhans island 3 and its message peptide is removed in the pool of endoplasmic retlCUlUm 'and It is encapsulated as a secondary cyst in Golgi, folded into its natural structure, and maintains this configuration by forming two double bonds. Specific protease activity can cut off a third knife in the center ' It is separated into C-peptide and released The bond is to the amine-terminated B-peptide of the carboxy group 200524957 A-terminus. Insulin produces its equivalent sprinting action by binding to a serosal receptor. This is the same for all cells. The receptor system is double Bonded bond glycoprotein. One of the functions of insulin (except its role in signal transmission) is to increase the glucose transmission in extrahepatic tissue, which is increased by the increase of glucose in the membrane. The number of molecules. Glucose transport molecules are continuously changing their state. The increase in the number of transport molecules in the serosa is derived from the rate of replenishment of new transport molecules into the human polymembrane. In a specific group of pre-formed transport molecules. In addition to its role in regulating glucose metabolism (and its use in the treatment of diabetes), insulin can stimulate the production of lipids, reduce lipolysis, and increase amino acids. Transmitted into cells. Insulin can also regulate the cell content of mRNAs that are transfected, modified, and modified. It stimulates growth, ο · synthesis, and cell repair, and has ^ ". And Common effect of bradykinin. A conjugated insulin can be used to treat diabetes. Neurophthalein Y (SEQ ID NOS: 383-389)-neuropeptide γ (Nργ) is a peptide with 36 amino acid groups It is one of the most neuropeptides in the peripheral and central nervous system. It belongs to the pancreatic peptide family of peptides. Like its related substances, namely peptide ΥΥ (ργγ) and pancreatic peptide (ρρ), Nργ system Bending is a hairpin configuration that is important for bringing the free ends of the molecules together to bind to the X body. NPs have a wide range of effects on the medial sacral nervous system (CNS) and peripheral parts. The role of CMS includes major effects on eating and energy utilization, as well as effects on heartbeat, blood pressure, excitement, and emotional change. At week 200524957

On the side, NPY causes vasoconstriction and hypertension. It is also found in the gastrointestinal and urogenital tracts, which exerts its function by acting on the target organs of the gastrointestinal and kidney. In recent research, the hypothalamus Nργ has been found to play an important role in the development of obesity characteristics, and it is an important transmitter in the path of transmitting body fat information to the hypothalamus and regulating body fat content. The Leipting line is a product of an obesity gene, which has been found to reduce the expression of the NPY gene in obese (0b / 0b) mice. Tengdaosu and corticosteroids are also related to the regulation of NPY synthesis in the inferior colliculus, that is, insulin decreases Nργ and corticosteroids increase the performance of NPY. A conjugated Nργ can be used to treat obesity in patients with obesity and MODM (type 11 DM). (PP) (SEQ ID NOS: 390-39fH-pancreatic polypeptide (pp) is a hormone with 36 amino acids, which is produced by F cells between pancreatic islets and exocrine pancreas. It is a regulatory cell A member of the pp-folding family of peptides, which increases glycolysis and regulates gastrointestinal activity. Therefore, one version of the conjugation can be used to change food absorption and metabolism. These versions YY_ (SEQ_ID. NOS: 397- 400)-PYY is a trisomycin with a length of 36 amino acids. It was originally isolated from the gut tissue and mainly located in the endocrine gland cells of the intestine. It has many biological activities, including the digestive system. A variety of activities and possible inhibition on intestinal electrolytes and fluid secretion. I long hormone release inhibition factor (SEO ID NOS: 171inn ~ growth hormone release inhibition factor secreted by the d cells of the pancreas is one ] 4 amino acid peptides, which are the same as the growth hormone release inhibitors secreted by the hypothalamus. In neural tissues, the growth hormone release inhibitors can inhibit the secretion of 200524957 GH and therefore have a whole body, where the Qin Ring. In the pancreas, the somatostatin release inhibitory factor is a pancreatic inhibitory factor for pancreatic and pancreatic hormones, and therefore it also has a systemic effect on the whole body. It is called ngongkang \ It has been speculated that the growth hormone release inhibitory factor d secretion system It is mainly reflected in the blood ^ ^ J. ^ gR ^. When the word sugar is 1, when the blood is in Portuguese. The upper diurnal date is increased, and therefore Mu Yi. Causes the decrease in the secretion of two blood glucose hormones. Therefore, a conjugated growth growth hormone release inhibitor can be used to help the treatment of diabetes. F · Digestive hormones and their phases mm Carbachol-CCK line is a 33 amino acid peptide, which was originally Isolated from the small intestine of piglets, it stimulates gallbladder contraction and bile hunger, and increases the secretion of digestive enzymes from the pancreas. It exists in many types, including CCK-4 and CCK-8, i is the eight wins Peptides and the main molecular species that exhibit the greatest activity. They belong to the CCK / gastric peptide family and are centrally distributed in the nervous system and peripherally in the gastrointestinal system. They have a variety of biological roles, including stimulating pancreatic fluid secretion, gallbladder contraction, and to Possible regulation of intestinal peristalsis and satiety and painful stimulation in the digestive tract. A conjugated CCK can be used for diagnostic studies of the gallbladder and for chronic cholecystitis.

GRP (SEO ID NOS: 417-429)-GRP is a peptide of 27 amino acids, which was originally isolated from the non-sinus stomach tissue of pigs, and is homogenous to green Gui Skin's Victory's name is Bomb New Growth Factor. Its center and periphery are widely distributed in tissues including the brain, lung, and gastrointestinal tract. It regulates the physiological processes of a variety of cells, including secretion, contraction of smooth muscle, nerve conduction, and cell growth. One conjugated GRp can be used to treat adynamic Ueus or constipation in the elderly. And the vegetative & related Yousheng version (SEQ ID NOS: 417-429)-the gastric hormone is a 17 amino acid polypeptide, which is produced by the stomach chamber (stomach antrum) and its stimulating acid and Pepsin secretion. Gastric hormones also stimulate the secretion of pancreatic juice. A variety of active products are produced by precursors of gastric hormones and have multiple control points in the role of gastric hormone biosynthesis. Biosynthetic precursors and intermediates (Moroccus hormone and GI y-gastric hormone) are inferred growth factors, and their products, imidized gastric hormone, regulate the proliferation of epithelial cells, and wall cells that produce acid Differentiation of intestinal chromophil (ECL) cells such as histamine secretion, expression of genes related to histamine synthesis and storage in ECL cells, and intense stimulation of acid secretion. Gastric hormones also stimulate the production of members of the epithelial growth factor () family, which in turn inhibits the function of parietal cells but stimulates the growth of epithelial cells. Upon infection, blood gastrohormone concentrations are increased, which is known to have increased risk factors for duodenal ulcer disease and gastric cancer. Therefore, gastric hormones and gastric hormone antagonists are used as a therapeutic substance to treat most diseases of the upper gastrointestinal tract. See Pharmacokinetic Inhibition of LK (SEQ ID NOS: 417-429). A gastric hormone inhibitory peptide is a 43 amino acid polypeptide that inhibits the secretion of gastric hormones. A conjugated GIP can be used to treat severe gastric ulcers. JUSLACmotilin) CSEO ID NOS: 430-433)-Motilin is a 22 amino acid peptide that controls gastrointestinal muscles. Motilin-producing cell lines are distributed in the duodenum, upper jejunum, and rectum. 38—200524957 Adenocarcinoma and carcinoid tumors in the middle gastrointestinal tract. Motilin stimulates peristalsis of the intestine.

Soil_endocrine ID NOS: 434- “η-small intestinal endocrin is a polyamidine with 27 amino acids secreted by duodenum at pH below 4.5, which stimulates pancreatic cells to release bicarbonate And H20. The small intestinal endocrin system is a nerve conduction substance (a chemical communication factor) in the neural crest group. It is one of the hormones that control digestion and decomposition (the other are gastric hormones and cholecystokinin). It is composed of 27 A peptide composed of amino acids, and when the fasting system is secreted by cells in the digestive system. Small intestinal endocrine stimulates the gland to release digestive juice, which is rich in bicarbonate and can neutralize Intestinal acidity, which also stimulates the stomach to produce pepsin (an enzyme that helps protein digestion) and bile to the liver. Small intestinal endocrins can be used to treat autism. In one study, children with autism were treated Gastrointestinal endoscopy and intravenous administration of small intestinal endocrine to stimulate pancreatic and bile secretions. When compared with non-isolated patients, all three have an increased pancreatic and bile secretory response (7 · 5 to 10 ml / mi η pair 1-2 ml / min). Within 5 weeks of this small intestinal endocrine injection, it was found that the gastrointestinal symptoms of children were significantly improved, and their behaviors were also amazingly improved. The improvement can be achieved by Improved visual contact, improved sensitivity, and improved speech expression. These clinical findings provide a correlation between gastrointestinal and brain functions in patients with solitary behavior. Vasoactive Intestinal technology peptides A 28-residue peptide produced by the inferior colliculus and the gastrointestinal tract. It relaxes the stomach and intestines, inhibits the secretion of acid-39 — 200524957 and pepsin, acts as a peripheral neurotransmitter that automatically controls the nervous system, and increases h2o and electrolysis. The fluid is secreted from the pancreas and the digestive tract. It is first found in the lungs and intestines, and also found in the brain, liver, pancreas, smooth muscle and lymphoid tissues. It is structurally similar to PACAP,

PZI, small intestinal endoglin, and glucagon peptides are related. It has a wide range of biological functions, including vasodilation, secretion of electrolytes, regulation of immune functions, and neurotransmission. A conjugated Vip can be used to treat hydrochloric acid deficiency, ischemic colitis, and irritable bowel syndrome (IBS). G · Natriuretic Peptides-there are three members in the hormonal group of natriuretic · atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP: brain sodium Urine peptides), C-type natriuretic peptides (CNP), etc., which involves the regulation of blood pressure and body fluid homeostasis, namely 0-Atrial-Natriuretic Peptides (ANP) (SEQ_ID NOS: 465-507) -ANP is a peptide hormone with 28 amino acids containing a double sparse bond. It exhibits natriuretic, diuretic, and blood pressure-lowering effects and plays an important role in the balance of body blood volume and blood pressure. See Smith, F. G. et al., J. Dev. Physiol. 12, 55 (1 989). The mechanism of controlling ANP release has been the goal of a high degree of research, but it is not clearly understood today. The decisive factor for ANP secretion is the extension of muscle cells. Although little is known about the factors that regulate the release of BNp from the heart, the extension of muscle cells has been reported to stimulate βNρ -ΔΠ- 200524957 to be released from both the atrium and the ~ chamber. However, whether the wall extension system directly acts a, > to α such as endothelial hormone-, nitric oxide, or heparin contraction 11 released in response to vasodilation has not been determined. Recent studies have shown that in conscious animals, by stimulating the type A endothelial hormone receptor, this endothelial hormone plays an important role in the mediator of ANP triggered by the acute volume load secreted from atrial muscle cells. Physiological role. In fact, this release shows that the endogenous peripheral secretion / autocrine factor system responds to the atrial wall extension rather than the direct extension. It is used to respond to the activation of ANP secretion to reflect the volume load. It is of type A / B. The binding inhibition of endothelin and angiotensin receptors was confirmed by the almost complete obstruction of ANP secretion. Furthermore, under certain experimental conditions, angiotensin π and nitric oxide can also exhibit a significant regulatory effect on the activation of ANP secretion. The molecular mechanism of ΑΝρ secretion activated through the coordinated regulation of extension by endothelin-1, hemoconstrictor Π, and nitric oxide has not yet been clearly understood. Abstract Volume 75 Issue 11/12 (1997) pp 876-885, Journal of Molecular Medicine. One conjugate can be used to treat malignant hypertension or severe high blood pressure and renal failure. Linawei H (MP) (SEO ID NOS: 5Π741ίη-brain natriuretic peptide (BNP) is a member of the natriuretic peptide family, which is produced and released by the ventricle. BNP is transmitted through the A-type black Purine nucleotide cyclase-coupled X-body to regulate body fluid volume, blood pressure, and vascular tone. BNP plays a role in electrolyte-body fluid balance, such as the role of Fang Na urine wins 肷 (ANP). Conjugated BNP can be used for the treatment of heart failure. C-type natriuretic peptide (CNP) (SEQ ID NO: 517-524)-C-type 200524957 Natriuretic peptide (CNP) is natriuretic peptide The third member of the family, which is produced by vascular endothelial cells (ECs) and acts as an endothelium-derived loose peptide. Although atrial natriuretic peptide and brain natriuretic peptide are known to be involved in cardiovascular and endocrine Functional § Weekly Controlled ΤΤΠ is a cyclic hormone family, but the role of C ~ -type urinary sodium (CNP) is unknown. Although ANP and BMP are cardiac hormones, CNP is mainly found in the central nervous system and In vascular endothelial cells, ANP is mainly produced in the atrium of the adult heart, while BNP is produced by both the atrium and the ventricle. H. tachykinin (SEQ ID NOS: 525-627) __ group includes neurokinin A and substance P peptides, which share a common c-terminal sequence (FX-GLM-NH2), It includes neurokinin a, B, and substance P, and is the substance required for complete biological activity. I want to teach Yue A (gg Zhi rokinin A)-neurokinin system is a ten-capeptide, the early system is considered It is substance K. It is a member of the tachykines of neurons that include substance p and neurostimulus b. It exhibits a variety of activities related to smooth muscle contraction, pain transmission, vasodilation, and regulation of the immune system. Ij ^ uromedin)-neuromodulin, namely smooth-muscle-stimulating peptides, is generally divided into four groups: Bombusin-like, kassinin-like, and neuron-like Angiotensin and neurotonin [j. These neuropeptides and their fork systems are limited to all the components of the HPA, the pituitary pituitary axis, except for neurokinin B, which is not found In the pituitary gland lobe (adenohypophysis). Neuromodulin exhibits a variety on the HPA axis — 厶 2 — 200524957, and its effect equal to the adrenal gland implies that it is involved in the regulation of the growth 'structure and the function of the adrenal cortex. Neurotonin can directly and indirectly act on the adrenal cortex. The direct action is by stimulating the mineral cortex Hormones and glucocorticoid therapeutic peptides are performed by the flow of [Ca2 +] in the body, and these hormones are obtained from the isolation or culture of adrenal cortex cells. On the other hand, indirect effects can be regulated by ACTH, arginine-vasoPreSSln, angiotensin π, catecholamine, or other myelin regulatory substances. The related saccharin-substance P is an 11 amino acid peptide, which is first obtained from the brain and intestine. It is expected to be a neuromodulator related to painful transmission of the spinal cord. It also affects the contraction of smooth muscle, the reduction of blood pressure, the stimulation of secretory tissues, and the release of constituent amines from mast cells. 0 I. Angiotensin renin-related vicin (SEQ ID NOS: 6 plex- 677) Angiotensin is a peptide with 10 amino acids, which is obtained by the cleavage of a2-hemoglobin by the renal enzyme angiotensinogenase. Then c-terminal two amino acids are released to obtain angiotensin I, which responds to essential hypertension by stimulating the synthesis and release of copper alcoholate by adrenal cells. It is a multifunctional hormone that regulates blood pressure, plasma volume, neuronal function thirst, and water intake. Angiotensin 11 is an octapeptide derived from angiotensin I by the action of an angiotensin-converting enzyme, and its center i is widely distributed around organs such as heart, kidney, and liver. 200524957 in. Angiotensin μ is six fragments of angiotensin u, which are formed by proteolytic cleavage of angiotensin or vasoconstrictor. And it is controlled in blood vessels: heart growth, renal blood It plays a role in flow and memory functions. Angiotensin II is an important peptide hormone that regulates smooth muscle tension, blood pressure, free water intake, and sodium retention. It stimulates vasospasm by increasing tension. , Increase in sodium retention, and increase in free water intake to control the homeostasis of blood vessels to compensate for the loss of vascular accumulation. NOS: 678- Leg-Angiotensin material H is often special aspartase The differentiated smooth muscle cells (called granular epithelial cells) in the vasculature of the kidney are synthesized and released. Angiotensinogenase has specificity for its matrix and proangitensin f, and its specific resection Lei ^ 10-Valll bonds to form ten-capeptide, that is, angiotensin I). Angiotensinogen-angiotensin system involves the control of the balance of fluids and minerals in vertebrates. Angiotensin Protoenzymes can be found in mammals, birds, reptiles, osteochondria, cartilage, and jawless groups. Specific angiotensinogen inhibitors can be expected, which have been used to treat blood pressure and proliferative properties such as southern blood pressure Application of Xinmeng Wentang Tongnong exhaustion in the treatment of cases (B1 unde 11 et al. '1987). Endothelin and related peptides (SEQ ID Nos: 685-744)-the endothelin peptide One family consists of 21 isoforms of amino acids, namely, endothelin-1, endothelin-2, endothelin-3, sarofur toxin (a snake venom), and scorpion. 200524957 Endothelial hormones are found on a variety of endothelium in organ systems. Examples of pathological and physiological processes related to changes and synthesis of endothelins include: atherosclerosls and hypertension, coronary arteries Spasm 'acute renal failure, changes in intracellular Ca2 + levels, and effects on angiotensinogen-angiotensin system. Endothelin is released in response to vasoconstriction, vasopressin and cytokine (Cyt 〇k ines) (eg TGF- / ?, TNF a IL yS-), and other physiological phenomena including increased blood flow. The endothelial hormone family of dermatoses is composed of high-potential endogenous vasoconstrictors, It was originally isolated from the supernatant of endothelial cells. It regulates the blood flow to the organs by outputting a vasoconstriction effect on the arteries. Endothelin is derived from macro-endothelin, which is derived from a The unique cell membrane-bound metalloproteinase (endothelin-converting enzyme) cleaves 21 biologically active forms of amino acids (£ 丨, ET-2 and ET-3). _ Among these three isomeric forms (ET-1, ET-2, ET-3), the endothelin-1 line is the main isoform and plays an important role in regulating vascular function. Endogenous endothelin hormone peptides and their receptors are distributed on smooth muscle tissues throughout the body, including blood vessels, organs, gallbladder, and intestines. Through its wide and local distribution, it has its biological function in regulating blood vessel tension and initiating mitosis. Ets and their receptor subtypes also exist in various endocrine organs. It appears as a regulator of prolactin, gonadotropin GH, and TSH secretion. Endothelin can also be a signal of ischemic heart disease, atherosclerosis, congestive heart failure, renal failure, systemic hypertension, pulmonary hypertension, and cell vasospasm. Etiological factors. Endothelin-1 supplied by external factors has been shown to increase peripheral resistance and blood pressure in a dose-dependent manner. However, during the first period of intravenous administration, endothelin also reduces peripheral resistance and blood pressure. This may be due to the release of vasodilator compounds such as nitric oxide, prostacyclin, and atrial natriuretic peptide. ET (A) receptor antagonist factor-endothelial hormone receptor system exists in two types: A (ET-A) and β (ET-B1 and ET-B2) ° ET-A receptor system is used to respond when ET- B1 and ET-B2 regulate vasodilation and vasoconstriction, respectively. The toxin wins __ As mentioned earlier, the endothelial hormone (ET) peptide is a potential growth factor that binds to the G protein-coupled receptor. Sarofoxin (S 6) isolated from (a snake) has southern homology with endothelial hormone. Sarofox toxin has obvious vasoconstrictive activity and is used to respond to local hemorrhagic limb loss after snake or scorpion bite. These are used therapeutically as a peptidase-stabilizing peptide 'as a pressor for shock and sepsis. Κ · Opioid peptides (SEQ ID NOS: 745-927) ~ Opioids are a large group of drugs, which are used clinically as analgesics and include alkaloids obtained and synthesized from plants and Endogenous peptides found in the brains of mammals. Although this plant-derived alkaloid system has been known and used for thousands of years, the endogenous opioid species Sakae -46 — 200524957 was only discovered in mid-1970. Opioid shellfish includes casmorphine (casommorphjn), morphorphine (demmorphins), brain endorphin, enkephalin, deltorphins, dynorphin, and the like , And their derivatives ± _ | ^ _ morphin peptide-casomorphine peptide system is a novel opioid peptide derived from casein (§-card morphine). The 々-casomorphine is a widely studied opioid peptide, which is produced by food protein (0-casein). It was originally isolated from bovine casein, and the same sequence was found in the sheep-buffalo casein. Dimorphine is a peptide with seven amino acids, Shoujiyi, and the pain given by PhyJomedusa sauvagei is isolated today. It is a ligand that binds to the mu opioid receptor with high affinity and has a variety of biological roles, including analgesia, endocrine regulation, immune regulation, increased K + conduction, and α and action potential inhibition. The phase M victorin-dynorphin is a group of endogenous opioids. It exists in the central nervous system in various forms. The dynorphin line is derived from the precursor dynorphin (proenkephalin B) pay. Dynorphin, also known as dynorphin A1-Π, is a known opioid, "/, has the following sequence: Ding 71 " -01 广 017-? | 16-16115-human ^-

g lie Arg ~ Pr〇10 ~ Lys-Leu ~ Lys-Trp-Asp, 5-Asn-Gln j SEQ ID NO.i. It is known that most dynorphin derivatives and their analogs include Dyn A1-13, SEQ ID NO: 2, Dyn A2-13, SEQ ID N0: 3 'Dyn A1-12, Dyn A2-12, and Dyn A2-17, similar to the amidine analogues mentioned in US Patent No. 4,462,941 to Lee et al., Dynorphin analogues with N-terminal excision 200524957, such as the international patent application of Lee et al. 96/06626, and analogs of des-Tyr or des-Tyr-Gly, such as those also disclosed in the international patent application WO93 / 252π of Lee et al. Dynorphin is an extremely useful opioid ' and has proven to be selective for affinity kappa receptors. See Gollstein, Α ·, peptides,

Structure and Function, Proceedings of the 8th American Peptides Symposium, Hruby, V. J. and Rich, D.H., eds., 409 (1983). The mesencephalon endorphins are derived from the precursor protein lipotropin. They have been found to trigger a variety of biological responses, such as analgesia, behavioral changes, and growth hormone release. See Akil, J. et al., Ann Rev. Neurosci. 7, 7, 223 (1984). The osteopeptide-enkephalin and enkephalin are neurohormone's, which inhibit the transmission of pain pulses. Neuronal activity in one of the central and peripheral nervous systems is affected by most neurohormones, and it acts on cells that are far away from their release sites. Neurohormones can alter the ability of nerve cells to respond to synaptosome neurotransmitters. Recently, a variety of small peptides with far-reaching effects on the nervous system have been found, for example, non-monthly printed editions (ie, Met-enkephalin and Leu_enkephalin) and endorphin (ie, cold-encephalophorphin) ° These three contain a shared four peptide sequence (Tyr_Gly-Gly-Phe) 'which is necessary for their functions. Enkephalins and endorphins are first-in-class analgesics or opiotes, and they can reduce the pain response in the mid-frame nervous system. See also Aki 1, H. etl al., Ann. ReV. NeurOSC1, 7, 223 (1984). 200524957 L. sacral peptide (SEQ ID NOS: 928-934)-The thymus is considered to reflect both infants and adults-the development and regulation of cellular immunity. The thymus can exert its regulatory function through the non-cellular, hormone-like products (called thymosin peptides) secreted by various sacral epithelial cells. Thymosin has been reported to have many functions on T cells. Various studies have reported that thymosin can help immature, precursor cells develop into fully competent T cells. When the immune system is invaded, the thymus can regulate the expression of a variety of cytokine and monomer hormone (mone) hormone receptors on τ cells, as well as induce IL-2, interferon α, and interference 7 (disease resistance substance) secretion. It has been reported that the use of thymic hormones in children with immunodeficiency caused by chemotherapy has caused circulating cell increase, normalization of the T cell subfamily, and delayed hypersensitivity. Reply. 'Urngpoietinl-thymosin is the largest of the known thymic hormones, and it is composed of 49 amino acids. H & AJllIliymiilin)-an early known thymic serum factor' is the thymic polymer The peptide hormone is the smallest of the chemically-characterized thymic hormones. It is composed of 9 amino acids. A thymic polypeptide hormone is a hormone produced in response to stimulating T cells of the immune system. ^ AfejHLCThymopentin)-Thymosin is a small, synthetic thymosin peptide drug, also known as therapeutic peptide-5 or Timunox. In the United States, it was developed by the Immune Research Center as an AIDS treatment. Thymosin is more widely studied than other thymosin peptides in 200524957. At least one study has been requested to significantly increase the number of τ cells, and there was a slight clinical improvement in patients who received thymosin 3 times per week compared to control participants who did not receive thymus. Compared with 14 control participants who did not receive thymosin, these patients who took this drug showed better "immunological stability, and some clinical improvement. Thvmosinl_r thymosin is A mixture of 15 or more proteins. One of these proteins is thymosin alpha -1, which is composed of 28 amino acids. Thymosin has therapeutic uses, can treat innate immune deficiency, and can be used as A supplement to influenza vaccine for renal dialysis patients. It is now undergoing clinical trials against chronic hepatitis B and C, HIV infection, and some types of tumors. Shy rabbit a.am-thf is a recent Test the thymus as a primary anti-My treatment. In the pre-b-bed test of rabbits with CMV-related immunosuppression, THF can restore immune activity through the regulation of T cells. In addition, it is used in critical treatment Rapid application of viral infections (found at least in one study) and therapeutic application of increased T-cell types. L. Other peptides are active in JL education (AMLXSEQ ID NOS: 935-iUFn) One Adrenomedullin is an effective vasodilator peptide, and its main function is on cardiovascular function. Its systemic administration will cause rapid and significant decrease in blood pressure and increase in pulmonary blood flow. The other work is 500-1200524957, which is used for bronchiectasis, which is an inhibitor of drunkenness and an inhibitor of aldosterone secretion caused by angiotensin. The content can be found in The Journal of Biological Chemistry, Vol. 270, No. 43, pp 25344-25347, 1 995 and the references cited therein. Allatostatin peptide (SEQ ID NOS: 946-Mil-Yatostatin is an insect research institute 6-1 8 amino acids are synthesized to control the production of juvenile hormones, which also control the functions including metamorphosis and oviposition. Although the neuropeptides of the Aristostatin family It inhibits the production of naive hormones in vitro. The naive hormones regulate the development and reproduction of cockroaches. The aristostatin inactivates hemolymph, intestines, and peptidases bound to internal tissues. Very sensitive. Amyloid Bet a-Protein fragments (SE0 ID NOS: 950-1010)-These are the main components of powdery protein plaques which accumulate intracellularly and extracellularly in Az Hemner's disease (Mzheimer, s Dlsease) in the brain's nerve plaque. Aβ is a 4.5 kD protein, about 40-42 amino acid length 'It is a protein precursor protein from the protein powder ( App) is derived from the C-terminal. APP is a glycoprotein that crosses the cell membrane. In the normal mechanism, App k cuts the internal Aβ protein to produce α-sAPP, which is a secreted form of APP. The formation of a ~ SAPp hinders the formation of Aβ. It has been hypothesized that Aβ will accumulate due to abnormal handling of APP, making it sought for an inhibitory compound for responding to the enzyme activity of Aβ production. Visible as a〗. Bi〇tech.

Report (1994/1995), ρρ · 106-107; and Selkoe (1993) TINS-1 51 — 200524957

1 6: 40 3-409. Under a certain file of λ n RL card, the Aβ peptide will first gather, and then deposited as a -folded β-sheet structure, which is the characteristic of the amyloid protein dimension m powdery protein (1_42 ) Are aggregated at a significantly faster rate and reach a greater extension than β-amyloid (Bu 40). -Antimicrobial peptides, which are the main components of the natural immune system of most multicellular organisms ... mnmne systems), which are activated against one or more microorganisms such as' bacteria, bacteria, protozoa, yeast Bacteria and mycobacteria. Examples of such peptides include defensin, πποΡ1Γ〇, buforin, and magainin. In addition to the vast differences in sequence and taxonomy, most The antimicrobial peptides share the same mechanism of action-that is, the permeability of the pathogen's cell membrane. They are divided into two broad groups: linear and cyclic. In linear antimicrobial peptides, there are two Subgroups: tend to use. _ Straight peptides with a spiral amphoteric configuration, and straight peptides with a more unusual composition, the peptides are rich in amino acids such as Pro, Arg 'or Trp. The The cyclic population contains all of the cysteine-containing peptides, and can be further divided into two subgroups according to 3 or more bisparse structures. Most of the antimicrobial peptides will trigger serosal permeability. It also has evidence of other mechanisms 'such as' inhibition of specific membrane proteins, synthesis of stress proteins, prevention of DNA synthesis, single-stranded damage caused by antagonists, and DNA caused by baffling. Interaction (without blocking ), Or the production of hydrogen peroxide. Antimicrobial peptides can also be solved by self-destructive mechanisms (such as apoptosis in eukaryotic cells or thin window markers -52- 200524957) Antimicrobial peptides are also known to act as inhibitors of the enzymes produced by the protozoa, which can be used as pseudo-substances or tightly bound to the active region (which prevents Qualitative entry) comes. • The increase in the number of veterinary microorganisms has been reported in a variety of animal and human infections, such as mycorrhizal genus in Mycobacterium, Pasteurella, or Cryptosporidium The increase in the amount, as well as the increase in the amount of polysaccharide in the vesicles and injured body fluids. The inflammatory state or irritation state is also related to the induction of antimicrobial peptides. The decrease in the amount of antimicrobial proteins is related to various pathological conditions. Therefore Patients with a specific particle deficiency syndrome (which is completely deficient in O-antagonism) face frequent and severe bacterial infections. In HIV patients, hi statins originating from the saliva are scarcely associated with the oral cavity. Candidiasis The higher incidence of fungal infections is related to human pathology. The most powerful example of this antimicrobial peptide in science may come from cystic fibrosis (cy stic 9 fi bros is). Diseases related to Air Force infection. Defective gas ion channels of this disease will increase the “salinity” of oral fluid and thus destroy the g-killing activity of yS-antagonists, because the / 5-antagonists are salt-sensitive. Peptides. Andreu D, (Ed.) (1 998) " Antimicrobial »Bicpolymers (Peptide Science) v〇l 47, N. 6, pp41 3-491. A. Andreu, L. Rivas (1 998) Animal antimicrobial wins: An Overview, Biopolymers (Pep. Sci.) 47:] p415-433.气 气化 物 胜 ak (SEQ ID NOS: 1048-1050 ″ —- • Antioxidant 200524957 π ίτ, an agent to prevent oxidative damage to tissues. Mammal cell lines are constantly exposed to 圼 / 圼For example, peroxides (S 叩 π⑽ 丨 de), argon oxides, hydrogen radicals, and monooxygen. These intermediates of activated oxygen are produced by fine vesicles in the living body that react to the following conditions, which The conditions are aerobic metabolism, degradation of drugs and other xenobiotics, UV and X-ray irradiation, and macrophages (such as white blood cells) to kill fine particles such as those introduced by fork injuries. Breathing difficulties caused by hydrogen peroxide, such as that produced by most living organisms during breathing, especially by stressed and injured cells. One example of antioxidants is natural killer cell promoting factor B (NKEF-B ), Which belongs to a highly conserved group of recently discovered antioxidants. Natural killer cytokine promoting factor (化 £ ??) was discovered and selected based on its ability to increase the cytotoxicity of NK .Two genes That is, NKEF-A and -B are encoding NKEF protein and the analysis of the existing sequences implies that they are a highly reserved group of antioxidants. The role of NKEF-B as an antioxidant It has been demonstrated by its ability to protect transfected cells from the oxidative damage of hydrogen peroxide. NKEF-B has anti-oxidative activity against prooxides such as alkyl peroxides and MeHg. Combined with these oxidants Activity, due to the induction of NKEF-B of ΗP may indicate that n KEF-β is a key protein of emulsification stress to protect it from the damage of toxic substances of various xenobiotics. The phase of Αίίΐϋα apoptosis Peptides (SEQ 丄 D NOS. · 1051- Animal cells can self-destruct through internal cell death (Steller, 1 995). Planned apoptosis is the planned form of cell death 200524957 It is characterized by the occurrence of specific external and biochemical characteristics (Cttyl 1 ie et ai, 198). In terms of appearance, planned cell apoptosis is characterized by a series of structural changes in dead cells: blistering of the serosa (ie, 'making Blistering), The contraction of the cytoplasm and nucleus, and the fragmentation of cells, become membrane-like planned apoptotic cells (SteUer, 1 995; WyUie al., 1980). In biochemical aspects, planned cell apoptosis is characterized by the degradation of chromatin, The original line became a large fragment of 50-300 kilobases, and then it became a smaller fragment 'which is a 200-base monomer and multimers) (Oberhammer et al., 1 993; Wyllie, 1 980). Other biochemical indicators of planned cell apoptosis are the induction or increase of the amount of protein Clusterin (also known as trpm-2 or SGP-2) (Pearseetal ·, 1992), and the type 11 transaminaminase enzyme Activation, which cross-links proteins to the mantle of apoptotic cells (Fesus et a 1 ·, 1 991). Planned apoptosis is a complex phenomenon related to appearance and biochemical processes, which can change with tissue and cell type (Zakeri et al., 1995). The implementation of the planned apoptosis of the cells can reduce the leakage of the cell composition from the dead cells (the planned apoptosis of the cells complicates the cells). For example, protease can harm nearby cells or stimulate an inflammatory response. The main characteristic of this kind of cell apoptosis is that it is different from cell necrosis. Cell necrosis is usually caused by trauma, which causes the injured cells to swell and decompose, and releases cytoplasmic substances that can stimulate the inflammatory response ( SteUer, 1 995; Wyllie et a 1 ,, 1 980). -55-200524957 Pouch cell peptide (BCP) (SEQ ID NOS: 1076_1080) ~ In the sea The neurogenic winch pouch cell line of larvae is involved in animal spawning behavior. These neurosecretory cells can produce primary hormone (ELH) precursor protein, which can produce a variety of biologically active peptides, including ELH, several kinds of bag cell peptides (BCP), and acidic peptides. The neurogenic sacral cell line of the marine mollusk has been identified as a neuroendocrine cell that can initiate spawning behavior. During sexual maturity, these cells (bag cell neurons) develop the ability to store hormones that are released during nervous system stimulation. These hormones are important during the spawning process, so most of them are not released until the animals are sexually mature. Alpha-bag cells are peptides belonging to a small group of constructively related versions that can trigger bag-cell activity in vitro. (SEQ ID NOS: 1081-1090) -Bombusin is a neuroactive peptide with fourteen peptides with biological activity, which belongs to a common C-terminal sequence (Trp-Ala_X-Gly-His-Met) -NH2) and an victorious ethnic group in the N-terminal region. It was found to have a tone & color in the brain nerves and intestines, which can prevent gastric damage through the release of endogenous gastric hormones. The mammalian Bombob homologue is the gastric hormone releasing factor (GRP). Peptone (SEO ID NOS ·· 1091 -1097 ^ Osteocalcin (Gla-protein of bone, or BGP) is produced and secreted by bone germ cells during bone formation. Like collagen, this Protein is a group of components of bone. When bone formation speed increases, serum bone calcium factor rises. When bone grows during the fastest period of spring, its amount is more local. In diseases with high bone turnover (such as parathyroid) Hypothyroidism 200524957 Hyperparathyroidism and hyperthyroidism) The amount is usually high. In osteoporosis in postmenopausal women, the amount of osteocalcin occasionally increases, and its response should be Increased bone turnover is inferior to rapid bone resorption. In the old-fashioned osteoporosis, which generally occurs in longer cases, the amount of osteocalcin may be smaller to reflect bone turnover and bone formation. The rate of both decreases. A therapeutic food therapy that increases bone formation can also increase the amount of osteocalcin in the serum. QART Winning Edition (SEQ ID NOS: 1098-11 〇〇) 1 The cocaine and isopropylamine-regulated transcription peptide is a recently discovered qiqiusheng 肷, which has an effective appetite (desire) inhibitory activity. In rabbits, the CART gene can encode a protein with 1 29 Or 116 peptides of amino acid residues, however, there are only smaller versions in humans. The expected signal sequence is to have 27 amino acid residues, which results in a peptide with 102 or 8 9 protohormones of amino acids. The C-terminus of CART (which consists of 48 amino acid residues and 3 disulfide bonds) is considered to consist of one molecule of a biologically active site. In the central nervous system In the system, CART is highly expressed in the nucleus of many hypothalamus, some of which are related to the regulation of eating behavior. The CAR Dna's Mrna is regulated by Leipting, and the performance of CART is a The effective inhibitor of eating can even reject the eating response caused by the neuropeptide γ. Therefore, the expected CART system may be a therapeutic target for weight loss drugs. This can be seen in CART, a new anorectic peptide Thim L; Kristensen P; Larsen PJ; Wulff BS, Int J Biochem Cell Biol, 30 (12): 128, 4 199, Dec. -57- 200524957 Anti-adhesive peptide XgE_Q ID NO: ll〇n-Cell attachment peptides are directly related to cells foreign Stimulus response. For example, during the inflammatory response, 'white blood cells must leave the blood compartment (CD 叩 analization (CD ^)) and migrate to the site of antigen invasion. The mechanism of this migration event is a complex interaction between soluble mediators and membrane-bound cell attachment molecules. Soluble cell chemokines produced by a variety of resident cells in the injured tissue establish a chemical concentration gradient towards the blood compartment. The interaction between these factors and their receptors on white blood cells will cause white blood cells to move directionally where the concentration of chemokine increases. At the same time, various attachment peptides on white blood cells are positively regulated. These peptides can regulate the initial movement on endothelial tissue, bind to specific ligands on activated endothelial tissue, and eventually between endothelial cells. Move to organization. The cascade of this event is regulated by the interaction of specific cell surface proteins (called cell adhesion molecules), such as E-selectin (seiect, endothelial leukocyte adhesion molecule-1), ICAM-1 ( Intracellular adhesion molecules 丨 丨), and KAM-! (Vascular cell adhesion molecule-1). NOS: 1102-1113)-Chemotactic peptides are peptides that stimulate white blood cells, white blood cells, and macrophages to move into the infected or injured tissue, or prevent the same cells from moving away from them. position. ID N0S: 1114_1120)-Suppression of complement attack Xenograft can be achieved through the use of complement inhibitors. This type of rejection for S transplantation may involve both a very rapid and extremely severe rejection (HAR) and a chronic cellular rejection. Xenotransplantation 58-200524957 The HAR of the plant is initiated by a pre-formed "natural" antibody that can be transferred to the endothelial tissue of the donor's organ and attacked by the recipient's immune system activation complement. Activation of complement will lead to the generation of fluid phases (C3a, C5a) and cell membrane-bound proteins (C3b and C5b-9, κ e., C5b) with properties such as chemotaxis, pre-aggregation, pre-inflammation, attachment, and cytolysis. , C6, C Ding, C8, and C9). Complement inhibitors can inhibit this process. U⑷ pibei balance is obviously acting by antagonizing the effect of the acetylcholine of the cortex's susceptibility, thereby causing the synchronization of slow brain waves, and its mRNA accumulates during lack of sleep. Cortical balance hormone-14 (csT-i々) and growth hormone release inhibitor 14 (SRIF-14) share 11 of the residues. However, it and sleep growth hormone release inhibitor are important for sleep physiology and migration. The behavior and function of the hypothalamus are quite different. The lysine fragment peptide CSEO ID Ν05;--Fibronectin is a large glycoprotein, which is composed of three kinds of repeating blocks (blocks). The homologous fragments form functional domains, which are arranged in a linear arrangement on the arms of two adjacent identical subunits. Each arm can be divided into functional regions, which are generally referred to as regions that can bind to receptors, such as hairpin-Mndmg fragment, fibrin-binding fragment, and cell-binding fragment. In many cell types, the Arg-Gly ~ Asp (RGD) sequence on the cell-binding region of fibronectin can interact with glycoproteins on the surface of cells named hb / II la. Fibronectin can also bind to extracellular and basal cell membrane components, virus envelope glycoprotein 200524957 (envelope glycoprotein), a variety of thin windows including staphylococci and streptococci, and as far as TV and pa 卯Such as chat

Leislmania's post! L A ±. Fibrin has the functions of various attachments, such as cell-to-cell attachment, cell-to-basal cell membrane attachment, and clot stability. In addition, fibronectin promotes embryogenesis, neural regeneration, fibroblast migration, the function of macrophage cells, and the binding of pathogens such as viruses, molds, bacteria, and protozoa to mammalian cells and extracellular matrix. Therefore, the fibronectin line is related to the etiology of infection from the initial stage of infection to the last step of wound healing. This can be seen in

Proctor, R.A., Rev. Infect. Dis., 9, 317 (1987).

Ej [RF and similar winners_CSEQ ID NOS: 1175-1187)-FMRF is a neuropeptide encoded by the FMRF amidine gene and has a common c-terminus but different extensions ^ FMRP amidine Base-related peptides (FaRPs) are found in all animal kingdoms and affect both nerve and gastrointestinal functions. Organisms have a variety of FaRps & genes that can encode several species with a common C-terminal structure but different N-terminal amino acid extensions. H · La—Shi & Zunong's Victory (SEQ ID NOS: Ιΐ88-12η? Η-Jala is a peptide with 29-30 amino acids, which was first produced by the pig's small intestine Isolated. It has been found to have two biologically active forms: Dagger (1-1 9) and GAL (1-30), which are non- · amidine forms. It has a variety of biological roles including: Inhibition of biogenic amine release in optic mounds, pre- and post-synaptic inhibition of this choline function, maintenance of gastrointestinal balance, and regulation of insulin and glucagon hormone secretion. -60- 200524957 (SEQ ID N (S ... I20tl240)-

Growth factor is a group of proteins that regulate cell division. Certain growth factors are cell-specific factors that only stimulate the division of these cells with the appropriate receptors. Other growth factors are more common in their effects. There are also extracellular factors that antagonize the effects of growth factors and slow or prevent cell division (such as transforming growth factor plants and tumor necrosis factor). These extracellular Λs act through cell surface receptors, which are very similar to the hordes of forks and act through similar mechanisms: the generation of secondary signals in cells, the phosphorylation of proteins, And the last change in gene expression. G-therapeutic peptide binding protein fragment (SEQ ID NOS: 1241-1246)-members of the G-therapeutic peptide binding regulatory protein ((j-protein) family can be derived from cell membrane-bound receptors The message is transduced to the intracellular acting factors. This group includes Gs and (; 丨, which are used to respond to the respective stimulation and inhibition of adenylate cyclase. Retinal rod outer segments The transduction protein (τ) of the discoid cell membrane of) is coupled by light to activate rhodopsin and increase the activity of cyclic GMP phosphodiesterase. The g0 line originally found in bovine brain was used for this purpose. The fourth member of the ethnic group.

The purified G protein has similar physical properties. It is a heterodimer composed of α, stone, and τ subunits. This alpha subunit binds and hydrolyzes the G therapeutic peptide. It can be found in s. M. Mumby et al., PNAS 83, 265 (1986) and Lehninger p. 764. Guanylin (UroguanylirO (SEQ I Wei-61-200524957) 4 Ning and Urinidine is a peptide derived from the intestinal mucosa and urine, which regulates exophagia. The clothing-like GMP produced in the cell binds and activates the uridine nucleotides to cyclize C and control the transmission of salts and water in vertebrate epithelial cells, mimicking the effects of a variety of thermally stable cellular enterotoxins. In the kidney, both of them have known natriuretic and potassiumuria effects. The secretory system of intestinal air is regulated by these hormones by activating uridine nucleotide% enzyme C (GC-C). This dipeptide It is manifested in various tissues and benefits, including the kidney. In the isolated perfused kidney and living body, these hormones can cause natriuresis and diuresis, however, they act in the kidney Its location and cellular mechanism are still unknown. The first disc 1250-inhibin system is composed of two subunits (alpha system is 134 amino acids; $ system is 115 and 116 amino acids). Its role is in Inhibit FSH secretion. These two isoforms of inhibin, inhibin A and inhibin B It is produced by the gonads during gamete maturation, and it has different secretion patterns during the menstrual cycle. Inhibin can also be produced by the placenta and placenta, and it can be related to the physiological adjustment of conception. Clinically Inhibin can be used as a marker of tumor sensitivity in postmenopausal women, or as an effective tool to evaluate the reversal of imprinting in infertile women; it can also be used in the diagnosis of maternal-fetal symptoms to avoid maturation of egg cells or to inhibit typesetting .

(Interleukin) (IL) and Jie Bai Xing Ling Ye Ye White Matter "^ EQ IA NOS: 1.2.56-1263)-Jie Bai Su is a growth factor targeting cells of hematopoietic origin. Various biological and immune-related reactions -62- 200524957 The bioactivity system has been attributed to carbesin. These reactions include fever, cartilage damage, bone resorption, thymocyte proliferation, activation of D and 8 lymphocytes, induction of acute proteins synthesized by liver cells, fibroblast proliferation and differentiation, and bone marrow Cell proliferation. Serotonin

It is the main non-collagen protein of the basement membrane, which has been shown to promote the adhesion, extension, and migration of various tumor cell types in vitro. In particular, the main recent research in the laboratory is to functionally determine the activity on this large protein using intact kumburanic acid, purified proteolytic kumburamate fragments, and synthetic kumburamate peptides. position. This basal cell membrane composition is an important regulatory factor for the growth, development, and differentiation of various cell types. A conjugated kumburanic acid is used to prevent tissue inflammation and tissue fibrosis. This category also includes peptide kringle-5 (or K-5). The term referred to herein, kringle 5, refers to the region of mammalian plasminogen with three double bonds, which contributes to the development of mammalian plasminogen. The fifth kringle region defines a particular three-dimensional configuration. This disulfide bond connects the cysteine at positions 462 and 5 41 of the amino acid, and the second bond connects the cysteine at positions 4 8 3 and 524 of the acid, The third line is linked to the cysteine at positions 512 and 536. The term " Kring] Le) 5-peptide victory version π refers to the victory version having anti-angiogenic activity between 4 and 104 amino acids (inclusive), the 4 and 104 amino acids There is a sequence that is substantially homologous to equivalent fragments of mammalian plasminogen. 63-200524957 Leptin fragment peptide (SEQ ID NOS. 1285-1288) -Leptin is a protein product of the obesity gene, which is secreted by adipocytes. Leputin is involved in the regulation of male weight and metabolism, and may involve the pathophysiology of insulin rejection syndrome, which is related to the development of cardiovascular disease. Leukokinins (SEQ ID NOS: 1289-98)-

Leukocyte kinases are a group of widely distributed insect hormones that stimulate the rate of gastrointestinal screw movement and tube fluid secretion. In tubes, their main role is to increase the permeability of gas ions by binding to a receptor located on the basal membrane.琏 Prunus 艎 Adenylate cyclase activated polypeptide (PACAP) (SEQ ID NOS: 1299-1311)-a 38 amino acid tritium, originally isolated from sheep's inferior colliculus, which A 27 amino acid version was also found, called PACAP-27. PACAP is distributed in the hypothalamus, other parts of the brain, the respiratory tract, and the gastrointestinal system. It has a variety of biological functions, including neurotransmitting substances and hormonal functions, regulation of energy metabolism, and neuronal cell protective activity. Pancreastatin (SEQ ID NOS: 1312-1324)-Pancreatin is a 49-amino acid peptide that was originally isolated, purified, and characterized from the pancreas of pigs. Its biological activity in different tissues can be attributed to the C-terminal site of the molecule. Pancreatin has a prohormona 1 precursor, that is, troponin A, which is a glycoprotein present in neuroendocrine cells, including the endocrine pancreas. Polyphthalide (SEQ ID NOS · 1325-1326)-these are repeating chains. A 64- 200524957 ^ -η \) This provides two examples: (pro-Hyp-Gly) 10 * 20H20 and Poly-L-lysine Hydrogenide (Lysine Hydrochloride). Xundong's Guide Oath (SEO ID NOS: 1327-1367)-Message transmission is a process that amplifies an extracellular message (such as a chemical, mechanical, or electrical message) and transforms it into a cellular response. Many substances are involved in this process, such as achat in-1, glycose synthase, autocamtide 2. Calcineurin autoinhibitory peptide, dependence Calmodulin in dependent protein kinase II, analogues of protein kinase substrates that depend on momenin, analogs of protein kinase substrates that rely on disruptin, CKS-17, Cys-Kemper peptide (Kemptide ), Self-obtained peptide 2, malantide, melittin, acceptor peptide, protein kinase c fragment, P34cd2 kinase fragment, P60c-src substrate II , Protein kinase A fragments, tyrosine protein kinase substrates, synthetic amidines, S6 kinase substrate peptide 32, tyrosine-specific protein kinase inhibitors, and derivatives and fragments thereof. Dad-blood release inhibiting soil 1368-1377

Enzymes are the main regulatory enzymes in the coagulation cascade, and they have multiple roles as both positive and negative feedback regulators. In addition to the direct effects of / and Yu Zhim, thrombin also exerts direct effects on various cell types, which supports and expands the pathological effects of arterial thrombosis. This enzyme is the strongest platelet activating factor that causes platelets to aggregate and release substances (ie, ADP TXA · _.2NE), which can further increase the agglutination cycle. Yu Jiao--, the platelets in the heart fibrin network contain — 65 — 200524957 The main components of white thrombus. Thrombin also acts directly on endothelial cells. The release of hematopoietic f-contracting substances and the displacement of attachment molecules act as a drag. The attachment molecules can be repositioned for the attachment of immune cells. In addition, this enzyme is responsible for mitosis of smooth muscle cells and proliferation of fibroblasts. From this analysis point of view, it is clear that the inhibition of coagulation activity by thrombin inhibitors can provide a survival treatment method for the block of proliferative events related to thrombosis.

Branches (SEQ ID NOS: 1378-1415)-toxins can be conjugated using the method of the invention to target cancer cells, recipients, viruses, or blood cells. Once the toxin binds to the target cell, the toxin is allowed to be endocytosed and causes cytotoxicity and most cell death. Toxins have been widely used as a treatment for cancer. An example of this group of toxins is the degranulated peptide of mast cells, which is a peptide having 22 amino acid residues with two disulfide cations, which is isolated from bee venom. At low concentrations, it causes degranulation of mast cells and release of histamine, but at high concentrations it has anti-inflammatory activity. It is an effective anti-inflammatory substance that is 100 times more effective than cortisol in reducing the inflammatory response. Because of its unique immunological properties, MCD peptides can be used to study the secretory mechanisms of inflammatory cells (such as mast cells, basophils, and white blood cells) to guide the design of compounds with therapeutic potential. An example of a mast cell degranulating peptide is mastoparans, which is derived from wasp venom. It can degranulate the mast cells' at a concentration of 0.5 # g / ml and can release histamine from the cells at the same concentration. See IY. Hirai et al., Chem. Phan 200524957

Bui1 27, 1942 (1979). Other examples of such toxins include omega-agatoxin TK, ageenin, apamin, calculudine, calciseptine, gabutu Toxins (charbdotoxin), air toxins, cotoxins, endotoxin inhibitors, gegraphutoxins, iberiotoxin, kal iotoxin , Degranulated peptides for obese cells, margatoxin, neurotoxin, PLTX-II, scylliatoxin, stichodactyla toxin, and derivatives thereof With fragment. ID NQSr is a trypsin inhibitor that functionally acts as an inhibitor of trypsin and other serine proteases. It can effectively and effectively treat pulmonary inflammation, pancreatic inflammation, myocardial infarction, and cerebral vascular ischemia. ‘NOS: 1419-—Virus-related peptides are viruses-related proteins, such as virus receptors, virus inhibitors, and envelope proteins. This example includes not only peptide inhibitors of human immunodeficiency virus (HI v), peptide inhibitors of respiratory sigma group virus (RSV), peptide inhibitors of human parainfectious disease (HPV) , Measles virus (MeV) peptide P factor monkey immunodeficiency virus (SIV) peptide inhibitor factor, fluorine-producing human CMV protease substrate 'Hcv nuclear protein, HCV NS4a protein, type 8 liver human disease t fork Binding fragment, Hepatitis β virus pre-region, Herpesvirus 200524957 Inhibitory factor 1] Factor 2, ΗIV envelope protein fragment, η IV gag fragment, Η Π ▼ substrate, HIV-1 inhibitor peptide, peptide T, T21, ν3 Tokamate peptides, viral replication inhibiting peptides, and fragments and derivatives thereof.

The peptides are useful for therapeutic administration. For example, the peptide T is an 8 amino acid chain derived from the V2 region of ΗIV -1 gp 1 2 0. These amino acids are similar to those of the envelope of η I v. His research has been used as a treatment for const i tutional symptoms related to ΗIV. At the same time, Sheng version τ can reduce fever, night sweats, weight loss, and fatigue. It has been shown to resolve the symptoms of psoriasis.

(AiMiAlkCSEQ ID NOS: 1529-1617)-It includes adjuvant-type products, α-binding factor, arrhythmia prevention and control of skin, appetite control-type, α ~ 1 antitrypsin, bovine pineal body anti-reproductive peptide, 荠Bursin, C3 peptide P16, attachment factor, daughter peptide, chromogranin a fragment, contraceptive tetrapeptide, kinetagin G, kinetajinτ, crustaceans , C-terminal peptide, cytochrome b588 peptide, hypocorsin, dirison, △ ~ sleep-induced peptide, diazempam-binding inhibitory factor fragment, nitric oxide synthase Blocking peptides, 0VA peptides, platelet inhibitors (P1), inhibitors of plasminogen living pseudofactors 1 'retin, schizophrenia related peptides, sodium potassium A therapeutic enzyme Inhibitory factors-1, spoyat, sperm activation, systemin, thrombin receptor agonists (three peptides), all new drugs, fat use hormones, uremic decapeptide, anticoagulant peptides, Tumor necrosis factor, hirudin [Des Asp10] hypocoxin, L-uramine taurine gas hydrogenation, p-aminobenzene New services are acyl Ac-G1 u-G1 u-Va 1 -Va 1-A 1 a-Cys-pNA, Ac-Ser-Asp- 200524957

Lys-Pro, Ac-rfWink_NH2, Cys_Gly-Tyr-Gly_Pro_Lys-

Lys-Lys-Arg-Lys-Va, Gly-Gly, DAia-Leu, DUD-d, DDDDDD, IP-NANPNA, VAITV-LH M., one G — VRVR > ViH ~ S ^ VPDP ^ R. Val- Thr-Cys-Gly ^ RS ^ R > Sea Urchin Sperm Activation Peptide, SHU-9119 MC3-R and MC4-R Antagonists, Glaspimodor (Immunostimulator, used to fight bacteria , The fungus Y and the immune disease of immunodeficiency 'leukocyte deficiency disease', hp_228 (melanocortin), used to fight chemotherapy-induced vomiting, toxicity, pain, diabetes, inflammation, rheumatism Obesity), α 2 plasmin inhibitor (plasmin inhibitor), APC tumor suppressor (tumor suppressor, which is used to fight against neoplasms), early conception (immunosuppressive factor), Endozepine, benzodiazepine binding inhibitor (receptor peptide), τ interferon (for anti-leukemia), glandular kallikrein (immunostimulator), placental ribonuclease Inhibitor, Sarcolecin-binding protein, Surfactant egg White D, wUms, tumor suppressor, Wllm, s tumor suppressor, GABAB lb receptor peptide, protein infectin-related peptide (i PrP 1 3), biliary test protein fragment (thin-related peptide) , Telomerase inhibitor, cardiacostatin peptide, endostatm-derived peptide (angiogenesis inhibitory factor), protein infectin inhibitory peptide, N-methyl D-aspartamine salt Receptor antagonists, c-peptide analogs (for combating complications of diabetes). -69—

200524957 2. Improved therapeutic peptide The present invention relates to an improved therapeutic peptide and its derivatives. The improved therapeutic peptide of the present invention includes a reactive group which can interact with an effective reactive performance group on a blood component to form a covalent bond. The invention also relates to such improvements, such combinations with blood components, and methods used therefor. These methods include prolonging the half-life of effective treatment of the modified therapeutic peptide in vivo. In order to form a covalent bond with a functional group on a protein, most reactive carboxyl groups can be used as reactive groups, especially esters, in which the hydroxyl group is also physiologically acceptable to the extent necessary to improve the therapeutic peptide. Although there are many different radicals that can be used in the linking agent, the most commonly used are N_Roroliquidylamine (NHS) and N-hydroxy-sulfonic acid succinimidine (sulfonic acid -NHS). Primary amines are the main targets of NHS esters, as shown in Figure 1a below. Acceptable alpha-amine groups present on the N-terminus of proteins can interact with NHS esters. However, α-amino groups on proteins are not suitable or available for NHS transfer. Although five of the amino acids have nitrogen on their side chains, only the epsilon-amino group from the amino acid can effectively react with NHS esters. When the NHS esters shown in Figure 1A below react with primary amines to undergo a conjugation reaction and release a hydroxysuccinamidofluorenyl group, a monoamine bond is formed. -70- 200524957

ο NHS-Ester Reaction Diagrams Figure 1A ♦ In a specific embodiment of the present invention, the functional group on the protein may be a thiol group and the reactive group may be a group containing a maleimide group. A group such as T-cisbutadieneimide-butyramide (GMBA) or MPA. When the pH of the reaction mixture is maintained at 6.5 to 7.4, the cisbutanyl diimino group is preferably selected from the sulfhydryl group on the peptide, as shown in Figure 1B below. At pH 7.0, the reaction rate of the maleimide group with the sulfhydryl group is 1,000 times faster than the reaction with the amine group. A suitable thioether system is formed between the maleimide group and the sulfhydryl group, and its physiological state cannot be cut off.

-71- 200524957 Use 2: The therapeutic version and its peptide derivatives can be modified with the specific label of the liquid component of the dish solution. The therapeutic peptides labeled with the present invention are preferably designed to have a specific reaction with the succinyl group on the moving blood protein. Such reactions are preferably established by covalent bonding of the therapeutic version. It can be improved by connecting G Hall, MPA or other cis-butyrene imine) to a thiol group on a blood protein (such as serum albumin or igG). In some cases, cis-butyrylene The imine-specific calibration provides more advantages than moving proteins with a non-specific rod such as NHS and sulfonic-NHS groups. Thiols in vivo are less common than amino groups. Because: The cis-butene diimine derivative of the invention will covalently bond to fewer proteins. For example, albumin (the most blood protein) contains only a single thiol group. Therefore, the therapeutic advantage Peptide-cis-butene diimine ~ albumin complex will contain therapeutic peptides Albumin ratio]: Molar ratio of 1. In addition to albumin, IgG molecules (type π) also have free thiol groups. When IgG molecules and serum albumin make up most of the soluble protein in the blood, They also constitute most of the free thiol groups in the blood, which can be covalently bonded to cis-butene diimine modified therapeutic peptides. In alcohol blood proteins, the specific labeling with cisbutanylimine will lead to the preferential formation of the therapeutic peptide-cisbutanimine-albumin conjugate, which is attributed to albumin itself -72- 200524957 Unique characteristics. The single autocol group in the highly retained albumin of this genus is located on amino acid residue 34 ((^ 334). Cys34 of this albumin has recently been shown to have a relative Increased reactivity of other free thiol groups on other free thiol-containing proteins. This is partly due to the

A very low value of 5.5 pK on Cys34. It is generally lower than the standard ρK value of the cysteine group, and the ρK value of the cysteine group is generally about 8. Due to this low ρκ value, under normal physiological conditions, Cys34 of albumin mainly exists in ionic form, which surprisingly increases its reactivity. In addition to the low Pκ value of Cys34, other factors that can increase the reactivity of Cys34 are at their selected positions in the gaps on the surface of a ring near the V region of albumin. This positioning allows Cys34 to be used as a ligand for all kinds of species, and is an important factor for the biological role of Cys34 ', such as a scavenger for free radicals or a free thiol. These characteristics make Cys34 highly reactive with the therapeutic peptide-cis-butenediamidoimide group, and the increase in the rate of hydrazone response relative to the therapeutic peptide-cisbutenediamidoimide group with other free The reaction rate of thiol protein is up to 1000 times. The other advantage of the therapeutic victory-cis-butene-diimine-albumin complex lies in the reproducibility of the peptide in relation to the 1: 1 load of albumin, which is mainly on Cys34 of albumin . Other technologies' such as glutaraldehyde, DCC, EDC and other chemical activations, such as free amine groups, lack this selectivity. For example, albumin contains 52 lysine residues, of which 25-30 ir are located on the surface of albumin and can be used for conjugation. Activation of these lysine residues or modification of peptides by combining these lysine residues can result in heterogeneous conjugates. Even if a 1: 1: 1 molar ratio of peptide to albumin 73-200524957 white is used, the product will contain a variety of conjugated products, sometimes each albumin contains 0, 1, 2 or more peptides, and Each conjugate has a peptide that is randomly coupled to any of the available lysines from 25-30. Due to the ε of most combinations, it is difficult to characterize the positive composition and the nature of each batch, and the batch-to-batch reproduci bi 11 ty is not reproducible between batches. Possibly, making this conjugate less suitable as a therapeutic substance. In addition, although it has been shown that the conjugation of lysine residues through albumin can have at least the advantage of delivering multiple therapeutic substances per albumin molecule, studies have shown that the ratio of therapeutic substances to albumin is:丨 The ratio is better. At Stehle, et aL, " The Loading Rate Deteounes

Tumor Targeting Properties of Methotrexate-Albumin

In the literature of Conjugates in Rats, " Anti-Cancer Drugs, Vol. 8, pp. 677-685 (1 997), the authors point out that anti-cancer The most promising results are obtained when the ratio is ι: 1. The entire content of this document is hereby incorporated by reference. These conjugates can be absorbed by tumor cells, however, conjugates containing a methotrexate molecule from 5: 1 to 20: 1 have an altered HPLC pattern and can be quickly absorbed by the liver in vivo. Of course, at high ratios, changes in the configuration of albumin will reduce its effect as a therapeutic carrier. By controlling the supply of maleimide-therapeutic peptides in vivo, specific markers of albumin and IgG in vivo can be controlled. In a typical drug delivery, 80-90% of the supplied maleimide-therapeutic peptide will be labeled with albumin and less than 5% with IgG. Tracking labels for free thiol groups, such as glutathione, can also occur. When this mark allows accurate calculation of the half-life measured by the supplied substance ~ 74- 200524957, this particular mark is preferably used in vivo. In addition to providing specific markers for control in vivo, cisbutadiene-therapeutic peptides can provide specific markers for serum albumin and IgG in vitro. This in vitro labeling involves the addition of maleimide-therapeutic peptide to blood, serum, or physiological saline containing serum albumin and / or IgG. When changed in vitro with cis- butylenediimide-therapeutic peptides, the blood'sera, or physiological saline solution can be re-supply to the blood for in vivo use. In contrast to the NHS-peptide, the cis-butenediimine-therapeutic peptide is generally very stable in the presence of aqueous solutions and free amine groups. Once the maleimide-therapeutic peptide can only react with free thiol groups, a protective group is generally not required to protect the maleimide-therapeutic peptide from it The role of itself. In addition, the increased stability of the peptide allows its use in further purification steps, such as hPLC, to produce a product of southern purity suitable for use in living limbs. Finally, this increased chemical stability can provide a product with a longer life. B. Non-specific labeling. The therapeutic peptides of the present invention can also be modified for non-specific labeling of blood components. It is generally used for the formation of non-specific labels by binding to amine groups, especially with amine bonds. In order to form this bond, a wide variety of activated carboxyl groups, especially esters, can be used as chemically reactive groups coupled to the therapeutic belly plate, where the base portion is physiologically accessible -75- 200524957 The amount required for the article. Although most of the different hydroxyl groups can be used in these linkers, the most commonly used are N-hydroxysuccinamidofluorenyl (N-hydroxysuccinylsulfonamide) and N-methyl-sulfosuccinaminosulfonyl (sulfonamide) Acid-Guan Magic. Other useful linking agents are described in U.S. Patent No. 5,6 丨 2, 034, 'herein and for reference. This chemical reaction with non-specific therapeutic peptides Sex group

The different positions of internal action include cells, especially red blood cells (erythrocytes) and platelets, and proteins such as immunoglobulins (including IgG and IgM), serum albumin, ferritin, steroid-binding proteins, transferrin, Thyroxine binding protein, alpha-2 macroglobulin and so on. The body that reacts with the derived therapeutic peptide (which is not long-standing)-will generally be removed from the human host within three days. Based on its equal concentration in the bloodstream, the proteins (including proteins of the cells) described in the above formulation will be retained in the bloodstream for at least three days, and may be retained for five or more days (usually not more than 60). Days, usually not more than 30 days), especially the half-life. For the most part, it reacts with moving components in the blood, especially blood proteins and cells, and more particularly blood proteins and red blood cells. "Movement" means that the component does not have a fixed position for a long period of time, which usually does not exceed 5 minutes, and more often is] minutes. However, a certain blood electrical point can stay relatively -period of time. At first, there were labeled proteins and cells that were relatively heterogeneous. However, for the most part, within a few days of the medication, the population will change to depend on the origin of the population.

200524957 * L ~ privately remembered protein half-life. Therefore, usually within three days or longer τ, gG will become the main marker protein in the bloodstream. "丨," After 5 days of administration, 1 button, serum albumin, and red blood cells will be mol% of the 0% compound in the solution, usually at least for mol, and IgG IgM (which is essentially a (Smaller range) and serum albumin T will be at least 50 mole% of the non-cellular conjugation component, 'more often to / at 75 mole%, and more often about 80 mole%. The ideal compound for conjugating non-specific therapeutic peptides to blood components can be prepared in vivo + ^ ^, and is used for food and beverage. The patient can be a human or other animal. The medication can be supplied in pellet form, or in a slow manner by injection using a metered flow or the like. If desired, the target conjugate can also be prepared in vitro, which allows covalent bonding of the improved therapeutic peptide by combining blood with the improved therapeutic peptide of the invention To the reactive functional group on the blood component, and then the conjugated blood is recovered or supplied to the host. Furthermore, the above can also be achieved by a method in which a single blood component or a limited number of components such as red blood cells, immunoglobulin, serum albumin, etc. is first purified, and The component or groups of knives, '' are ex vivo. A therapeutic peptide that binds to a chemical reactivity. The labeled blood or blood component can then be sent to the host to provide the target therapeutic conjugate in vivo. The blood can also be processed to prevent agglutination during burial outside the body. -77- 200524957 3. Synthesis of the therapeutic phthalein used in the present invention The victorious fragment can be synthesized by standard methods of solid state chemistries known to those skilled in the art. For example, peptide fragments can be synthesized by the quasi-method of solid-state chemistry, which can follow Steward and Young (Steward, M. and Young, JD, Solid Phase Peptide

Synthesis, 2nd Ed., Pierce Chemical Company, Rockford, H1. Similarly, most wins can be combined and then joined together to form larger segments. These synthetic fragments can be prepared from amino acid substitutions at specific positions. For solid-state peptide synthesis, a brief description of many techniques can be found in J. M. Stewart and J. D. Young, Solid Phase Peptide

Synthesis, W. H. Freeman Co. (San Francisco), 1 963 and J. Meienhofer, Hormonal Proteins and Peptides, vol. 2, P. 46 ’Academic Press (Mew York), 1 973. Typical solution synthesis can be found in G. Schroder and K. Lupke, The Peptides, Vol. 1, Acacemic Press (New York). Generally speaking, these methods include the sequential addition of one or more amino acids, or the addition of a suitable protective amino acid to form an extended peptide chain. Generally, the amine or amyl group of the first amino acid is protected by a suitable protective group. The protective or derived amino acid is then attached to an inert solid support or used in solution by adding the next amino acid, which has a complementary group (amino or carboxylic ), The group has proper protection and is suitable for forming -78-200524957 into the amidine bond under certain conditions. Then, the protective group is removed from the newly added amino acid residue, and the next amino acid (with appropriate protection) is added, etc.

After the desired amino acids are linked in the proper order, any existing protective groups (and any solid supports) are removed sequentially or simultaneously to provide the final polypeptide. With simple changes to the process, it can add more than one amino acid at the same time to obtain an extended chain, such as by coupling a protective tri-peptide to a suitable protective di-peptide to After deprotection, one or five wins are formed (without racemizing the chirai centers). A preferred specific method for preparing the compounds of the present invention involves the synthesis of a solid peptide in which the α-N-terminus of the amino acid is protected by an acid or base sensitive group. This protective group must have the property that the conditions for the formation of the peptide are stable. At the same time, it can be easily removed without damaging the extended peptide chain or without racemic chiral centers. Suitable protective groups are 9-fluorenylfluorenyloxycarbonyl (Fmoc), t-butoxycarbonyl (Boc), benzenefoxycarbonyl (Cbz), diphenylisopropoxycarbonyl, t-pentyl Oxycarbonyl, isoboxoxycarbonyl, α, α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, o-nitrobenzylsulfenic acid, 2-cyano-t-butoxycarbonyl, etc. . The 9-methylmethoxycarbonyl (Fmoc) protective group is preferably used for the synthesis of fragments of a therapeutic peptide. Other preferred side-chain protective groups are as follows. For the side-chain amine group, for example, the group for lysine and arginine is 2,2,5,7,8-pentafluorenyl- 6- Phase group (fluorene), nitro, p-methylbenzyl-gamma, m-benzyl-continuyl-Cbz Boc, and hard rock oxycarbonyl; the group used for tyrosine is benzyl-79-

200524957 groups, bromobenzyl methoxycarbonyl, 2, 6-dichlorobenzyl, isopropyl, butyl (t-Bu), cyclohexyl, cyclopentyl and acetamyl (Ac); groups for serine The group is t-butyl ,; group, and tetrahydropiperan; the groups used for histidine are dibenzylmethyl, benzyl, Cbz, p-fluorenylsulfonyl, and 2,4-dinitro The group of phenyl 'for tryptophan is methylamyl; the group for aspartic acid and glutamic acid is ¥ group and t-butyl group; and the group for cysteine is tris Benzomethyl (trityl). In the solid-state synthesis method, the α-C-terminal amino acid is attached to a suitable support or resin. Suitable support systems for the above synthesis methods are the condensation of the various steps-deprotection of the reactants of the reaction and substances that do not react under the reaction conditions. The substances are also insoluble in the medium used. The preferred solid support for the synthesis of a-C-terminal carboxyl peptides is 4-tetrahydroxyfluorenylbenzyloxyfluorenyl-copolymer (benzyl ethylene-1% diethylene). The preferred solid support for the synthesis of aC-terminated amine peptides is 4- (2,4, _dioxophenyl-FmOC-aminoamido) phenoxyacetamidoethyl resin , Which can be obtained from Applied Biosystems (Foster City, Calif.). The a-c-terminal amino acid is coupled to the resin by the following substances, namely N, N, -dicyclohexylcarbodiimide (DCC), N, N--isopropylcarbodiimide (DIC) Or 0-phenylhydrazide-1-yl-N, N, N ,, N, -tetramethyl-urea cation hexafluorophosphate (HBTU), and the following are optional: 4 ~ 2 Pyridylamine p ratio (0 from eight?), 1- ^ benzylamine azide ([] 〇81 '), Benzylamine azide-1 monooxy-tris (diamidamine) phosphorus -Hexafluorophosphate (BQp) or bis (2-keto__3 one% σ sitting bite) gasified phosphine (B0PC1) 'which is equal to one of the two gas scorch or off 80—200524957 and 50 ° At a temperature between C, the regulatory coupling is about 1 to

In solvent at 10%. 24 hours. When the solid support is 4- (2,, 4, -dioxobenzyl_Fmoc-aminoamido) ethoxyacetamidoethyl resin, the Fmoc group is preferably related to Before the aforementioned α-C-terminal amino acid coupling, it is cut with a secondary amine, preferably hexahydropyridine. The method for combining 4- (2,4, -dioxobenzyl_Fmoc-aminomethyl) benzyloxetamine ethyl resin into the protection is O-benzene dissolved in DMF Open trisazo- 丨 -based-N, N, N ,, N 'tetramethyl-urea cation hexafluorophosphate ^ (HBTU, 1 equivalent) and hydroxybenzotrisazo group (基 0ΒΤ, 1 equivalent) . 4 Coupling of successful protective amino acids can be carried out in automatic multi-port machines known in the art. In a preferred embodiment, the a-N-terminal amino acid of the extended peptide bond can be protected with Fmoc. The Fmoc protective group is. The removal of the terminal side of the meta-elongated peptide is by using a primary or secondary amine, preferably hydrogen and / or hydrogen. Biffine, processed and finished. Then, each protective amino acid was introduced in an amount of about 3 times the number of moles, and the reaction was preferably ordered in DMF. The coupling agent is generally 0-benzidotrisyl-]-yl-n, n, n ', n'-tetrafluorenyl-urea cation hexafluorophosphate (HBTU, i equivalent) and And trisazo (Η0ΒΤ, 1 equivalent). At the end of the solid-state synthesis, the polypeptide is removed from the tree and deprotected, which is performed in a continuous or single operation. Removal and deprotection of the polypeptide can be accomplished in a single action by treating the resin-bound polypeptide with a resection agent comprising thianisole, water, and ethanedisulfide. Alcohol and trifluoroacetic acid. In this example, the a to c-terminus of the polypeptide is alkylated ammonium amine, and the resin is hydrolyzed with an alkylated ammonium amine solution. In addition to 200524957, the peptide can be removed by transesterification, that is, methanol, and then the amino group is hydrolyzed or directly transamined. The protective peptide can be purified in this step or directly in the next step. The removal of the side chain protective group is performed using the tail-end division described above. The fully deprotected peptide is purified by a chromatographic step of Elektrol, which can use any or all of the following steps: ion exchange (acetate form) on a weak base resin; underivatized Hydrophobic Adsorption Chromatography on Polyethylene Diethylene Diethylene (such as XAD); Silica Gel Adsorption Chromatography; Ion Exchange Chromatography on carboxymethylcellulose; Layered Layers Analytical methods, such as on Sephadex G-25, LH-20, or countercurrent distribution; high-efficiency liquid chromatography (HPLC), especially on octyl- or octadecylsilyl-stone Coated reverse HPlc. The molecular weight of these therapeutic peptides is based on a Fast Atom Bombardment (FAB) Mass Spectroscopy ° The therapeutic peptides of the present invention are compatible with the protective properties of the N- and C-termini Group is synthesized as a prodrug. (1) N-terminal protective group As mentioned above, the term "protective group" refers to those α-N-terminals that can protect monoamino acids or peptides during the synthetic process, or Monoamino acids or peptide amino groups are protected from unwanted reactions. Commonly used N-protective groups are disclosed in Greene, "Protective Groups In Organic Synthesis /" (John Wiley & Sons ,, New York 8-2-200524957 (1 981)) 'It is here and is a reference for reference. In addition, protective groups can also be used as prodrugs, which can be easily removed in vivo, For example, by enzymatic hydrolysis, the biologically active substance α N⑷ is released. The manganese group contains a lower bond alkanyl group (Alkanoy), such as Acetyl (" Ac "), propionyl, trimethylethynyl, t-ethylbutyryl, and the like; other fluorenyl groups, including 2-chloroethynyl, 2-bromoethynyl, Trifluoroacetamido, trifluoroacetamido, phthalimidine, 0-nitrobenzyloxyethenyl, -butyridine, benzamidine, 4 monobenzyl Fluorenyl, 4-bromobenzyl, 4-azabenzylmethyl, and the like; sulfonyl groups, such as benzophenone, p-fluorenylsulfonyl, and the like; aminophosphonate formation Groups such as: methoxycarbonyl, P-oxybenzyloxycarbonyl, P-fluorenylbenzyloxycarbonyl, P-nitrobenzyloxyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxy Carbonyl, 3, 4-dimethybenthomethoxycarbonyl, 3, 5-dimethoxybenzyloxycarbonyl, 2, 4-dimethoxybenzyloxy, 4-ethoxybenzylmethoxine, 2-nitro, -4,5 -dimethoxybenzylmethoxycarbonyl, 3,4,5-trisoxybenzyloxycarbonyl, 1- (P-diphenyl) -buthenylethoxyl, α, α-dimethyl -3,5-dioxophenoxycarbonyl, dibenzyloxycarbonyl, t-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxy%, methoxycarbonyl, alkenyl Propoxycarbonyl, 2,2,2, -trifluoroethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, fluorenyl-9-fluorenyloxycarbonyl, cyclopentylol, hard rock oxygen (adamantyloxy) ) Carbonyl, cyclohexyloxycarbonyl, benzylthiocarbonyl, etc .; aralkyl groups such as octyl, tribenzylmethyl, benzyloxy, 9-fluorenyl Methoxy carboxyl (Fmoc), etc., and silyl groups, such as' trimethylsilyl, etc. — 8 3_ 200524957 (2) carboxyl protective group as described above, the term “carboxyl protective group "Group" refers to a carboxylic acid-protective § motif or amine group, which is used to block or protect the functional group of the benzine, and at the same time, the reaction involving the position of other functional groups of the compound is still proceeding. Protective groups are disclosed in Greene, Protective Groups in Organic Synthesis "pp. 1 52-1 86 (1 981), which is hereby incorporated by reference. In addition, a carboxy-protective group can be used as a prodrug, whereby the carboxy-protective group can be easily excised in the living body, such as by enzymatic hydrolysis to release the biologically active substance itself . These carboxyl protective groups are known to those skilled in the art, and they are widely used in the protection of penicilHn and cephalosporin, which are disclosed in US Patent No. 3 ' 840,556 and 3,719, and 667, the disclosures of which are hereby incorporated as reference materials for reference. A typical silk protective group is C] _CS lower alkyl (eg, methyl, ethyl, or butyl, etc., a wide aromatic alkyl group, such as phenyl ethyl or ¥, and its substituted derivatives, such as , Oxy-benzyl or phenyl-benzyl, etc .; aromatic materials, such as, styrene, etc .; aryl: their substituted derivatives, such as' 5_2,3_-diarginyl, etc .; Burning amines, such as -methyl groups, etc .; alkanoloxyalkyl, oxomethyl, butyromethyl, pentyloxymethyl, oxomethyl , Q, methyl, bu (propion oxygen) + ethyl 'pentamidine) — 1 monoethyl, 1 —methyl and quot; Gong Wang Guang, Sagamethyl-1 ~ (propyl oxymethane) —丨 monoethyl, trimethyl, sulfonyl, propyl methyl, etc. | @ 土,. Oxymethyl ", ethoxyl group", such as, cyclopropyl — 84- 200524957 ^ oxygen τ group, Cyclobutylfluorenyl, oxo, cyclohexyl, oxomethyl, etc., arylalkyl, such as benzene, oxo, phenyl, oxo, ethyl, etc., aryl Burning bases, such as stupid methyloxyl, certain, monomethyl ethyl, etc. ; Alkoxycarbonylalkyl or cycloalkoxycarbonylalkyl, various :, methoxycarbonylmethyl, cyclohexyloxycarbonylmethyl, bumethoxycarbonyl-buethyl, and other oxooxy methoxy groups or cycloalkyl Hexyloxyl, such as ^ carbonyloxymethyl, bubutoxycarbonyloxymethyl, buethoxycarbonyloxyethyl, bucyclohexyloxycarbonyloxy-!-Ethyl, etc .; arane Carbonyloxyalkyl, such as' ^ oxybenzyl) ethyl, 2- (5_2,3-dihydrobenzyloxyfluorenyl) ethoxy, etc., alkoxyalkylcarbonyloxyalkyl, such as , 2— (Methoxymonomethylpropane-2, oxy) ethyl, etc .; arylsilylpyridinyl, _ (benzyloxycarboxyoxy) ethyl, etc .: dilute aryl bonds Oxyeoxyoxyalkyl, such as 2- (3-phenylpropan-2-yloxyoxy) ethyl, etc .; alkoxyalkylamino, e.g. Methyl group, etc .; alkyl group, such as methylamino, carbonamino, methyl, etc .; alkyl group, such as methylamino, methyl, etc .; heterocyclic carbonyloxyalkane, etc. Radicals, such as 4-methylpyridinyloxymethyl, etc .; dialkylaminoalkyl, such as dimethyl Aminoaminomethyl, diethylaminomethyl, etc., (5- (lower alkyl) 2 keto-1,3-dioxo-4-yl) alkyl, such as -2-keto-1,3-dioxo-4-yl) fluorenyl and the like; and (5-benzyl_2-keto-1,3-dioxo-4-yl) alkyl, For example, (5-benzyl_2_keto- 丨, 3-dioxo-4-yl) fluorenyl and the like. Typical amido protecting groups are amine carbonyl and lower alkyl amine carbonyl. -85- 200524957… The preferred carboxy-protective compound of the month is the following chemistries = in which the protective slow-base system is a low, Qian base, cyclic wide base base, or μ soil, S said as a S , Ethyl ester, propyl ester, isopropyl ester, butyl ester, second butyl ester, isobutyl ceramide, amyl pentamidine, isofluorenyl § | Base, ring-fired oxyalkyl, aryloxyxanyl, or monoaryl oxalyl, preferably amine, borophenyl, low-grade

A few amino amines. For example, 'aspartic acid can be protected at the α-c-terminus by an acid-labile base (e.g., butyl), and protected by β by an unstable base (eg, amidino) of a hydrogenation reaction. -C-terminus and then selectively deprotected during synthesis. In addition, it is also possible to obtain a fragment by cleaving the naturally occurring amino acid sequence using a method of proteolytic enzymes known to those skilled in the art. Furthermore, it is also possible to obtain a desired therapeutic peptide fragment by using the recombinant DNA technology method known to those skilled in the art. 4. Improvements in therapeutic peptides The manner in which the improved therapeutic peptides of the present invention are produced is altered, depending on the characteristics of the various elements containing the molecule. The synthetic process can be chosen to be simple, provide high yields, and allow a highly purified stable product. Generally speaking, the reactive group can be generated in the last step. For example, esterification of an alkyl group to form an active ester can be the last step in the synthesis. Specific methods for producing the improved therapeutic peptides of the present invention are described below. 86-200524957 In general, the improved therapeutic peptides of the present invention can be manufactured blindly or by activating substitution as a structural activity correlation (SAR). sar is a knife analysis method that defines the correlation between the molecular structure of a series of compounds and their pharmacological activity. Various studies related to unique therapeutic peptides have shown that how the activity of the peptides is altered according to changes in chemical structure and chemical properties. In detail 5 ', the therapeutic activity of the free peptide is first analyzed. Next, the peptide is modified according to the method of the present invention, that is, the peptide is modified at the N-terminus, C-terminus, or the middle part of the peptide using only one linking group. The linking group includes the reactive group disclosed above. The improved peptide-linking group is then analyzed, and a decision regarding the position of the improvement is made based on the activity detected. Next, the peptide conjugate is prepared and its therapeutic activity is determined. If the therapeutic activity of the peptide is not substantially reduced after conjugation (ie, if the therapeutic activity is reduced by no more than 10 times), then the stability of the peptide is measured, and it is equal to live The existence time is indicated. If the far stability has not been improved to a desired level, improve the peptide to another position and repeat the process until a desired degree of therapeutic activity and a desired stability are achieved. The details of '5. The therapeutic peptides that are selected to be derivatized with a linking group and a reactive group will be improved according to the following criteria: If the therapeutic victory of Zhi Xuan can be a side betrayal And the retention of the pharmacological activity of the terminal tether group is not decisive, and no other sensitive functional group is present on the therapeutic peptide, the carboxyl group can be selected as the linking-reactive group Improved contact points. If the marginal carboxyl group is involved in pharmacological activity, or if a carboxyl group cannot be obtained, then any other sensitive functional group that is not decisive for pharmacological activity-87- 200524957 retention will be selected as the link-reactivity Modified contact points. If multiple sensitive functional groups are available on the therapeutic profile, the set of protective groups can be used to improve it through the following methods: that is, adding the linking group / reactive group with all the protection After the sensitive functional groups are deprotected, the retention of pharmacological activity can still be obtained. If there is no sensitive functional group on the therapeutic peptide, or if a simpler modification is needed, the effect of 'synthesis will allow the original peptide to be modified in the following way, that is, a biological agent can be obtained. Retention of activity and specificity of receptor or target. In this example, the improvement occurred at the opposite end of the peptide. An NHS derivative can be synthesized from a monoacid in the therapeutic peptide in the absence of other sensitive guanyl groups. In particular, the therapeutic peptide is reacted with a non-aqueous CH2 Cl2 and N-hydroxysuccinimide group, and the product is obtained by chromatography or from The NHS derivative can be obtained by recrystallization from a suitable solvent system for purification. Φ In addition, an NHS derivative can be synthesized from a sigma-curing agent containing an amine group and / or a thiol group and a tertiary group. When a free amine or thiol group is present in the molecule, it is preferred to protect the sensitive functional group before adding an NHS derivative. For example, if the molecule contains a free amine group , It is necessary to convert the amine group to Fmoc or preferably tBoc protective amine group before the above chemical reaction is performed. The amine functional group is not deprotected before the preparation of the NHS derivative. Therefore, This formula can only be applied to a compound, and its amine group need not be in a free state to trigger a pharmacologically desired effect. If the amine group must be in a free state to maintain the original biological properties of the molecule 88-200524957, The other chemical species described in Example 3-6 In addition, a derivative can be synthesized from a therapeutic peptide containing an amine group or a thiol group but no carboxyl group. When the selected molecule does not have several groups, a series of bifunctional linkers The group can be used to convert the molecule into a reactive NHS derivative. For example, ethylene glycol-bis (No. 醯 醯 胺 imine No.% acid g) (EGS) and triethylamine are dissolved in DMF and added to On the free amine containing the molecule (a ratio of 10: 1 is favorable for EGS), it will produce the single nhs derivative. In order to produce an NHS derivative from a molecule derived from a thiol, it can be used in DMF Ν- [γ-maleimide butimidooxy] succinimide imide (GMBS) and triethylamine. The maleimide group will react with the free thiol, and The NHS derivative can be purified from the reaction mixture by chromatography on the silica or by HPLC. An NHS derivative can also be obtained from a therapeutic peptide containing multiple 'sensitive functional groups Synthesis. Examples will have to be analyzed and solved in different ways. However, thanks to the large list of commercially available The protective group and the bifunctional linking group can be applied to any therapeutic peptide. The method of the present invention preferably has a chemical step, that is, only derivatizing the therapeutic peptide (such as in Example 1 or 3), or two steps (as described in Example 2, which involves the protection of early sensitive groups), or three steps (protection, activation, and deprotection). Only in exceptional cases Otherwise, multiple-step (more than one step) synthesis is required to convert a therapeutic peptide into an activated NHS or maleimide derivative. Maleimide derivatives may be contained in one A free amino group and a 200524957 free slow-acid therapeutic peptide were synthesized. In order to produce a cis-butene diimide from a molecule derived from a monoamine group, it can be used in DM {? [Γ Cis-butyro-imine and bis-imine butanyloxy] succinimide imide (GMBS) and triethylamine. The station imine sulfonium ester group will be able to react with the free amine group, and the cisbutane diimine derivative will be able to react from the reaction compound by chromatography on silica or by HpLC Purified. Finally, the '-cis-butene diamidine derivative is also synthesized from a therapeutic peptide that contains multiple other sensitive functional groups and does not contain free acid. When the selected molecule does not contain a carboxylic acid, a 'bifunctional cross-linking substance can be used to convert the molecule to a reactive NHS derivative. For example, cis-butanedimine propionate (MPA) can be coupled to the free amine group through the reaction of the free amine with the carboxylic acid of MPA to produce a maleimide derivative, as described above. The reaction was performed in DMF using HBTU / HOBt / DIEA activation. In addition, an lysine residue can be added to the C-terminus of the peptide to allow conjugation to the amine group of the lysine described above. The added lysine allows a simple and efficient modification on the C-terminus of the peptide, while keeping the terminus trapped by the monoamine functional group of the original resin design. In addition, many other commercially available heterobifunctional crosslinkers can also be used if desired. Many bifunctional compounds can be used to connect all of them. The cross-linking agents include: azidobenzylidene, N- [4- (p-azidosalamido) butyl] -342 (bis-bis-methyl) propylamine), bis-contanoic acid amber Pyridylamine sebate, dipyridylhexanediamine diamine, disuccinylideneimine tartaric acid, Ny-maleimide bisimidebutyrate oxypermethimide, N-Hydroxysulfonic acid succinimidoamino azidobenzoic acid-910 and humane 200524957 eg, N-No. Succinic acid [renazidobenzyl ^, 3, -dithiopropionate, iV succinamido [4-iodoacetamido] amine benzoate, glutaraldehyde, and succinoamido 4- [N-cisbutenylimidofluorenyl] cyclohexanecarboxylic acid . In more detail, 'these peptides are preferably modified depending on the characteristics of the substituents and the presence or absence of free cysteine. Most peptides are aggregated into the following four individual classes: (1) peptides that do not contain cysteine; (2) peptides that contain one cysteine; (3) peptides that contain two Hemi-deaminate is a peptide having a disulfide bond (photoamine); and (4) a peptide containing multiple cysteine. A. Vicinity without hemicidal acid. When the winning version does not contain cysteine, all residues cut from the support resin are added by the c-terminus and completely protected. The c-terminal solution phase carried out by DEC and NHS can be used in a container to react with monoamine-carbyl-cis-butenedifluorene imine. The peptide system was then completely deprotected. In addition, an lysine residue can be added to the c-terminus of the peptide to allow modification of the E (epSiion) amine group of the lysine and at the same time make the carboxyl terminal an amine group Trapped. The addition of this lysine residue is performed only when the addition does not substantially affect the therapeutic activity of the peptide. The general reaction chart of the improvement effect of the cysteine-free peptide 0-terminus is shown in the following chart. -91- 200524957

1% TFA 5% TIS RH ^ aa ^ N / 1 ^ Ni ^ a ^ Resin

RH ^ nN H

Resin 〇

Or soluble in CHCl; Pd (0), H〇Ac, NMM

C〇2 Bu

Η II 〇

R = Boc or Ac R '= Ac or H R "= NH2 or H P = protective group Mtt or Aloe

Aaa =-includes an amino acid of Lys protected by Boc 〇 〇

R’H $, ^ || ^ a ^; c〇2Rn KH πν ^ Resjn

〇 o If an N-terminal modification is more appropriate, and it is stated once again, r does not contain a cysteine peptide. The addition effect on the N-terminal is better to still exist in the support resin All residues on it and protected completely. live

The addition of the NHS-Mal bifunctional linker can be performed on the N-terminus which is still on the resin to protect it. Then the peptide system was completely deprotected. Examples of peptides containing no cysteine and modified at the C-terminus are described in Examples 7-26. Examples of the peptides which do not contain cysteine and have been modified at the ends are described in Examples 27-38. The general reaction chart of the improvement effect of the N-terminal peptide of the cysteine-free peptide is shown in the following chart, which uses iso-NHS cis-butanedimine (like GMBS) and 3-MPA, respectively. -92- 200524957

Iso-NHS cis-butene diS ylidene (^ gmbs)

3-MPA -93- 200524957 In addition, the peptide is also modified on the amino acid in the middle position (i.e., neither the C-terminus nor the N-terminus). The summary reaction diagram of the intermediate amino acid modification effect of the free version of the free cysteine-free intermediate is illustrated in the following chart, which uses cis-butene diimine of the same bis-NHS and iso-NHS.

η 〇 〇 R = NH2 or Η Aaa =-amino acid

T ^ C02R 〇

Same double NHS -94- 200524957

Iso-NHS cis-butenyldiimide (like GMBS) These cysteine-free peptides can be modified as described above, including knngle 5 peptide fragments, GLpq peptide fragments , Fragment of dynorphin A peptide, human growth hormone releasing factor, human nerve failure 1 to 24 fragments, and human small intestinal endocrin. A complete description of the chemical properties of each such victory is documented in the paragraphs of the practical examples. -95- 200524957 B. Peptide containing a cysteine When the cysteine version contains a cysteine, the cysteine must be covered after the addition of cis- butylene diimide. If the cysteine is involved in the binding site, one must estimate how much potential activity is lost when the cysteine is covered by a protective group. If the cysteine can be present in a covered state, then the route of the synthesis is similar to that described in Part A above, i.e., a C or N-terminal modification. In addition, the peptide can be modified at the position of the intermediate amino acid (i.e., neither at the C-terminus nor at the N-terminus). The general reaction chart of the improvement effect of the intermediate intermediate amino acid containing a cysteine is illustrated in the following chart, which uses cis-butene diisobutene diimide and iso-NHS, respectively. Hydrazone (like GMBS).

Isobiscis-butene difluorenimine 200524957

〇 Iso-NHS cis-butene dihydrazone (like GMBS)

Examples of the therapeutic peptide containing a cysteine include G σ (the alpha subunit of the G therapeutic peptide, the 724-739 fragment of nitric oxide synthase blocking protein in the brain of the rat, The 1-32 fragment of the alpha subunit of the human [TyrO] inhibin, the 254-274 fragment of the HIV envelope protein, and the P34cdc2 kinase fragment. C. Contains two cysteine acids as a disulfide bridge ( Peptide field of cystine) ° When Xuansheng Peptide 3 has two cysteine acids as a double sulfur bond bridge, the peptide is excised from the support resin before the addition of cisbutanediamine In order to improve the peptide from the G-terminus, all protective groups exist in addition to the basal end and the-分 μ 一 玄 一 + cystine acid (because it should be The target body 200524957 is cut off from the resin. First, it exists in an unprotected state.) When the peptide is cut off from the resin, it must be deprotected. After mild gas oxidation, the effect will be The double sparse bridge is generated, and the peptide can be purified in this step. Then when the liquid phase chemistry system is the presence of the double sulphide bridge This end and the addition of the maleimide diimide to the c-terminus (via monoamino-alkyl-maleimide diimide) are required. Then, the peptide system is completely deprotected. % To improve the peptide at the N-terminus, the peptide may be present on the support resin. The two cysteine acids are selectively deprotected before the addition of maleimide The gas oxidation which can be assisted by a catalyst (heterogeneous) can generate the disulfide bond, and the peptide still exists on the resin. And the 'cis-butenediamidoimide system is added to the N-terminus, In addition, the peptide was cut from the resin and completely deprotected. The general reaction diagram of the improvement effect of the N-terminal amino acid containing two cysteine acids as a disulfide bridge is illustrated in the following In the chart: Lu Fmoc ^ eys ^ iys ^ 3 ^-age

Acm Acm g_ ^ 1 20% N-Six SPJtt Syndrome

200524957 In addition, the peptide can be modified at an intermediate amino acid position (ie, neither the C-terminus nor the N-terminus). The general reaction chart for the improvement of the intermediate amino acid of the peptide containing two cysteine amino acids as a disulfide bridge is illustrated in the following chart.

NHP

TI (CF3CQ2) ^ R = Boc or Ac R. = Ac or Η RM = NH2 or H P = Protective group Mn or Aloe Aaa = — Including an amino acid of Lys protected by Boc

RH

Cys € ys 〇 N I \ H

nh2 I i ^ CH2C1: 1% TFA and 5% TIS are dissolved in CHC1.

1. 3 · maleimide dipropionate Pd (0), HOAc, NMM

Resin-99- 200524957 Examples of therapeutic schizoides containing two cysteine acids as a double sparse bond bridge include human osteogenesis factor 49, human diabetes-related embryos I, human / dog room natriuresis 5-28 fragments of peptide, bovine bactenecm, and human [TyrO cortisol 29. D. Peptide containing multiple cysteine. When the peptide contains multiple cysteine as a disulfide bridge, the peptide must be removed from the target resin before adding cis Cut off. In order to improve the peptide from the C-terminus, all protective groups exist at positions other than the enemy's base and the second half of the amino acid which is believed to establish a disulfide bridge (because The support resin is cut off from the resin, so it exists in an unprotected state. After the skin is cut off from the resin, it must be deprotected. These half-amine amino acids that involve other disulfide bridges are protected with diamidine. The selected groups are sequentially deprotected in pairs. It is recommended to coat and purify each disulfide bridge at the same time before moving to the next disulfide bridge. Mild gas oxidation can produce double sparse bonds. Bond bridge, and the peptide can be purified at each step. Then the 'liquid-phase chemistry' system activates the C-terminus in the presence of a double sparse bond bridge and adds cis-butene diamidine to 1 (by Amino-alkyl-cis-butene-diimine) is required. However, the peptides are completely deprotected. In order to improve the peptide from the N-terminus, it can be The version stays on the resin of the building and selectively protects it Jianxiner 4 disulfide bond under oxidation. Before adding cis butylene diimide, protect one I in order to supply other disulfide bonds. This can be mistaken by a catalyst (heterogeneous) To help the chaos to the oxidation can produce the double ~ 100—200524957 sulfur bonds, and the peptide still exists on the resin. Then, the cis-butene dihydrazone system is added to the N-terminus, and from the resin The peptide was excised and completely deprotected. In addition, the peptide can be modified at the position of the intermediate amino acid (ie, not at the C-Afb nor at the N-terminus). The cysteine-containing peptides include human endothelial hormone and [Lys4] sarofur toxin S6c. 5. · The method of administration of the improved therapeutic agent The improved peptide can be administered by dissolving in a physiologically acceptable medium, such as deionized water, phosphate-buffered physiological saline, physiological saline, aqueous Alcohol or other alcohols, blood packs, protein solutions, glycerol, aqueous glucose, alcohols, vegetable oils, etc. Others can be included therein = the additive includes a buffer, wherein the media is generally buffered in the range of 5 to 10, and the concentration of the buffer is generally in the range of 50 to 25 0 "Salts" wherein the concentration of the salts is generally in the range of about 5 to 5 times a 'physiologically acceptable stabilizers and the like. These compositions can be freeze-dried for storage and transportation. • Most of the improved therapeutic peptides can be taken orally, parenterally ^ such as intra-iliac (IV), intra-arterial (IA), muscle (I heart, subcutaneous (sc). Temple hunting. In appropriate conditions It can be administered by transfusl㈤. Under certain conditions, that is, when the response of the functional group is quite low, it can be administered by administration, nasal, rectal, transdermal or spray. The characteristics of this combination 6 allow its transfer to the vasculature. Although multiple injections can be used if necessary, it is usually two single injections. The improved therapeutic version can be obtained by Any conventional device for administration, including syringes, cannula gages, catheters, etc. The particular method of administration is to vary depending on the agent to be administered, whether it is a single bolus or a continuous supply Etc. Why is it preferred that the location of the introduction is administered in an intravascular manner to the present invention is not absolute, but it is preferably at a location where the blood is flowing rapidly, such as the periphery of a vein or the central vein. Can find other routes of administration, The administration method here is combined with slow-release technology or a protective matrix. The purpose is that the therapeutic peptide can be effectively distributed in the blood and can interact with blood components. The concentration of the conjugate is wide The change is generally between about 1 pg / ml and 50 mg / mU & perimeter. The total dose in the blood vessel is in the range of about 0.1 mg / m to about 10 mg / ml. It is more often in the range of 1 mg / ml to about 5 mg / ml. By binding to long-standing blood components such as immunoglobulin, serum albumin, red blood cells, and platelets, many advantages The activity of the improved therapeutic peptide compound is extended to several days to several weeks. During this period, only one administration is required when the substance first binds to the macromolecule. When the activity is closed At this time, strong specificity can be achieved, which is less suitable for absorption in the cell and interferes with other physiological processes. The formation of covalent bonds between blood components can occur in vivo or

200524957 It is modified with cis-butanine and imine, and it reacts with human serum albumin prepared in physiological saline solution. Once the therapeutic peptide reacts with the blood component to form a therapeutic tritium-protein conjugate, the complex can be supplied to a patient. In addition, the modified therapeutic peptide can be directly supplied to a patient so that a covalent bond can be formed between the modified therapeutic peptide and a blood component in vivo. In addition, when the targeted delivery of the therapeutic version is ideal, multiple delivery methods can be used: A. Lavage of the open surgical range has multiple indications for topical therapeutic compounds, which accompany the therapeutic The compound is used as an additive for open surgery. In this example, 'the therapeutic compound can be perfused at the surgical site (or a part of the site) before suture, or: The therapeutic compound can also be placed in a restricted area for a period of time (ie, in the artery Endometrial resection is performed after one of the arteries has been severed (or part of the gastrointestinal tract during resection), and then the excess fluid is discharged. Β · Tissue Culture Tissue transplantation, such as autologous and xenobiotic vein / arterial and membrane transplantation, and organ transplantation, can be pre-treated with therapeutic compounds that have been modified to allow the Covalent bonds are formed by soaking in a therapeutic solution and / or immersing them in this solution. 103-200524957 c. Catheterization 'σ is used as part of an internal medicine procedure to deliver the therapeutic skin to the inside of an organ (ie, bursa, digestive tract vagina / uterus), or attached to a heart A procedure for a VS, such as a balloon dilatation (OnnPiaSty). Standard catheters such as newer drug delivery and iontophoretic (1QntGphQret⑷ catheters) can be used.

D. Direct injection Yes. The poorly-regulated hemorrhagic area, such as the intra-articular space, and the direct injection of therapeutic compounds can be biologically conjugated to the surface tissue for the desired period of drug action. Other applications include intramedullary injection, intratumoral injection, intravaginal injection, intrauterine injection, enteral injection, otoropharynx > main shot, intracapsular injection, subcutaneous injection, intraarticular injection, intraperitoneal injection or Intraocular injections, and surgery via bronchoscope, nasogastric tube, and nephrostomy. 6. · Monitoring of the existence of the improved therapeutic peptide derivative Another object of the present invention is to determine the therapeutic peptide and / or the like, or the derivatives thereof in a biological sample such as blood, and Methods of composition concentration, and methods of determining the peptidase stability of the improved therapeutic peptide. The blood of a mammalian host can be monitored one or more times for the presence of the modified therapeutic version. By taking a portion of the host's blood or blood sample, it can determine whether the therapeutic peptide is bound to the long-standing blood component in an amount sufficient for the therapeutic activity, and then determine the blood-104 " 200524957 Of the therapeutic peptide compound. If desired, it can also be determined which blood component is bound to the therapeutic peptide-derived molecule. This is particularly important when using non-specific therapeutic peptides. For specific cis-butene diimide-therapeutic peptides, calculate the half-life of the serum albumin and IgG. Θ Ju Ju / r ^ T σ. F 早 Early among the car parents. The method for determining the concentration of the therapeutic peptide, analog, derivative, and conjugate is to use the therapeutic peptide or the therapeutic analog, or a derivative and conjugate thereof. Specific antibodies, and use of these k-body as a treatment for toxicity that may be associated with this therapeutic peptide, analog, and / or any organism and conjugate thereof. Because the increased stability and duration of action of the therapeutic peptide in vivo may cause new problems during treatment, including the possibility of increasing toxicity, this anti-zhao has this advantage. It must be mentioned, however, that in some cases, this traditional antibody test cannot identify the difference between the cleaved and uncleaved therapeutic peptides. In these examples, other detection techniques can be applied, such as LC / MS (liquid chromatography / mass spectrometry). The use of single or multiple antibodies specific to a particular therapeutic agent, analog, or derivative thereof can help mediate any of these problems. The K-body can be produced or obtained from a host that is immunized with the specific therapeutic peptide, analog, or derivative thereof, or an immunological fragment of a substance, or relative to a substance The epitope is synthesized by immunogens. The preferred resistance system has specificity and affinity for the natural form, derived form, and conjugated form of the therapeutic peptide or the analog of the therapeutic peptide. These antibodies can also be labeled with enzymes, fluorescent-105-200524957 pigments, or radiation. Antibodies specific for the derivatized therapeutic peptide can be generated by using tritiated therapeutic peptides to induce the derivatized therapeutic peptide-specific entities. By induction of the antibody, it not only wants to obtain an immune response stimulus by injecting it> into the animal body, but also wants to obtain similar steps in the production of synthetic antibodies or other specific binding molecules, such as histone immunity Protein Depot. Both the single and multiple antibodies can be produced by processes known to those skilled in the art. In some cases, the use of a single antibody is preferred to the use of multiple antibodies, such as when degradation occurs in more than one epitope / anti-Zhao region. The antibody can be used to treat toxicity caused by administration of the therapeutic peptide, analog, or derivative thereof, and can be used in vitro or in vivo. Methods of in vitro treatment may include toxic immuno-dialysis treatment in which the antibody is immobilized on a solid tadpole. The method of internal treatment can administer an antibody that can effectively cause the scavenging of the antibody-substance complex. The antibody can be used to remove the therapeutic peptides, derivatives, and the like in vitro from a patient's blood in vitro. Contact. For example, the antibody can be immobilized or immobilized on a column matrix, and the patient's blood can be removed from Disease I and passed through the matrix. The therapeutic peptide, analog: derivative, or conjugate will be bound to the anti-zhao, and then the blood containing a small amount of therapeutic m analog, derivative, or compound can be returned to the patient's Circulatory system. The amount of the therapeutically winning compound removed can be controlled by adjusting the pressure and flow rate. The priority comes from the second patient -106- again

The therapeutic peptides, analogs, derivatives, or conjugates removed in 200524957 are affected by the use of " such as " semipermeable membranes, or by methods known to those skilled in the art The iI component is first affected from the plasma component separated from the cellular component through a matrix containing the anti-therapeutic peptide. In addition, 'the preferentially removed therapeutic peptide-conjugated blood cells including red blood cells' are subject to collecting and concentrating blood cells in the patient's blood and binding the cells to a fixed anti-therapeutic peptide The antibody is in contact and the serum components of the patient's enterprise fluid are removed. The antibody can be administered parenterally in vivo to a patient receiving the therapeutic peptide, analog, derivative, or conjugate for therapeutic use. The antibody system binds the therapeutic peptide compound and conjugate. If the activity is not completely blocked, once the therapeutic peptide is combined, it can block the activity to thereby reduce the biologically effective concentration of the therapeutic peptide compound in the patient's bloodstream and reduce noxious side effects. In addition, the bound carcass-therapeutic peptide complex helps the therapeutic peptide compounds and conjugates derived from the patient's bloodstream. Heretofore, the fully detailed invention in this case is exemplified by the following non-limiting examples. — 107— 200524957 Example A. General method for synthesizing the improved therapeutic survival

The modified peptide was synthesized on a 100 μίΒΟ 1 e level solid phase peptide in a Symphony peptide synthesizer, which uses Fmoc-protective Rink Amide MBHA resin and Fmoc-protective Amino acid, prepared in Λ /, Λ / -dimethyl dimethylamine (DMF) solution. Benzene methyl azide-1-yl-A /, Λ /, ΛΤ, Λ / '- Tetramethyl-urea cation hexafluorophosphate (Hbtu) and activation with Λ / -methylmorphine (NMM), and deprotection of piperidine of the Fmoc group (step 1) . The deprotection of the fmoc group at the side is using a 20% N-hexahydropyridyl group (step 2) and then 3-maleimide diimide propionate (3-MPA) It can be achieved by the combination of the two, the conversion of the second base, or the coupling of one or more Fmoc-AEEA after the 3-MPA is combined (step 3). Resin removal and product separation using 86% TFA / 5% TIS / 5% H2〇 / 2% benzyl methylbenzene and 2%

Phenol, and then precipitation by dry-ice-cold Et20 (step 4). The product was purified by preparative reverse-phase HPLC using a Varian (Rainin) preparative dual-effect HPLC system using a guard module equipped with Dynamax C18, 60A, 8 μιτι module) Dynamax C18, 60A, 8 μηΊ, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detector (Varian Dyn a max UVD II) at λ214 and 254 nm. The product must have a purity of> 95% determined by an RP-HPLC mass spectrometer using a Hewlett Packard LCMS- 1 π only 200524957 1100 continuous spectrometer equipped with a secondary body array detector. Design and use electrospray ionization methods. B. Alteration of the natural peptide chain In order to help improve the state of victory, one or more amino acid residues can be added to the winning version described in Examples 1 to 5, and / or the one or more amines The amino acid residue may be substituted with another amino acid residue. This change can help the attachment of reactive groups.

Gallery Example 1-Lys was added to the C-terminal NAc-Pro-Arg-Lys-Leu-Tyr_Asp-Tyr-Lys.NH2.3TFA of KRINGLE-5. Protective amino acids were sequentially added to the Rink Amide MBHA resin: "^ 10〇〇 乂 乂 (8〇 (:)-〇H, Fmoc-Ty" (tBu) 〇H, Fmoc-Asp (〇tBu ) -〇H, Fmoc-Ty ((tBu) OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Pro-OH. In the deblocking of the Fmoc group, the N-terminus of the resin-bound amino acid was treated with 20% N-hexahydromorphinyl group prepared in DMF for about 15-20 minutes. The coupling of acetic acid was The amino acid was mixed under similar conditions. The final step of excision from the resin was performed using the excision mixture as described above. The product was separated by hard work and purified by preparative HPLC to obtain the desired The product is a white solid after freeze-drying. -109- 200524957 ϋ Example 2-Lys added to the C-terminal NAc-Arg-Lys-Leu-Tyr_ASp_Tyr_Lys_NH2.2TFA.3TFA of KRINGLE-5 Using the automatic win-win synthesis method, the following guarantee Department of amino acids

Sequentially added to Rink Amide MBHA resin: "Towel 〇〇 ^^ (8〇〇) -〇H, FmooTyr (tBu) 〇H, FmooAsp (〇tBu) -〇H, Fmoc-Tyr (tBu) 〇H , Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H,

Fmoc-Arg (Pbf) -OH. In the deblocking of the Fmoc group, the N-terminus of the resin-bound amino acid is treated with a 20% N-hexahydrofluorenyl group prepared in DMF for about 15-20 minutes. The coupling of acetic acid is carried out under conditions similar to those of amino acid selection. The last step of excision from the resin is performed using the excision mixture as described above. This product was isolated by sinking and purified by preparative HPLC to obtain the desired product, i.e., a lyophilized white solid. Male Example 3-Lys added to the N-terminal N Ac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH2.3TFA of kringle-5 An automatic peptide synthesis method was used for the preparation. The following protective amino acids were sequentially added to the Rink Amide MBHA resin: "〇1〇〇1 ^ 5 (巳 〇 (:)-〇H, Fmoc-Tyr (tBu) 〇H, FmooAsp (〇tBu) -〇H, Fmoc-Tyr (tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, 200524957

Fmoc-Arg (Pbf) -〇H, Fmoc-P 「o-〇H, Fmoc-Asn (T「 t) -〇H, Fmoc-Th 」(tBu) -〇H, FmooTh「 (tBu) -OH, Fmoc-

Tyr (tBU) OH. In the deblocking of the Fmoc group, the N-terminus of the resin-bound amino acid is treated with 20% N-hexahydropyridyl group prepared in DMF for about 15-20 minutes. Coupling of acetic acid is performed under similar conditions to amino acid bonding. The final step of excision from the resin is performed using the excision mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to obtain the desired product, i.e., a white solid after freeze-drying. Option 4-Lys was added to the N-terminus of kringle-5, and Cys NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp was replaced by Ala at position 524 -Ala524-Tyr-Thr-Thr-Asn_Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH2.4TFA

Using an automatic peptide synthesis method, the following protective amino acids were sequentially added to Rink Amide MBHA resin. Fmoc-Lys (Boc) -OH, Fmoc-Tyr (tBu) OH, Fmoc-Asp (〇tBu> -〇H, Fmoc-Ty "(tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc> -〇H, Fmoc-A" g (Pbf) -〇H, Fmoc-Pro -〇H, Fmoc-Asn (Trt) -OH, Fmoc-Thr (tBu) -〇H, Fmoc-Thr (tBu) -OH, Fmoc-Tyr (tBu) 〇H, Fmoc-Ala-〇H, Fmoc- Trp-〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Vabu 〇H, -111- 200524957

FmooAsp (〇tBu) -OH, Fmoc-Asp (〇tBu) -OH, Fmoc-Pr〇-OH, Fmoc-Asn (T "t) -OH, Fmoc-Arg (Pbf) -OH. Fmoc

In the deblocking of the group, the N-terminus of the resin-bound amino acid is treated with 20% N-hexahydropyridyl group prepared in DMF for about 15-20 minutes. The coupling of acetic acid was performed under similar conditions to the coupling of amino acids. The last step of excision from the resin is performed using the excision mixture as described above. The product was isolated by precipitation and purified by preliminary HPLC to obtain the desired product, i.e., a white solid after freeze-drying. Example 5-Lys added to the N-terminal NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp Lys-NH2.2TFA added to kringle-5 An automatic peptide synthesis method in which the following protective amino acids are sequentially added to Rink Amide MBHA resin: "111〇〇 ^^ (80 (:)-〇H, Fmoc-Trp-〇H, Fmoc-P, o-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H 'Fmoc-Asp (OtBu) -〇H, Fmoc-Gly-〇H, Fmoc-Vabu 〇H, Fmoc-Asp (〇tBii) -OH, Fmoc-Pro-OH, Fmoc-Asn (Trt) -OH, Fmoc-Arg (Pbf) -OH. In the Fmoc group

Deblocking the N-terminus of the resin-bound amino acid to prepare a 20% N-hexahydrosigma ratio in d M F for about 15-20 minutes. Consumption of acetic acid is performed under conditions similar to those of amino acids. The last step of excision from the resin is performed using the excision mixture as described above. The product was separated by Shen Dian and purified by the preparative ΗPLC to obtain the desired product -112- 200524957. That is, a white solid after freeze-drying. JL Example 6 -D-Ala2 GLP-1 (7-36) Preparation of amine group The solid phase peptide synthesis system of this GLP-1 analog at 100pm level uses artificial solid phase synthesis and Symphony version of the synthesizer is used, which uses Fmoc-protected Rink Amide MBHA resin, Fmoc-protected amino acid, prepared in dimethylformamide ([) 1 ^ ?: ) 0-benzylazide-l-yl- Λ in solution; / V, ΛΓ, Λ / · -tetramethyl-adenocation hexafluorophosphate (HBTU) and methylmorpholine ( NM) activation, and deprotection of the N-hexahydrosigma pjperjdjne of the Fmoc group (step 1). Resin removal and product separation were performed using 85% TFA / 5% TIS / 5% phenylthiomethane and 5% phenol, and then precipitated by dry-ice-cold Etz0 (step '2). This product was purified by preparative reverse HPLC. This HPLC uses a Varian (Rainin) preparative dual-effect HPLC system. A flow rate of 9.5 mL / min can be used. Gate 〇11 ^ 116 Father 1_1_] 113 1〇 phenyl-hexyl

A gradient dilution of 30-55% B (0.045% TFA (A) in water and 0.045% TFA (B) in CH3CN), 21 mm X 25 cm column, and UV at λ 214 and 254 nm Detector (Varian Dynamax UVD M) to provide the ideal peptide with> 95% purity, which was determined by rP-HPLC. These steps are illustrated in the following diagram. -113- 200524957

Fmoc-Rink Amide MBHA resin

Step 1 SPPS

H.N-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-PS Step destruction 2 l 85% TFA / 5% TIS / 5% phenylthiomethane / 5. /. phenol

TFA

TFA TFA K N-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH.

TFA D-Ala ^ GLP-1 (7-36) -NH. C. Improved peptides made from this cysteine-free peptide

The preparation of maleimide peptides from therapeutic peptides containing multiple protective functional groups without cysteine can be exemplified by the synthesis of the peptides described below. The peptide is modified on the N-terminus, C-terminus, or amino acid between the N-terminus and C-terminus. The modified peptide is synthesized by unlinking the N-terminus of the natural winning sequence or by unlinking the C-terminus of the natural winning sequence. One or more additional amino acids can be added to the therapeutic peptide to facilitate the attachment of reactive groups. 1. Improvement on the c-terminus of the therapeutic peptide Example 7 _ Improvement on the epsilon-amino group of the C-terminal lysine residue added to RSV

Val-lle-Thr-Ile-Glu-Leu-Ser-Asn-lle-Lys-Glu-Asn-Lys- —u 厶 一 200524957

Met-Asn-Gly-Ala-Lys-Val-Lys-Leu-IIe-Lys-GIn-Glu-Leu-Asp-Lys-Tyr-Lys-Asn-Ala-Val-Lys. (N8-MPA) &. ^ Prepared

This DAC analog was synthesized on a 100 μmol solid-phase version using an artificial solid-phase synthesis method, Symphony: Synthesizer, and Fmoc protective Rink Amide MBHA. The following protective amino acids are sequentially added to the resin. Fmoc-Lys (Aloc) -OH, Fmoc-Val-OH " Fmoc-Ala-OH ^ Fmoc-Asn (Trt) -OH ' Fmoc-Lys (Boc) -〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Asp (tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Glu (tBu) -OH, Fmoc-Gln (Trt) -OH, Fmoc-Lys (Boc) -OH, Fmoc-lle-OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH , Fmoc-VabuH, Fmoc-Lys (Boc) -OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Asn (Trt) -OH, Fmoc-Met-OH, Fmoc -Lys (Boc) -〇H, Fmoc-Asn (T``t) -〇H, Fmoc-Glu (tBu) -〇H, Fmoc-Lys (Boc) -〇H, Fmoc-lle-〇H, Fmoc- Asn (Trt) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Glu (tBu) -〇H, Fmoc-lle-OH, Fmoc-Thr ( tBu) -〇H, Fmoolle-〇H, Fmoc-VahOH. These are sequentially dissolved in N, N-dimethylformamido (DMF), and azido-1- -N, N, N, N ,, N, -tetrafluorenyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Removal of the Fmoc protective group is used N-N-Difluorenylamido (DMF) 20% (V / V) N-Hexahydropyridinyl Solution -115-

200524957 Achieved 20 minutes of action (step 丨). The selective deprotection of the Lys (Aloe) group was performed manually, and by using 3 eq of Pd (PPh3) dissolved in 5 mL of CHCI3: NMM: H0Ac (18: 1: o.5) 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin was washed with CHCl3 (6 × 5 mL), 20% HOAc (6 × 5 mL), DCM (6 × 5 mL), and DMF (6 × 5 mL) dissolved in DCM. The synthesis was then re-automated to add 3-cis-butenediiminopropionic acid (step 3). Between each coupling, the resin was washed three times with N, N-dimethylformamide (DMF) and three times with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% benzylthiopentane and 5% phenol, and then re-precipitated with dry-ice-cold Et20 (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) preparative dual-effect HPLC system: using a Phenomenex Luna 1 0 μ benzene with a flow rate of 9.5 mL / min and more than 180 min Gradient dilutions of 30-55% Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN) based on hexyl, 21 mm X 25 cm columns, and λ214 and 254 UV detection of nm (VarianDynamax UVD 丨 丨) to provide the ideal peptide with> 95% purity, which is determined by hplc. -116- 200524957 Example 8-Synthesis of C-terminal lysine residue on Dyn A 1-13 e > Modification of amine group-Synthesis of Dyn Α 1-13 (Nε-MPA) -ΝΗ2 Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-Lys- (N8-MPA) -NH2

This modified Dyn A 1-1 3 solid phase peptide synthesis method at 100 μ mole grade was performed using an artificial solid phase synthesis method, Symphony Synthesizer, and Fmoc protective Rink Amide MB HA Of it. The following protective amino acids are sequentially added to the resin: Fmoc-Lys (Aloc) -OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH, Fmoc-Pro-OH , Fmoc-Arg (Pbf) -OH, Fmoc-lle-OH, Fmoc-Arg (Pbf) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Leu-OH, Fmoc-Phe-〇 H, Fmoc-Gly-OH, FmooGly-OH, Fmoc-Tyr (tBu) -OH. These are sequentially dissolved in N, N-diamidinofluorenylamino (DMF), and 0-benzyl-1-azide-1-yl-N, N, N1, N, -tetrafluorenyl- Urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Removal of the Fmoc protective group was achieved by using a 20% (V / V) N-hexahydropyridyl solution in N, N-diamidinofluorenyl (DMF) for 20 minutes. (Step 1) ° The selective deprotection of the Lys (Aloe) group was performed manually, and by dissolving 3 of 5 in CHCI3: NMM: H0Ac (18: 1: 0.5) eq of Pd (PPh3) 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin was washed with CHC13 (6 X 5 mL), 2Q% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL) dissolved in DCM. . Then, the synthesis was re-automated to add 3_cis Dingguiji -117-! 200524957

Pyrimidate propionate (step 3). Between each coupling, the resin was washed three times with N, N-dimethylamidoamine (DMF) and three times with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% benzylthiomethane and 5% phenol, and then re-precipitated by dry-ice cooling at 20 [step 4). The product was purified by preparative reverse HPLC using a Varian (Ramin) preparative dual-effect HPLC system: using a flow rate of 9.5 1111 ^ / 11 ^ 11 and more than 18〇11 ^ 11 ? 1 ^ 11〇111611 with [11112 10μphenyl-hexyl 30-55% B (0.045% TFA (A) prepared in water and 0.045% D ?? ) Gradient dilution, 21 mmx25 cm column and UV detector (VarianDynamaxUVDII) at λ214 and 254 nm to provide the ideal peptide with> 95% purity, which is determined by RP-HPLC. This product The structure is,

H2K-Tyr-Gty-Gly-Phe-Leu-Ar〇-Ar〇-lle-Ar〇-Pra-Lys-Leu-Ly3 -NH2 CCM008 Example 9-Added C-terminus on Dyn A 2-13 Modification of the ε-amino group of lysine residues-Synthesis of DynA2-13 (Ns-MPA) -NH2 Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-Lys- ( Νε-ΜΡΑ) -ΝΗ2 — 118 — 200524957 Using an automatic version synthesizer, the following protective groups were sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Mtt) -OH, Fmoc-Leu-〇 H, Fmoc-Lys (Boc) -〇H, Fmoc-P 「o-〇H, Fmoc-A」 g (Pbf) -〇H, Fmoc-lle-〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-A, g (Pbf) -〇H, Fmoc-Leu-〇H, FmooPhe-〇H,

Fmoc-Gly-OH and Boc-Gy-OH. The next step is the use of artificial synthesis: in DMF, by using the activation of HBTU / HOBt / DIEA, the Mtt group is selectively removed and combined with MPA. The dynorphin-labeled analog was removed from the resin, and the product was isolated by precipitation and purified by preliminary HPLC to obtain the desired product in a yield of 35%, that is, freeze-dried Followed by a white solid. Anal. HPLC showed a purity of> 95% and Rt = 30.42 minutes. EShMS m / z was C73H123N25〇15 (MH +), the calculated value was 1590.0, and the actual value was MH3 + 531 · 3.

Example 1. Modification of ε-amino group of c-terminal lysine residue added on Q_- Dyn A 1-13-Synthesis of Dyn A 1_13 (AEA3-MPA) -NH2 Tyr-Gly-Gly- Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-

Lys- (AEA3-MPA) -NH2 uses an automatic peptide synthesizer. The following protective groups are sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Mtt) -〇H, Fmoc-Leu-〇H , Fmoc-Lys (Boc) -〇H, Fmoc-Pro-〇H, -119- 200524957

Fmoc-Arg (Pbf) -〇H, Fmoc-lle-〇H, Fmoc-A "g (Pbf) -〇H, FmoccA" g (Pbf) -〇H, Fmoc-Leu-〇H, Fmoc-Phe-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, and Boc-butyr (B〇c) -〇H. And the steps are called i, and two artificial synthetic methods: Activating HBTU / H0Bt / DIEA in 0m F to selectively remove mu-based fluorene, and three -Fmoc-AEA- 0H groups (AEA = amine ethoxyacetic acid) 'Coupled with MPA' and remove Fmoc between each coupling. The dynorphin-labeled analog was removed from the resin, the product was isolated by precipitation and purified by preparative HPLC to 29 The desired product was obtained at a yield of%, that is, a white solid after freeze-drying. Anal. HPLC showed that the product had a purity of > 95% and Rt: = 33.06 minutes. ESUMS m / z was C94H154N29〇23 (MH +), The calculated value is 2057.2, the actual value is MH4 + 515.4, MH3 + 686.9, MH2 + 1029.7.

TFA

TFA TFATFA TFA # Lu Lu · Modification of ε-amino group of c-terminal lysine residue added on 13-Synthesis of Dyn Α 2 · 13 (ΑΕΑ3-ΜΡΑ) -ΝΗ2 Gly-Gly-Phe-Leu-Arg-Arg-Ile -Arg-Pro-Lys-Leu-Lys- (AEA3-MPA) -NH2 Using an automatic win-win synthesizer, the following protective groups are in order -120- 200524957

Added to Rink Amide MBHA resin: Fmoc-Lys (Mtt) -〇H, FmooLeu-〇H, FmooLys (Boc) -〇H, Fmoc-P, o-〇H, Fmoc-A, g (Pbf)-. H, Fmoc-lle-〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-A, g (Pbf) -〇H, Fmoc-Leu-〇H, Fmoc-Phe-〇H, Fmoc-Gly-〇 H, and Fmoc-Gly-〇H. The following steps are used. Artificial synthesis method: In DMF, [^ 丁 11 出 〇 已 {/ 0 丨 has been activated to selectively remove the Mtt group 3, Three Fmoc-AEA-OH groups are coupled to MPA, and Fmoc is removed between each coupling. The analog of the dynorphin is removed from the resin, and the product is separated and isolated by precipitation. It was purified by preparative HPLC to obtain the desired product at a yield of 29%, ie, a white solid after freeze-drying. Anal. HPLC showed that the product had a purity of > 95%, and Rt = 31.88 minutes ES and MS m / z is C85H145N25〇21 (MH +), the calculated value is 1894.3, the actual value is MH4 + 474.6, MH3 + 632.4, MH2 + 948.10.

H2N-G) y-Gfy-Phe-Leu-ArchArg-l ^ -Afy-Prc > -Lys-Lei > -Lys-NH2 CCI-1010 Example 12-Addition of C-terminal ionamine on neuropeptide Y Improvement of ε-amino group of acid residue

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Lys- Preparation of (N-sMPA) -NH2 121-121-200524957 This modified neural version of the Y analog at 100 μm ο I e grade solid phase peptide synthesis method uses artificial solid phase synthesis method, Symphony (Symphony ) Peptide synthesizer and Fmoc protective Rink Amide MBHA. The following protective amino acids are sequentially added to the resin: Fmoc-

Lys (Aloc) -oH, Fmoc-Leu-oH, Fmoc-Ala, oH, Fmoc-Ser (tBu) -oH, Fmoc-Tyr (tBu) -oH, Fmoc-Tyr (tBu) -o H, Fmoc-Arg (Pbf) -OH, FmooAla-OH, Fmoc-Met-OH, Fmoc-Asp (tBu) -OH, Fmoc-Glu (tBu) -OH, Fmoc-Ala-OH , Fmoc-Pro-〇H, Fmoc-Ala-〇H, Fmoc-Asp (tBu) -〇H, Fmoc-Glu (tBu) -〇H, Fmoc-Gly-〇H, FmooPro-〇H, Fmoc-Asn (Trt) -OH, Fmoc-Asp (tBu) -OH, Fmoc-Pro-OH, Fmoc-Lys (Boc) -OH, Fmoc_Ser (tBu) -OH, Fmoc_Pro-OH, Fmoc-Tyr (tBu) -OH. These are sequentially dissolved in n, N-difluorenylfluorenylamine (DMF), and 0-benzylhydrazide-i-yl-N, N, N ,, N, -tetramethyl -Urea-cationic hexafluorodiskate (HBTU) and diisopropylethylamine (DIEA) to activate it. The Fmoc protective group was removed using 20% (V / V) N-hexahydrogen dissolved in N, N-dimethylamidoamine (DMF). This is achieved by a 20-minute solution of pyridyl (step 1). The selective deregulation of the Lys (Aloe) group was performed manually, and by dissolving 5 μL of ^ (3 丨 3: from [\ ^: 锁 〇 八 〇 (18: 1: 〇.5) of 3 69 卩 € 1 (卩? [13) 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin was dissolved in CHC13 (6 X 5 mL), dissolved in 20% HOAc (6 x 5 mL) in DCM, DCM (6 x 5 mL), and DMF (6 x 5 mL) were used to clean it. The synthesis was then re-automated to add 3-cis-butene Dimethylimide Propionate (Step-122- 200524957

Step 3). Between each coupling, the resin was washed twice with N, N-dimethylformamide (DMF) and three times with isopropanol. Use μ% DFA. The peptide was excised from the resin by% TIS / 5% benzylthiomethane and 5% phenol, and then re-precipitated with dry-ice-cooled dagger 20 (step 4). The product was purified by preparative reverse HPLC using a Vanan (Rainin) preparative dual-effect HPLC system: using a Phenomenex Luna 10 μ with a flow rate of 9 · 5 mL / min and more than 180 min. Phenyl-hexyl 30-50% Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN) in a gradient dilution, 21 mm X 25 cm column With II) to provide the ideal peptide with> 95% purity, it was determined by RP-HPLC. AJfe »J13-C: GLP-1 (7-36) modified GLP-1 (7-36) -EDA-MPA on GLP-1 Preparation of this modified GLP-1 analog at 100pmole grade The solid-phase peptide synthesis method was performed manually and performed on a Symphony-like synthesizer SASRIN (Super Acid Sensitive Resin). The following protective amino acids are sequentially added to the resin: Fmoc-AΓg (Pbf) -OH, Fmoc-Gly-OH ^ Fmoc-Lys (Boc) -OH ^ Fmoc-Val-OH-Fmoc- Leu-〇H, Fmoc-T, p (Boc) -〇H, Fmoc-Ala-〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc -Lys (Boc) -〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc--123-200524957

Gln (Trt) -OH, Fmoc_Gly-OH, Fmco-Glu (OtBu) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -〇H, Fmoc-VabuOH, Fmoc-Asp (tBu) -〇H, Fmoc-Ser (tBLi) -〇H, Fmoc-Th, ((tBu) -〇H, Fmoc- Phe-〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Ala-〇H, Boc-His (T``t) -〇 H. They are sequentially dissolved in N, N-dimethylfluorenylamine (DMF), and 0-benzylhydrazide-1-yl-N, N, N ', Nf-tetramethyl -Urea cationic hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. The removal of the Fmoc protective group was performed using a solution of N, N-dimethylformamidine (DMF) 20% (V / V) solution of N-hexahydropyridinyl for 20 minutes (step 1). The complete protective peptide was processed by 1% TFA / DCM Then, it is cut off from the trunk (step 2). Then, the ethylenediamine group and 3-cis-butymine-imine propionate are sequentially added to the free C-terminus (step 3). Protective group and the product uses 85% TFA / 5% TIS / 5% H20 / 5% The hydrazine was separated from 5% phenol, and then was precipitated by dry-ice cooling [20% (step 4). The product was purified by a prepared reverse phase PLC, the η PLC It uses a double-effect PLC system prepared by Va ian (Raini η). The system uses a protection module (gUa`` (j module)) equipped with γnamax C 彳 8, 6〇A, 8 μηι. Dynamax C18, 60A, 8μπι, 21 mmx25cm column, 21 mmx25cm column, and UV detector (x / arianDynamax UVD 丨 丨) at λ214 and 254 nm to obtain purity determined by RP_HPLC > 95 % Ideal DAC. These steps are described in the following chart. — (24-200524957

SASRIN resin step S1 I SPPS γ Boc-HAEGTFTSDVSSYLEGQAAKEHAWLVKGR-language step 2 j 1% TFA / DCIV1 Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-〇H 1. Ethylene diamino group 2. 3-cisbutadiene diiminopropionate 3

Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-0

〇 〇 Step 4 85% TFA / 5% TIS / 5% H2〇 / 5% Phenylthiomethane / 5% Phenol H2N-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-0

〇 〇

GLP-1 (7-36) -EDA-MPA

f Example 1 4-Preparation of C-terminal serine modified Exendin-4 (1_39) -EDA-MPA on Exendin-4 The solid phase peptide synthesis method of 〇〇μmol level was performed manually and performed on a SYRIN (symphony) synthesizer SASRIN (Super Acid Sensitive Resin). The following protective amino acids are sequentially added to the resin: Fmoc-Ser (tBu) -OH, Fmoc-

Pr〇-〇H, Fmoc-P, "〇-〇H, Fmoc-Pro-〇H, Fmoc-Ala-〇H, FmOoGly-OH, Fmoc-Ser (tBu) -OH, Fmoc- Ser (tBu) -〇H, -125- 200524957

Fm〇cP o-OH, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Lys (B〇c) -〇H, FmooLeu-〇H , Fmoc-Trp (Boc) -OH, Fmoc-Glu (〇tBu) -〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Leu-〇H, Fmocc g (Pbf) -〇H, Fmoc-VabuH, Fmoc-Ala-OH, Fmoc-Glu (〇tBu) -OH, Fmoc-Glu (〇tBu) -OH, FmooGlu ( 〇tBu) -〇H, Fmoc-Met-OH, Fmoc-Gln (Trt) -〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ser (tBu) -OH, Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Gly -〇H, Fmoc-Glu (〇tBu) -OH, Fmoc-Gly-OH, Boc-His (Trt) -OH. These are sequentially dissolved in N, N · difluorenylamidoamine ( DMF), and using 0-benzyl azide-1-yl-N, N, N ', N'-tetramethyl-urea cation hexafluorodipate (HBTU) and diisopropylethylamine (D | eA) to activate it. Fmoc protective group is removed using a 20% (V / V) N-hexahydrogen dissolved in N, N-dimethylformamidine (DMF) The cross-linked solution was reached for 20 minutes (step 1). The completeness The protective peptide was excised from the trunk by treatment with 1% TFA / DCM (step 2). Then, the ethylenediamine group and the maleimide diimide propionate were sequentially added to the The free C-terminus (step 3). The protective group is then excised and the product is isolated using 86% TFA / 5% TIS / 5% Η20 / 2% phenylthiomethane and 2/0 phenol Next, it is precipitated by dry-ice cooling (%) (step 4). The product is purified by the prepared reverse phase PLC.

A dual-effect HPLC system prepared by Varian (Rainin). This system uses -126 — 200524957 Dynamax C18, 60A, 8 μηι guard module equipped with Dynamax C18, 60A, 8 μπι, 21 mm x 25 cm column, 21 mm X 25 cm column, and UV detectors (Varian 〇 old 〇13 乂 1 ^ 0 1 丨) at λ214 and 254 _ : Ideal DAC with determined purity> 95%.

SASRIN resin

Buchen 1 1 SPPS V

Boc-HGEGTRSDLSKQMEEEAVRLREWLKNGGPSSGAPPPS · Resin Buchen 2 | 1% TFA / DCM

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-OH 丨. 'Ethylenediamine t 2. 3 · maleimide diimide propionate

Boc-HGEGTFTSDLSKQMEEEAVRLFfEWLKNGGPSSGAPPPS-〇,

0 0 Buchen 4 | 85% TFA / 5% TIS / 5% H20 / 5% Phenylthiomethane / 5% Phenol h2n-hgegtftsdlskqmeeeavrlfiewlknggpssgappps-ck

Eisen Ingot Bucket (1-39) · Ι) Α-ΜΡΑ -127- 200524957 Real soul: Improved ε-amino group of C-terminal lysine residue added to sword-endocrine

His-Ser-Asp-GIy-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Glu-Arg-Leu-Leu-GIn-Gly- Leu-Val-Lys- (N8-MPA) -NH2 ^^

The modified small intestinal endocrin analogue is 100 μm ο I e grade solid-phase synthesis method using artificial solid-phase synthesis method, Symphony peptide synthesizer, and Fmoc protective Rink Amide MBHA. The following protective amino acids are sequentially added to the resin: 010010 Lys (Aloc) -OH 'Fmoc-Val-OH' Fmoc-Leu-OH 'Fmoc-Gly-OH, Fmoc-Gln ( Trt) -〇H, Fmoc-Leu-〇H, Fmoc-Leu-〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Glu (tBu) -〇H, FmooLeu-〇H, Fmoc-A``g (Pbf) -OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Glu (tBu) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Leu-OH, Fmoc- Arg (Pbf) -〇H, Fmoc-Ser (tBu> -〇H, Fmoc-Leu-OH, Fmoc-Glu (tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, FmooThr (tBu) -〇H, Fmoc-Gly-OH, Fmoc-Asp (tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-His (Boc ) -OH. They are sequentially dissolved in N, N-difluorenylaminoamine (DMF), and 0-phenylhydrazide-1-yl-N, N, N1, N ' -Tetrafluorenyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. The removal of the Fmoc protective group is by using a NH, N-difluorenyl group 20% (V / V) N-hexahydropyridinyl group in DMF (DMF)-200524957 / hydration effect is achieved by 20 knives (step process). The Lys (a 〇c) The trapping deprotection of the group was performed manually, and was performed by dissolving 3 eq of pd (5) in CHCI3: NMM: h〇Ac (18: 1: 0.5). The resin was treated with pphA solution for 2 hours (step 2). Then, the resin was made with CHC13 (6 X 5 mL), 20% HAc (6 λ 5 mL) dissolved in dCM towel, DCM (6 x 5 mL), and DMF (6 x 5 mL) to wash it. Then, the osmium synthesis system was re-automated to add cis-butene diimide propionic acid (step 3). Between the mother and the primary light, The resin was washed three times with n, n-dimethyl methylamine (DMF) and three times with isopropanol. 85% TFA / fi% TIS / 5% phenylthioxane and 5% phenol The peptide was excised from the resin and then re-precipitated with dry-ice-cold Et20 (step 4). The product was purified by preparative reverse HPLC using a dual-effect HPLC prepared by a Varian (Rainin) System: Use one that can flow at 9.5 mL / min and can use more than 18〇111111? 11611〇11 ^ 1 ^; (1 ^ 1 ^ 1104 phenyl-hexyl 30-50% 6 (prepared in water 0.045% butyl? Eight (eight) and prepared in 〇 ^ 3〇1 ^ Of 0.045% TFA (B)) in gradient dilution, 21 mm X 25 cm column, and 214 and 254 11 detectors (\ ^ 1 ^ 11〇 ¥ 1 ^ 11 ^); 1] \ ^ Π) to provide the ideal peptide with> 95% purity, which is determined by RP-HPLC. Example 16-Modification of ε-amino group of c-terminal lysine residue added to kringle-5 N Ac-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys- Preparation of (N8-MP Α) -NH2_2TFA 200524957 The modified kringle-5 peptide in a 100 μmole grade solid-phase synthesis method uses artificial solid-phase synthesis and Symphony. Synthesizer and Fmoc protective Rink Amide MBHA. The following protective amino acids are sequentially added to the resin. Fmoc-Lys (Aloc) -OH, FmooTyΓ (tBlJ) -OH, Fmoo A sp (t B u) -〇Η, F m 〇c-T yr (t B u) -〇Η, F m 〇c-Leu-〇 Η, Fmoc-Lys (Boc) -〇H 'Fmoc-A "g (Pbf) -〇H, Fmoc- Pro-〇H. These are sequentially dissolved in N, N-dimethylformamidine (DMF), and using 0-benzyl azide-1-yl-N, N, N *, N , -Tetramethyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Fmoc protective group is removed using a NH A solution of 20% (V / V) N-hexahydropyridinyl in sulfonylamine (DMF) was achieved for 20 minutes (step 1). At the end of the synthesis, ethyl < acid > The needle was acetated at the N-terminus. The selective deprotection of the Lys (Aloe) group was performed manually and by dissolving it in 5 mL of CHCI3: NMM: H0Ac (18: 1: 0.5). 3 eq of Pd (PPh3) 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin was CHCI3 (6 X 5 mL), 20% HAc (6x5mL) dissolved in DCM. ), DCM (6x5mL) w & DMF (6x5mL)

Come clean it. Then, the synthesis system was automatized to add 3-cis-butenediiminopropionic acid (step 3). Between each coupling, the resin was washed three times with one N, N-dimethylphosphonium amine (DMF) and three times with isopropanol. The winner was cut from the resin using 85% TFA / 5% TIS / 5% benzylthiomethane and 5% phenol, and then re-sinked with dry-ice-cold Et20; Dianzhi (step 4). The product was purified by preparative reverse HPLC. The HPLC-130-200524957 was a dual-effect hplC system prepared using a Varian (Rainin). · A flow rate of 9.5 mL / min and the use of more than 180 mjn Phenomenex Luna 10 μ Benzo-Hexyl 30-55. /. Β (0.045 prepared in water) (8 (eight) and eight (eight) of 0.045% d ^ 3: eight (B)) in a gradient dilution, a 21 mm X 25 cm column, and λ 214 and 254 nm UV detectors (Varian Dynamax UVD II) to provide the ideal peptide with> 95% purity, which is determined by rp-hplC. fjfe Example 17 -Kringle- Modification of the ε-amino group of the C-terminal lysine residue added on 5 MPA) -NH2_2TFA is produced using only an automatic peptide synthesizer, and the protective amino acids described below are sequentially added to Rink Amide MUHA resin: 卩 阳 〇〇 [^ 5 (八 丨 〇 ( :)-〇H, Fmoc-Ty "(tBu) 〇H, Fmoc-Asp (〇tBu) -OH, Fmoc-Ty" (tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc)- 〇H, Fmoc-Arg (Pbf) -〇H, FmooPro-OH, Fmoc-Asn (T``t) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc_

Tyr (tSu) OH (step 1). In the deblocking of the Fmoc group, the N-terminus of the resin-bound amino acid was used to prepare 20% N-hexaaza in DMF. Than. Bite treatment about 15-20 minutes. The last step of excision from the resin is performed using the excision mixture as described above. The product was separated by Shen Dian, and purified by preparative ΗPLC to obtain the desired product ', that is, cold; Donggan 131 — 200524957 white solid after drying. The selective deprotection of the Lys (Aloe) group was performed manually, and was performed by dissolving 々3 eq of Pd (PPh3) in CHCI3: NMM: HOAc (18: ΐ: 〇 · 5) in 5 mL · 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin was dissolved in DCM with CHC13 (6 X 5 mL)? 〇% H〇Ac (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL). Then, the synthesis system was re-automated to add 3 · maleimideimidopropionic acid (step 3). Between each coupling, the resin was washed three times with N, N-diamidinofluorenylamine (DMF) and three times with isopropanol. Using 85% TFA / 5% TIS / 5% benzylthiopentane and 5% phenol, the tritium was excised from the resin, and then dried-ice-cooled at £ t20 and then re-sinked in the temple (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) preparative dual-effect HPLC system: using a Phenomenex Luna 10 μphenyl group with a flow rate of 9.5 mL / min and more than 180 min -A gradient dilution of 30-55% B in hexyl (0.045% TFA (A) prepared in water and 0.045% D? 8 (6) prepared in 0 ^ 30 ^), a 21 mm x 25 cm column, and λ214 and A UV detector at 254 nm (Varian Dynamax UVD II) provides the ideal peptide with> 95% purity, which is determined by RP-HPLC. Example 18-Improved ε-amino group of C-terminal lysine residue added on kringle-5 NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly- Gly-Pro-

Trp-AIa-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp- -132-200524957

Preparation of Tyr-Lys- (Ns-IVIPA) -NH2.3TFA

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to the Rink Amide MBHA resin: "〇1〇〇1_ 乂 5 (八 丨 〇〇) -〇H, Fmoc-Tyr ( tBu) 〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc · Tyr (tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Arg (Pbf) -〇 H, Fmoc-P, o-〇H, Fmoc-Asn (Trt) -〇H, Fmoc_Thr (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Tyr (tBu) 〇H, Fmoc- Ala-〇H, Fmoc-Trp-OH, Fmoc-Pro-〇H 'Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Va BOH, Fmoc-Asp (〇tBu) -〇H, FmooGly-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-P 「o-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-A」 g (Pbf) -〇H (Step 1) In the deblocking of the Fmoc group, the N-terminus of the resin-bound amino acid is treated with 20% N-hexahydropyridyl group prepared in bMF for about 15-20 minutes. Coupling system of acetic acid Performed under similar conditions to the amino acid handle. The final step of excision from the resin was performed using the excision mixture as described above. The product was isolated by precipitation and purified by preparative ΗPLC to obtain The desired product, that is, cold A white solid after freeze-drying. The selective deprotection of the Lys (Aloe) group was performed manually, and by dissolving it in 5 1 ^ 之 (^ < 3 丨 3: quest 1 \ / ^: bolt 〇3 (: (18: 1: 0.5) 3 eq of Pd (PPh; 3) 4 solution to the resin for 2 hours to complete the process (step 2). Then the resin is based on CHCI3 (6 X 5 mL ), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DK4F (6 x 5 mL) -133- 200524957 dissolved in DCM. Then, the synthesis was It was then automatized to add Hongshun dilute diimine propionate (step 3). Between each combination, the tree deer was washed three times with N, N-difluorenyl amidoamine (DMF) and treated with Isopropyl alcohol was washed twice. The 85% TFA / 5% TIS / 5% benzylthiopentane and 5% phenol were used to cut off the winner from the resin, and then re-sinked with dry-ice-cold ElO; (Step 4). The product was purified by preparative reverse HPLC, which uses a Varian (Rainin) preparative dual-effect HPLC system. · A flow rate of 9.5 mL / min can be used for more than 180 min. Phenomenex Luna 10 μphenyl-hexyl 30-50% B (prepared A gradient dilution of 0.045% TF A (A) in water and 0.045% TFA (B) in CH3CN, 21 mm X 25 cm column, and UV detector (Vanan Dynamax at λ 214 and 254 nm) UVD II) to provide the ideal peptide with> 95% purity, which was determined by RP-HPLC. Example 19-Modification of ε-Cytomeric Addition of C-Terminal Amino Acid Residue on Kringle-5 NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly- Pro-Trp-Lys- (Ne-MPA) -NH2.TFA is produced using only an automatic peptide synthesizer. The following protective amino acids are sequentially added to Rink Amide MBHA resin: "171〇〇1 ^ (8) -〇H, Fmoc-Trp-OH, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Val-〇H, Fmoc-Asp ( 〇tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Pr〇-〇H, 134- 200524957

Fmoc-Asn (Trt) -OH, Fmoc-Arg (Pbf) -OH (Step 1) The selective deprotection of the Lys (Aloe) group is performed manually, and by dissolving 5〇 ^ 之 〇 ^ 1 (: 丨 3: ~ ^^^ 1 汨 〇80 (18: 1: 0.5) of 3 69

Pd (PPh3) 4 solution was processed for 2 hours to complete the resin (step 2). The resin was then washed with CHC13 (6 X 5 mL), 20% HOAc (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) dissolved in DCM. . The synthesis was then re-automated to add 3 -cis-butene diimine

Propionate (step 3). Between each coupling, the resin was washed three times with N, N-diamidinofluorenylamine (DMF) and three times with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% phenylthiomethane and 5% phenol, and then re-precipitated with dry-ice-cold Et20 (step 4). The product was purified by preparative reverse HPLC using HPLC

A dual-effect HPLC system prepared by Varian (Rainin): using a Phenomenex Luna 10 μ phenyl-hexyl 30-55% Β (prepared in water at a rate of 9.5 > mL / min and more than 1 80 min) % TFA (Α) and 0.045% TFA (B)) in CH3CN, a gradient dilution, 21 mm X 25 cm column, and UV detector (Varian Dynamax UVD II) at λ214 and 254 nm to provide The ideal victory of> 95% purity is determined by RP-HPLC. Example 20-Modification of the ε-amino group of the C-terminal acid residue on kringle_5 N Ac-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys- (N8 -MPA)-Preparation of NH2.2TFA — 135- 200524957 Using an automatic version synthesizer, the following protective amino acids are sequentially added to Rink Amide MBHA resin: Fm0C-LyS (A 丨 0C) -OH ^ Fmoc-Tyr (tBu) OH > Fmoc-Asp (OtBu) -OH ^ Fmoc-

Ty "(tBu) 〇H, Fmoc-Leu_〇H, Fmoc-Lys (Boc) -〇H,

FmoccAg (Pbf) -OH (step 1). In the deblocking of the Fmoc group, the N-terminal system of the resin-bound amino acid was prepared to 20% N-hexahydrogen in dmF ° Specific bite treatment is about 15-20 minutes. The coupling of acetic acid is performed under similar conditions to the coupling of amino acid. The last step of excision from the resin is performed using the excision mixture as described above. The product is borrowed Isolated from Shen Di'an and purified by preparative HPLC to obtain the desired product, ie, cold) East: white solid after drying. The selective deprotection of the Lys (Aloe) group was performed manually, And it was completed by treating the resin with a 3 eq Pd (PPh3) 4 solution in 5 mL of CHC 丨 3: NMM: HOAc (18: 1: 0 5) for 2 hours (Step 2 ). Then, the resin was based on CHC13 (6 X 5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 x 5 mL) dissolved in DCM. Wash it. Then, the synthesis system is re-automated to add 3 · maleimide diimidopropanoic acid (step 3). Between each coupling, the resin is N, N-difluorenyl Amine (DMF) was washed three times with different Wash three times with alcohol. Use 85% TFA / 5% TIS / 5% phenylsulfanoxane and 5% phenol to cut off the winner from the fat, and then dry-ice-cold £ (; 20 re-sink; Dian (Step 4). The product was purified by preparative reverse HPLC. The hplch +, a dual-effect HPLC system prepared using a Varian (Rainin): using a Koji 200524957 speed of 9.5 1111 ^ / 111 丨 11 and can be Use more than 18〇111 丨 11?} 1611〇111 £ 1 ^ \ 1> 11 [12 10 μbenzyl-hexyl 3 0-55% B (0.04 59c TF A (A) prepared in water and prepared A gradient dilution of 0.045% TFA (B)) in CH3CN, a 21 mm x 25cm column, and a UV detector (Varian Dynamax UVD II) at λ214 and 254 nm to provide the ideal of> 95% purity The peptide is determined by RP-HPLC. • f. Although Example 21 • The modified ε-amino group of the c-terminal amine acid residue added to kringle-5, N Ac- Pro-Arg-Lys-Leu-Tyr-Asp-Lys- (Ns-MPA) -NΗ2 · 2 Butan FA was prepared using an automatic peptide synthesizer, and the following protective amino acids were sequentially added to Rink Amide MBHA tree ii: Fmoc-Lys (AI〇c) -〇H, Fmoc-Asp (〇tBii ) -〇H, FmooTy "(tBu) 〇H, Fmoc-Spring Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-A" g (Pbf) -〇H,

Fmoc-P'o-OH (step 1). In the deblocking of the Fmoc group, the N-terminus of the resin-bound amino acid was treated with 20% N-hexahydropyridyl prepared in dmf Approximately 15-20 minutes. The coupling of acetic acid is performed under similar conditions to the coupling of amino acids. The final step of excision from the resin is performed using the excision mixture as described above. The product is separated by precipitation And purified by preparative HPLC to obtain the desired product, that is, a white solid after freeze-drying. 的 Selective deprotection of Lys (Aloe) group. Manually performed, a 137-200524957 and by A solution of 3 eq in Pd (PPh3) 4 dissolved in 5〇 ^ (^ 〇 丨 3: ~ [\; ^, 〇 八 (: (18: 1: 0.5)) was completed for 2 hours to complete the treatment. (Step 2) Then, the resin was washed with CHCI3 (6 X 5 mL), 20% HOAc (6x5mL), DCM (6x5mL), a & DMF (6 x 5 mL) dissolved in DCM. ... and then the synthesis was re-automated to add 3_

Maleimide diimide propionate (step 3). Between each coupling, the resin was washed three times with N, N-dimethylformamide (DMF) and three times with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 50/0 benzylthioxane and 5% phenol, and then re-sinked with dry-ice-cold Et20 (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) preparative dual-effect HPLC system: using a Phenomenex Luna 10 μ phenyl- with a flow rate of 9.5 mL / min and more than I80 min A gradient dilution of 30-55% Β in hexyl (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21mm X 25 cm column, and UV at λ214 and 254 nm Detector (Varian Dyn am ax UVD M) to provide the ideal peptide with> 95% purity, which is determined by Rp-HPLC. Ai Wei Case 22-kr ingle-5 ε-amino group modified C-terminal lysine residue added N Ac-Pro-Arg-Lys-Leu-Tyr-Asp-Ty r -Lys- (Ne-AEEA-MPA) _NH2.2TFA is produced using an automatic synthesizer. The following protective amino acids are added to Rink Amide MBHA resin in the order of -138-200524957. FmodyyAfoc) -〇H, Fm0oTy "(tBu) 0H, Fm0oAsp (〇tBu)-0H, Fm0c_

Ty "(tBu) OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH,

Fmoc-A "g (Pbf) -OH, Fmoc-P" o-OH (step 1). In the deblocking of Fmoc-based fluorene, the N-terminus of the resin-bound amino acid was prepared in The 20% N-hexahydropyridyl group in DMF is treated for about 15-20 minutes. The coupling of acetic acid is performed under conditions similar to those of amino acids. The selective deprotection of the Lys (Aloe) group It was performed manually and completed by treating the resin for 2 hours with a solution of 3 eg Pd (PPh3) 4 in 5 mL of CHCI3: NMM: H0Ac (18: 1: 0.5) (step 2). Then, the resin was CHC13 (6 λ 5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 x 5 mL) dissolved in DCM. To clean it. Then, the synthesis system was re-automatically added. Then, the synthesis system was re-automated to add AEEA (amine ^ ethoxyethoxyacetic acid) group and 3-cis-butene diimide propionate. Takahata Yataka) (Step 3). Resin removal and product separation are performed using 85% TFA / 5% TIS / 5% phenylthiomethylbenzene and 5% phenol ', and then precipitated by dry_icy elo And proceed (step 4) ° The product is prepared in the reverse direction η plc For purification, the η PLC is a dual-effect HPLC system prepared by a Varian (Rainin): a phenomenex Luna with a flow rate of 9.5 mL / min and more than min. 30 μ-55% of benzyl-hexyl b (0.445 / 〇TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), a gradient dilution, a 21 mm x 25 cm column, and a UV detector at λ214 and 254 nm ( Varian Dynamax UVD II). -139- 200524957 Example 23-Kenning can Uringle) -5 Modified ε-amino group of C-terminal lysine residue added on N Ac-P ro_Arg-Lys-Leu- Ty r-Asp-Ty r-Lys- (Ns_AEE Αη · MPA) -NH2.2TFA was produced using an automatic peptide synthesizer, and the following protective amino acids were added to Rink Amide MBHA resin in the order : Fmoc-Lys (Aloc BUH, Fmoc-Tyr (tBu) OH, FmooAsp (〇tBu) -OH, Fmoo Ty "(tBu) OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH, Fmoc-A "g (Pbf) -OH, Fmoc-P" o-OH (step 1). In the deblocking of the Fmoc group, the N-terminus of the amino acid bound by the resin was used to prepare 20% N-hexahydrogen in DMF. It is about 15-20 minutes longer than pyridyl treatment. The conversion of acetic acid is carried out under conditions similar to those of amino acids. The selective deprotection of the Lys (Aloe) group was performed manually, and was modified by dissolving 3 eq of CHC in 5 mL of 3: NMM: H0Ac (18: 1: 0 · 5). Pd (PPh3) 4 solution was processed for 2 hours to complete the resin (step 2). Then, the resin was washed with CHCI3 (6 X 5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 x 5 mL) dissolved in DCM. . The synthesis was then added automatically. 'The synthesis was then re-automated to add AEEA (amineethoxyethoxyacetic acid) groups and 3-cis-butenediiminopropionic acid (MpA) (step 3). Resin excision and product separation were performed using 85% Tfa / 5% TIS / 5% bulky methylbenzene and 5% phenol, and then carried out by Shen Dian'er 140-200524957. (Step 4). The product was purified with a prepared reverse hplc. The HPLC was a dual-effect HPLC system prepared using a varian (Rainin): using a Phenomenex Luna 10 μ phenyl with a flow rate of 9.5 mL / min and more than 180 min. -A gradient dilution of 30.5% of hexyl b (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), a 21mm X 25 cm column, and λ214 and 254 nm UV detector (Varian Dynamax U VD 11).

Practical Example-Improvement of ε-Amine Group of C-Terminal Amino Acid Residue on GLP_1

Production of GLP㈣ 1 (1-36) -Lys37 (Ns_MPA) -NH2.5TFA; His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp- Val-Ser-Ser-Tyr-Leu-Glu-GIy-GIn-Ala-Ala-Lys-Glu-Phe-lle-Ala-T rp-Leu-Val-Lys-Gly-Arg-Lys (N8-MPA)- NH2.5TFA uses an automatic peptide synthesizer, and the following protective amino acids are sequentially added to Rink Amide MBHA resin: "111〇〇1 ^ 5 (八 100〇) -〇H 、 Fmoc-Arg (Pbf) -〇H, Fmoc-Gly-OH, Fmoc-Lys (tBoc) -〇H, Fmoc-VabuH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH , Fmoc-lle-OH, Fmoc-Phe-OH, Fmoc-Glu (〇tBu) -OH, Fmoc-Lys (tBoc) -OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln (T``t) -〇H, Fmoc-Gly-OH, Fmoc-Glu (〇tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Tyr (Pbf)-200524957 〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoo Va BOH, Fmoc-Asp (〇tBu) -OH, Fmoc-Se, ((tBu) -OH, ^ Fmoc-Thr ( tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBu) -〇H,% Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -OH,

Boc-His (N-T 「t) -〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Phe-OH, Fmoc-Glu (〇tBu) -〇H,

Fmoc-Asp (〇tBu) -〇H, Boc-His (NT "t) -〇H (step 1). • The selective deprotection of the Lys (Aloe) group is performed manually, and by Pd (PPh3) 4 solution dissolved in 3 eg of 5 111 B (: ^ 1 < 313: Q [\ / 11 ^ 卞 〇 八 〇 (18: 1: 0.5)) to treat the resin for 2 hours (Step 2). Then, the resin was CHC13 (6 X 5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 x 5 mL) to clean it. Then, the synthesis system was re-automated to add 3 · cis butyrimidine imine propionate (step 3). Resin removal and product separation system used 85% TFA / 5% TIS / 5% phenylthioxane and 5% phenol, and then precipitated by φ dry-ice-cold Ets0 (step 4). The product was purified by preliminary reverse HPLC, which was A dual-effect HPLC instrument prepared with a vaian (Rainjn) was used. A Phenomenex Luna 10 μ stupid, 30% 55 ° / 55 ° / 〇Β (flow rate 9.5mL / min and more than 180 minutes) can be used. Gradient dilution of 0.045% TFA (Α) prepared in water and 0.045% TFA (B)) prepared in CH3CN Liquid, μ mmx25 cm column at λ214 and 254 nm, and the UV detector (va 'jan

Dynamax UVD II). The product must have a purity of> 95% as determined by the RP_HPIX mass spectrometer. The mass spectrometer uses a continuous Hewlett Packard LCMS-1 1 00 equipped with a secondary body -142 '200524957 array detector. Spectrometer and method for ionizing two electrosprays. These steps are described in the following diagram.

Fmoc-Rink Amide MBHA resin

Buijij SPPS

Boc-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys (Aloc) -PS

Buchen 2j ^ Pd (PPh.), / NMM / HOAc / CHCL

Boc-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-PS

〇

Boc-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-N. H〇 Step 85 ° /. TFA / 5. /. TlS / 5 ° /. Phenylthiomethane / 5% phenol

TFA

TFA

〇 NhL

TFA

H. N-HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR- N H〇

TFA GLP-1 (1-36VLvs ^ fE-MPAVNH.

Example 25-Modification of ε-amino group of C-terminal lysine residue added to GLP-1 GLP-1 (1-36) -Lys37 (Nk-AEEA-AEEA-MPA) -NH2.5TFA preparation;

His-Asp-Glu-Phe-Glu-Arg-His-AIa-Glu-Gly-Thr-Phe-Thr-

Ser-Asp-Val-Ser-Ser-Tyr-Leu-GIu-Gly-Gln-AIa-Ala-Lys- -1 Δλ- 200524957 GIu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg -Lys (N6-AEEA-

AEEA-MPA) -NH2.5TFA

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin: "〇1〇〇 [^ 3 (八 丨 〇〇) -〇H, Fmoc-Arg (Pbf ) -〇H, Fmoc-Gly-OH, Fmoc-Lys (tBoc) -OH, Fmoc-VabuH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-GIu (〇tBu) -〇H, Fmoc-Lys (tBoc) -〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc -Gln (Trt) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Tyr (Pbf) -〇H, FmooSer (tBu) _〇 H, FmooSer (tBu) -〇H, Fmoc-

Va Bu〇H, FmooAsp (〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, »·

Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBii) -〇H, F moc-GI y -〇H, F moc-GI u (〇t B u) -〇H , F moc A1 a -〇H, Boc-His (N-Trt) -〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Phe-〇H, Fmoc -Glu (〇tBu) -OH, Fmoc-Asp (〇tBu) -OH, Boc-His (N-Trt) -OH (step 1). The selective deprotection of the Lys (Aloe) group was performed manually and by using 3 eq of Pd (PPh; 3) in 5 mL of CHCI3: NMM: HOAc (18: 1: 0.5). 4 solution to process the resin for 2 hours to complete (step 2). Then the resin was made with CHCl3 (6 X 5 mL), 20% HAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL) dissolved in DCM.

Come clean it. The synthesis was then re-automated to add two AEEA-144-200524957 (amine ethoxyethoxyacetic acid) groups and the 3 · maleimideiminopropionate (step 3). Removal of resin and separation of products are precautionary. /. tfa / 5% TIS / 5% benzylthioxane and 5% phenol, and then precipitated by dry-icing (step 4). The product was purified with preparative reverse HpLC. The HPLC uses a Varian (Rainin) preparative dual-effect P LC. Use a flow rate of 9 · 5 mL / miπ and can use more than 1 80 Which? ^ 16 Gate 0 Yang Yang Yang Father 1 ^ 叩 1 (^ Benyl_hexyl 30_55% 8 (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN) gradient dilution , 21 mmx25 cm column, and UV detector (Varian Dynamax UVD II) at λ214 and 254 nm. The product must have a purity of> 95% determined by RP-HPLC mass spectrometer. This mass spectrometer is used A continuous spectrometer equipped with a Hewlett Packard LCMS-1100 equipped with a secondary body array detector and an electrospray ionization method. The ES MS MS / z is C174H26'5N44〇56 (MH +) and the calculated value is 3868. , The actual value is [M + H2] 2+ 1 934, [M + H3] 3+ 1 290, [M + H4] 4+ 967. These steps are described in the following chart. -145- 200524957

Fmoc-Rink Amide MBHA resin

Buchen ij SPPS

巳 oc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys (Aloc > PS

Step 2j ^ Pd (PPh.) ./NMM/HOAc/CHCL

Boc-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-PS Step carbonyl 3j 1. Fmoc-AEEA-〇H (2 times) 2. 3-ButenediSimine Propionic Acid

Boc-HAEGTFTSDVSSYLEG〇AAKEFIAWLVKGR-

〇 〇 〇 〇 M 〇 Buchen 4j j 85. /. TFA / 5. /. TlS / 5 ° /. Phenylthiomethyl $ / 5% Phenol TFA TFA TFA H. N-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR- CCI-1051 TFA GLP-1 (7-36-K (ΑΕΕΛ, »ΜΡΑ))-ΝΗ.

〇 〇 〇

Example 26-Modification of the epsilon-amino group of the added C-terminal lysine residue on GLP-1

Preparation of GLP-1 (7-36) -Lys37 (Nk-MPA) -NH2.4TFA His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-GIn-Ala-AIa-Lys-Glu-Phe-lle-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys (Ns-MPA) -NH2.4TFA uses an automatic peptide synthesizer, which The following protective amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Aloc)--146 200524957 〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Gly-〇H , Fmoc-Lys (tBoc) -〇H, Fmoc-VabuH, FmooLeu-〇H, Fmoc-T, p-〇H, Fmoc-Ala-〇H, Fmoc-lle-〇H, Fmoc-Phe- 〇H,

Fmoc-Glu (〇tBu) -〇H, Fmoc-Lys (tBoc) -〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc-Gln (T``t) -〇H, Fmoc-Gly -〇H, Fmoc-Glu (OtBu) -OH > Fmoc-Leu-OH > Fmoc-Tyr (Pbf) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Se "(tBu) -〇 H, Fmoc-VakOH, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, FmooThr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBu) -〇 H, Fmoc-Gly-OH, Fmoc-Glii (〇tBu) -OH, Fmoc-Ala-OH, Boc-His (NT "t) -OH (step 1). The Lys (Aloe) group The selective deprotection effect is carried out manually, and by dissolving one of (: ^ ~ 1 (: 丨 3: ~ [\ / ^, 〇 八 (: (18: 1: 0_5)) dissolved in 5〇11 3 eq of Pd (PPh3) 4 solution was used to process the tree > fat for 2 hours to complete (step 2). Then, the resin was CHC13 (6 X 5 mL), 20% HAc in DCM (6 X 5 mL ·), DCM (6 x 5 mL), and DMF (6 x 5 mL) to clean it. Then 'the synthesis was re-automated to add the 3-cis-butene-imine propionate (Step 3). Resin removal and product separation are performed using 85% TFA / 5% TIS / 5% benzylthioxane and 5% phenol, and then by -Ice-cold EtaO was precipitated and carried out (step 4). The product was purified by preparative reverse HPLC using a Va "ian (Rainin) preparative dual-effect Η P LC system using a flow rate Is g. 5 m L / mi η and can use more than 18,171, and 9 of 9 gates, 716 gates, 0 parent, 1 »11 gates, 3 10 and 30-55% of phenyl-hexyl β (prepared in 0.045% in water DFA (Aj and 0.045% TFA (B) prepared in -147- 200524957 CH3CN), a gradient dilution, 21 mmx25 cm column, and UV detection at λ214 and 254 nm (Varian Dynamax UVD 丨 丨). The product must have a purity of> 95% determined by the RP-HpLc mass spectrometer, which uses a Hewlett Packard LCMS- 1 1 00 continuous spectroscopic juice and using electrospray ionization method. fExample 27-Modified GLP-1 (7-36) -Lys37 (Ns-AEEA-AEEA-MPA) -NH2 with ε-amino group of C-terminal lysine residue added to GLP-1. 4TFA Preparation

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-

Leu-Glu-Gly-GIn-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-

Val-Lys-Gly-Arg-Lys (N8 " AEEA-AEEA-MPA) -NH2.4TFA

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin: "111〇〇1 ^ 5 (八 丨 〇 (:)-〇H, Fmoc-A" g (Pbf) -OH, Fmoc-Gly-OH, Fmoc-Lys (tBoc) -OH, Fmoc-VaBOH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH. H, Fmoc-lle-〇H, FmooPhe-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Lys (tBoc) -〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc -Gln (Trt) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Tyr (Pbf) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc- -148-200524957

Va Bu〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Th ((tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Ala-〇H,

Boc-His (N-Trt) -OH (step 1). The selective deprotection of the Lys (Aloe) group is preferably performed manually, and is performed by dissolving 3 eq of Pd (5 in CHCI3: NMM: H0Ac (18: 1: 0.5) in 5 mL). PPh3) 4 solution to process the resin for 2 hours to complete (step 2). Then the resin was CH C13 (6 X 5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL) dissolved in DC M. Come clean it. Then the synthesis system was re-automated to add two AEEA (amine ethoxyethoxyacetic acid) groups and the 3-cis-butene diamidoimine propionate (step 3). Resin removal and product separation were performed using 85% TFA / 5% TIS / 5% phenylthiomethane and 5% phenol, and then sacrificed by dry-cooling Ets0 (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) dual effect Η PLC system: using a Phenomenex Luna with a flow rate of 9.5 m L / miη and more than 180 min 10 μ phenyl-hexyl 30-55% Β (0.0450 / 0 TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mm X 25 cm Column and UV detector (VarianDynamax UVD II) at λ214 and 254 nm. The product must have a purity of> 95% determined by an RP-hplc mass spectrometer using a Hewlett Packa "d LCMS-1 100 continuous spectrometer equipped with a secondary body array detector. And using electrospray ionization. -1A9- 200524957

Example 28-Modified D-Ala2 GLP-1 (7-36) -Lys37 (Ne-MPA) -NH2 with the ε-amino group of the C-terminal lysine residue added to D-Ala2 GLP-1. 4TFA system

His-d-Ala-GIu-Gly-Thr-Phe-Thr-Ser-Asp-Val-

Ser-Ser-Tyr-Leu-Glu-Gly-GIn-Ala-Ala-Lys-Glu-

Phe-lle-Ala-Trp-Leu-Val-Lys-Gly-Arg-

Lys (Ns-MPA) -NHh2.4TFA uses an automatic peptide synthesizer, and the following protective amino acids are sequentially added to Rink Amide MBHA resin: 卩 111〇1 ^ 5 (八 １０〇) -〇H, Fmoc-A, g (Pbf) -〇H, FmooGly-〇H, Fmoc-Lys (tBoc) -〇H, Fmoc-VaU〇H, Fmoc-Leu-〇H, Fmoc-Trp-〇H , Fmoc-Ala-OH, Fmoc-ll1e-OH, Fmoc-Phe-OH, Fmoc-Glu (〇tBu) -OH, Fmoc-Lys (tBoc) -OH, Fmoc-Ala-OH, Fmoc-Ala-〇H, Fmoc-Gln (T``t) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Tyr (Pbf) -〇H, Fmoc-Ser (tBu) -〇H, FmooSer (tBu) _〇H, Fmoc_ VabuH, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc -Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-d-Ala- 〇H, Boc-His (N-Trt) -〇H (step 1). The selective deprotection of the Lys (Aloe) group was performed manually, and by using a solution of 5 mL of CHCI3: NMM: -150- in H〇Ac (.18: 1: 0.5)

200524957 3 eq of Pd (PPh3) 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin is based on chC13 (6 X 5 mL),-) dissolved in DCM-) 0% H0Ac (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 x 5 mL). Clean it. The synthesis was then re-automated to add 3-cis-butanylimine propionate (step 3). Resin removal and product separation were performed using 85% TFA / 5% T1S / 5% phenylthiomethane and 5% phenol, and then precipitated by dry-icy E t20; step 4 (Step 4 ). The product was purified by preparative reverse HPLC using a Varian (Rajnin) dual effect Η PLC system: using a Phenomenex Luna 10 with a flow rate of 9.5 m L / m iη and more than 180 min. 30-55% μ phenyl-hexyl Β (4.05% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN) in a gradient dilution, μ mm χ 25 cm column And UV detectors at λ 214 and 254 nm (varjan Dynamax UVD 丨 丨). The product must have a purity of> 95% as determined by an rP seven pLC mass spectrometer using a continuous spectrometer equipped with a Hewlett Packard LCMS-11〇〇 equipped with a secondary body array detector and An electrospray ionization method was used. These steps are described in the following diagram. — 151- 200524957

Fmoc-Rink Amide MBHA Resin Step 1 SPPS v

Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys (Aloc) -PS

) YPd (PPhJ7NMM / HOAc / CHCL

Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-PS Buchen 3] 3-cis-butene-diimide-propionate T Η /. Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR- Νϊί 93 _, Η〇 I 4jj 85% TFA / 5. /. TIS / 5% Phenylthiomethane Academy / 5% Phenol

TFA

TFA H. N-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR- N H〇 TFA D-Ala ^ GLP-1 (7-36) -Lvs ^ fE-MPA) -NH.

TFA

NhL

Example 29-Modification of ε-amino group of C-terminal lysine residue added to D-Ala2 GLP-1 D-Ala2 GLP-1 (7-36) -Lys37 (N8-AEEA-AEEA- MPA) -NH2.4TFA Preparation -Phe-lle-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys (Nε-ΑΕΕΑ-ΑΕΕΑ-MPA) -NH2.4TFA Using an automatic peptide synthesizer, the following protective amino acids are By 200524957

Added to Rink Amide MBHA resin: "! 71〇〇1 ^ 5 (八 丨 〇 ::-OH, Fmoc-Arg (Pbf) -OH, Fmoc-Gly-OH, Fmoc-Lys (tBoc ) -OH-Fmoc-Val-OH 'Fmoc-Leu-OH ^ Fmoc-Trp-〇H, Fmoc-Ala-〇H, Fmoc-Me-〇H, Fmoc-Phe-〇H, Fmoc-Glu (〇tBu ) -〇H, Fmoc-Lys (tBoc) -〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, Fmoc-Gln (T``t) -〇H, Fmoc-Gly-〇H, Fmoc- Glu (〇tBu) -〇H, FmooLeu-〇H, Fmoc-Ty "(Pbf) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc · VahOH, Fmoc -Asp (〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Gly -OH, FmooGlu (〇tBu) -OH, Fmoc-d-Ala-OH, Boc-His (NT "t) -OH (step 1). Selective deprotection of this Lys (Aloe) group The action was performed manually, and by using a solution of 3 eq in Pd (PPh3) 4 dissolved in 5 ~ ^^^^ 3: ~ 1〇11 ^ old〇80 (18: 1: 0.5). The resin was treated for 2 hours to complete (step 2). Then, the resin was CHC13 (6 X 5 mL), 20% HAc (6 X 5 mL) dissolved in DCM, and DCM (6 X 5 mL). ), And DMF (6 X 5 mL) To clean it. Then, the synthesis system was re-automated to add two AEEA (ethoxyethoxyacetic acid) groups and the 3-maleimide dipropionate (step 3). Resin removal The product was separated using 85% TFA / 5% TIS / 5% phenylthiomethane and 5% phenol, and then precipitated by dry-ice-cold Et2O (step 4). The product was Purified by reversed-phase HPLC, which uses a Varian (Rainin) -prepared dual-effect HPLC system: using a flow rate of 9.5 mL / min and using more than 1 80 — 153- 200524957

min-^ Phenomenex Luna 10 μ 30-55 0 / 〇B of benzyl-hexyl (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), gradient dilution, 21mmx25cm tube Column and UV accumulator (Varian Dynamax UVD II) at λ214 and 254 nm c The product must have a purity of> 95% as determined by a RP--PLC mass spectrometer. This mass spectrometer uses a Hewlett Packard LCMS-1100 continuous spectrometer for secondary body array detector and using electrospray ionization method. These steps are described in the following diagram. Gong 1

Fmoc-Rink Amide MBHA Resin SPPS

BooHaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys (AI) -PS Step 2] JPd (PPK.) ./ NMM / HOAc / CHCl

Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Lys-

Boo

"FA 3 1. Fmoc-AEEA-〇H (2 times) 2. 3-cis-butene-diimine-propionamidine% 丨

PS o a) I 85% TFA / 5% TIS / 5% phenylthiomethyl f / 5. /. phenol

K mHaEGTFTSDVSS ^ LEGQAAKEFIAWLVKG ^ I

TFA TFA

PS 〇

3ί ^ / 5% ^ Q

Ό 〇

TFA D-Ala ^ GLP-1 (7-36νίν§7Ε-ΑΕΕΑ.-ΜΡΑ) -ΝΚ. -154- 200524957 Example 30-Addition of C-terminus on Isodium-4 (1-39) Improvement of ε-amino group of amino acid residue

Debt-making of Eisen-4 (1-39) -Lys4 ° (Ns-MPA) -NH2; His-Gly-GIu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn- Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-lle-Glu-Trp-Leu-Lys-Asn-GIy-GIy-Pro-Ser-Ser-Gly-AIa-Pro-Pro-Pro- Ser-Lys (Ns-MPA) -NH2.5TFA

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin: 卩 171〇〇1 ^ 5 (八 丨 00:)-〇H, Fmoc, Ser (tBu ) -〇H, Fmoc-Pro-〇H, Fmoc-Pro-〇H, Fmoc-Pro-〇H, Fmoc-Ala-〇H, FmooG 丨 y-〇H, Fmoc-Ser-〇H, Fmoc-Ser (tBu) -OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc_Gly-OH, Fmoc-Asn (Trt) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Leu- 〇H, Fmoc-Trp-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-lle-〇H, Fmoc-Phe-OH, Fmoc-Leu-OH 'Fmoc-Arg (Bpf) -〇H' Fmoc-Val-OH 'Fmoc-Ala-〇H, Fmoc-Glu (〇tBu) -〇H, FmooGlu (〇tBu) -〇H, FmooGlu (〇tBu) -〇H, Fmoc-Met-〇H, Fmoc -Gln (Trt) -〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Leu-〇H, Fmoc_Asp (〇tBu) -〇H, Fmoc-Ser (tBu ) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Gly-OH, Boc-His (T "t) -OH (step 1). -155- 200524957 The selective deprotection of the Lys (Aloe) group is preferably performed manually, and by using One soluble in 5 ^ 之 (^ (: 丨 3, ^; 1 [\ / 1 汨 〇 八 (: (18: 1.05)) 3 eq of Pd (PPh3) 4 solution to process the resin for 2 hours to complete ( Step 2). Then the resin is based on c HC 丨 3 (6 X 5 mL), dissolved in 〇◦μ t20% HOAc (6x5mL), DCM (6x5mL), w & DMF (6 X 5 mL ) To clean it. Then, the synthesis system was re-automated to add two AEEA (fc ethoxyethoxyacetic acid) hydrazones and the 3-cis-butyric acid: propionic acid (step 3). Resin removal and product separation were performed using 85.0 / Q TFA / 5% TIS / 5% phenylthiomethane and 5% phenol, and then precipitated by dry and ice-cold E ^ 〇 (step 4 ) ^ The product was purified by preparative reverse HPLC. This HPLC uses a Varian (Rainin) dual effect Η PLC system. · A flow rate of 9 · 5 m L / miη and a flow rate of more than 180 ° C can be used. Gate & 116 gate 〇1116 叩 \ 1_11113 10-5 phenyl-hexyl 30-55% Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN) gradient dilution Liquid, 21 mm x 25 cm column, and UV detector at λ214 and 254 nm (χ / arianDynamax U V D I 丨). The product must have a purity of> 95% as determined by an RP-Η PLC mass spectrometer using a Hewlett Packard LCMS-1 100 spectrometer equipped with a secondary body array detector. And using electrospray ionization. These steps are described in the following diagram. -156- 200524957

Fmoc-Rink Amide MBHA Resin SPPS Buchen 1

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-Lys (A! Oc) -PS Pd (PPh.) ./NMM/HOAc/CHCL

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-Lys-PS Step 3

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-N Η〇 3-maleimide diimide propionate

PS Step 4U 85% TFA / 5. /. T1S / 5% Phenylthiomethane Academy / 5% Phenol

TFA

TFA

TFA

H. N > HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS- N H〇 TFA

PS

Exendin-4 (1-39Rvs ^ (E-MPAVNH,

Example 31-Modification of the ε-amino group of the C-terminal lysine residue added to Eisenze-4 (1_39) (Eisenzee-4 (1-39) -Lys4C) (NbAEEA-AEEA- Preparation of MPA} -NH2_5TFA; His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn- Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe -lle-Glu-Trp-Leu- Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser- Lys (N8-AEEA-AEEA-MPA) -NH2.5TFA- 157- 200524957

Using an automatic Victory Synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin: "111〇〇1 ^ 5 (八 丨 〇 (:)-〇H, Fmoc-Ser (tBu ) -〇H, Fmoc-P "o-〇H, Fmoc-P" o-〇H, Fmoc-Pro-〇H, FmooAla-〇H, Fmoc-Gly-〇H, Fmoc-Se "-〇H, Fmoc-Ser (tBu) -OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Asn (Trt) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Leu-〇H, Fmoc-Trp-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Leu-OH-Fmoc-Arg (Bpf ) -〇H > Fmoc-Val-OH-Fmoc-Ala-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Glu (〇tBu) -〇 H, Fmoc-Met-〇H, Fmoc-Gln (Trt) · OH, Fmoc-Lys (Boc) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Asp ( 〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Buthr (tBu) -〇H, Fmoc-Gly-〇 H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Gly-〇H,

Boc-His (Trt) -OH (step 1). The selective deprotection of the Lys (Aloe) group is preferably performed manually, and by dissolving it in 5 11 ^ (^ (: 丨 3: ~ [\ / 1 [^ 锁 〇 八 〇 :( 18: 1: 0.5) 3 eq of Pd (PPId3) 4 solution to process the resin for 2 hours to complete (Step 2). Then, the resin was dissolved in CHCl3 (6 x 5 mL), dissolved in 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL) in DCM were used to clean it. The synthesis was then re-automated to add two AEEA (amine Ethoxyethoxyacetic acid) group and the cis-butene diiminopropanoic acid (step 3). The resin was cut off and the product was separated using 85〇〇200524957 TFA / 5% TIS / 5% benzene Thiomethane with 5% phenol, and then precipitated by dry and ice-cold Et20 (step 4). The product was purified by preparative reverse HPLC, which was prepared using a Varian (Rainin) preparation. Double effect Η PLC music system · Use a Phenomenex Luna 10 μ benzyl-hexyl 30, 55% Β (prepared in water 0 045) with a flow rate of g · 5⑺L / mi η and can make two more than 180 min / 〇tFA (Α) and 0.045 in the preparation of kCH3cn % TFA (B)), gradient dilution, 21 mm X 25 cm tube, UV # and detector (Varian Dynamax □ ▽ 0 1 丨) at λ 21 4 and 254 nm. The product must have a ruler [ ^ [[(: Determined by mass spectrometer >> 95% purity ') This mass spectrometer uses a continuous spectrometer equipped with a Hewlett Packard LC MS-11 00 equipped with a secondary body array detector and uses electrospray. Ionization method. These steps are described in the following diagram.

-159- 200524957

Fmoc-Rink Amide MBHA WaM

Step λ! I SPPS

Boc-HGEGTFTSDLSKQMEEEAVRLF! EWLKNGGPSSGAPPPSLys (Aloc) -PS

p J D jpdfPPh ^ yNMM / HOAc / CHCl ^

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSLys-PS

.? J 1. Fmoc-AEEA-OH (2 times)

Boc-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSf

〇 〇 I 85 ° /. TFA / 5% TIS / 5. /. Phenylthiol / 5% phenol

TFA

TFA

TFA

〇 H ^ M-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSjvj "

TFA

Example 32-Modification of the epsilon-amino group of the C-terminal lysine residue added to Eisenite-3 (1-39) Eisenite-3 (1-39) -Lys4 ° (Ns: -MPA) _NH2,5TFA Preparation;

His-Ser-Asp_Gly-Thr_Phe-Thr-Ser-Asp-Leu_Ser-Lys-Gln-

Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-lle-GIu-Trp-Leu-

Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-

Lys (Ns-MPA) -NH2.5TFA uses an automatic peptide synthesizer, and the following protective amino acids are sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Aloc)--1 60- 200524957

〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Pro-〇H, Fmoc-Pr〇-〇H, Fmoc cP o-〇H, Fmoc-Ala-〇H, Fmoc-Gly- 〇H, Fmoc-Se "-〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Asn (Trt) -〇 H, Fmoc-Lys (巳 〇c) -〇H, Fmoc-Leu-〇H, Fmoc-Trp-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-lle-〇H, Fmoc-Phe- 〇H, Fmoc-Leu-OH-Fmoc-Arg (Bpf) -OH > Fmoc-Val-OH ^ Fmoc-Ala-OH, Fmoc-Glu (〇tBu) -〇H, Fmoc-Glu (〇tBu)- 〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Met-〇H, Fmoc-Gln (Trt) -〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Ser (tBu) -〇H , Fmoc-Leu-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr ( tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Se "(〇tBu) -〇H, Boc_His (Trt) -〇H (Step 1) This Lys ( The selective deprotection of the Aloe) group is preferably performed manually, and by using 3 eq of Pd (PPh3) in 5 mL of CHCI3: NMM: H0Ac (1 8: 1: 0.5) 4 solution to process the resin for 2 hours to complete (step 2). Then, the tree The lipids were washed with CHC 丨 3 (6 X 5 mL), 20% HOAc (6x5mL), DCM (6x5mL), w & DMF (6x5 mL) dissolved in DC M. Then, the The synthesis system was re-automated to add 3-cis-butenediiminopropionic acid (step 3). Resin removal and product separation were performed using 85% TFA / 5% TIS / 5% benzylthiomethane and 5% Phenol, and then by precipitation with dry ice-cold EhO (step 4). The product was purified using a preparative reverse Η PLC, and the η PL 0 was -161-

200524957

A dual-effect HPLC system prepared by Varian (Rainin): using a 9.5 dagger / 111 丨 gate with a flow rate of more than 18 〇 [1 ^ 门 之 卩 [1611〇1116 gate 0 乂 1_1] gate 3 10 μbenzyl -A gradient dilution of 30-55% Β in hexyl (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mm X 25 cm column, and λ 21 4 and UV detector at 254 nm (Varian Dynamax UVD II). The product must have a purity of> 95% determined by an RP-HPLC mass spectrometer using a Hewlett Packard LCMS-1 100 continuous spectrometer equipped with a secondary body array detector and using Electrospray ionization method. These steps are described in the following diagram.

Fmoc-Rink Amide MBHA Resin BUSEN ll SPPS v

H.N-HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-PS 2jv 85% TFA / 5% TIS / 5% phenylthiomethanine / 5% phenol

TFA TFA TFA KN-HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH.

TFA

Exendin-3 Ι1-39) -ΝΗ. Example 33 · Modified ε-amino group of C-terminal lysine residue added to EISEN-3 (1-39) 1-39) -Lys4 ° (Nk-AEEA-AEEA, MPA) -NH2.5TFA Preparation; -162- 200524957

His-Ser-Asp-GIy-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn-

Met-Glu-Glu-GIu-Ala-Val-Arg-Leu-Phe-lle-Glu-Trp-Leu-

Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-

Lys (N8-AEEA-AEEA-MPA) -NH2.5TFA

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin: Liyang 〇〇1 ^ $ (八 丨 〇 (:)-〇H, Fmoc-Ser (tBu ) -〇H, Fmoc-P "o-〇H, Fmoc-Pro-〇H, Fmoc-Pro-〇H, Fmoc-Ala-〇H, Fmoc-Gly-〇H, Fmoc-Se" -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Asn (T``t) -〇H, Fmoc-Lys (Boc)- 〇H, Fmoc-Leu-〇H, Fmoc-Trp-〇H, Fmoc-Glu (〇tBu> -〇H, Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Leu-OH ^ Fmoc-Arg (Bpf) -〇H ^ Fmoc-Val-OH ^ Fmoc-Ala-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Glu (OtBu ) -〇H > Fmoc-Met-OH-Fmoc-Gln (Trt) -〇H, F moc-Lys (B oc) -〇H, F moc-Ser (t B u) -〇H, F moc _ Leu-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ser (tBu) -〇H, F moc-T h "(t B u) -〇H, F moc-P he -〇 H, F moc-T h "(t B u) -〇H, Fmoc-Gly-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ser (〇tBu) -〇H, Boc-His ( Trt) -OH (step 1). Selectivity of the Lys (Aloe) group Deprotection is preferably performed manually, and the resin is treated with a 3 eq Pd (PPh3) 4 solution in 5 mL of CHCI3: NMM: H0Ac (18: 1: 0.5). Hours (step 1163-200524957 step 2). Then, the resin was CHC13 (6 x 5 mL), 20% HAc (6 X 5 mL), DCM (6 X 5 mL) ), And DMF (6 X 5

mL). The synthesis was then re-automated to add two AEEA (amine ethoxyethoxyacetic acid) groups and the 3-cis- butyrimodiimidopropanoic acid (step 3). Resin removal and product separation were performed using 85% TFA / 5% T1S / 5% benzalkolide and 5% hope, and then precipitated by dry-ice-cooled -20 (step 4) . The product was purified by preparative reverse HPLC using a VaΓian (Rainin) preparative dual-effect HPLC system: using a Phenomenex Luna 10 μ benzene with a flow rate of 9.5 mL / min and more than 180 min Gradient dilutions of 30-55% Β (0.045% TFA (Α) in water and 0.045% TFA (B) in CH3CN)), 21 mm X 25 cm column, and λ 21 4 And 254 nm UV detector (Varian Dynamax UVDII). The product must have a purity> 95% determined by an RP-HPLC mass spectrometer using a Hewlett Packard LCMS-1100 continuous spectrometer equipped with a secondary body array detector and using electrospray Ionization method. Example 34-Modification of HIV-1 DP178 on the C-terminus Production of the modified HIV-1 DP 178 anti-fusid peptide; Tyr_Thr-Ser-Leu-lle-His-Ser-Leu-lle-Glu- Glu-Ser-Gln-Asn-Glu-Glu-GIu-Lys-Asn-Glu-Glu-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp- Phe-Lys- (Νε-ΜΡΑ) -ΝΗ2 200524957

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin ... Fmoc-Lys (Mtt) -OH, Fmoc-Phe-〇H, Fmoc-Trp (Boc ) -〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Trp (Boc) -OH, Fmoc-Leu-〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Ala-〇H, Fmoc- Trp (Boc) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Asp (tBu) -OH, Fmoc-Leu-OH, Fmoc-Glu (tBu) -OH, FmooLeu-OH, Fmoc-Leu-〇H, Fmoc-Glu (Tbu) -〇H, FmooGln (Trt) -〇H, Fmoc_Glu (tBu) -〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Lys (Boc)- 〇H, Fmoc-Glu (tBu) -〇H, Fmoc-Gln (Trt) -OH, Fmoc-Gln (Trt) -〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Gln (Trt) -〇 H, Fmoc-Ser (tBu) -〇H, Fmoc-Glu (tBii) -〇H, FmooGlu (tBu) -〇H, Fmoc-lle-〇H, Fmoc-Leu-〇H, Fmoc-Ser (tBu) -〇H, Fmoc-His (Trt) -〇H, Fmoc-lle-〇H, Fmoc-Leu-〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Thr (tBu) -〇H, and Boc- Tyr (tBu) -OH. The next step is the use of artificial synthesis: the selective removal of the Mtt group and the activation of HBTU / HOBt / DIEA used in DMF consumes cis-butane diimide propionate (MPA). The target molecule was removed from the resin; the product was isolated by precipitation and purified by preparative HPLC to obtain the desired product, ie, a white solid after freeze-drying. »Example 35-Modification of HIV-1 DP 107 on the C-terminus Preparation of modified HIV-1 DP 107 anti-fusid peptide;-165- 200524957

Asn-Asn-Leu-Leu-Arg-Ata-lle-Glu-AIa-GIu-Glu-His-Leu-Leu-Glu-Leu-Thr-Val-Trp-Glu-Ile-Lys-Glu-Leu-Glu- Ala-Arg-lle-Leu-Ala-Val-GIu-Arg-Tyr-Leu-Lys-Asp-Glu-Lys- (Νε-ΜΡΑ) ΝΗ2

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to the Rink Amide MBYA resin: "171〇LYs (Mtt) -OH, Fmoc-Gln (Trt) -OH, Fmoc -Asp (tBu) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Glu ( tBu) -〇H, Fmoc-Vabu〇H, Fmoc-Ala-〇H, Fmoc-Leu-〇H, Fmoc, lle-〇H, Fmoc-Arg (Pbf) -〇H, FmooAla-〇H, Fmoc -Gln (Trt) -〇H, Fmoc-Leu-〇H, Fmoc-Gln (Trt) -〇H, Fmoc-Lys (Boc) -〇H, Fmoc-lle-〇H, Fmoc-Gln (Trt)- 〇H, Fmoc-T, p (Boc) -〇H, Fmoc-Vabu〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Gln (Trt) -〇H, Fmoc -Leu-〇H, Fmoc-Leu-〇H, Fmoc-His (Trt) -〇H, Fmoc-Gln (Trt) -〇H, Fmoc-Gln (T``t) -〇H, Fmoc-Ala-〇 H, Fmoc-Glu (tBu) -〇H, Fmoc-lle-〇H, Fmoc-Ala-〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Leu-〇H, Fmoc-Leu-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Asn (Trt) -〇H. The next step is the use of artificial synthesis: selective removal of Mtt groups and HBTU / H〇Bt / used in DMF. DIEA activation and consumption Dimethyimine propionate (MPA). The target analog -166 — 200524957 was removed from the resin; the product was isolated by precipitation and purified by preparative tritium PLC to obtain the desired compound. The product, that is, a white solid after freeze-drying. 2. Improvement on the N-terminus of the therapeutic version

fExample 36-Modification of ε-amino group of added N-terminal lysine residue on RSV peptide (Ns-MPA) -Lys-Val-lle-Thr-lle-Glu-Leu-Se r-As n-lle-Lys-GIu-Asn-Lys-Met-Asn-Gly-Ala-Lys-Val-Lys-Leu-lle-Lys-Gln-Glu-Leu-Asp-Lys-Tyr-Lys-Asn -Ala-Val maker This modified RSV peptide is a 100 pmole grade solid phase peptide synthesis method using an artificial solid phase synthesis method, a Symphony Synthesizer, and Fmoc protective Rink Amide MBHA Come on. The following protective amino acids are sequentially added to the resin: Fmoc-VaNOH, Fmoc-Ala-OH, Fmoc-Asn (Trt) -OH, Fmoc-Lys (Boc) -OH, Fmoc- Tyr (tBu) -〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Asp (tBu) -OH ^ Fmoc-Leu-OH, Fmoc-Glu (tBu) -OH, Fmoc-Gln (Trt) -〇 H, Fmoc-Lys (Boc) -〇H, Fmoc-lle-〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-VabuH, Fmoc-Lys (Boc)- 〇H, FmooAla-〇H, FmooGly-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Met-〇H, Fmoc-Lys (Boc) -〇H,

Fmoc-Asn (Trt) -〇H, Fmoc-Glu (tBu) -〇H, Fmoc- -167- 200524957

Lys (Boc) -〇H, Fmoc-lle-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Se, ((tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Glu (tBu)- 〇H, • Fmoc-lle-〇H, Fmoc-Thr (tBu) -〇H, Fmoc-lle-〇H, • Fmoc-VabuOH, Fmoc-Lys (Aloc) -〇H, etc. It is sequentially dissolved in ^ :, N-dimethylformamido (DMF), and 0-benzidine azide-i-yl-N, N, N ', N · -tetramethyl- Urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) were used to activate it. The removal of the Fmoc protective group was made using Φ-soluble in N, N-diamidinoamidoamine ( DMF) 20% (V / V) N-Hexane

A solution of pyridyl is achieved for 20 minutes (step 1). The selective deprotection of the Lys (Aloe) group was performed manually and by using 3 eq of Pd (PPh3) 4 dissolved in 5 mL of CHCI3: NMM: H〇Ac (18: 1: 0.5) The solution was processed to complete the resin for 2 hours (step 2). The resin was then washed with CHCI3 (6 X 5 mL), 20% HOAc (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) in DCM. . Then, the synthesis system was re-automated to add 3-cis-butenediimidopropionate φ acid (step 3). Between each coupling, the resin was washed three times with N, N-difluorenylaminoamine (DMF) and three times with isopropanol. The peptide was cut from the resin using μ% TFA / 5% TIS / 5% bulky methylbenzene and 5% PAN, and then re-sinked with dry-ice-cold E t20; Dianzhi (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) preparative dual-effect HPLC system: using a Phenomenex Luna 10 μ phenyl with a flow rate of 9.5 mL / min and more than 180 min -A gradient dilution of 30-55% β in hexyl (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 -168 — 200524957 mm x 25 cm column, and λ 21 4 and 254 nm UV detectors (Varian Dynamax UVD II) to provide the ideal 95% purity peptide, which is determined by RP-HPLC. Example 37-Modification of the ε-amine group of the added N-terminal lysine residue on the neuropeptide Y

(N-8MPA) -Lys-Tyr-Pro-Ser-Lys-Pro-Glu-Asn-Pro-Glye, Glu-Asp-Ala-Pro-A la-Glu-Asp-Met-Ala-A rg-Tyr- Preparation of Tyr-Ser-Ala-Leu The modified neuropeptide was synthesized at 100 pmole level using a solid phase peptide synthesis method using an artificial solid phase synthesis method, a Symphony Synthesizer, and 卩 111 °. Protective ruler || 11 < Six111 丨 (^ 6 1 \ / 18). The following protective amino acids are sequentially added to the resin of the tree: Fmoc-Leu-〇H,

Fmoc-Ala-〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Ala -〇H, Fmoc-Met-〇H, Fmoc-Asp (tBu) -〇H, Fmoc-Glu (tBu) -〇H, Fmoc-Ala-〇H, Fmoc-P, o-〇H, Fmoc-Ala -〇H, Fmoc-Asp (tBu) -〇H, Fmoc-Glu (tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Pro-〇H, Fmoc-Asn (T``t) -〇H, Fmoc-Glu (tBu) -〇H, Fmoc-Pro-〇H, Fmoc_Lys (Boc) -〇H, Fmoc_Se`` (tBu) -〇H, Fmoc-Pr〇-〇H, Fmoc-Ty`` (tBu)- 〇H, Fmoc-Lys (Aloc) -〇H. These are sequentially dissolved in N, N-diamidinoamido (mf)), and 〇-phenylhydrazide-1_yl_N , N, N ,, N, -tetrafluorenyl-adenocation hexafluoro-169- 200524957

Phosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. The Fmoc protective group was removed by using a solution of 20% (V / V) N-hexahydropyridyl group dissolved in N, N-dimethylfluorenylamine (DM F) for 20 minutes. Achieved (step 1). The selective deprotection of the Lys (Aloe) group was performed manually, and was performed by dissolving 3 eq of Pd (PPh3 in 5 mL of CHCI3 · NMM · · HAc (18: 1: 0.5)). ) 4 solution to process the resin for 2 hours to complete (step 2). The resin was then washed with CHCI 3 (6x5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 x 5 mL) in DCM. Then, the synthesis system was re-automatized to add 3-cis-butenediiminopropionic acid (step 3). Between each coupling, the resin was washed three times with N, N-diamidinofluorenylamine (DMF) and three times with isopropanol. The winner was cut from the resin using 85% TFA / 5% TIS / 5% phenylthiomethane and 5% phenol, and then reprecipitated with dry-ice-cold EtA (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) dual effect Η PLC system: using a Phenomenex Luna with a flow rate of 9 · 5 mL / miη and more than 1 80 min 10 μ phenyl-hexyl 30-55% B (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), a gradient dilution, 21 mmx25 cm column, and λ214 and 254 UV meter of nm (Varian Dynamax U VD 11): to provide the ideal peptide with> 95% purity, which is determined by rp-HPLC. Masked Example-Modification on the ε-Amino Group of the N-Terminal Amino Acid Residue Added on Neural Edition Y-170- 200524957 (N-8MPA) -Lys-Tyr-Pro-Ser-Lys-Pro- Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu Injury

The modified neuropeptide was synthesized on a 100 μπιΐθ grade solid phase peptide using an artificial solid phase synthesis method, a Symphony skin synthesizer, and Fmoc protective Rink Amide MBHA. The following protective amino acids are sequentially added to the resin: Fmoc-Leu-〇H,

Fmoc-Ala-〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Ala -〇H, Fmoc-Met-〇H, Fmoc_Asp (tBu) -〇H, Fmoc-Glu (tBu) -〇H, Fmoc-Ala-〇H, Fmoc_Pro-〇H, Fmoc-Ala-〇H, Fmoc- Asp (tBu) -〇H, Fmoc-Glu (tBu) -OH, Fmoc-Gly-〇H, Fmoc-Pro-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Asp (tBu) -〇H , Fmoc-Pro-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-P "〇-〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-Lys (Aloc)-0H. These are sequentially dissolved in N, N_: fluorenylformamidine (dmf), and azide-butyl_N, N, N ,, N1 Tetrafluorenyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (diea) to activate it. Fmoc protective group is removed using a N, N-diamidinofluorene A 20% (v / V) solution of NH-hexahydropyridinyl in DMF was applied for 20 minutes (step 1). Selective deprotection of the Lys (AIoc) group Manually, and by using 3 eq of Pd (P in PHCl (5 · CHCl3: NMM: H〇Ac-171- '200524957 (18 · 1 · 0 · 5)) Ph3) 4 solution to process the resin for 2 hours to complete (step 2). Then the resin is chCI3 (6 X 5 mL), 20% HAc (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) to wash it. The synthesis was then re-automated to add 3-cis-butenediimidopropanoic acid (step 3). At each coupling In the meantime, the resin was washed three times with N, N-dimethylfluorenylamine (DMF) and three times with isopropanol. 85% TFA / 5% TIS / 5% benzylsulfonium and 5% It is hoped that the win version is cut off from the resin, and then re-precipitated with dry-ice-cold EhO (step 4). This product is purified by preparative reverse HPLC, which uses a Varian (Rainin) prepared double -Effect HPLC system: use a flow rate of 9.5 mL / min and can use more than 1 80 □ 1'111? [1611〇1116 gate 0 乂 1 »1 ^ 3 10-port phenyl-hexyl 30-50% 6 (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), a gradient dilution, a 21mmx25cm column, and a UV detector at λ214 and 254 nm (Varian Dynamax UVD I 丨) To provide this > 95% pure The ideal peptides, to its line of RP-HPLC to decide. Example 39-Modification of ε-Amino Group with Added N-Terminal Amino Acid Residue on Dyn A 1-13-Synthesis of (Ns-MPA) -Dyn A 1-13-NH2 (Ns-I \ / IPA) -Lys-Tyr-Gly-GIy-Phe-Leu-Arg ^ Arg-lle-Arg-Pro-

Lys-Leu The improved Dyn A 1-13 at 100 μιηοΐθ grade solid phase victory Synthetic method uses artificial solid phase synthesis method, SymPhony -172- 200524957

Synthesizer, and 卩 〇100〇 protective (^ gate 1 < eight [11 丨 (^ 8 ^ 8) to perform. The following protective amino acid is sequentially added to the resin: "1110 〇Lys (Boc) -〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-P "〇-〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-lle -〇H, Fmoc > Arg (Pbf) -OH 'Fmoc-Arg (Pbf) -OH ^ Fmoc-Leu-OH > Fmoc-Phe-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Tyr (tBu) -OH, Fmoc-Lys (Aloc) -OH. These are sequentially dissolved in N, N-dimethylformamidine (DM F), and O-benzidine Azide-1-yl-N, N, Ν 'Ν'-Tetrafluorenyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Fmoc protective group Removal was achieved by using a 20% (V / V) N-hexahydropyridinyl solution in N, N-dimethylformamidine (DMF) for 20 minutes (step 1) The selective deprotection of the Lys (Aloe) group was performed manually and by using 3 eq of CHCI3: NMM: H〇Ac (18: 1: 0'.5) dissolved in 5 m L Pd (PPh3) 4 solution to process the resin for 2 hours to complete (step 2). The resin was washed with CHCI3 (6 X 5 mL), 20% ΗAc (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) dissolved in DCM. Then, the synthesis system was re-automated to add 3-maleimide diimidopropanoic acid (step 3). Between each coupling, the resin was based on N, N-diamidinoamido ( DMF) three times and isopropyl alcohol three times. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% benzylthioxane and 5.0% phenol, and then dried-ice-cooled Ets0 was reprecipitated (step 4). The product was purified by preparative reverse HPLC using HPLC

Varian (Rainin) prepared dual-effect hpLC system: make the angle one can flow -173- * 200524957

9.5 mL / min and Phenomenex Luna 10 μ benzyl-hexyl 30-55% B (0.045% TFA * (Α) prepared in water and 0.045% TFA (Β) prepared in CH3CN) can be used for more than 180 min Gradient Dilution • Liquid, 21! 7 ^ 1 parent 250,000 columns, and 214 and 254 gates [71 of 1 ^ Detectors ^ 3 ^ 3 gates 0 gate 3 [113 \ 1 ^ 01 丨) In order to provide the ideal peptide with> 95% purity, it is determined by RP-HPLC. • Example 40-Improvement of Dyn A 2-17-ΝΗ2 on N-terminal glycine-Synthesis of MPA-AEA3_Dyn Α 2.17 · ΝΗ2 (MPA-AEA-AEA-AEA) -Gly-Gly-Phe- Leu-Arg-Arg-lle-Arg-

Pro-Lys-Leu-Lys-Trp-Asp-Asn-Glu uses an automatic peptide synthesizer, and the following protective amino acids and cis-butyrene imine are sequentially added to Rink Amide MBHA resin:

Fmoc-Gln (Trt) -〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Asp (〇iBu) -〇H, Fmoc-Trp (Boc) -〇H, Fmoc-Lys (Boc) -〇H , Fmoc_Leu_〇H, Fmoc-Lys (Boc) _〇H, Fmoc_Pro_〇H, Fmoc-A, g (Pbf) -〇H, Fmoc-lle-〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Leu-〇H, Fmoc-Phe-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-AEA-〇H, Fmoc-AEA-OH , Fmoc-AEA-〇H, and MPA. The dynorphin-labeled analog was removed from the resin, and the product was isolated by precipitation; purified by preparative HPLC to 32%. The desired product was obtained in the yield, that is, 'light-yellow solid after freeze-drying. Anal · HPLC showed that the product had a purity of -174-', 200524957 > 95%, and Rt = 33.44 minutes. ES and MS m / z It is Cl09Hi72N35〇29 (MH), the difference value is 2436.8, and the reward value is MH3 + 813.6.

TFATFA TFA TFA TFA ca. 1011

Example 42-Modification of ε-amino group of the added N-terminal lysine residue on kringle-5 (Nε-MP A) -Lys-Pro-Arg-Lys-Leu-Tyr- Preparation of Asp-Ty r-NH2_2TFA>

The improved kringle-5 is better than 100 μηηοΐθ grade solid phase peptide synthesis method using artificial solid phase synthesis method, Symphony peptide synthesizer, and Fmoc protective Rink Amide MBHA to Do it. The following protective amino acids are sequentially added to the resin: "阳 〇〇

Tyr (tBu) -〇H, Fmoc-Asp (tBu) -〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Arg (Pbf ) -OH, Fmoc-PrO-OH, Fmoc-Lys (Aloc) -OH. These are sequentially dissolved in N, N-difluorenylfluorenylamine (DMF), and 0-benzylazide-1-yl-N, N, N ', rr-tetrafluorenyl- Urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Fmoc protective group was removed using a solution of 175-200524957-20% (V / V) N-Hexahydrogen σ to N-N-dimethylaminino (DMF) solution The effect was achieved for 20 minutes (step 彳). At the end of the synthesis, ethyl < acid > anhydride was added to acetate ... The selective deprotection of Lys (Aloe) -based® was performed manually and by using 3 eq of Pd (PPh3) in 5 mL of CHCl3: NMM: H0Ac (18: 1: 0.5) 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin was CHCI3 (6 X 5 mL), 20% H0Ac (6 x 5 mL) dissolved in DCM,

DCM (6 x 5 mL) and DMF (6 x 5 mL). The synthesis was then re-automated to add 3-cis-butenediamidopropionic acid (step 3). Between each coupling, the resin was washed three times with ν, N-dimethylformamide (DM F) and three times with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% benzylthiopentane and 5% phenol, and then re-precipitated with dry-ice-cooled 20% (step 4). The product was purified with 'Preparative Reverse HPLC, which uses a Varian (Rainin) dual-effect HPLC system: using a Phenomenex Luna with a flow rate of 9.5 mL / min and more than 180 min. 10 μ phenyl-hexyl 30-55% Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), a gradient dilution, 21 mmx25 cm column, and λ214 and 254 A UV detector (Varian Dynamax UVD II) of nm to provide the ideal peptide with> 95% purity, which is determined by RP-HPLC. Example 43-Improved kr ingle-5 on N-terminal proline (MPA-AEEA) -Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys- 176- 200524957 NH2 .2TFA is produced using an automatic peptide synthesizer, and the following protective amino acids are sequentially added to the gate 1 < ^ 5 (6〇 (:)-〇1 ~ 1,

Fmoc-Tyr (tBu) 〇H, Fmoc-Asp (OtBu) -〇H, Fmoc-Ty 「(tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-A」 g (Pbf) -〇H, Fmoc-Pro-〇H (step 1). The deprotection of the Fmoc group at this end is by using 20% N-hexahydrocarbyl (step 2) and then Fmoc-AEEA The resulting Fmoc-AEEA-peptide with 20% N-hexahydropyridyl deprotection prepared in DMF allows the subsequent addition of 3-MPA (step 3). Resin removal and The separation of the product was performed using 86% TFA / 5% TIS / 5% H2O / 2% phenylthiomethane and 2% phenol, followed by Shen Dian by dry-ice-cold Et2O (step 4). It was prepared by reverse phase HPLC, which was purified using a Varian (Rainin) dual-effect HPLC system prepared by a protection module equipped with Dynamax C18, 60, 8 and 8 μηι ( Guard module) Dynamax Ci8, 60A, 8 μηι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detector (Varian Dynamax UVD II) at λ214 and 254 nm. This product must have > 95% purity determined by RP-HPLC mass spectrometer, the The spectrometer was a continuous spectrometer equipped with a Hewlett Packard LCMS-1 100 equipped with a secondary body array detector and an electrospray ionization method. Example 44-kr ingle _5 at the N-terminal Modification of Prolic Acid 177-200524957 was prepared using an automatic peptide synthesizer. The following protective amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Boc) -OH, Fmoc -Tyr (tBu) OH, Fmoc-Asp (OtBu) -OH, Fmoc-Tyr (tBu) OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH,

Fmoc-Arg (Pbf) -OH, Fmoc-Pro-OH (step 1). The deprotection of the Fmoc group at this end was accomplished by using 20% N-Hydroxy-Hydroxyl (Step 2) and then 3-MPA (Step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H2O / 2% benzylthiosulfonate and 2% phenol, followed by dry-icy cold E ^ 〇 to Shen Dian ( Step 4). The product was purified by a prepared reverse phase PLC. The ηPLC used a Varian (Rainin) dual-effect HPLC system using a protection module (giJa equipped with Dynamax C18, 60A, 8 μηη). "D

module), Dynamax C ”, 60A, 8 μm, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detector (Varian Dy na max UVD II) at λ214 and 254 nm. The product must be With> 95% purity determined by RP-HPLC mass spectrometer using a continuous spectrometer equipped with a Hewlett Packard LCMS-11 00 equipped with a secondary body array detector and using electrospray ionization Example 45-Improved Kringle-5 on N-terminal tyrosine (MPA-AEEA) -Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr- -178 -200524957

Preparation of Asp-Tyr-NH2.2TFA

Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to Rink Amide MBHA resin ... Fmoc-Lys (Boc) -OH, Fmoc-Tyr (tBu) OH, Fmoc-Asp (〇tBu) -OH, Fmoc-Tyr (tBu) OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Pro-OH Fmoc-Asn (T "t) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Tyr (tBu) OH (step 1). Fmoc at this end Deprotection of the group is accomplished by using a 20% N-hexahydrobenzyl group (step 2) and subsequent conversion of Fmoc-AEEA. The resulting is 20% N-hexahydro prepared in DMF. The pyrimyl-deprotected Fmoc-AEEA-peptide allows the subsequent addition of 3-MPA (step 3). Resin removal and product isolation are performed using 86% TFA / 5% TIS / 5% H20 / 2% Phenylthiomethane and 2% phenol were then precipitated by dry-ice-cold Et20 (step 4). The product was purified by preparative reverse-phase HPLC using a Varian (Rainin ) Prepared dual-effect HPLC system using a guard module equipped with Dynamax C18, 60A, 8 μηη

Dynamax C18, 60A, 8 μηι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detector (Varian Dynamax UVD 丨 丨) at λ 21 4 and 254 nm. The product must have a purity> 95% determined by an rp-hplC mass spectrometer using a Hewlett Packard LCMS-1100 continuous spectrometer equipped with a secondary body array detector and using electrospray Ionization method. -179 — 200524957 Example 46-Kringle-5 Modification on N-Terminal Tyrosine (MPA) -Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-

Tyr-NH2.2TFA was prepared using an automatic peptide synthesizer. The following protective amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Boc) -OH, Fmoc-Tyr (tBu) 〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Ty "(tBu) 0H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-A" g (Pbf) -〇 H, Fmoc-P, o-〇H, Fmoc_Asn (Trt) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-

Tyr (tBu) OH (step 1). The deprotection of the Fmoc group at this end was accomplished by using 20% N-hexahydropyridyl (step 2) and then 3-MPA (step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H2O / 2% phenylthioxane and 2% phenol, and then immersed in the temple with dry-ice-cold Ets. (Steps 4). The product was purified by a preparative reverse-phase HPLC using a Va ian (Rainin) preparative dual-effect HPLC system using a

Dynamax C18, 60A, 8 μιτι protection module (gUa "cj modu | e), Dynamax C '8, 6, 0 A, 8 μm, 21 mmx 2 5 cm column, 21 mm x 25 cm tube branch, and λ214 and 254 _ UV detector (Varian

Dynamax UVD II). The product must have a purity> 95% determined by the rp_hplc mass spectrometer, which uses a secondary body -180-

200524957 Hewlett Packard LCMS-11 00 array spectrometer continuous spectrometer and using electrospray ionization method. f 例 _41-Kringle-5 improvement on N-terminal arginine (MPA-AEEA). Arg-Asn-Pro-Asp-Gly-Asp-Gly.Pro-Trp.

The production of Ala-Tyr-Thr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH2_3TFA uses an automatic peptide synthesizer, and the following protective amino acids are sequentially added to Rink On Amide MBHA resin: Fmoc-Lys (Boc) -〇H,

Fmoc-Tyr (tBu) 〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-

Tyr (tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H,

Fmoc-Arg (Pbf) -〇H, Fmoc-P, o-OH, Fmoc_Asn (Trt) -〇H,

Fmoc-Thr (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc-

Tyr (tBu) 〇H, Fmoc-Ala-OH, FmooT, p-〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Vabu OH,

Fmoc-Asp (〇tBu) -〇H, Fmoc-Gly-〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Pro-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-A g (Pbf) -OH (step 1). The deprotection of the Fmoc group at this end is accomplished by using a 20% N-hexahydrontpyridyl group (step 2) and then Fmoc-AEEA coupling. The resulting Fmoc-AEEA-peptide with a 20% N-hexapyridyl deprotection prepared in DMF allows the subsequent addition of 3-MPA (step 3). Resin removal and product isolation It was carried out using 86% -181-'200524957 TFA / 5% TIS / 5% H2〇 / 2% phenylthiomethane and 2% phenol, followed by precipitation from dry-ice-cold Et2O (step 4) The product was purified by reverse phase HPLC prepared using a Varian

(Rainin) Prepared dual-effect HPLC system. This system is equipped with a Dynamax C18, 60A, 8 μm guard module, Dynamax C18, 60A, 8 μm, 21 mmx25cm column, 21 mm x 25cm column and UV detector (Varian DynamaxUVDII) at λ214 and 254 nm. The product must have a purity of> 95% determined by an RP-HPLC mass spectrometer using a Hewlett Packard LCMS-11 00 continuous spectrometer equipped with a secondary body array detector and a Spray ionization method. Example 48-Improved kringle-5M N-terminal spermine (MPA) -Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr -Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH2.3TFA was prepared using an automatic peptide synthesizer, and the following protective amino acids were added to Rink Amide MBHA sequentially Resin: Fmoc-Lys (Boc) -OH, Fmoc-Tyr (tBu) OH, Fmoc-Asp (〇tBu) -OH, Fmoc-Ty "(tBu) OH, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Pro-OH, Fmoc-Asn (T``t) -OH,

Fmoc-Thr (tBu) -〇H, Fmoc-Thr (tBu) -〇H, Fmoc- -182- 200524957

Tyr (tBu) 〇H, Fmoc-Ala-〇H, Fmoc-Trp-〇H, Fmoc-Pro-〇H, Fmoc-Gly-〇H, Fmoc-Gly-〇H, Fmoc-Vabu 0H, Fmoc -Asp (〇tBu) -〇H, Fmoc-Gly-〇H, FmooAsp (〇tBu) -〇H, FmooPro-〇H, FmooAsn (Trt) -〇H, Fmoc-Arg (Pbf) -OH (Step 1 ). Deprotection of the terminal Fmoc group is accomplished by using 20% N-hexahydropyridinyl (step 2) and subsequent 3-MPA depletion (step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H20 / 2% benzylthiomethane and 2% phenol, followed by precipitation with dry ice-cold Et20 (step 4) . The product was purified by preparative reverse-phase HPLC using a Varian (Rainin) preparative dual-effect HPLC system using a protection module equipped with Dynamax C18, 60A, 8 μιτι (Guard module) Dynamax C18, 60A, 8 μηι, 21 mm x 25 cm column, 21 mm yx 25 cm column, and UV detector (Varian Dynamax UVD II) at λ 21 4 and 254 nm . The product must have a purity of> 95% determined by an RP-HPLC mass spectrometer using a Hewlett Packard LCMS-11 00 continuous spectrometer equipped with a secondary body array detector and a Spray ionization method. Example 49-Improved kringle-5 on N-terminal arginine (MPA-AEEA) -Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp -NH2.TFA is produced using an automatic peptide synthesizer. The following protective amino acids are added to Rink Amide MBHA resin in the order of -183- 200524957: Fmoc-Lys (Boc) -OH, Fm. cT 「p-〇H, Fmoc-P」 o-〇H, Fmoc-Gly-〇H, Fmoc-Gly-OH-Fmoc-Va! -OH ^ Fmoc-Asp (OtBu) -OH ^ Fmoc-Gly-〇 H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Pro-〇H, Fmoc-Asn (T "t) -〇H, Fmoc-Arg (Pbf) -〇H (step 1). Fmoc at this end

Deprotection of the group was accomplished by using 20% N-hexahydropyridinyl (step 2) and then Fmoc-AEEA coupling. The resulting Fmoc-AEEA-peptide deprotected with 20% N-hexahydropyridyl group prepared in DMF allows the subsequent addition of 3-MPA (step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H2O / 2% phenylthioamidine and 2% phenol, followed by precipitation by dry-ice-cold Et2O (step 4). The product was purified by preparative reverse-phase HPLC using a Varian (Rainin) preparative dual-effect HPLC system using a guard module equipped with Dynamax C18, 60A, 8 μm module) Dynamax C18, 60A, 8 μm, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detector (Varian Dynamax UVD II) at λ214 and 254 nm. The product must have a purity> 95% determined by an RP-HPLC mass spectrometer using a continuous spectrometer equipped with a Hewlett Packard LCMS-1100 equipped with a secondary body array detector and using electrospray Ionization method. Example 5 0-kr ingle-5 (MPA) improvement on N-terminal arginine-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp- Preparation of NH2.TFA

200524957 Using an automatic peptide synthesizer, the following protective amino acids were sequentially added to RinkAmide MUHA resin: Fmoc-Lys (B〇c) -OH,

Fmoc-Trp-〇H, Fmoc-P "〇-〇H, Fmoc-Gly-〇H, Fmoc-Gly-OH ^ Fmoc-Val-OH > Fmoc-Asp (OtBu) -OH > Fmoc-Gly- 〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Pr〇-〇H, Fmoc-Asn (Trt) -〇H, Fmoc-Arg (Pbf) -〇H (step 1). Fmoc at this end Deprotection of the group is accomplished by using 20% N · hexahydropyridyl (step 2) and subsequent 3-MPA lightening (step 3). Resin removal and product separation are performed using 86% TFA / 5 % TlS / 5% Η20 / 2% benzylpyrene and 2% phenol, followed by precipitation with dry-ice-cold Et2O (step 4). The product was obtained by preparative reverse-phase HPLC For purification, the HPLC is a dual-effect HPLC system prepared by Varian (Rainin). The system uses a Dynamax C18, 60A equipped with a Dynamax C18, 60A, 8 μm protection module (gUa "d module). , 8 μηη, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detector (Varian Dynamax UVD 丨 丨) at λ 214 and 254 nm. The product must have a mass spectrometer using RP-Η PLC > 95% purity, the mass spectrometer uses a secondary body array Side spectrometer Hewlett Packard LCMS-1 100 continuous spectrometer and electrospray ionization method. 185- 200524957 Example 51-Kringle-5 Modification of N-Terminal Arginine (MPA -AEEA) -Arg-Lys-Leu-Tyr-Asp-Tyr-NH2-2TFA was prepared using an automatic peptide synthesizer, and the following protective amino acids were sequentially added to the ruler | | ^ 八 〇1_丨 € 16 [\ / 18 ^ 1 On the eight resin: corpse 〇〇〇〇〇1 ^ 5 (6〇〇> -〇 latch,

Fmoc-Tyr (tBu) 〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc · ty "(tBu) OH, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Arg ( Pbf) -OH (step 1). The deprotection of the Fmoc group at the end was accomplished by using a coupling of 20% N-hexahydropyridyl (step 2) and then Fmoc-AEEA. The resulting was prepared Fmoc-AEEA-peptide with 20% Να hydrogen deprotection ratio in DMF allows the subsequent addition of 3-M PA (step 3). Resin excision and product isolation are performed using 86% TFA / 5% TIS / 5% H2 0/2% benzylthioxane and 2% hope, followed by precipitation by dry-ice-cold E ^ 0 (step 4). The product was prepared by the reverse phase Purified by HPLC. The HPLC is a dual-effect HPLC system prepared by Varian (Rainin). The system uses a Dynamax C18, 60A, 8 μm equipped with a guard module of Dynamax C18, 60 A, 8 μπη. , 21mmx25cm column, 21mm 乂 25 (^ column, and 214 and 254 1 of 1 ^ detector (\ / 3 「丨 扣

Dynamax UVD II). The product must have a purity of> 95% as determined by an RP-HPLC mass spectrometer using a Hewlett Packard LCMS-11 00 continuous spectrometer equipped with a secondary body array detector and using Electrospray ionization method. -186- 200524957 Example 52-Kr Ingle-5 Modified Arginine (MPA) -Arg-Lys-Leu-Tyr-Asp-Tyr-NH2.2TFA & ij ^ Use automatic win Peptide synthesizer, the following protective amino acids are sequentially added to the ruler ^! ^ 八 111 丨 (^ " 6 latch eight resin: 卩 111〇〇1_ > ^ (3〇 (:)-0 Latch, FmooTyr (tBu) 〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Tyr (tBu) 〇H, Fmoc-Leu-〇H, Fmoc-Lys (Boc) -〇H, Fmoc-Arg ( Pbf) -OH (step 1). The deprotection of the Fmoc group at this end was accomplished by using a coupling of 20% N-hexahydropyridyl (step 2) and then 3-MP A (step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H2O / 2% phenylthiomethane and 2% phenol, followed by precipitation with dry-ice-cold Et2O (step 4 The product was purified by a preparative reverse-phase HPLC using a Varian (Rainin) preparative dual-effect HPLC system.

Dynamax C18, 60A, 8 μηι guard module, Dynamax C18, 60A, 8 μηι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detection at X214 and 254 nm (Varian

Dynamax UVD II). The product must have a purity of> 95% determined by an rp_hplc mass spectrometer using a Hewlett Packard LCMS-11 00 continuous spectrometer equipped with a secondary body array detector and using electrospray ionization化 方法。 Methods. Example 1 Improved Kringle-5 N-terminal Proline (MPA-AEEA) -Pro-Arg-Lys-Leujy Asp-NH2 2TF_ Policy

200524957 An automatic peptide synthesizer is prepared. The following protective amino acids are sequentially added to RinkAmide MBHA resin: FmooLys (Boc) -〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Tyr (tBu) OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH, Fmoc-A, g (Pbf) -OH, Fmoc-Pro-OH (step 1). Fmoc at this end Deprotection of the group is accomplished by using 20% N-hexahydropyridinyl (step 2) and then Fmoc-AEEA. The resulting is 20% N-hexahydro prepared in DMF. Fmoc-AEEA-peptide deprotection allows the addition of 3-MPA (step 3). Resin removal and product isolation are performed using 86% TFA / 5% TlS / 5% H20 / 2% Phenylthioxane and 2% phenol were then precipitated by dry-ice-cold 巳 20〇 (step 4). The product was purified by a preparative reverse-phase ΗPLC, which was a PLC system. A Varian (Raini η) dual-effect Η PLC system is used. This system uses a Dynamax 〇18, 60 input, equipped with a guard module (Dy namax Ci8, 60A, 8pm), 8 mouths, 21〇1 [11 father 25 (: 01 pipe column, 21111111 father 25 (: 171 tube and UV bond test at λ214 and 254 nm || (VarianDynamax UVDI 丨). The product must have a purity of> 95% determined by RP-Η PLC mass spectrometer. The mass spectrometer is A continuous spectrometer using a Hewlett Packard LCMS-1100 equipped with a secondary body array detector and using an electrospray ionization method. — 188-

3. 200524957 Example 54-Improved (MPA) of kringle-5 on the N-terminated phosphonic acid_Pro-Arg-Lys-Leu-Tyr-Asp-NH2.2TFA Peptide synthesizer, the following protective amino acids are sequentially added to Rink Amide MBHA resin: Fmoc-Lys (Boc) -〇H, Fmoc-Asp (〇tBu) -〇H, Fmoc-Tyr (tBu ) OH, Fmoc-Leu-OH, Fmoc-Lys (Boc) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Pro-OH (step 1). The deprotection of the Fmoc group at this end was accomplished by using a coupling of 20% N-hexahydropyridyl (step 2) and then 3-MPA (step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H2O / 2% phenylthiomethane and 2% phenol, followed by precipitation with dry-ice-cold Et2O (step 4). The product was purified by a prepared reverse-phase PLC. The PLC was a double-effect PLC system prepared by Va "ian (Rainiη). This system was equipped with a Dynama χ Cw, 60A, Dynamax C18, 60A, 8μm, 21mmx25cm column, 21mmx25cm column, and UV detector (Varian Dynamax UVD ll) at λ 214 and 254 nm, 8 μηι guard module. The product must have Rp-HPLC mass spectrometer > 95% purity 'This mass spectrometer uses a continuous spectrometer equipped with a Hewlett Packard LCMS-1 100 equipped with a secondary body array detector and uses an electrospray ionization method. Improvement on Intermediate Amino Acids -189 — 200524957 您 你 羞 55 ·! ^ 526 (8-1 \ / ^ 八) 01 ^ -1 (7-36) * ^ Synthesis of this modified GLP -1 The synthesis of the solid-phase peptides at 100 μm οe level was performed in a Symphony peptide synthesizer using Fmoc-protected Rink Amide MB Η A resin. The following protective amino acids were sequentially added to the resin: Liyang 〇 (:-六 「9 (" 51:) ·· 〇H, FmooGly-〇H , Fmoc-Lys (Boc) -〇H, Fmoc-VahOH,

Fmoc-Leu-〇H, Fmoc-Trp (Boc) -〇H, Fmoc-Ala-〇H,

Fmoc-lle-〇H, Fmoc-Phe-〇H, Fmoc-Glu (〇tBu) -〇H,

Fm〇c-Lys (Aloc) -〇H, Fmoc-Ala-〇H, FmooAla-〇H,

Fmoc-Gln (Trt) -〇H, Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Leu-〇H, Fmoc-Tyr (tBu) -〇H, Fmoc-

Se "(tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Va Bu〇H,

Fmoc-Asp (tBu) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-, ...

Thr (tBu) -〇H, Fmoc-Phe-〇H, Fmoc-Thr (tBu) -〇H,

Fmoc-Gly-〇H, Fmoc-Glu (〇tBu) -〇H, Fmoc-Ala-〇H,

Boc-His (Trt) -OH. These are sequentially dissolved in N, N-diamidinofluorenylamine (DMF), and 0-phenylhydrazino-1-yl-N, N, N1, N · -tetrafluorenyl- Urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Removal of the Fmoc protective group was performed by using 20% (V / V) N * · hexahydrogen dissolved in N, N-difluorenylamino group (DMF). This was achieved by a 20-minute solution of pyridyl (step 1). The selective deprotection of the Lys (Aloc) group is performed manually 'and by using 3 eq of Pd (PPh3) 4 dissolved in 5 m L iCHCl3: NMM: H〇Ac (18: 1: 0.5) The solution was processed to complete the resin for 2 hours (step 2). Then, the resin was based on CHCI3 (6 -190- 200524957

x 5 mL), 20% HOAc (6 X 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) in DCM. The synthesis was then re-automated to add 3-butanedioyl iminopropanoic acid (step 3). Between each coupling, the resin was washed three times with N, N-difluorenylamino (DMn) and three times with isopropanol. 85% TFA / 5% TIS / 5% bulk With 5% hope, Satsuma was excised from the resin and reprecipitated with dry-ice-cold ELO (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) Prepared double-effect Η P LC system: Use a Phenomenex Luna 10 μ phenyl-hexyl 30-55% Β (0.045% TFA prepared in water) with a flow rate of 9.5 m L / mi η and can be used for more than 180 minutes A) and a gradient dilution of 0.045% TFA (B)) prepared in CH3CN, a 21 mm x 25 cm column, and a UV accumulator (VarianDynamax □ ▽ □ 丨 丨) at λ214 and 254nm to provide The> 95% purity ideal peptide is determined by 卩 卩 _} ^ 1 ^. These steps are described in the following chart.

-191- 200524957

Fmoc-Rink Amide MBHA resin

• Buchen ^ SPPS

... ~ V

巳 oc-HAEGTRSDVSSYLEG〇AA-Lys (Aloc) -EFIAWLVKGR-PS | pd (PPh3) 4 / NMM / HOAc / CHCI3

Boc-HAEGTFTSDVSSYLEGQAA-Lys-EFIAWLVKGR-PS Step 3-cisbutene diKimine propionate

〇 Π Boc-HAEGTFTSDVSSYLEGQAA

T Buchen 4 I 85% TFA / 5% TIS / 5% H20 / 5% phenylthiomethane / 5% phenol

H2 N ~ HAEGTRSDVSSYLEG〇AA

Lys26 (E-MPA) GLP-1 (7-36) -NH2 -192- 200524957 D. Self-contained modified peptide made from phthalocyanine containing a free hemi-seric acid, treatment with self-containing cysteine Preparation of cis-butene diisotropic peptides from sex peptides • The imide peptides can be exemplified by the synthesis of the following peptides. This version is modified on the N-terminus, C-terminus, or amino acid between N-terminus and C-terminus. From 3 few protective g-energy groups and all cysteine residues (ie, one cysteine other than one cysteine) with only one free hemideamine I: the acid is double The s-type bond is bound) and the therapeutic peptide is' prepared cis-butene-vinyl imine. Linked from an intermediate amino acid in a natural sequence, as in Example 5. The free cysteine can be covered or replaced with other amino acids (e.g., alanine, methionine, etc.).

The 1-32 fragment of the subunit, HIV, and when the peptide contains a cysteine, the cysteine must be in a > capped state after the addition of maleimide . Mouth μ-human premature), 739 fragment of nitric oxide in the brain of rats, 254_274 fragment of human [Tyr〇] inhibin with HIV envelope protein, and P34cdc2 kinase fragment. -193- 200524957 1. Improved N-terminal TMM3A-Improved N-terminal lysine added to inhibin peptide (Ns-MPA) -Lys-Tyr-Ser-Thr-Pro-Leu-Met -Ser-Trp-Pro-Trp-Ser-Pro-Ser-AIa-Leu-Arg-Leu-Leu-GIn-Arg-Pro-Pro-Glu-Glu-Pro-Ala-A 丨 a-Ala-His-Ala -Asn-Cys-His-Arg

A modified inhibin-derived analogue was used to synthesize a solid-phase solution of 100 μm 〇 丨 e using a manual solid-phase synthesis method, a Symphony synthesizer, and “〇1〇 〇Protection ratio 1 < 〇〇1 丨 (^ 1 \ / 13 latch eight. The following protective amino acids are sequentially added to the resin: "〇〇〇 六" 9 (口 刀 〒) -〇H, Fmoc-His (Boc) -〇H, Fmoc-Cys (Trt) -〇H, Fmoc-Asn (T``t) -〇H, Fmoc-Ala-〇H, Rmoc-His (Boc)- 〇H, Fmoc-Ala-OH > Fmoc-Ala-OH ^ Fmoc-Pro-OH, Fmoc-GI u (t B u) -〇H, F m ο o GI u (t B u) 〇H, F moc-P ro -〇H, Fmoc-Pro-〇H, Fmoc-Arg (Pbf) -〇H, Fmoc-Gln (Trt) -〇H, Fmoc-Leu-〇H, Fmoc-Leu-〇H, Fmoc -Arg (Pbf) -OH, Fmoc-Leu-OH, FmooAla-OH, Fmoc-Ser (tBu) -OH, Fmoc-Pro-OH, Fmoc-Ser (tBu) -OH, Fmoc- Trp (Boc) -〇H, Fmoc-Pro-〇H, Fmoc-Trp (Boc) -〇H, Fmoc-Ser (tBu) -〇H, Fmoc-Met-〇H, Fmoc-Leu-〇H, Fmoc -Pro-〇H, Fmoc-Thr (tBu) -〇H, Fmoc-Ser (tBu) -OH, Fmoc-Tyr (tBu) -OH, FmooLys (Aloc) -OH, etc. In N N: Diamidinofluorenamine-194- 200524957 (DMF), and 0 · phenylhydrazino-1-yl-N, N, N ', N1-tetramethyl-urea cation hexafluorophosphate Salt (HBTU) and diisopropylethylamine (DIEA) to activate it. Fmoc protective groups are removed using 20% of N, N-dimethylformamidine (DmF) (V-8,) N-hexahydropyridyl solution was obtained by hydration for 20 minutes (step 1). The selective deprotection of the Lys (Aloe) sulfonium was performed manually, and by dissolving it in 5 mL Of

CHCl3: NMM: H0Ac (18: 1: 0.5) 3 eq of Pd (PPh3) 4; S solution to process the resin for 2 hours to complete (step 2). The resin was then washed with CHCI3 (6 X 5 mL), 20% HO Ac (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) in DCM. Then, the synthesis system was re-automated to add 3-maleimideiminopropionic acid (step 3). Between each coupling, the resin was washed three times with ν, N · dimethylaminomethylamine (DMF) and three times with isopropanol. The 85% TFA / 5% TIS / 5% benzyl chloride and 5ipan were used to cut the winning version from the resin, and then re-precipitate it with dry-ice-cold Et20 (step 4). The product was purified by preparative reverse HPLC using a Varian (Rainin) preparative dual-effect HPLC system: using a PhenomeπexLLιna with a flow rate of 9.5 mL / min and more than 180 min. 30 μbenzyl-hexyl -55% B (0.045% TF A (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), a gradient dilution, 21 mm X 25 cm column, and UV at 2U and 254 nm Detector (Varian Dynamax UVD 丨 |) to provide the ideal peptide with> 95% purity, which is determined by RP_HPLC. -195-200524957 Example 57-RSV Antifusogenic is superior to the modified 3- (MPA) -VaI-IIe-Thr-lle-GIu-Leu-Ser-Asn-lle-Lys- GIu-Asn-Lys-Cys-Asn-Glu-Ala-Lys-Val-Lys-Leu-lle-Lys-Glu-Glu-Leu-Asp-Lys-Ty and Lys-Asn.Ala_Val was originally borrowed from this nature In the sequence, cysteine (Cys) was replaced with methionine. The synthesis of the improved anti-RSV analogue at 100pmole grade was performed in a Symphony peptide synthesizer using Fmoc-protected Rink Amide MBHA resin 'Fmoc-protected amine Acid, prepared in Λ /, Λ / -dimethylfluorenylamine (DMF) solution, 0-benzyl azide-1-yl- / V, Λ /, ΛΓ, Λ / ·-tetra Methyl-urea cation hexafluorophosphate (HBTU) and activated with Λ / -fluorenyl morpholine (NMM), and "□ ^ (: group of ... hexahydrolaridinyl group" ^ 丨 门 ㊀丨 The deprotection effect of step 1). The deprotection of the edge Fmoc group is achieved by using the coupling of 20% N-hexahydrosigmapyridyl (step 2) and then 3-MPA (step 3 Resin removal and product separation were performed using 86% TfA / 5% Τ 丨 S / 5% Η20 / 2% phenylthiomethane and 2% phenol, and then precipitated by dry_ice-cold EhO (Step 4). The product was purified by preparative reverse-phase HPLC using a Varian (Rainin) dual-effect Η PLC system. The system uses a device equipped with 〇 乂 mon a⑺a χ C18 6〇A 8 μηη Module (gUa "d module) Dynamax C18 6〇A 8pm, 21mmx25cm column, 21mmx25cm column, and UV detector (VarianDynamax -196— 200524957 UVDII) at 214 and 254 nm. The product must have a RP -> 95% purity determined by an HPLC mass spectrometer using a Hewett Packard LCMS-1100 continuous spectrometer equipped with a secondary body array detector and using an electrospray ionization method. These steps are described in the following diagram.

Fmoc-Rink Amide MBHA Resin SPPS Buchen 1

Fmoc-VITIELSNIKENKMNGAKVKLIKQELDKYKNAV-PS Buchen 2 i20% N-hexagjlft pyridyl h2n-vitielsnikenkmngakvklikqeldkyknavk-ps {step-pro 3j 3-cis-butene-diimine-propionate

V [TIELSNIKENKMNGAKVKL! KQELDKYKNAV-PS [Stephen 4 j j 85 ° /. TFA / 5% TIS / 5. /. Phenylthiol / 5% Phenol TFA TFA TFA TFA VITIELSNIKENKMNGAKVKLIKQELDKYKNAV-NH • · · TFA TFA TFA 2 2. Improved Example at the C-terminus 58-Addition of C-terminated Leucinic Acid Modification on N-terminal lysine added to Inhibin peptide (Ns-MPA) -Lys-Cys-Asn-Leu-Lys-Glu-Asp-Gly-lle-Ser-Ala-Ala -Lys-Asp-Va and Lys's instrument-197- 200524957 A modified inhibin peptide analogue in a solid phase of 100 μmol; fc: The synthesis system uses a manual solid-phase synthesis method, a sinferni ( Symphony) Winning Edition Synthesizer, and "171〇〇Protective 1 ^ 丨 Gate 1 < 8111 丨 (^ 1 \ / 1 Day Latch Eight.) The following protective amino acids are sequentially added to the resin: "010 (>

Lys (Boc) -OH-Fmoc-Val-OH-Fmoc-Asp (tBu) -OH ^ Fmoc-Lys (Boc) -〇H, Fmoc-Ala-〇H, Fmoc-Ala-〇H, F m 〇c-S θ r (t B u) -〇H, F moc -11 e -〇H, F moc-G1 y -〇H,

F iti o cA sp (t B u)-〇 H n Fmoc-Glu (tBu) -OH n Fmoc-Lys (Boc) -〇H, Fmoc-Leu-〇H, Fmoc-Asn (T``t) -〇 H, Fmoc-Cys (Trt) -OH, Fmoc-Lys (Aloc) -OH. These are sequentially dissolved in N, N-dimethylformamide (DMF), and O-benzyl Hydrazide-i-yl-N, N, Ν ·, Ν'-tetrafluorenyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEAA) to activate it. Fmoc protective Removal of the groups was achieved by using a 20% (V / V) solution of N-hexahydrosigma-pyridyl group dissolved in N, N-dimethylamidoamine (DMF) for 20 minutes ( Buxiang 1). The selective deprotection of the Lys (AI 〇c) group was performed manually and by dissolving 3 of 5 in CHCI3: NMM: H〇Ac (18: 1: 0.5). eq of

Pd (PPh3) 4 solution to process the resin for 2 hours to complete (step 2) ^ Then, the resin was made with CHCI3 (6 X 5 mL), 20% HAc (6x5 mL), DCM ( 6x5mL), and DMF (6x5mL). Then, the synthesis system was re-automated to add 3-cis-butylated diiminopropionic acid (step 3). Between each coupling, the resin was washed three times with N, N-dimethylformamide (DMF) and three times with isopropanol. Using 85% TFA / 5% T1S / 5% benzalkonium oxide and 5% phenol, the -198- 200524957 peptide was excised from the resin, and then reprecipitated with dry water-cooled dagger (step 4) . The product was purified with a preparative reverse hplC. The HPLC was performed using a Va "ian (Rainin) preparative dual-effect HPLC system: using a Phenomenex Luna 10 μ with a flow rate of 9.5 mL / min and a pressure of more than 180 rnin. Bentyl-hexyl 30-55% B (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), a gradient dilution, 21mmx25cm column, and λ214 and 254 nm UV analyzer (Varian Dynamax UVD II) to provide the ideal peptide with> 95% purity, which is determined by rP-hplc. Example __ EXAMPLE 59-RSV Fusogenic peptide C-end improvements

Val-lle-Thr-lle-GIu-Leu-Ser-Asn-lle-Lys-Glu-Asn-Lys-Cys-Asn-Gly-Ala-Lys-Val-Lys-Lfeu- lie- Lys-GIn-Glu- Leu-Asp-Lys-Tyr-Asn-Ala-Val- (AEEA.MPA)

Preparation of a cis-butyrylimine peptide from a peptide containing multiple protective functional groups and a cysteine can be exemplified by the synthesis of a modified RSV shuttle peptide. The modified RSV shuttle peptide is synthesized by adding an lysine residue to a natural sequence to leave the c-terminus, which is illustrated by the following chart. In the case where cysteine is included in the peptide sequence but is not important for the peptide's biological activity, the residue must be replaced with another amino acid (ie, alanine, thiosine) Etc.). In the following synthesis, cysteine -199- 200524957 (Met) was substituted in the natural RSV sequence (Cys

The cis-butenyl diimino RSV shuttle peptide was synthesized on a solid phase version of 100 ^ ⑴ ... ㊀ grade using a manual solid-phase synthesis method and a Symphony peptide synthesizer. The synthetic machine uses Fmoc-protected Rink Amide MBHA, Fmoc-protected amino acid, and is prepared in the dimethyl dimethylamino (DMF) solution. /, ΛΓ, ΛΓ-tetrafluorenyl-urea cation hexafluorophosphate (hbtu) and activated with Λ / -methylmorpholin (NMM), and deprotection of the N-hexahydro group at the Fmoc group Effect (step 1). The selective deprotection of the LyS (Aloe) group was performed manually, and was performed by dissolving 3 eq of Pd in CHCI3: NMM: H0Ac (18 ·· 1: 〇 · 5) in 5 mL ( PPh3) 4 solution to process the resin for 2 hours to complete (step 2). Then, the resin was washed with CHCI3 (6 X 5 mL), 20% HOAc (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL) dissolved in DCM. The synthesis was then re-automated to add 3-cis-butenediamidopropionic acid (step 3). Between each coupling, the resin was washed three times with N, N-dimethyl methylamine (DMF) and three times with isopropanol. Use 85.0 / fat / 5% TIS / 5% phenylthiomethane with 5. /. The peptide was excised from the resin with phenol and reprecipitated with dry-ice-cold Et20 (step 4). This product was purified by preparative reverse HPLC using a Varian (Rainin) preparative dual-effect HpLC system. · Using a Phenomenex Luna 10 μ 笨 with a flow rate of 9.5 mL / min and more than 180 min. A gradient dilution of 30-55% Β (0.045% TFA (Α) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 — 200 — 200524957 mm x 25 cm column and UV spectrometers at λ214 and 254 nm. 3 "丨 3 gates 0 7 gates 3 [7 ^ \ 1 ^ 0 丨 丨) to provide the ideal peptide with> 95% purity, which is based on This was determined by RP-HPLC. These steps are described in the chart below.

Fmoc-Rink Amide MBHA Tree Moon Purpose ^ Steps

) SPPS V

Boc-VITIELSNIKENKMNGAKVKLlKQELDKYKNAVK (A! Joc) -PS Buchen 2 I vPd (PPh3) 4 / NMM / HOAc / CmCI3

Boc-VlTiELSNIKENKMNGAKVKLIKQELDKYKNAVK-FPS

Step ^ 4 | j 85. /. TFA / 5. /. TIS / 5. /. Phenylthiol Academy / 5. /. phenol

TFA TFA TFA TFA TFA • # «» ♦

H2N-V1T1ELSNIKENKMNGAKVKLIKQELDKYKNAV

TFA

TFA

TFA 3. Improvement on intermediate amine pickling Example 60-Improvement of Ga peptide -201 200524957

Cys Asn-Leu_Lys-Glu_Asp_Gly-lle_Ser-Ala_Ala-Lys-Asp-

Val's preparation of maleimide from a peptide containing multiple protective functional groups and a cysteine can be exemplified by a modified Gα-like synthesis. The modified Ga peptide is synthesized by the linkage at an intermediate amino acid, as described below. In instances where cysteine is included in the sequence of the tritium but is not important to the biological activity of the tritium, the residue must be capped or replaced with another amino acid (ie, alanine,曱 Thionine, etc.). The modified Ga peptide was used for 100 μΓΤ | 0 | θ grade solid phase peptide synthesis using a manual solid phase synthesis method and a Symphony peptide synthesizer, which uses Fmoc protective properties. Rink Amide MBHA, Fmoc protection > Amino acid, prepared in Λ / -diamidinofluorenylamine (DM F) solution. Benzo-1-denyl-1-yl- Λ /, Λ / , Λ / ', ΛΓ-tetrafluorenyl-adenocation hexafluorohydrochloride (HBTU) and activated with fluorenylmorpholine (NMM), and deprotection of the N-hexahydropyridyl group of Fmoc group ( Step 彳). The selective deprotection of the Lys (Aloe) group was performed manually and by using 3 eq & P d (PP h3) in 5 mL of CHCI3: NMM: H〇Ac (18: 1: 0.5) 4 solution to process the resin for 2 hours to complete (step 2). Then the resin was washed with CHCI3 (6 X 5 mL), 20% HOAc (6x5 mL), DCM (6x5 mL), and DMF (6x5 mL) dissolved in DCM. The synthesis was then re-automated for addition; cis-butane diimine propionate (step 3). Between each coupling, the resin was washed three times with a 20? -200524957 N, N-methyl methyl fe-methyl (DMF) and three times with isopropanol. Using 85% TFA / 5% TIS / 5% benzylthioxane and 5%, it was excised from the resin, and then dried with ice-cold Et20 (step 4). The product was purified with a prepared reverse η PLC using a Varian (Rainin) prepared dual-effect HPLC system: using a Phenomenex Luna 10 μ with a flow rate of 9.5 mL / min and more than 180 min Phenyl-hexyl 30-55% B (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), a gradient dilution, 21 mm X 25 cm column, and human 214 And 254 nm UV detector (Varian Dynamax UVD II) to provide the ideal peptide with> 95% purity, which is determined by rp_hplc. E. Improved peptides made from peptides containing two cysteine acids in the disulfide bridge. When the win version contains two cysteine acids as a disulfide bridge, the win-like system It was removed from the support resin before maleimide was added. We must add a Lys protected with a Mtt group to selectively deprotect the lysine in the presence of other t-Boc protective lysines. All protective groups are present except for the carboxyl terminus (which exists in an unprotected state because it is cut off from the support resin) and the position of the cysteine ', the peptide is from the resin After removal, they must be deprotected. Mild gas oxidation will produce the disulfide bridge, and the peptide can be purified in this step. Then, in the presence of a disulfide bridge, the liquid-phase chemistry system dilutes the c-terminus and adds the maleimide diimide to the c-terminus (by monoamine-alkyl-maleimide Imine). The peptide was then deprotected after winter. Examples of therapeutic peptides containing two cysteine amino acids as a disulfide bridge include: human bone calcium factor 丨 49, human diabetes related diarrhea, human / dog room natriuretic peptide 5_28 Fragments, bovine texin, and human [TyrO] -cortical balance 29. Since the therapeutic peptide containing two cysteine amino acids as a disulfide bridge is a bis-succinic acid-imino group, it can be exemplified by the following synthesis. The peptide can be modified at the N-terminus, C-terminus, or amino acids at the N-terminus and C-terminus. 1 · Improvement on the N-terminus' Example 61 — Modification of the TH-1 win on the N-terminus (N ^ MPA) NH2.Lys-Arg-Gly-Asp.Ala.Cys-Glu-Gly.Asp. Ser-Gly-Gly-Pro-Phe-Cys is prepared from multiple protective functional groups and free cysteine residues (ie, all cysteine residues are in a disulfide bridge s manner The method for preparing thio-cyclized cis-butene diimide-based peptides is illustrated by the synthesis of a modified TH-1 peptide. Far improved TH-1 is better than 100μιηοΙθ grade solid-phase synthesis. Synthesis -204-200524957 uses a manual solid-phase synthesis method and a Symphony Synthesizer, which uses Fmoc protective properties. Rink Amide MBHA, Fmoc-protective amino acid, 0-benzyl azide j-group prepared in a solution of d-amidinofluorenylamino (dmf) ... w ,, w, -tetrafluorenyl- Urea cation hexafluorophosphate (BTU)) and activated with morphomorpholine (NMM) and deprotection of the N-hexahydropyridyl group of the Fmoc group (step 1). The removal of the Acm group and the oxidation caused by the two cys residues to form the degraded DAC on the resin are accomplished by using D (CF3c0) 2 (step 2). The deprotection of the side Fmoc group was achieved using a combination of 200 / 〇 hexahydropyridyl and then 3-MPA (step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H20 / 20 /. Benzothiomethane with 2% phenol, and then was precipitated by dry-ice-cold Et20 (step 4). The product was purified by a preparative reverse phase hplc. The HPLC was a dual-effect HPLC prepared by Varian (Rainin). The system used a Dynama XCama8, 6 0 A, 8 μ Dynamax C18, 60A, 8 μΓπ, 21 mmx25cm column, 21 mmx25cm column, and UV accumulator at λ214 and 254 m (Varian Dynamax UVD 11) The product must have a purity of> 95% determined by a RP--PLC mass spectrometer using a flail spectrometer equipped with a Hewlett Packard LCMS-1100 equipped with a secondary body array detector. And using the electrospray ionization method, the ES MS MS m / z is C66H95N20〇26S2 (MH +), 1646.8 · actual value is 1 646.7. These steps are described in the following chart. -205- 200524957

Fmoc-Rink Amide MBHA Tree Step 1 I SPPS

V

Fmoc-K (Boc) R (Pb〇GD (OtBu) AC (Acm) E (OtBu) GD (OtBu) SC) (tBu) GGPFC (Acm) -Resin Buchen 2.

Fmoc-K (Boc) R (Pbf) GD (OtBu) ACE (OtBu) GD (OtBu) S (tBu) i) GGPFC-Resin Step 3, .20. / 〇Hexyl pyridyl 2.3. Maleic acid diimide propionate

〇 〇 K (Boc) R (Pbf) GD (OtBu) ACE (OtBu) GD0 (OtBu) S (tBu) GGPFC-Resin Buchen 4 j 86% TFA / 5. /. TIS / 2% Phenylthiomethyl Academy / 2% Phenol: FA f-f

Y ^ ΐΓ ^ KRGDACEGDSGGPFC.N ^ H2 TFA Example 62-Synthesis of AMVIPA-Ser1- Growth Hormone Release Inhibitor-28 DAC: Analogue of Growth Hormone Release Inhibitor-28 on 100 μιτιοΐθ-grade solid phase The Victory Synthetic System uses a manual solid-phase synthesis method and a Symphony Victory Synthesizer, which uses Fmoc protective Rink Amide MBHA. The following protective amino acids are sequentially added to the resin: Fmoc-Cys (Acm) -OH, Fmoc-Se "(tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Phe- OH, Fmoc-Thr (tBu) -OH,

Fmoc-Lys (Boc) -OH, Fmoc-Trp (Boc) -OH, Fmoc-Phe-OH, -206- 200524957

Fmoc-Phe-OH, Fmoc-Asn (Trt) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Cys (Acm) -OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Lys (Boc ) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Glu (OtBu) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc -Ala-OH, Fmoc-Pro-OH, Fmoc-Asn (Trt) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Asn (T``t) -〇H, Fmoc-Ala-〇H, Fmoc- Ser (tBu) -OH, etc. are sequentially dissolved in N, N-dimethylamidoamine (DM F), and using benzene azide-1-yl-N, Ν, N ′, N′-tetramethyl-urea-cationic hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) were used to activate it. The removal of the Fmoc protective group was performed by dissolving in N, N -A solution of 20% (V / V) N-hexahydropyridinyl in dimethylfluorenylamine (DMF) for 20 minutes (step 1). Removal of Acm group and two Cys The oxidation of the residues to form the disulfide bridge is accomplished by using iodine (step 2). The deprotection of the side Fmoc group uses 20% N-hexahydropyridyl and then 3-MPA The car was reached together (step 3). Resin removal and product separation were performed using 86% TFA / 5% TIS / 5% H2 / 2% phenylthioxane and 2% PAN 'and then by dry-ice-cold Et20 (step 4) ° The product was purified by preparative reverse-phase HPLC to provide a Ideal DAC with> 95% purity as determined by RP-HPLC. This HPLC uses a dual-effect HPLC system prepared by Varian (Rainin). This system uses a protection equipped with Dynamax C18, 60A, 8 μητι. DynamaxC18, 60A, 8μηι, 21 mmx25 for guard module

cm column, 21 mm x 25 cm column, and UV-207-200524957 detector (Va "i an Dy na max UVD II) at λ 214 and 254 nm. These steps are described in the diagram below .

Fmoc-Rink Amide MBHA resin

Step 1 SPPS v

Fmoc-SANSNPAMAPRERKAGC ^ AcmJKNFFWKin ^ TSCiAcm) · Street Step 2 1γι2

Resin

Fmoc-SANSNPAMAPRERKAGCKNFFWKTFTSC- Buchen 3 1. 20% N · Hex ® Dtt pyridyl 2. / 3-cis-butene diimide propionate

H ff ^ SANSNPAMAPRERKAGCKNFFWKITTSC · Street month step 4 j 85% TFA / 5% TIS / 5% H20 / 5% phenylthio group H ff V >rV; v / SY ^ SANSNPAMAPRERKAGCKNFFWKTFTSC-〇H 〇〇N-MPA -Ser1-Inhibitor of Growth Hormone Release-28 -208- 200524957 2 · Improved Ai selection on C-term 63_ · Synthesis of Inhibitor of Growth Hormone-28-EDA-MPA

DAC: Growth hormone release inhibitor 28 analogue at 100 μmol. The solid-phase peptide synthesis system uses a manual solid-phase synthesis method and a Symphony peptide synthesis machine. The synthesis machine uses SASRIN (Super Acid Sensitive Resin). The following protective amino acids are sequentially added to the resin: Fmoc-Cys (Acm) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Phe- 〇H, Fmoc-buthr (tBu) -〇H, Fmoc-Lys (Boc) -OH, Fmoc-Trp (Boc) -OH, Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Asn (Trt) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Cys (Acm) -OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Lys (Boc) -OH, Fmoc-Arg (Pbf) -OH , Fmoc-Glu (OtBu) -OH, Fmoc-Arg (Pbf) -〇H, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Pro-〇H , FmooAsn (Trt) -OH, Fmoc-Ser (tBu) -OH, Fmoo Asn (T "t) -OH, Fmoc-Ala-OH, Boc-Ser (tBu) -OH, etc. Sequentially soluble in N, N-dimethylfluorenylamine (DMF) and using 0-benzylazide-1-yl-N, N, N ', N · -tetrafluorenyl-urea cation Hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Fmoc protective groups are removed using a solution of N, N-dimethylformamidine (DMF) 20% (V / V) solution of N-hexahydropyridyl for 20 minutes (step 1). The complete protective peptide was processed by 1% TFA / DCM at 209-200524957. And since the trunk Removal (step 2) The removal of the QAcm group and the oxidation caused by the two Cys residues to form the disulfide bridge are completed (step 3). Then, ethylenediamine And 3-cisbutane diamine • Alanine is added sequentially to the free C-terminus (step 4). The protective group is then excised and the product uses 86% TFA / 5% T | s / 5% & 〇 / 2% This thiomethane was separated from 2% phenol, and then was precipitated by dry-ice cooling at 20% (step 5). The product was prepared by the reverse phase HpLC was used for purification. The HPLC was a double-effect HpLC system prepared by Va "ian (Rainin). This system was equipped with a protection module (gua" dm〇du | e ) Dynamax c ", 60a,

8 μm, 21 mmx 2 5 cm tube branch, 21 mmx 2 5 cm column, and UV detector (va "jan Dynamax UVD U)" at λ 214 and 254 nm to obtain purity determined by RP-HPLC > The ideal dac of 95%. These steps are described in the following chart.

-210-200524957 SASRIN resin step 1 SPPS 'r

Boc-SANSNPAMAPRERKAGC (Acm) KNFFWKTFTSC (Acm) -Resin Step Pro 2 j1% TFA / DCM

Boc-SANSNPAMAPRERKAGC (Acm) KNFFWKTFTSC (Acm) -〇H Step 3 | l2

Boc-SANSNPAMAPRERKAGCKNFFWKTFTSC-OH ϋ. · 丨. 20% Ν · hexahydropyridinyl j 2. maleic acid

Boc-SANSNPAMAPRERKAGc! KNFFWKTFTSci-0

Buchen 5 j 85% TFA / 5% TIS / 5% H20 / 5% Phenylthiomethane Academy / 5% ft)

H2M-SANSNPAMAPRERKAG0KNFFWKTFTS0-0

Growth hormone release inhibiting factor-28-EDA-MPA -211- 200524957 3. Improvement on mesoamino acid Synthesis of LM-Lys14 (E ∓ MPA)-growth hormone release inhibiting factor-28

DAC · Growth Hormone Release Inhibitory Factor-28 Analogue was manually synthesized on 100 μηιοΐθ grade solid phase peptide synthesis method on a Symphony peptide synthesis machine, which uses Fmoc ^^ Protective Rink amide Μ BHA resin. The following protective amino acids are sequentially added to the resin: 卩 17100〇73 (八 (: 171) -〇 十 卩 010〇

Ser (tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Phe-OH, Fmoc-Thr (t 巳 u) -〇H, FmooLys (Boc) -〇H, Fmoc-T``p (Boc) -〇H, Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Asn (Trt) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Cys (Acm) -OH, Fmoc-Gly-OH, Fmoc -Ala-OH, Fmoc-Lys (Aloc) -OH, Fmoc-Arg (Pbf) -OH, Fmoc-Glu (OtBu) -OH, Fmoc-Arg (Pbf) -〇H, Fmoc-Pro-OH, Fmoc- Ala-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn (Trt) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Asn (Trt) -〇H, Fmoc-Ala-OH, Fmoc-Ser (tBu) -OH. They are sequentially dissolved in N, N-diamidinofluorenylamine (DMF), and O-benzyl-1 -N-N, Ν, Ν ·, Ν, tetramethyl-urea cation hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) to activate it. Removal of Fmoc protective groups is used A solution of 20% (WV) N-hexahydropyridyl group dissolved in N, N-dimethylamidoamine (DM F) was achieved by acting for 20 minutes — 212-200524957 (step 1). Acm group The removal of the group and the oxidation caused by the two residues to form the disulfide bridge are completed by using iodine (step 2). The selective deprotection of the Lys (A | 〇c) group And completed by treating the resin for 2 hours with a 3 eq Pd (PPh3) 4 bath in CHCI3 · N_: h〇Ac (18: 1: 0.5) dissolved in 5 (step 3) The resin was then washed with CHCI3 (6 X 5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL) in DCM. Of it.

'The synthesis is then re-automated to add maleimide diimide propionate (step 4). Between each coupling, the resin was washed three times with N, N-diamidinofluorenylamine (DMF) and three times with isopropanol. The peptide was excised from the resin using 85% TFA / 5% TIS / 5% phenylthiomethane and 5% phenol, and then it was sacrificed by dry-ice-cooling at 20 (step 5). The product was purified by preparative reverse HPLC using a Varian (Rainin) preparative dual-effect HPL0 system. · Using a Phenomenex Luna 10μ phenyl with a flow rate of 9.5 mL / min and more than 180 min -A gradient dilution of 30-55% B in hexyl (0.045% TFA (A) prepared in water and 0.045% TFA (B) prepared in CH3CN), 21 mm X 25 cm column, and λ 214 and 254 nm UV detector (\ / 3 "'丨 3 gate 071131113 parent 11 \ / 0 11) to provide the ideal DAC with> 9 5% purity, which is determined by RP-HPLC. These The steps are described in the following chart. -213- 200524957

Fmoc-RinkAmideMBHA Tree? Purpose Step 丨

SPPS

Boc-SANSNPAMAPRER-Lys (Aloc) AGC (Acm) KNFFWKTFTSC (Acm) -iSgi Step 2

Boc-SANSNPAMAPRER-Lys (Aloc) AG0KNFFWKTFTSC! Resin Step 3

Pd (PPh3) 4 / NMM / HOAc / CHCl3

Boc-SANSNPAMAPRER-Lys-AGCKNFFWKTFTSC- ffigg Buchen 4 3-cis-butene diimide propionate

Y 〇 〇 Boc-SANSNPAMAPRER

85% TFA / 5% TIS / 5% H2〇 / 5% Phenylthiomethane / 5% Phenol 〇 Π Step 5

H2N-SANSNPAMAPRER \

Lys14 (E-MPA) -Inhibitor of Growth Hormone Release-28 -214- 200524957 F_ Preparation of improved peptides from a plurality of hemi-amyl peptides · Improvement at the N-terminus: tj | ^ Ul- W-MPA-Cys1-Endothelin-1 (1-21) · ΟΗ Synthesis of an improved endothelin-1 analogue in a 100 μηιοθ grade solid-phase synthesis system using manual solid-phase synthesis and a sineferney ( Symphony) wins the synthesizer, which uses Fmoc protective Rink Amide Μ β Η A resin. The following protective amino acids are sequentially added to the resin: Fmoc-Trp (Boc) -OH, Fmoc-lle-OH, Fmoc-lle-OH, Fmoc-Asp (〇tBu) -OH , Fmoc-Leu-OH, Fmoc-His (Trt) -OH,

Fmoc-Cys (Acm) -〇H, Fmoc_Phe-〇H, Fmoc-Tyr (tBu) -〇hl, >

Fmoc-Val-OH, Fmoc-Cys (tBu) -OH, Fmoc-Glu (OtBu) -OH, Fmoc-Lys (Boc) -OH, Fmoc-Asp (OtBu) -OH, Fmoc-Met-OH Fmoc-Leu -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Cys (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Cys (Acm) -OH. They are sequentially dissolved in N, N-dimethylformamide (DMF), and azide-1 · yl-N, Ν, Ν., Ν'-tetrafluorenyl group is prepared by using 0-benzene hydrazone. .. Urea cation hexafluoroandrosate (HBTU) and diisopropylethylamine (DIEA) to activate it. Removal of the Fmoc protective group was achieved by using a solution of 20% (V / V) N-hexaargonium in N, N-dimethylamidoamine (DMF) for 20 minutes. (Step 1). The removal of the Acm group and the oxidation caused by the first two Cys residues to form the first — 215-200524957 double-dope bridge system on the resin are accomplished by using a disk (step 2). The removal of the ίΒ u group and the oxidation of the other two Cys residues and the formation of a second disulfide bridge on the resin are accomplished by using thallium (III) (thallium (| 丨 丨) trifluoroacetate) (Step 3). The deprotection of the side Fmoc group g] is achieved using a 20% N-hexahydroσ sigma group and a subsequent 3-M PA conversion (step 4). Resin removal and product separation are performed using 86% TFA / 5% TIS / 5% H2O / 2% phenylthiomethane and 2% phenol, and then # precipitated by dry and ice-cooled [丨 2〇 Do it (step 5). The product was purified by preparative reverse-phase HPLC using a Varian (Rainin) preparative dual-effect HPLC system using a protection module equipped with Dynamax C18, 60A, 8 μιτι (Guard module) DynamaxC18, 60A, 8μηι, 21 mm x 25 cm column, 21 mm x 25 cm column, and UV detector (Varian Dynamax UVD Μ) at λ214 and 254 nm to provide the > 95 The ideal DAC with% purity is determined by RP-HPLC. These steps are described in the following diagrams: -216- 200524957

Fmoc-Rmk Amide MBHA ffiaa 歩 琛 1 SPPS v

FmocC (Acm) SC (tBu) SSLMDKEC (tBu) VYFC (Acm) HLDHW-Resin Buchen 2, γ

FmooCSC (tBu) SSLMDKEC (tBu) VYFCHLDIIW · Tree S Purpose Buchen 3 Trifluoride Acetate (III)

Fmoc-CS (j: SSLMDKE (^ VYFCHLDnW-Resin 3-S Buchen 4 1. 20% N-Hexa: pyridyl 1 3-cis-butene diimide propionate

CS (j: SSLMDKECjVYFCHLD 丨 丨 W-i Shuyuezhi S-S

Buchen 5 | 85% TFA / 5% TIS / 5% H2〇 / 5% Phenylsulfuric Acid A Academy / 5% Phenol

SCjSSLMDKECjVYFCHLDIIW-OH〇 s s

N-MPA-Cys1-Endothelin-1 U-21) -OH-217-200524957 2. Modified HMM 6-Endothelin-1 (1-21) Lys22- (Nε-MPA)- Synthetic modified endothelin-1 analogue of 〇Η in a 100 μmol grade solid phase 肷 synthesis system using a manual solid-phase synthesis method and a Symphony 肷 肷 synthesis machine 'This synthesis machine is used Fmoc protective Rink Amide Μ Β Η A resin. The following protective amino acids are sequentially added to the resin: Fmoc-Lys (Aloc) -OH, Fmoc-Trp (Boc) -OH, Fmoc-lle-OH, Fmoc-lle-OH, Fmoc -Asp (OtBu) -OH, Fmoc-Leu-OH,

Fmoc-His (Trt) -OH, Fmoc-Cys (Acm) -OH, Fmoc-Phe-OH,

Fmoc-Tyr (tBu) -OH, Fmoc-Val-OH, Fmoc-Cys (tBu) -OH,

Fmoc-Glu (OtBu) -OH, Fmoc-Lys > (Boc) -OH, Fmoc-

Asp (〇tBu) -OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-

Ser (tBu) -〇H, Fmoc-Ser (tBu) -OH, Fmoc-Cys (tBu) -OH,

Fmoc-Se "(tBu) -OH, Boc-Cys (Acm) -OH. They are sequentially dissolved in N, N-fluorenyl ammonium amine (DMF) 'and use 〇-benzene hydrazone Diyl-i · yl-N, Ν, Ν ', Ν'-tetramethyl-urea cation hexafluorophosphate (HBTU) and monoisopropylethylamine (DIEAA) to activate it. Fmoc protective group Removal of the group was achieved by using 20% (V / V) N-hexagon dissolved in N, N-diamidinofluorenylamino (DMF). The solution was treated for 20 minutes with a pyridyl solution ( Step ". The removal of the Acm group and the oxidation caused by the first two Cys residues to form the first double bond bridge on the resin are accomplished using iodine (step 2). (Βu group-218 -200524957 The second disulfide bridge formed on the resin by the removal of the group and the oxidation caused by the other two Cys residues uses the three gas acetic acid (丨 M) (tha || ium (丨 丨 丨) t "Ifluo" acetate) to complete (step 3). The selective deprotection of the Lys (A 丨 〇c) group is preferably performed manually, and by using a CHCI3 dissolved in 5 m L ·: 3MM of Pd (PPh3) 4 solution in NMM · HOAc (18: 1: 0.5) to complete the resin treatment for 2 hours to complete Step 4). Then, the resin was made with CHCI3 (6 X 5 mL), 20% HOAc (6 X 5 mL), DCM (6 X 5 mL), and DMF (6 X 5 mL). ) To clean it. Then, the synthesis system was re-automated to add 3-cis-butenediiminopropanoic acid (step 5). Resin removal and product separation were performed using 86% tfa / 57. TlS / 5 % H2〇 / 2 ° / 〇 Benzylthiosulfonate and 2% hope, and then by dry-ice-cold precipitation of 20 (step 5). The product was prepared by reverse phase HPLC To purify, the HPLC uses a Varian (Rainin) dual-effect PLC system. The system uses a Dynamax equipped with a Dynama X C18, 60A, and 8 μηι guard module. 18, 60 input, 8 port [11, 21〇1 ^ 1 parent 25〇111 column, 21 ^ 1〇1 parent 25 (: 171 tube branch, and UV primary detector (λ: 214 and 254 nm) VarianDynamax UVD II ) To provide the ideal DAC with> 95% purity, which is determined by rp-HPLC. These steps are described in the following chart. -219-200524957

Fmoc-Rink Amide MBHA Sae

Step 1 SPPS

V 巳 oc-C (Acm) SCitBu) SSLMDKEC (tBu) VYFC (Acm) HLDIIW-Lys (Aloc) -resin

Step 2 I U V ‘

Boc-i: SC (tBu) SSLMDKEC (tBu) VYFCHLDIIW-Lys (Aloch resin

Step 3 Europium (III) trifluoroacetate v

Boc-tS〒SSLMDKE (pVYFCHLDIIW-LysAI〇c> -Resin Buchen 4Pd (PPh3) 4 / NMM / HOAc / CHC! 3 Resin

Boc-0SCSSLMDKECVYFCHLD !! W-Lys- Step 5 3-ButenediKimine-propionic acid ν

Step 6 | 85% TFA / 5% TIS / 5% Η20 / 5% Phenylthiomethane / 5% Phenol

Endothelin-1 U-21) Lys22 (E-MPA) -OH-220-200524957 3. Modified jf on intermediate amino acids. Example 67-Lys4 (Ns-MPA) Saratoxin B Synthesis of (1-21) -OH-Modified Sarofoxin-B Analog at 1000 μm 〇e-grade solid-phase peptide synthesis using manual solid-phase synthesis and a Symphony Peptide Synthesizer 'This synthesizer uses Fmoc protective Rink Amide MBHA resin. The following protective amino acids were sequentially added to the resin: Fmoc-T "p (Boc) -OH, Fmoc-lle-OH, FmooVaBOH, Fmoc-Asp (〇tBu) -〇. H, Fmoc_Gln (Trt) -〇H, Fmoc-His (Trt) -OH, Fmoc-Cys (Acm) -OH, Fmoc-Phe-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Leu-OH, Fmoc -Cys (tBu) -OH, Fmoc-Glu (〇tBu) -OH, Fmoc-Lys 《Boc) -OH, Fmoc-Asp (OtBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Met- OH, Fmoc-Asp (OtBu) -OH, Fmoc-Lys (Aloc) -OH, Fmoc-Cys (tBu) -OH, Fmoc-Ser (tBu) -OH, Boc-Cys (Acm) -OH. They are sequentially dissolved in N, N-dimethylmethylamine (DMF), and azide-1-yl-N, N, N ·, N, -tetramethyl is prepared by using 0-phenylhydrazone. -Urea cationic hexafluorophosphate (H 巳 TU) and monoisopropylethylamine (DIEA) to activate it. The removal of the Fmoc protective group fluorene is a solution of N, N-difluorenylamine Solution (20% (V / V) N-hexahydropyridyl in DMF) for 20 minutes (step 1). The removal of the Acm group and the first two Cys residues The oxidation results in the formation of the first disulfide bridge on the resin. Using iodine to complete a 221-2: 200524957 (step 2). [Bu group of Removal of the second disulfide bridge formed on the resin by oxidation with the other two Cys residues is accomplished by using thallium (111) tnf | u〇r0acetate (step 3 ). The selective deprotection of the ^^ (Aloe) group is preferably carried out manually, and by using a > CHCI3: NMM ·· H〇Ac (18: 1 ··· 0.5) 3eq of Pd (PPI3) 4 solution to treat the resin for 2 hours to complete (step 4). Then, the resin was CHCI3 (6 X 5 mL), 20% HOAc ( 6x5mL), DCM (6x5mL), and DMF (6x5mL) to clean it. Then, the synthesis system was re-automated to add cis butadiene diacetate (step 5). Resin removal and product separation system This was performed using 86% TFA / 5% TIS / 5% H20 / 2% benzylthiomethane and 2/0 phenol, and then precipitated by dry-ice-cold Ets0 (step 5). The product was purified by a prepared reverse phase PLC, which uses a dual-effect HF prepared by Varian (Rainin); the LC system uses a system equipped with Dynamax C18, 60A, 8 μηι Dynamax C18, 60A, 8 μηι, 21 mm x 25 cm

Column, 21 mmx25 cm column, and UV detectors at 214 and 254 nm ^ 3 "_ 丨 3 门 0 丫 门 3 卬 3 乂 1 ^ 0 丨 1) to provide this > 9 5% purity The ideal DAC is determined by RP-HPLC. These steps are described in the following chart. -222- 200524957

Fmoc-Rink Amide MBHA resin

Buchen 1 SPPS T

Boc-C (Acm) SC (tBu) -Lys (Aloc) -DMTDKECtBu) LYFC (Acm) HQDVlW- Keynote Step Chen 2 1 丨. f-?

Boc-CSC (tBu) -Lys (AI〇d-OMTDK; EC (tBu) LYFCHQDVIW-November Step 3 Proium (III) trifluoroacetate

Boc-CS (p-Lys (Aloc) -DMTDKE < pLYFCHQDVlW-Resin S-S Step 4pd (PPh3) 4 / NMM / HOAc / CHCb

Boc-CSCp-Lys-DMTDKEfLYFCHQDVIW-Resin 3-S Step 5 3-cis-butene diimide propionate

Buchen 6 j. 85% TFA / 5% TIS / 5% H20 / 5%

Lys4 (E-MPA) Sarofoxin B (1-21) -〇H-223- 200524957 F · Peptide Stability Test Example 6 8-K5 Trial Stability Test test. (| ^ 「八） 卞 [* 〇- 八「 9-1_75-1 «611 * · Tyr-Asp-Lys-NH ^ TFA is synthesized by the above method and identified as MPA-K5. This unimproved correspondence The peptide prO-Arg-Lys-Leu-Tyr-Asp-Lys was synthesized by the method described in Example 20 without the addition of 3-MPA, and was identified as K5. K5 (MW1260.18, 918.12 free base) The system was prepared as a 100 mM storage solution in water. MPA-K5 (MW = 1411.17, 1 069.1 1 free base) was prepared as a 100 mM storage solution in water. Human serum white Protein (HSA) was obtained as a 25% solution (ca 250 mg / ml, 3.75 mM), which can be obtained from Alpha Therapeutic · Trademark Aibutein®. Human plasma was obtained from Golden West Biologicals. ⑴Human plasma The box-shaped K5 of K5 is prepared as a 1 μM solution and dissolved in 25% of human serum albumin. Then, the mixture is present in human plasma to a final concentration of K5 of KOMm. Cultured at 37 ° C. At 0,4 hours and hours, 100 µ | droplets were removed from the plasma. The 100 ... The blocking solution (5 hearts, 5%, 2%, 4/3/3 acetonitrile (Acetomt "ile) / 2 v0L methanol) was mixed to precipitate all proteins. -224- 200524957 The sample was rotated at a speed of 10,000 g Centrifuge for 5 minutes, and the supernatant containing the win plate was recovered and filtered through a 10 · 22 μηΊ filter membrane. The free and complete K5 peptides present were analyzed by hplC / MS. The results are As shown below. The η p lC factor system for detecting K5 peptides in serum is as follows. The HPLC method is as follows: a vydac C18 250 X 4.6 mm, 5 μ particle size column is used. The tube The temperature of the column was 30 ° C and the flow rate was 0.5 ml / min. The mobile phase a was 0.1% TFA / water. The mobile phase was already 0.1% TFA / acetonitrile. The injected volume was 10 (J The concentration gradient is as follows: Time (minutes)% A% B 0 95 5 20 70 '30 25 10 90 30 10 90 35 95 5 45 95 5 Detect this protein at 214, 254 and 334 nm. In mass spectrometry' The ionization model is an API electrospray (positive model) with an M / Z range of 300 to 2000. Its transmission ratio (gain) is 3.0, the voltage of the fragment 〇 ″ is ι2〇ν, the threshold is 20, and the step size is 0.1. The temperature of the gas is 350 ° C and the volume of the dry gas is OO-225-200524957 丨 / min. The Neb pressure system is 24 psi and the Vcap system is 3500v. The method of HpLc is as follows: a Vydac C18 250 x 46 mm, 5 μ particle size column is used. The temperature of the column was 3 (rc and the flow rate was 0.5 ml / min. The mobile phase A was 0.1% TFA / water. The mobile phase was already 0.1% TFA / acetonitrile. The injected volume was 10 μ The concentration gradient is as follows:

Time (minutes)% A% B 0 95 5 20 70 30 25 10 90 30 10 90 35 95 5 45 95 5 Detect this protein at 21 4, 254 and 334 nm. In mass spectrometry, the ionization model was an AP electrosprayer (positive model) with an M / Z range of 300 to 2000. The transmission ratio (gain) is 3.0, the voltage of the fragmentor is i20V, the threshold is 20, and the step size is 0.1. The temperature of the gas is 350 ° C and the volume of the dry gas is iQ.Q 丨 / min. The Neb pressure system is 24 psi and the Vcap system is 3500V. A 226- 200524957 sister to plasma 0 hrs. 100% 4 hrs 9% 24 hrs 0% peptide peptide This test fruit indicates that the unmodified K5 victory is unstable in the dish. May be due to the effect of protease activity Scabby. (2) H characterization of IR compound in blood number MPA-K5 (modified K5 peptide) was incubated with 25% HAS at room temperature for 2 hours. Then, the MPA-K5-HAS composition was cultured at 37 in the presence of human plasma at a final concentration of 1 60 µπη. . After the special culture period (0, 4 and 24 hours), 1000 μ μ droplets were taken out and filtered through a 0.22 μπΊ filter membrane. The presence of this complete conjugate was analyzed by HPLC-MS. # The column is an official column of Aquapo e RP-300, 250 X 4.6 mm, 7μ particle size. The temperature of the column is 50 ° C. The mobile phase A is TFA / water mobile phase b is% TFA / Acetonitrile. The volume of the injection is 1 μΐ. The gradients are as follows: -227- 200524957% A% B flow (ml / min) 〇 66 34 0.700 1 66 34 0.700 25 58.8 41.2 0.700 30 50 50 0.70 35 5 95 1.00 41 5 95 1.00 45 66 34 1.00 46 66 34 0.70

Four limbs were detected at 21 4 mm for quantification. In the analysis of Peptide 4, the 'the ionization model is an electric ejector in the range of 1280-1500 m / z', the transmission ratio (gain) of which is 1.0, and the frag men tor ) The voltage is 125v, the threshold is 100, and the step size is 0.40. The gas temperature was 350 ° C, and the volume of the dry gas was 13 〇 / min. The pressure is 60 ps! • and V c a p is 6 0 0 V. The results are shown below. About 33% of circulating albumin in the bloodstream is hydrogen thioalbumin (SH-a 丨 bumin) 'It is not endogenous to hydrogen sulfide compounds (such as' cysteine or glutamine ) Is blocked 'and can therefore react with the cis-butene-9 90 ^ 200524957 group. The other 66% of circulating albumin was blocked by hydrogen thio compounds. This HPLC MS analysis allows identification of capped HAS, SH-albumin, and K5-MPA-albumin. The MPA is covalently bonded to the free thiol group on albumin. The stability of the three forms of albumin in blood packs is shown below. HSA &%% SH- 白 j ％% K5-MPA-HSA 0 hrs. 61.3 16.6 22.1 4 hrs. 64.6 16.05 19.35 24 hrs 63 16.8 20.2 The percentage of the K5-MPA-HAS in 24 hours of plasma The analysis remained fairly consistent during the analysis, and in contrast to the unmodified K5, the unmodified K5 in plasma decreased to 9% of the original K5 content within 4 hours. The knot

The results show that, in contrast to K5, which is very unstable in plasma, the K5-MPA-HAS line in the plasma is quite stable to peptidase activity. Example 70-Dextrin version stability test To determine the stability of the winning composition in the presence of serum-like enzymes, the Dyn A- (1-13) -OH and Dyn A- (1 -13) Peptidase stability of -NH2 and Dyn A 1-13 (MPA) -NH2. The synthetic systems of Dyn A- (1-13) -OH, Dyn A- (1-13) -NH2, and Dyn A 1-13 (MPA) -NH2 -229- 200524957 are as described above. The Diffinin Edition was mixed with a human heparin-treated blood pack to a final endurance of 4 mg / MI. At 37 ° C, after the required incubation time (0, 20, 20, 60, 120, 180, 360, and 480 minutes), add 100 drops to 100 μL of blocking solution (5ν〇 | · 5% aqueous ZnSO4 solution, 3 vol. Acetonitrile, 2 vol · methanol), the blocking solution can sink all the proteins in the temple. After centrifugation (10,000 g, 2.5 minutes), the clear supernatant was recovered, filtered through a 0.45 μm transition membrane, and stored on ice until LC / MS analysis was performed. The sample was analyzed at 21 4 nm using an LC to detect the presence of different compounds, and analyzed by MS to determine the identity of the detected compound. Then, the integrated area area% of each peak obtained from the LC chromatogram was plotted against time and the determined relative stability in human plasma. The stability values of the Dyn A- (1-13) -〇H and Dyn A- (1-13) -NH2T are consistent with the values reported in the journal: the proteolytic degradation system of the dynorphin peptide Quite fast. Oyn A- (1 -1 3) -OH has a half-life of about 10 minutes. Dyn A_ (1-13 NH2 has a half-life of about 30 minutes. In contrast, Dyn A 1-13 (MPA) -NH2 line still shows amazing stability in the presence of a serum peptidase activity. Unmodified dynorphin The peptides were degraded within the meaning of 60. Conversely, the modified dynorphin peptide (〇 乂 118 乂 1-33 (MPA) -N㈠2) was quite stable to serum peptidase activity and could reach 480. Min. The determination of the stability of the dynorphin conjugate is determined by Elisa. In order to determine whether the signal that should be seen is due to the dynorphin conjugate and what kind of conjugate 230-200524957 produces, Analysis of the reaction mixture was performed by an LC mass spectrometer after 8 hours. The use of the mass spectrometer allows the determination of the molecular weight of the conjugate and allows the determination of whether any of the dynorphin conjugates have their heads cut off. Types exist. Mass spectrometry of human plasma shows two types of albumin, namely the free sulfotype of 66436 Da and the oxidized form of 66557 Da. Similarly, the mass spectrometer can distinguish a Dyn 2-13 cut mixed in equal volumes. Both the headless conjugate (68046 Da) and the complete Dyn 1-13 conjugate (68207 Da) The mass spectrometric analysis of the dynorphin sample after 480 minutes of serum exposure to serum peptidase was only the same as in the presence of the intact conjugate (681 92 Da), and different from the degraded conjugate. The stability of the dynorphin conjugate to serum prionase activity.

-231- 200524957

Table 1 Natural Amino Acids and Their Condensation Names 3-letter endings 1-letter abbreviation Protective Amino Acid ί 1 Alanine Ala A Fmoc-Ala-0 Η Arginine Arg R | Fmoc -A "g (Pbf) -〇H Aspartic acid Asn N Fmoc-Asn (Trt) -OH; Aspartic acid Asp D Asp (tBu) -〇H Cysteine Cys C Fmoc-Cys (T rt) Glutamic acid Glu E Fmoc-Glu (tBu) -OH Glutamic acid Gin 〇Fmoc-Gln (T``t) -〇H Glycine Gly G Fmoc-Gly-OH Histidine His H Fmoc-His (T``t) -〇H Isoleucine lie I Fmoc-lle-OH Leucine Leu L Fmoc-Leu-OH Lysine K Fmoc-Lys (Mtt) -OH Met M Fmoc- Met-OH phenylalanine Phe F Fmoc-Phe-OH Proline Pro P Fmoc-Pro-OH Serine Ser, s Fmoc-Ser (tBu) -OH Thr T Fmoc-Thr (tBu) -OH Tryptophan Trp w Fmoc-T, p (Boc) -〇H Tyrosine Tyr, Boc-Tyr (tBu) -〇H Val V Fmoc-Va, BOH-232- 200524957 Sequence Directory < 11 〇 > Conjuchem, Inc.

Bridon, Dominique Ezrin, Alan Milner, Peter Holmes, Darren — Thibaudeau, Karen. ≪ 120 > Protects endogenous therapeutic peptides from the effects of zymase activity by conjugation with blood components < 130 > 2110 < 140〉 < 141〉 < 150〉 60 / 134,406 φ < 151〉 1999-05-17 < 150〉 60 / 153,406 < 151 > 1999-09-10 < 150 > 60 / 159,783 < 151 > 1999-10-18 < 160〉 1617 < 170 > Patentln Ver. 2.1 < 210 > 1 < 211〉 19

< 212 > PRT < 213〉 Artificial sequence < 220 > ® < 223 > Explanation of artificial sequence: Synthetic victory < 400> 1

His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys ^ 15 10 15

Val Tyr Pro < 210〉 2 < 211〉 8 < 212 > PRT < 213 > Artificial Sequence 233 200524957 < 220〉 < 223 > Explanation of Artificial Sequence: Synthetic Victory < 400〉 2

Met Glu His Phe Arg Trp Gly Lys. ≪ 210 > 3 < 211〉 39. ≪ 212〉 PRT < 213 > Artificial Sequences < 220〉 < 223 > Explanation of Artificial Sequences: Synthetic Katsuyuki <; 400> 3 hit Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 15 10 15

Arg Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala 20 25 30

Glu Ala Phe Pro Leu Glu Phe 35 < 210 > 4 < 211〉 13 < 212〉 PRT < 213 > artificial sequence φ < 220 > < 223 > Explanation of artificial sequence: Katsuta Katsuta < 400〉 4

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val _ 1 5 10 < 210 > 5 < 211〉 16 < 212 > PRT < 213 > Artificial sequence < 220 > < 223 > Explanation of artificial sequence ： Synthetic Victory Moon 234 200524957 < 400〉 5

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 15 10 15 < 210 > 6 < 211〉 17 < 212 > PRT < 213 > artificial sequence. ≪ 220> < 223 > artificial Explanation of Sequence: Synthetic Winner: < 400〉 6

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 15 10 15

Arg < 210〉 7 < 211 > 24 < 212 > PRT < 213 > Artificial Sequence < 220〉 < 223〉 Explanation of Artificial Sequence: Synthetic Victory < 400〉 7

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 15 10 15

Arg Arg Pro Val Lys Val Tyr Pro 20 < 210〉 8 < 211〉 7 < 212 > PRT < 213 > Artificial Sequences < 220 > < 223> Explanation of Artificial Sequences: Synthetic Katsukitsu < 400 > 8

Met Glu His Phe Arg Trp Gly 235 200524957 < 210 > 9 < 211 > 32 < 212> PRT < 213 > artificial sequence. ≪ 220 > < 223 > Explanation of artificial sequence:. < 400〉 9

Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val 15 10 15

Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu Glu

< 210> 10 < 211> 22 < 212 > PRT < 213 > Artificial Sequence < 220 > < 223 > Explanation of Artificial Sequence: Synthetic Victory: < 400 > 10

Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu 15 10 15

Ala Phe Pro Leu Glu Phe

< 210 > 11 < 211〉 39 < 212〉 PRT < 213 > Artificial Sequence < 220> < 223 > Explanation of Artificial Sequence: Synthetic Victory < 400 > 11

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala Glu Asn Glu Ser Ala 236 200524957 20 25 30

Glu Ala Phe Pro Leu Glu Phe 35 < 210〉 12. ≪ 211〉 28 < 212〉 PRT-< 213 > Artificial Sequence < 220〉 < 223 > Explanation of Artificial Sequence: Katsuta Katsuta <Synthesis; 400〉 12

Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala • 1 5 10 15

Glu Asn Glu Ser Ala Glu Ala Phe Pro Leu Glu Phe 20 25 < 210 > 13 < 211 > 18 < 212 > PRT < 213 > Artificial Sequence < 220 > < 223 > Explanation of Artificial Sequence: Synthetic Katsuyuki < 400> 13

Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu

Glu Phe < 210 > 14 < 211〉 39 < 212 > PRT < 213 > Artificial sequence < 220 > < 223〉 Explanation of artificial sequence: Synthetic Katsuki Tsukita < 400〉 14

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 237 200524957 15 10 15

Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala Glu Asn Glu Ser Ala 20 25 30

Glu Ala Phe Pro Leu Glu Phe 35. ≪ 210〉 15 < 211 > 28 < 212〉 PRT < 213 > Artificial Sequence < 220〉 φ < 223 > Explanation of Artificial Sequence: Synthetic Victory < 400 > 15

Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala 15 10 15

Glu Asn Glu Ser Ala Glu Ala Phe Pro Leu Glu Phe 20 25 < 210〉 16 < 211〉 18 < 212 > PRT < 213 > Artificial Sequence < 220 > • < 223 > Explanation of Artificial Sequence: Synthesis Victory < 400 > 16

Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu 15 10 15

Glu Phe < 210〉 17 < 211〉 33 < 212 > PRT < 213 > artificial sequence < 220 > 238 200524957 < 223 > Description of artificial sequence: Katsuta Katsuta < 400〉 17

Val Cys Ser Cys Arg Leu Val Phe Cys Arg Arg Thr Glu Leu Arg Val 15 10 15

Gly Asn Cys Leu lie Gly Gly Val Ser Phe Thr Tyr Cys Cys Thr Arg 20 25 30

Val

< 210 > 18 < 211 > 34 • < 212〉 PRT < 213〉 Artificial sequence < 220 > < 223 > Explanation of artificial sequence: Synthetic victory: < 400 > 18

Gly lie Cys Ala Cys Arg Arg Arg Phe Cys Pro Asn Ser Glu Arg Phe 15 10 15

Ser Gly Tyr Cys Arg Val Asn Gly Ala Arg Tyr Val Arg Cys Cys Ser 20 25 30

Arg Arg Φ < 210 > 19 < 211〉 5 < 212 > PRT < 213 > Artificial sequence. ≪ 220> < 223 > Explanation of artificial sequence: Synthetic tsukiyuki < 400 > 19

Met Glu His Phe Phe 1 5

< 210〉 20 < 211〉 5 < 212〉 PRT 239 200524957 < 213 > Artificial Sequence < 220 > < 223 > Explanation of Artificial Sequence: Synthetic Katsukitsu < 400 > 20

Met Glu His Phe Phe 1 5 < 210〉 21 < 211〉 17 < 212〉 PRT < 213 > Artificial sequence < 220〉 < 223 > Explanation of artificial sequence: Katsuta Katsuta

< 400〉 21

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 15 10 15

Arg < 210 > 22 < 211〉 30 < 212〉 PRT < 213 > artificial sequence < 220〉 < 223 > Description of artificial sequence: Synthetic tsukiyoshi Φ < 400 > 22

Arg Lys Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly Arg Arg ^ 15 10 15 、 Asn Ser Ser Ser Ser Gly Ser Ser Gly Ala Gly Gin Lys Arg 20 25 30 < 210 > 23 < 211〉 43 < 212> PRT < 213 > Artificial Sequence < 220 > 240 200524957 < 223 > Explanation of Artificial Sequence: Synthetic Katsuyuki < 400 > 23

Phe Pro Thr lie Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg 15 10 15

Ala His Arg Leu His Gin Leu Ala Phe Asp Thr Tyr Gin Glu Phe Glu 20 25 30, Glu Ala Tyr lie Pro Lys Glu Gin Lys Tyr Ser 35 40 < 210 > 24 φ < 211 > 8 < 212〉 PRT < 213 > Artificial sequence < 220> < 223 > Explanation of artificial sequence: Synthesis of Katsuyuki < 400> 24

Leu Ser Arg Leu Phe Asp Asn Ala 1 5 < 210〉 25 < 211〉 9 < 212〉 PRT < 213 > Artificial Sequence • < 220 > < 223 > Explanation of Artificial Sequence: Katsuta Katsuta < 400 > 25

Cys Glu His Arg Trp Cys Lys Pro Val • 1 5 < 210〉 26 < 211〉 13 < 212〉 PRT < 213 > Artificial Sequence < 220〉 < 223 > Explanation of Artificial Sequence: Synthetic Victory 呔241 200524957 < 400〉 26

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 < 210 > 27 < 211 > 13 < 212 > PRT < 213 > Artificial sequence < 220> < 223 > Explanation of artificial sequence: Katsuyuki Katsuyuki < 400〉 27

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10

< 210 > 28 < 211> 18 < 212 > PRT < 213 > artificial sequence < 220 > < 223 > description of artificial sequence: S Satsuki of synthesis < 400 > 28

Asp Glu Gly Pro Tyr Lys Met Glu His Phe Arg Trp Gly Ser Pro Pro 15 10 15

Lys Asp

< 210 > 29 e < 211 > 13 < 212 > PRT. < 213 > Artificial sequence < 220 > < 223 > Explanation of artificial sequence: Synthetic tsukiyuki < 400〉 29

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 242 200524957 < 210〉 30 < 211〉 12 < 212 > PRT < 213〉 Artificial sequence < 220〉 < 223 > Explanation: Synthetic victory. ≪ 400 > 30

Ser Tyr Ser Met Glu His Arg Trp Gly Lys Pro Val _ 1 5 10

< 210 > 31 < 211〉 11 < 212 > PRT φ < 213 > Artificial sequence < 220 > < 223 > Explanation of artificial sequence: Synthetic victory fl too < 400〉 31

Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe 1 5 10 < 210 > 32 < 211 > 12 < 212〉 PRT < 213〉 Artificial Sequence < 220〉 ® < 223 > Explanation of Artificial Sequence: Synthesis Victory # 1 < 400 > 32

Lys Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe 1 5 10 < 210〉 33 < 211〉 3 < 212〉 PRT < 213 > Artificial Sequence < 220> < 223 > Explanation of Artificial Sequence: Synthesis Victorious limb: < 400 > 33 243 200524957

Pro Leu Gly 1 < 210> 34 < 211 > 6 < 212> PRT. ≪ 213 > Artificial sequence < 220 > • < 223 > Explanation of artificial sequence: Synthetic tsukitsuta < 400 > 34

Asp His Phe Arg Trp Lys 1 5 φ < 210 > 35 < 211〉 12 < 212〉 PRT < 213 > Artificial Sequence < 220> < 223 > Explanation of Artificial Sequence: Synthetic Victory < 400 > 35

Ser Tyr Ser Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10

< 210> 36 < 211 > 12 < 212 > PRT ❿ < 213> Artificial sequence < 220 > < 223 > Explanation of artificial sequence: Synthetic tsukitsuta < 400 > 36

Ser Tyr Ser Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 < 210 > 37 < 211〉 6 < 212 > PRT < 213 > Artificial Sequence < 220> 244 200524957 < 223 > Explanation of Artificial Sequence : Satsuki Katsuyuki < 400 > 37

Glu His Phe Arg Trp Gly 1 5 < 210 > 38. ≪ 211 > 22 < 212〉 PRT-< 213 > Artificial Sequence < 220 > < 223 > Explanation of Artificial Sequence: Synthetic Victory)} too < 400 > 38

Ala Glu Lys Lys Asp Glu Gly Pro Tyr Arg Met Glu His Phe Arg Trp • 1 5 10 15

Gly Ser Pro Pro Lys Asp 20 < 210〉 39 < 211〉 12 < 212 > PRT < 213 > Artificial Sequences < 220〉 < 223 > Explanation of Artificial Sequences: Synthetic Victory fl too &400; 39

Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly Φ 1 5 10 < 210 > 40 < 211〉 7 • < 212〉 PRT < 213 > Artificial Sequence < 220〉 < 223 > Explanation of Artificial Sequence : Satsuki Katsuyuki < 400〉 40

Tyr lie Gin Asn Pro Leu Gly 1 5 245 200524957 &lt; 210 &gt; 41 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉. &Lt; 223〉 Explanation of Artificial Sequence Too <400> 41-Cys Tyr lie Gin Asn Cys Pro Leu Gly 1 5

&lt; 210 &gt; 42 &lt; 211〉 7 • &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400 &gt; 42

Tyr He Thr Asn Cys Pro Tyr 1 5

&lt; 210〉 43 &lt; 211〉 6 &lt; 212 &gt; PRT call &lt; 213〉 Artificial sequence w &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 43

Cys Tyr lie Gin Asn Cys 1 5

&lt; 210〉 44 &lt; 211〉 9 &lt; 212 &gt; PRT 200524957 &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequences: Synthetic Victory Moon &lt; 400> 44

Cys Tyr lie Gin Asn Cys Pro Leu Gly 1 5 &lt; 210> 45 &lt; 211 &gt; 9 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 45

Met Asn lie Lys Gly Ser Pro Trp Lys 1 5 &lt; 210〉 46 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon Too &lt; 400 &gt; 46 e Tyr Phe Gin Asn Pro Arg Gly 1 5 &lt; 210〉 47 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence 247 200524957 &lt; 220 &gt; &lt; 223> artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400〉 47

Tyr lie Gin Asn Pro Arg Gly 1 5 &lt; 210 &gt; 48-&lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> φ &lt; 223 &gt; Explanation of Artificial Sequence &lt; 223 &gt;; 400 &gt; 48

Cys Tyr Phe Gin Asn Cys Pro Lys Gly 1 5 &lt; 210〉 49 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220>

&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 49

Cys Tyr Phe Gin Asn Cys 1 5 &lt; 210〉 50 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 248 200524957 &lt; 400 &gt; 50

Tyr Phe Val Asn Cys Pro Gly 1 5 &lt; 210〉 51 • &lt; 211〉 7 &lt; 212 &gt; PRT, &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta • &lt; 400〉 51

Tyr Phe Gin Asn Cys Pro Arg 1 5 &lt; 210 &gt; 52 &lt; 211 &gt; 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 52 ^ Cys Tyr Phe Gin Asn Cys Pro Arg Gly 1 5 &lt; 210> 53. &Lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Satsuki Tsutsuki &lt; 400 &gt; 53 249 200524957

Cys Tyr Phe Gin Asn Cys Pro Arg 1 5 &lt; 210 &gt; 54 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt;; 400〉 54

Cys Tyr Phe Gin Asn Cys Pro Arg Gly

&lt; 210 &gt; 55 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400〉 55

Tyr Phe Gin Asn Cys Pro Arg Gly

&lt; 210 &gt; 56 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 56

Tyr Phe Gin Asn Cys Pro Arg Gly 1 5 250 200524957 &lt; 210〉 57 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Status &lt; 400 &gt; 57

Ala Phe Gin Asn Cys Pro Arg Gly 1 5 φ &lt; 210〉 58 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 58

Tyr Phe Val Asn Cys Pro Gly 1 5 &lt; 210〉 59 ® &lt; 211 &gt; 8 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence, &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Moon of Synthesis M &lt; 400> 59

Tyr Phe Gin Asn Cys Pro Arg Tyr 1 5 &lt; 210 &gt; 60 200524957 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsura &lt; 400〉 60, lie Phe lie Asn Cys Pro Arg 1 5

&lt; 210〉 61 &lt; 211〉 8 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 61

Tyr Phe Val Asn Cys Pro Arg Gly 1 5

&lt; 210 &gt; 62 &lt; 211 &gt; 8 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 62

Tyr Phe Gin Asn Cys Pro Arg Gly 1 5

&lt; 210> 63 &lt; 211> 6 &lt; 212 &gt; PRT 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 63

Glu Asn Cys Cys Pro Arg 1 5 &lt; 210 &gt; 64 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213> artificial sequence

&lt; 220> &lt; 223 &gt; Explanation of the artificial sequence: S Satsuki of synthesis &lt; 400 &gt; 64

Phe Phe lie Asn Cys Pro Arg Ala 1 5 &lt; 210〉 65 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence Φ &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta &lt; 400〉 65, Tyr Phe Gin Asn Cys Pro Lys 1 5 &lt; 210〉 66 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 200524957 &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Limb: &lt; 400 &gt; 66

Phe Phe lie Asn Cys Pro Arg Ala 1 5 &lt; 210〉 67 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence φ &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 67

Cys Tyr Phe Gin Asn Cys Pro Lys Gly 1 5 &lt; 210 &gt; 68 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> # &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 眈&lt; 400 &gt; 68

Tyr Phe Val Asn Cys Pro Gly 1 5 &lt; 210 &gt; 69 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence 254 &lt; 220〉 200524957 &lt; 223> Explanation of artificial sequence: Synthetic victory 0 &lt; 400 &gt; 69

Cys Phe lie Gin Asn Cys Pro Gly 1 5 &lt; 210〉 70 &lt; 211 &gt; 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; φ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 70

Cys Tyr lie Gin Asn Cys Pro Arg Gly 1 5 &lt; 210 &gt; 71 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta

&lt; 400〉 71

Tyr He Gin Asn Cys Pro Gly 1 5 &lt; 210〉 72 &lt; 211〉 25 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 255 200524957 &lt; 400> 72

Ser Glu Ala Ala Ala Leu Pro Arg Ala Ser Ala Ala Ala Met Arg Ala 15 10 15

Ala Trp Pro Ser Pro Ser Val Glu Gly 20 25 &lt; 210〉 73 &lt; 211〉 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence

&lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 73

Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gin Leu Ala 15 10 15

Gin Glu Ala His Lys Asn Arg Lys Leu Glu He lie 20 25

&lt; 210〉 74 &lt; 211〉 30 w &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉. &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 74

Phe His Leu Leu Arg Glu Met Leu Glu Met Ala Lys Ala Glu Gin Glu 15 10 15

Ala Glu Gin Ala Ala Leu Asn Arg Leu Leu Leu Glu Glu Ala 20 25 30 256 200524957 &lt; 210 &gt; 75 &lt; 211〉 41 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence, &lt; 220〉 &lt; 223 &gt; artificial Explanation of sequence: Synthetic victory 0 too &lt; 400 &gt; 75

Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15 • Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala His 20 25 30

Asn Asn Arg Lys Leu Leu Asp lie Ala 35 40 &lt; 210〉 76 &lt; 211〉 41 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of the artificial sequence: Synthetic Victory Moon &lt; 400 &gt; 76 _ Ser Glu Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Glu Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala His 20 25 30

Ser Asn Arg Lys Leu Met Glu lie lie 35 40 &lt; 210 &gt; 77 257 200524957 &lt; 211〉 41 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 77

Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala His 20 25 30

Ser Asn Arg Lys Leu Leu Asplie Ala 35 40 &lt; 210 &gt; 78 &lt; 211 &gt; 41 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 78

Ser Glu Glu Pro Pro He Ser Leu Asp Leu Thr Phe His Leu Leu Arg ^ 15 10 15

Glu Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala His 20 25 30

Ser Asn Arg Lys Leu Met Glu Asn Phe 35 40 &lt; 210> 79 &lt; 211 &gt; 21 258 200524957 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Tsuki. <400> 79

Ser Glu Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg. 15 10 15

Glu Val Leu Glu Cys 20 • &lt; 210〉 80 &lt; 211 &gt; 33 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400> 80

Asp Leu Thr Phe His Leu Leu Arg Glu Met Leu Glu Met Ala Lys Ala 15 10 15 ^ Glu Gin Glu Ala Glu Gin Ala Ala Leu Asn Arg Leu Leu Leu Glu Glu ^ 20 25 30

Ala &lt; 210 &gt; 81 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Description of Artificial Sequence: Synthetic Victory Moon 259 200524957 &lt; 400> 81 &lt; 210 &gt; 82 &lt; 211 &gt; 28 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400 &gt; 82

Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gin Leu Ala φ 1 5 10 15

Gin Gin Ala His Ser Asn Arg Lys Leu Glu lie lie 20 25 &lt; 210 &gt; 83 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsukita® &lt; 400 &gt; 83

Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gin Leu Ala. 15 10 15. Gin Glu Ala His Lys Asn Arg Lys Leu Glu He lie 20 25 &lt; 210 &gt; 84 &lt; 211 &gt; 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences 260 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 84

Ser Glu Glu Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg Glu 15 10 15

Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala His Ser-20 25 30

Asn Arg Lys Leu Met Glu lie lie 35 40 φ &lt; 210 &gt; 85 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 85 Val Gly Ser Glu 1 &lt; 210〉 86 ® &lt; 211 &gt; 4 &lt; 212 &gt; PRT. &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Too &lt; 400 &gt; 86 Ala Gly Ser Glu &lt; 210 &gt; 87 261 200524957 &lt; 211 &gt; 41 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Yuetai &lt; 400 &gt; 87

Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala His 20 25 30

Ser Asn Arg Lys Leu Leu Asp lie Ala 35 40 &lt; 210 &gt; 88 &lt; 211〉 40 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of the artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 88

Ser Gin Glu Pro Pro He Ser Leu Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Glu Val Leu Glu Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala Tyr Ser 20 25 30

Asn Arg Lys Leu Leu Asp He Ala 35 40

&lt; 210 &gt; 89 &lt; 211 &gt; 27 &lt; 212> PRT 262 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400> 89 -Ser Leu Asp Ser Pro Ala Ala Leu Ala Glu Arg Gly Ala Arg Asn Ala 15 10 15

Leu Gly Gly His Gin Glu Ala Pro Glu Arg Glu 20 25 &lt; 210〉 90 • &lt; 211〉 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsu Ichita &lt; 400〉 90

Glu Gly Pro Pro lie Ser lie Asp Leu Ser Leu Glu Leu Leu Arg Lys 15 10 15

Met lie Glu lie Glu Lys Gin Glu Lys Glu Lys Gin Gin Ala Ala Asn 20 25 30

Asn Arg Leu Leu Leu Asp Thr lie 35 40 &lt; 210 &gt; 91 &lt; 211〉 42 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt;; 400〉 91 263 200524957

Tyr Ser Glu Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu 15 10 15

Arg Glu Val Leu Glu Met Ala Arg Ala Glu Gin Leu Ala Gin Gin Ala 20 25 30. His Ser Asn Arg Lys Leu Met Glu He lie 35 40

&lt; 210 &gt; 92 &lt; 211> 42 &lt; 212 &gt; PRT φ &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 92

Tyr Ser Gin Glu Pro Pro lie Ser Leu Asp Leu Thr Phe His Leu Leu 15 10 15

Arg Glu Val Leu Glu Met Thr Lys Ala Asp Gin Leu Ala Gin Gin Ala 20 25 30

His Ser Asn Arg Lys Leu Leu Asp lie Ala

&lt; 210 &gt; 93 &lt; 211〉 9 &lt; 212〉 PRT Miscellaneous &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic victory fl too &lt; 400〉 93

Tyr Asn Arg Lys Leu Leu Asp He Ala 264 200524957 1 5 &lt; 210> 94 &lt; 211 &gt; 41 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • Description of &lt; 223 &gt; Artificial Sequence: Synthetic Katsuta &lt; 400 &gt; 94

Tyr Asp Asp Pro Pro Leu Ser lie Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Thr Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu 20 25 30

Gin Asn Arg lie lie Phe Asp Ser Val 35 40 &lt; 210> 95 &lt; 211 &gt; 41 &lt; 212> PRT &lt; 213 &gt; artificial sequence

&lt; 223 &gt; Explanation of the artificial sequence: Synthetic Victory Moon &lt; 400〉 95 -Tyr Asp Asp Pro Pro Leu Ser lie Asp Leu Thr Phe His Leu Leu Arg 15 10 15

Thr Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu 20 25 30

Gin Asn Arg lie He Phe Asp Ser Val 35 40 265 200524957 &lt; 210 &gt; 96 &lt; 211〉 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 96

Asp Asn Pro Pro Leu Ser lie Asp Leu Thr Phe His Leu Leu Arg Thr 15 10 15

Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu Gin 20 25 30

Asn Arg lie lie Phe Asp Ser Val 35 40 &lt; 210> 97 &lt; 211 &gt; 40 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence_ &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 97 ^ Asp Asp Pro Pro Leu Ser lie Asp Leu Thr Phe His Leu Leu Arg Thr 15 10 15

Leu Leu Glu Leu Ala Arg Thr Gin Ser Gin Arg Glu Arg Ala Glu Gin 20 25 30

Asn Arg lie lie Phe Asp Ser Val 35 40 266 200524957 &lt; 210 &gt; 98 &lt; 211 &gt; 41 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 98

Asn Asp Asp Pro Pro lie Ser lie Asp Leu Thr Phe His Leu Leu Arg 15 10 15 ^ Asn Met lie Glu Met Ala Arg lie Glu Asn Glu Arg Glu Gin Ala Gly 20 25 30

Leu Asn Arg Lys Tyr Leu Asp Glu Val 35 40 &lt; 210 &gt; 99 &lt; 211〉 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 99

Ala Gly Thr Ala Asp Cys Phe Trp Lys Tyr Cys Val 1 5 10 &lt; 210 &gt; 100 &lt; 211〉 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 267 &lt; 220 &gt; 200524957 &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 100

Ala Gly Asn Leu Ser Glu Cys Phe Trp Lys Tyr Cys Val 1 5 10-&lt; 210 &gt; 101 &lt; 211〉 46-&lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223〉 of artificial sequence Explanation: Synthetic victory over moon too

&lt; 400〉 101

Thr Gly Ser Gly Pro Ser Leu Ser lie Val Asn Pro Leu Asp Val Leu 15 10 15

Arg Gin Arg Leu Leu Leu Glu lie Ala Arg Arg Arg Met Arg Gin Ser 20 25 30

Gin Asp Gin lie Gin Ala Asn Arg Glu He Leu Gin Thr lie 35 40 45 &lt; 210 &gt; 102 ® &lt; 211 &gt; 41 &lt; 212 &gt; PRT. &Lt; 213 &gt; Artificial sequence. &Lt; 220 &gt; &lt; 223 &gt; Artificial Explanation of sequence: Synthetic victory rib: &lt; 400〉 102

Ser Glu Asp Pro Pro Met Ser lie Asp Leu Thr Phe His Met Leu Arg 15 10 15

Asn Met lie His Met Ala Lys Met Glu Gly Glu Arg Glu Gin Ala Gin 268 200524957 20 25 30 lie Asn Arg Asn Leu Leu Asp Glu Val 35 40 &lt; 210〉 103-&lt; 211〉 29 &lt; 212〉 PRT-&lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too φ &lt; 400 &gt; 103

Phe Glu Cys Thr Thr His Gin Pro Arg Ser Pro Leu Arg Asp Leu Lys 15 10 15

Gly Ala Leu Glu Ser Leu lie Glu Glu Glu Thr Gly Gin 20 25 &lt; 210〉 104 &lt; 211 &gt; 29 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence® &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuyuki &lt; 400〉 104 .Phe Glu Cys Thr Thr His Gin Pro Arg Ser Pro Leu Arg Asp Leu Lys 15 10 15

Gly Ala Leu Glu Ser Leu lie Glu Glu Glu Thr Gly Gin 20 25 &lt; 210〉 105 &lt; 211〉 13 269 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence : Synthetic Winner:. &400; 105

Asp Ala Glu Asn Leu He Asp Ser Phe Gin Glu lie Val. 1 5 10

&lt; 210> 106 &lt; 211 &gt; 13 &lt; 212 &gt; PRT φ &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 106

Asn Thr Glu His Leu Val Asp Ser Phe Gin Glu Met Gly 1 5 10 &lt; 210> 107 &lt; 211 &gt; 13 &lt; 212> PRT &lt; 213 &gt; artificial sequence

&lt; 220 &gt; m &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory flfl &lt; 400 &gt; 107

Asp Thr Ser His His Asp Gin Asp His Pro Thr Phe Asp 1 5 10 &lt; 210 &gt; 108 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 270 200524957 &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 108 &lt; 210 &gt; 109, &lt; 211〉 26 &lt; 212〉 PRT, &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory H too &lt; 400〉 109 ^ Trp Cys Leu Glu Ser Ser Gin Cys Gin Asp Leu Ser Thr Glu Ser Asn 15 10 15

Leu Leu Ala Cys lie Arg Ala Cys Lys Pro 20 25 &lt; 210 &gt; 110 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220>

&lt; 223〉 Explanation of artificial sequence: Synthetic victory: &lt; 40〇 &gt; 110

Gin His Trp Ser Tyr Gly Leu Ser Pro Gly 1 5 10 &lt; 210 &gt; 111 &lt; 211〉 44 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Peptide 271 200524957 &lt; 400> 111

Tyr Ala Asp Ala He Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg Gin Gin Gly ‘20 25 30 * · Glu Ser Asn Gin Glu Arg Gly Ala Arg Ala Arg Leu 35 40

&lt; 210〉 112 &lt; 211〉 44 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 112

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Asn Arg Gin Gin Gly 20 25 30

Glu Arg Asn Gin Glu Gin Gly Ala Lys Val Arg Leu 35 40 &lt; 210 &gt; 113 &lt; 211〉 44 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tokiyuki &lt; 400 &gt; 113 272 200524957

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp He Met Ser Arg Gin Gin Gly 20 25 30

Glu Arg Asn Gin Glu Gin Gly Ala Arg Val Arg Leu 35 40 &lt; 210 &gt; 114 &lt; 211〉 29 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence

&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 114

His Ala Asp Ala lie Phe Thr Ser Ser Tyr Arg Arg lie Leu Gly Gin 15 10 15

Leu Tyr Ala Arg Lys Leu Leu His Glu lie Met Asn Arg 20 25

&lt; 210> 115 &lt; 211 &gt; 30 # &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;. &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 115

Val Asp Ser Met Trp Ala Glu Gin Lys Gin Met Glu Leu Glu Ser lie 15 10 15

Leu Val Ala Leu Leu Gin Lys His Ser Arg Asn Ser Gin Gly 20 25 30 273 200524957 &lt; 210 &gt; 116 &lt; 211〉 29 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence- &lt; 220 &gt; &lt; 223 &gt; Artificial Explanation of Sequence: Synthetic Victory &lt; 400> 116

Tyr Ala Asp Ala He Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15 • Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg 20 25 &lt; 210 &gt; 117 &lt; 211〉 29 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400> 117

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15 -Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg 20 25 &lt; 210 &gt; 118 &lt; 211〉 29 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon 274 200524957 &lt; 400 &gt; 118

Tyr Arg Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg. 20 25

. &lt; 210〉 119 &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence φ &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400〉 119

His Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp He Ser Arg Gin Gin Gly 20 25 30

&lt; 210 &gt; 120 &lt; 211> 37 &lt; 212> PRT ⑩ &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 120

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg Gin Gin Gly 20 25 30 275 200524957

Glu Ser Asn Gin Glu 35 &lt; 210 &gt; 121 &lt; 211〉 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence ^ &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 121

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin # 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp He Met Ser Arg Gin Gin Gly 20 25 30

Glu Ser Asn Gin Glu Arg Gly Ala 35 40 &lt; 210 &gt; 122 &lt; 211〉 40 &lt; 212〉 PRT &lt; 213〉 artificial sequence

&lt; 223〉 An explanation of the artificial sequence: Synthetic Victory Moon m &lt; 400 &gt; 122 -Tyr Ala Asp Ala He Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg Gin Gin Gly 20 25 30

Glu Ser Asn Gin Glu Arg Gly Ala 35 40 276 200524957 &lt; 210 &gt; 123 &lt; 211 &gt; 15 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence, &lt; 220〉 &lt; 223 &gt; description of artificial sequence: born of synthesis Yuetai &lt; 400 &gt; 123

Glu Gin Gly Glu Ser Asn Gin Glu Arg Gly Ala Arg Ala Arg Leu 1 5 10 15

&lt; 210> 124 &lt; 211 &gt; 42 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400> 124

His Val Asp Ala He Phe Thr Thr Asn Tyr Arg Lys Leu Leu Ser Gin 15 10 15 • Leu Tyr Ala Arg Lys Val lie Gin Asp lie Met Asn Lys Gin Gly Glu 20 25 30

Arg lie Gin Glu Gin Arg Ala Arg Leu Ser, 35 40 &lt; 210〉 125 &lt; 211〉 44 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 277 &lt; 220〉 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tokiyuki &lt; 400 &gt; 125

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys lie Leu Gly Gin 15 10 15 • Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Asn Arg Gin Gin Gly 20 25 30 Thai

Glu Arg Asn Gin Glu Gin Gly Ala Lys Val Arg Leu 35 40 &lt; 210〉 126 φ &lt; 211 &gt; 43 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis Tokiyuki &lt; 400 &gt; 126

His Ala Asp Ala lie Phe Thr Ser Ser Tyr Arg Arg lie Leu Gly Gin 15 10 15

Leu Tyr Ala Arg Lys Leu Leu His Glu lie Met Asn Arg Gin Gin Gly 20 25 · 30

Glu Arg Asn Gin Glu Gin Arg Ser Arg Phe Asn 35 40 &lt; 210〉 127 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory呔 278 200524957 &lt; 400〉 127

His Trp Ala Trp Phe Lys 1 5 &lt; 210〉 128-&lt; 211〉 6

^ &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki

&lt; 400〉 128

His Trp Ala Trp Phe Lys 1 5 &lt; 210 &gt; 129 &lt; 211 &gt; 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta

&lt; 400〉 129 -Ala Ala Trp Phe Lys 1 5 &lt; 210〉 130 &lt; 211 &gt; 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory呔 200524957 &lt; 400 &gt; 130

His Trp Lys Trp Phe Lys 1 5 &lt; 210 &gt; 131 _ &lt; 211〉 6

r &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuyuki

&lt; 400〉 131

Ala Ala Ala Trp Phe Leu 1 5 &lt; 210> 132 &lt; 211 &gt; 45 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory B too 400〉 132

His Ala Asp Gly Met Phe Asn Lys Ala Tyr Arg Lys Ala Leu Gly Gin _ 15 10 15 ^ Leu Ser Ala Arg Lys Tyr Leu His Thr Leu Met Ala Lys Arg Val Gly 20 25 30

Gly Gly Ser Met lie Glu Asp Asp Asn Glu Pro Leu Ser 35 40 45 &lt; 210〉 133 &lt; 211〉 44 280 200524957 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation: Satsuki Katsuyuki &lt; 400〉 133

Tyr Ala Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin 15 10 15

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Asn Ser Arg Gin Gin Gly

Glu Ser Asn Gin Glu Arg Gly Ala Arg Ala Arg Leu 35 40 &lt; 210 &gt; 134 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Peptide Φ &lt; 400〉 134

Tyr Ala Asp Ala He Phe Thr Asn Cys Tyr Arg Lys Val Leu Cys Gin ^ 15 10 15 ^ Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Ser Arg 20 25 &lt; 210 &gt; 135 &lt; 211 &gt; 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 28] 200524957 &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 135

Phe Ser Lys Lys Leu Lys Pro Ala 1 5 &lt; 210 &gt; 136, &lt; 211 &gt; 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> 说明 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 136

Glu His Trp Ser His Gly Trp Tyr Pro Gly 1 5 10 &lt; 210〉 137 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory)} &lt; 400> 137

Glu His Trp Ser Tyr Gly Leu Arg Pro Gly 1 5 10 &lt; 210 &gt; 138 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Yuetai 282 200524957 &lt; 400〉 138

Phe Ser Tyr Leu Arg Pro Ala

&lt; 210 &gt; 139 &lt; 211〉 10 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta

&lt; 400 &gt; 139

Glu His Trp Ser Tyr Ala Leu Arg Pro Gly 1 5 10 &lt; 210 &gt; 140 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory limb:

&lt; 400〉 140

Glu His Trp Ser Tyr Gly Leu Gin Pro Gly 1 5 10 • &lt; 210〉 141 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsu fl too 283 200524957 &lt; 400 &gt; 141

His Trp Ser Tyr Val Arg Pro 1 5 &lt; 210 &gt; 142 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory • &lt; 400〉 142

Glu His Trp Ser Tyr Lys Leu Arg Pro Gly 1 5 10 &lt; 210 &gt; 143 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 143 • Glu Phe Pro Ser Tyr Phe Leu Arg Pro Gly 1 5 10 &lt; 210> 144, &lt; 211> 9 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Synthetic Katsuyuki &lt; 400〉 144 284 200524957

Phe Trp Ser Tyr Ala Leu Arg Pro Gly 1 5 &lt; 210〉 145 &lt; 211〉 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 145 ^ Glu Phe Trp Ser Tyr Trp Leu Arg Pro Gly 1 5 10 &lt; 210〉 146 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory 0 too <400> 146

Glu His Trp Ser Tyr Gly Leu Arg Pro

&lt; 210〉 147. &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 147 285 200524957

Glu His Trp Ser Tyr Ala Leu Arg Pro 1 5 &lt; 210 &gt; 148 &lt; 211 &gt; 9 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223〉 Explanation of artificial sequence fl: victory over synthesis fl Too &lt; 400 &gt; 148

His Trp Ser Tyr Trp Leu Arg Pro Gly

&lt; 210〉 149 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 149

Glu His Trp Ser Tyr Trp Leu Arg Pro

&lt; 210 &gt; 150. &lt; 211 &gt; 8 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 150

His Trp Ser Tyr Ser Leu Arg Pro 1 5 286 200524957 &lt; 210〉 151 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 M &lt; 400> 151

Glu His Trp Ser Tyr Arg Trp Leu Pro 1 5

&lt; 210> 152 &lt; 211 &gt; 4 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B too &lt; 400 &gt; 152 Leu Arg Pro Gly 1 • &lt; 210 &gt; 153 &lt; 211 &gt; 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &400; 153

His Trp Ser Tyr Gly Leu Arg Pro Gly 1 5 287 200524957 &lt; 210 &gt; 154 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too 4T. &Lt; 400 &gt; 154

Glu His Tyr Ser Leu Glu Trp Lys Pro Gly 1 5 10 # &lt; 210 &gt; 155 &lt; 211〉 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 155

Glu His Trp Ser Tyr Gly Trp Leu Pro Gly 1 5 10

&lt; 210 &gt; 156 &lt; 211〉 7 &lt; 212 &gt; PRT-&lt; 213 &gt; Artificial Sequence-&lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400〉 156

Ser Tyr Gly Leu Arg Pro Gly 1 5 288 200524957 &lt; 210 &gt; 157 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon Mt. &lt; 400〉 157

His Trp Ser Tyr Gly Leu Lys Pro Gly 1 5 &lt; 210 &gt; 158 • &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon Too &lt; 400 &gt; 158

Phe Phe Ser Tyr Leu Arg Pro 1 5 &lt; 210 &gt; 159 &lt; 211〉 9

• &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt;. &Lt; 223 &gt; Description of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 159

His Trp Ser Tyr Gly Trp Leu Pro Gly 1 5 &lt; 210〉 160 289 200524957

&lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉-&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory? &lt; 400> 160

His Trp Ser Tyr Ser Leu Arg Pro Gly 1 5 &lt; 210 &gt; 161 Φ &lt; 211 &gt; 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl Too &lt; 400 &gt; 161

Ala Phe Trp Ser Tyr Ser Leu Arg Pro 1 5

&lt; 210 &gt; 162 &lt; 211〉 31 &lt; 212 &gt; PRT-&lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400 &gt; 162

Glu Pro Asp Cys Cys Arg Gin Lys Thr Cys Ser Cys Arg Leu Tyr Glu 15 10 15

Leu Leu His Gly Ala Gly Asn His Ala Ala Gly lie Leu Thr Leu 290 200524957 20 25 30 &lt; 210〉 163 &lt; 211 &gt; 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb: &lt; 400〉 163

Arg Ser Gly Pro Pro Gly Leu Gin Gly Arg Leu Gin Arg Leu Leu Gin 15 10 15

Ala Ser Gly Asn His Ala Ala Gly lie Leu Thr Met 20 25 &lt; 210〉 164 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki

&lt; 400 &gt; 164

Arg Pro Gly Pro Pro Gly Leu Gin Gly Arg Leu Gin Arg Leu Leu Gin 15 10 15

Ala Asn Gly Asn His Ala Ala Gly lie Leu Thr Met 20 25

&lt; 210 &gt; 165 &lt; 211 &gt; 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 291 200524957 &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory: &lt; 400〉 165

Ser Arg Thr His Arg His Ser Met Glu He Arg Thr Pro Asp lie Asn 15 10 15

Pro Ala Trp Tyr Ala Ser Arg Gly lie Arg Pro Val Gly Arg Phe, 20 25 30

&lt; 210〉 166 &lt; 211〉 20 &lt; 212〉 PRT φ &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthesis of Katsuyuki Tai &lt; 400> 166

Thr Pro Asp lie Asn Pro Ala Trp Tyr Ala Ser Arg Gly lie Arg Pro 15 10 15

Val Gly Arg Phe 20 Φ &lt; 210〉 167 &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsukitsu &lt; 400> 167

Ser Arg Ala His Gin His Ser Met Glu Thr Arg Thr Pro Asp lie Asn 1 5 10 15 292 200524957

Pro Ala Trp Tyr Thr Gly Arg Gly lie Arg Pro Val Gly Arg Phe 20 25 30 &lt; 210 &gt; 168 &lt; 211〉 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Artificial sequence Explanation: Synthetic Victory Limb: &lt; 400 &gt; 168 ^ Thr Pro Asp lie Asn Pro Ala Trp Tyr Thr Gly Arg Gly lie Arg Pro 15 10 15

Val Gly Arg Phe 20 &lt; 210〉 169 &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223〉 An explanation of the artificial sequence: Satsuki Katsuta &lt; 400 &gt; 169

Ser Arg Ala His Gin His Ser Met Glu He Arg Thr Pro Asp lie Asn 1 5 10 15

Pro Ala Trp Tyr Ala Ser Arg Gly He Arg Pro Val Gly Arg Phe 20 25 30 &lt; 210〉 170 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 293 200524957 &lt; 220 &gt; &lt; 223 &gt; Artificial Explanation of sequence: Synthetic Tsukiyuki <400> 170

Thr Pro Asp lie Asn Pro Ala Trp Tyr Ala Gly Arg Gly lie Arg Pro-15 10 15 • Val Gly Arg Phe 20 &lt; 210 &gt; 171 &lt; 211〉 5

Φ &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic victory 0 too &lt; 400 &gt; 171

Ala Tyr Trp Lys Phe 1 5

&lt; 210 &gt; 172 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 8 too &lt; 400> 172

Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 1 5 10 &lt; 210〉 173 &lt; 211 &gt; 17 294 200524957 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyuki &lt; 400〉 173

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 15 10 15

Lys Φ &lt; 210 &gt; 174 &lt; 211 &gt; 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 174

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 15 10 15

. &lt; 210〉 175 &lt; 211 &gt; 14-&212; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 175 295 200524957

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 &lt; 210 &gt; 176 &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 176

Ala Gly Cys Lys Asn Phe Phe Lys Thr Phe Thr Ser Cys

&lt; 210 &gt; 177 &lt; 211 &gt; 13 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 177

Ala Gly Cys Lys Asn Phe Phe Lys Thr Tyr Thr Ser Cys 1 5 10

&lt; 210 &gt; 178 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400> 178

Cys His His Phe Phe Lys Thr Phe Thr Ser Cys 296 200524957 1 5 10 &lt; 210 &gt; 179 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; • &lt; 223〉 Explanation of artificial sequence : Satsuki Katsuyuki &lt; 400〉 179

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Trp Thr Ser Cys 1 5 10

&lt; 210 &gt; 180 &lt; 211> 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 180

Phe Cys Tyr Thr Thr 1 5

# &lt; 210 &gt; 181 &lt; 211〉 27 &lt; 212 &gt; PRT. &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400〉 181

Ser Ala Asn Ser Asn Pro Ala Ala Pro Arg Glu Arg Lys Ala Gly Cys 1 5 10 15 297 200524957

Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 &lt; 210 &gt; 182 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 182 • Phe Cys Phe Lys Thr Cys Thr 1 5 &lt; 210 &gt; 183 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223> Explanation of artificial sequence : Victory of Synthesis fl too &lt; 400 &gt; 183

Ala Pro Ser Asp Pro Arg Leu Arg Gin Phe Leu Gin Lys Ser Leu Ala ® 1 5 10 15

Ala Ala Ala Gly Lys Gin Glu Leu Ala Lys Tyr Phe Leu Ala Glu Leu 20 25 30 &lt; 210 &gt; 184 &lt; 211 &gt; 15 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence 298 200524957 &lt; 220> &lt; 223 &gt; Explanation of the artificial sequence: Satsuki Katsuyuki <400>

Tyr Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 15 10 15 &lt; 210 &gt; 185 • &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 H &lt; 223 &gt; Artificial Explanation of sequence: synthetic peptide &lt; 400 &gt; 185

Tyr Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 &lt; 210 &gt; 186 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence : Satsuki Katsuyuki &lt; 400 &gt; 186

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Tyr Arg Lys 1 5 10 &lt; 210 &gt; 187 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213〉 artificial sequence 299 &lt; 220 &gt; 200524957 &lt; 223 &gt; artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400〉 187

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Tyr Thr Ser Cys 1 5 10

• &lt; 210〉 188 &lt; 211〉 15 • &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta

&lt; 400 &gt; 188

Tyr Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 15 10 15 &lt; 210 &gt; 189 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory over moon too

&lt; 400 &gt; 189

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 &lt; 210> 190 &lt; 211 &gt; 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence : Victory of Synthesis 300 200524957 &lt; 400 &gt; 190 Phe Trp Lys Thr &lt; 210 &gt; 191 &lt; 211 &gt; 25 &lt; 212〉 PRT • &lt; 213> Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence : Synthetic Victory Moon too # &lt; 400 &gt; 191

Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly Cys Lys Asn 15 10 15

Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 &lt; 210 &gt; 192 &lt; 211〉 28 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence

&lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Synthetic Victory Moon &lt; 400〉 192 w Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly 15 10 15

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 &lt; 210 &gt; 193 &lt; 211〉 12 301 200524957 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic victory 0 too. &Lt; 400 &gt; 193

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu. 1 5 10

&lt; 210〉 194 &lt; 211〉 29 &lt; 212〉 PRT φ &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 194

Tyr Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala 15 10 15

Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 20 25 &lt; 210〉 195 Φ &lt; 211〉 28 &lt; 212〉 PRT &lt; 213〉 Artificial sequence. &Lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence : Satsuki Katsuyuki &lt; 400〉 195

Ser Ala Asn Ser Asn Pro Ala Leu Ala Pro Arg Glu Arg Lys Ala Gly 15 10 15

Cys Lys Asn Phe Phe Trp Lys Thr Tyr Thr Ser Cys 302 200524957 20 25 &lt; 210〉 196 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence : Synthetic Victory 0 Too <400> 196

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys φ 1 5 10 &lt; 210〉 197 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence Explanation: Katsuyuki Katsuta &lt; 400 &gt; 197

Phe Cys Tyr Trp Lys Val Cys Trp

. &lt; 210 &gt; 198 &lt; 211〉 8 • &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 22〇 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuyuki Katsuta &lt; 400〉 198

Phe Cys Tyr Trp Lys Val Cys Trp 303 200524957 &lt; 210〉 199 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 199

Phe Cys Tyr Trp Thr Thr

&lt; 210> 200 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 200

Ala Cys Tyr Trp Leu Val Cys Thr

&lt; 210> 201% &lt; 211 &gt; 14 &lt; 212> PRT. &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 201

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 304 200524957 &lt; 210 &gt; 202 &lt; 211〉 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Artificial Sequence Explanation: Synthetic winning rib: &lt; 400〉 202 His Pro Gly Φ &lt; 210 &gt; 203 &lt; 211〉 1 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 203 Thr

&lt; 210 &gt; 204 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 204 Thr His Pro 200524957 &lt; 210 &gt; 205 &lt; 211> 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide • &lt; 400> 205

Glu His Pro 1 &lt; 210 &gt; 206 • &lt; 211〉 3 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 206 Glu Gin Pro 1 &lt; 210〉 207 Φ &lt; 211 &gt; 2 &lt; 212〉 PRT. &Lt; 213〉 Artificial sequence, &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400〉 207 Glu His &lt; 210〉 208 200524957 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223〉 Artificial Sequences Description: Synthetic Katsukitsu &lt; 400 &gt; 208 His Pro Gly Lys &lt; 210 &gt; 209 &lt; 211〉 3

# &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Description of Artificial Sequences: Synthetic Victory Moon &lt; 400 &gt; 209 His Pro Gly 1

&lt; 210 &gt; 210 &lt; 211 &gt; 2 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 210 Glu Pro &lt; 210 〉 211 200524957 &lt; 211〉 2 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &400; 211 • Phe Pro 1

&lt; 210 &gt; 212 &lt; 211> 22 φ &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 212

Phe Leu Trp Lys Asp Leu Gin Arg Val Arg Gly Asp Leu Gly Ala Ala 15 10 15

Leu Asp Ser Trp lie Thr 20

&lt; 210> 213 &lt; 211 &gt; 24 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400> 213

Glu Glu Glu Glu Lys Asp lie Glu Ala Glu Glu Arg Gly Asp Leu Gly 15 10 15 308 200524957

Glu Gly Gly Ala Trp Arg Leu His 20 &lt; 210〉 214 &lt; 211〉 10 &lt; 212 &gt; PRT ^ &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 214

Ser Phe Pro Trp Met Glu Ser Asp Val Thr • 1 5 10 &lt; 210 &gt; 215 &lt; 211〉 32 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki

&lt; 400〉 215

Cys Ala Ser Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gin Glu Leu 15 10 15

His Lys Leu Gin Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro 20 25 30 &lt; 210 &gt; 216 &lt; 211 &gt; 32 &lt; 212> PRT &lt; 2] 3 &gt; Artificial sequence 309 200524957 &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Synthesis of Katsuyuki too <400> 216

Cys Ser Asn Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gin Glu Leu 1 5 10 15

His Lys Leu Gin Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro 20 25 30

&lt; 210〉 217 &lt; 211〉 32 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400 &gt; 217

Cys Gly Asn Leu Ser Thr Cys Met Leu Gly Thr Tyr Thr Gin Asp Phe 15 10 15

Asn Lys Phe His Thr Phe Pro Gin Thr Ala lie Gly Val Gly Ala Pro 20 25 30

&lt; 210 &gt; 218. &lt; 211 &gt; 32 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 218

Cys Ser Asn Leu Ser Thr Cys Val Leu Ser Ala Tyr Trp Arg Asn Leu 15 10 15 310 200524957

Asn Asn Phe His Arg Phe Ser Gly Met Gly Phe Gly Pro Glu Thr Pro 20 25 30 &lt; 210〉 219. &Lt; 211〉 32 &lt; 212 &gt; PRT-&lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Synthesis of Katsuyuki Tai φ &lt; 400 &gt; 219

Cys Gly Asn Leu Ser Thr Cys Met Leu Gly Thr Tyr Thr Gin Asp Leu 15 10 15

Asn Lys Phe His Thr Phe Pro Gin Thr Ser lie Gly Val Gly Ala Pro 20 25 30 &lt; 210 &gt; 220 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence_ &lt; 220〉 &lt; 223〉 Artificial Explanation of sequence: Synthetic victory 0 too <400> 220-Cys Ser Asn Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gin Glu Leu 15 10 15

His Lys Leu Gin Thr Tyr Pro Arg Thr Asn Thr Gly Ser Gly Thr Pro 20 25 30 &lt; 210 &gt; 221 311 200524957 &lt; 211〉 25 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning ribs: &lt; 400 &gt; 221 * Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys Leu Gin Thr Tyr Pro 15 10 15

Arg Thr Asn Thr Gly Ser Gly Thr Pro 20 25 # &lt; 210 &gt; 222 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory at &lt; 400 &gt; 222

Asp Met Ser Ser Asp Leu Glu Arg Asp His Arg Pro His Val Ser Met 15 10 15

Pro Gin Asn Ala Asn 20 &lt; 210 &gt; 223-&lt; 211〉 57 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsukita &lt; 4〇 0 &gt; 223 312 200524957

Ala Pro Phe Arg Ser Ala Leu Glu Ser Ser Pro Ala Asp Pro Ala Thr 15 10 15

Leu Ser Glu Asp Glu Ala Arg Leu Leu Leu Ala Ala Leu Val Gin Asp 20 25 30. Tyr Val Gin Met Lys Ala Ser Glu Leu Glu Gin Glu Gin Glu Arg Glu 35 40 45

Gly Ser Ser Leu Asp Ser Pro Arg Ser 50 55

&lt; 210 &gt; 224 &lt; 211〉 37 φ &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400〉 224

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Ser Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Gin Ala Phe 35 *. &Lt; 210 &gt; 225 &lt; 211 &gt; 19 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon 313 200524957 &lt; 400 &gt; 225

Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser 15 10 15

Lys Ala Phe &lt; 210〉 226 * &lt; 211〉 19 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt;

&lt; 223〉 Explanation of artificial sequence: Synthetic victory limb: &lt; 400 &gt; 226

Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser 15 10 15

Lys Ala Phe

&lt; 210 &gt; 227 &lt; 211> 15 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuyuki-&lt; 400 &gt; 227

Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe 15 10 15

&lt; 210〉 228 &lt; 211〉 37 &lt; 212> PRT 314 200524957 &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 228

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val 20 25 30 ❿ Gly Ser Lys Ala Phe 35 &lt; 210〉 229 &lt; 211 &gt; 37 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory I too &lt; 400> 229

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu 15 10 15

Ser Arg Ser Gly Gly Val Gly Lys Asn Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Lys Ala Phe 35 &lt; 210 &gt; 230 &lt; 211〉 37 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 31 $ 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 230

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu • 15 10 15 ， Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Lys Ala Phe

&lt; 210 &gt; 231 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Satsuki Taito &lt; 400 &gt; 231

Cys Gly Asn Leu Ser Thr Cys 1 5 Φ &lt; 210 &gt; 232 &lt; 211〉 16. &Lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence &lt; 400 &gt; 232

Asp Met Ala Lys Asp Leu Glu Thr Asn His His Pro Tyr Phe Gly Asn 15 10 15 316 200524957 &lt; 210 &gt; 233 &lt; 211〉 19 &lt; 212> PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt;-&lt; 223 &gt; Explanation of the artificial sequence: Satsuki Katsuyuki &lt; 400 &gt; 233

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser • &lt; 210 &gt; 234 &lt; 211 &gt; 18 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: synthetic victory 8 too &lt; 400> 234

Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys 15 10 15

Ala Phe • &lt; 210 &gt; 235 &lt; 211〉 30. &Lt; 212〉 PRT &lt; 213〉 artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of the artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 235

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val 317 200524957 15 10

Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe 20 25 30 &lt; 210〉 236 &lt; 211 &gt; 37 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation: Synthetic victory: φ &lt; 400〉 236

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Lys Ala Phe 35

&lt; 210〉 237 &lt; 211〉 37 &lt; 212〉 PRT call &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 237

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val 20 25 30 318 200524957

Gly Ser Glu Ala Phe 35 &lt; 210> 238 &lt; 211> 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400 &gt; 238 • Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Glu Ala Phe 35

&lt; 210> 239 &lt; 211 &gt; 30 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉. &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too. &lt; 400 &gt; 239

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val 1 5 10 15

Lys Asp Asn Phe Val Pro Thr Asn Val Gly Ser Glu Ala Phe 20 25 30 &lt; 210 &gt; 240 319 200524957 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Victory * &lt; 400 &gt; 240

Pro Thr Asn Val Gly Ser Glu Ala Phe 1 5 &lt; 210 &gt; 241 • &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence M &lt; 400> 241

Thr Asn Val Gly Ser Glu Ala Phe 1 5 &lt; 210〉 242 &lt; 211〉 7

W &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉. &Lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 242

Asn Val Gly Ser Glu Ala Phe 1 5 &lt; 210 &gt; 243 &lt; 211〉 6 320 200524957 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400〉 243 • Val Gly Ser Glu Ala Phe 1 5 &lt; 210〉 244 &lt; 211〉 6

• &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 244

Val Gly Ser Glu Ala Phe 1 5 &lt; 210〉 245 &lt; 211〉 4 '&lt; 212 &gt; PRT call &lt; 213〉 artificial sequence. &Lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 245 Ser Glu Ala Phe 1

&lt; 210 &gt; 246 &lt; 211〉 37 &lt; 212 &gt; PRT 200524957 &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki ^ &lt; 400 &gt; 246

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu * 15 10 15

Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val 20 25 30 ^ Gly Ser Lys Ala Phe 35 &lt; 210〉 247 &lt; 211〉 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 〉 &Lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 247

Ser Asn Leu Ser Thr Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys 1 5 10 15 -Leu Gin Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro 20 25 30 &lt; 210 &gt; 248 &lt; 211 &gt; 38 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon 322 200524957 &lt; 400>

Tyr Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu 15 10 15

Leu Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn. 20 25 30 • Val Gly Ser Lys Ala Phe 35

&lt; 210 &gt; 249 &lt; 211 &gt; 38 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400〉 249

Tyr Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu 15 10 15

Leu Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn 20 25 30 Lu Val Gly Ser Lys Ala Phe 35 &lt; 210 &gt; 250 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 250 323 200524957

Tyr Val Pro Thr Asn Val Gly Ser Glu Ala Phe 1 5 10 &lt; 210〉 251 &lt; 211〉 38 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic (Win)) Too <400> 251 • Tyr Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu 15 10 15

Leu Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn 20 25 30

Val Gly Ser Glu Ala Phe 35

&lt; 210 &gt; 252 &lt; 211〉 16 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Katsuyuki too. &lt; 400〉 252

Tyr Val Lys Asp Asn Phe Val Pro Thr Asn Val Gly Ser Glu Ala Phe 15 10 15 &lt; 210 &gt; 253 &lt; 211〉 37 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 324 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Katsuta Katsuta synthesis <400> 253

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu 15 10 15 • Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val 20 25 30

Gly Ser Glu Ala Phe 35

&lt; 210〉 254 &lt; 211〉 46 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 254

Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys 15 10 15 • Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala 20 25 30 »

Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin. 35 40 45 &lt; 210 &gt; 255 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213> Artificial sequence 325 &lt; 220 &gt; 200524957 &lt; 223 &gt; Artificial Explanation of sequence: Synthetic victory 0 too &lt; 400 &gt; 255

Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly 15 10 15

Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ala Lys Ser Gin 20 25 30

&lt; 210〉 256 &lt; 211〉 84 &lt; 212 &gt; PRT _ &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 256

Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser 35 40 45

Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu 50 55 60

Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys 65 70 75 80

Ala Lys Ser Gin &lt; 210 &gt; 257 &lt; 211〉 21 326 200524957 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Artificial sequence description: Synthetic B state &lt; 400 &gt; 257 • Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr 15 10 15

Lys Ala Lys Ser Gin

&lt; 210 &gt; 258 &lt; 211> 34 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 258

Ser Val Ser Glu lie Gin Leu Asn His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30 • Asn Phe &lt; 210〉 259 &lt; 211〉 34 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 327 &lt; 220 &gt; 200524957 &lt; 223> Explanation of the artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 259

Ser Val Ser Glu Cys Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Cys Gin Asp Val His 20 25 30

Asn Phe &lt; 210〉 260 # &lt; 211 &gt; 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 260

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin 15 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu He Ala Glu lie His

Thr Ala Glu lie Arg Ala Thr Ser-35 40 ^ &lt; 210 &gt; 261 &lt; 211〉 34 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 328 200524957 &lt; 400 &gt; 261

Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe &lt; 210〉 262 &lt; 211〉 32 &lt; 212 &gt; PRT • &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 262

Ala Val Ser Glu lie Gin Phe His Asn Leu Gly Lys His Leu Ser Ser 15 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt; 210〉 263

• &lt; 211〉 30 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 263

Ser Glu lie Gin Phe His Asn Leu Gly Lys His Leu Ser Ser Glu Arg 329 200524957 15 10

Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt; 210〉 264-&lt; 211〉 32 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence Explanation: The victory of synthesis fl too φ &lt; 400 &gt; 264

Ser Val Ser Glu lie Gin Leu His Asn Leu Gly Lys His Leu Asn Ser 15 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt; 210〉 265 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence call &lt; 220〉 &lt; 223〉 Artificial Explanation of Sequence: Synthetic Victory: Extravagant &lt; 400 &gt; 265 -Ser Val Ser Glu lie Gin Leu His Asn Leu Gly Lys His Leu Asn Ser 15 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt; 210〉 266 &lt; 211〉 30 330 200524957 &lt; 212〉 PRT &lt; 213〉 Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too. &Lt; 400 &gt; 266

Ser Glu lie Gin Leu His Asn Leu Gly Lys His Leu Asn Ser Glu Arg * 15 10 15

Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 • &lt; 210〉 267 &lt; 211〉 26 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223〉 of artificial sequence Explanation: Synthetic victory 0 too &lt; 400 &gt; 267

Phe His Asn Leu Gly Lys His Leu Ser Ser Glu Arg Val Glu Trp Leu 15 10 15

Arg Lys Lys Leu Gin Asp Val His Asn Tyr

. &lt; 210 &gt; 268 &lt; 211 &gt; 32 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400〉 268

Ala Val Ser Glu lie Gin Leu His Asn Leu Gly Lys His Leu Ala Ser 331 200524957 15 10 15

Val Glu Arg Gin Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25 30 &lt; 210〉 269 • &lt; 211〉 25 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220> φ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 269

Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu 15 10 15

Val Glu Ser His Glu Lys Ser Leu Gly 20 25

&lt; 210 &gt; 270 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉. &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon • &lt; 400〉 270

Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met 15 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Phe 20 25 30 332 200524957 &lt; 210 &gt; 271 &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉-&lt; 223 &gt; Description of artificial sequence: Synthetic victory # &lt; 400 &gt; 271

Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val

&lt; 210> 272 &lt; 211 &gt; 34 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 272

Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30 * Asn Phe &lt; 210 &gt; 273 &lt; 211〉 22 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence 333 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory: &lt; 400〉 273

Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu 15 10 15

Gin Asp Val His Asn Phe 20

&lt; 210> 274 &lt; 211> 34 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400 &gt; 274

Ala Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Ala 1 5 10 15

Ser Val Glu Arg Met Gin Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe &lt; 210 &gt; 275 • &lt; 211〉 38

&lt; 212 &gt; PRT • &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400> 275

Ser Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 334 200524957

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe Val Ala Leu Gly 35 &lt; 210 &gt; 276 &lt; 211〉 44 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt;# &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400 &gt; 276

Ser Val Ser Glu He Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg 35 40

&lt; 210 &gt; 277 &lt; 211 &gt; 21 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 277

Leu Gin Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro 15 10 15

Arg Asp Ala Gly Ser 335 20 200524957 &lt; 210〉 278 &lt; 211 &gt; 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 278

Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys

Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly 20 25 30 &lt; 210 &gt; 279 &lt; 211 &gt; 46 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223> Explanation of artificial sequence : The victory of synthesis fl too &lt; 400 &gt; 279

Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys 15 10 15

Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala 20 25 30

Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin 35 40 45 &lt; 210 &gt; 280 &lt; 211〉 32 336 200524957 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence Description: Synthetic Victory:. &Lt; 400 &gt; 280

Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly • 15 10 15

Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ala Lys Ser Gin 20 25 30

&lt; 210 &gt; 281 &lt; 211> 16 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400 &gt; 281

Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin 15 10 15 ® &lt; 210 &gt; 282 &lt; 211〉 15. &Lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Satsuki Katsuyuki &lt; 400 &gt; 282

Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gin 15 10 15 337 200524957 &lt; 210 &gt; 283 &lt; 211 &gt; 36 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Explanation of the sequence: Katsuyuki Katsuyuki &lt; 400 &gt; 283

Tyr Pro lie Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr

Arg Pro Arg Tyr 35 &lt; 210〉 284 &lt; 211 &gt; 41 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 284 • Tyr Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie 15 10 15

Gin Asp Leu Arg Arg Arg Phe Phe Leu His His Leu He Ala Glu He 20 25 30

His Thr Ala Glu lie Arg Ala Thr Ser 35 40 &lt; 210〉 285 338 200524957 &lt; 211〉 45 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Status &lt; 400 &gt; 285

Tyr Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu 15 10 15

Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val 20 25 30

His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg 35 40 45 &lt; 210 &gt; 286 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory Limb:

&lt; 400 &gt; 286

Tyr Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu 15 10 15

Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val 20 25 30

His Asn Phe 35 &lt; 210 &gt; 287 &lt; 211〉 34 339 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuyuki Katsuta &lt; 400 &gt; 287

Tyr Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn 15 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His 20 25 30

Asn Phe &lt; 210 &gt; 288 &lt; 211> 22 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsutsuki &lt; 400 &gt; 288

Tyr Leu Gin Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala 15 10 15

Pro Arg Asp Ala Gly Ser 20 &lt; 210 &gt; 289 • &lt; 211 &gt; 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 289 340 200524957

Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met Glu Arg Val Glu 15 10 15

Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn Tyr 20 25-&lt; 210〉 290 &lt; 211〉 26-&212; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuyuki Katsuta

&lt; 400〉 290

Tyr Arg Asp Ala Gly Ser Gin Arg Pro Arg Lys Lys Glu Asp Asn Val 15 10 15

Leu Val Glu Ser His Glu Lys Ser Leu Gly 20 25

&lt; 210〉 291 &lt; 211〉 33 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence_ &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400〉 291 • Tyr Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu 15 10 15

Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser 20 25 30

Gin 341 200524957 &lt; 210 &gt; 292 &lt; 211 &gt; 22 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 292

Tyr Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu 15 10 15

Thr Lys Ala Lys Ser Gin

&lt; 210 &gt; 293 &lt; 211> 34 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory H &lt; 400> 293

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin 15 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu He His 20 25 30 -Thr Ala &lt; 210〉 294 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 342 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400> 294

Ala Arg Ser Ala Trp 1 5 &lt; 210 &gt; 295 • &lt; 211 &gt; 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 295

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie Gin 15 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu He Ala Glu lie His 20 25 30

Thr Ala &lt; 210 &gt; 296 ® &lt; 211 &gt; 33 &lt; 212〉 PRT. &Lt; 213 &gt; Artificial sequence • &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: synthetic peptide &lt; 400〉 296

Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser He Gin Asp 15 10 15

Leu Arg Arg Arg Phe Phe Leu His His Leu He Ala Glu lie His Thr 343 200524957 20 25 30

Ala

&lt; 210 &gt; 297 &lt; 211〉 35 * &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400> 297 • Tyr Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser lie 1 5 10 15

Gin Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu lie 20 25 30

His Thr Ala 35

&lt; 210 &gt; 298 &lt; 211〉 34 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 298

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser He Gin 15 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu He Ala Glu He His 20 25 30

Thr Tyr 344 200524957 &lt; 210〉 299 &lt; 211〉 37 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 299

Ala Val Ser Glu His Gin Leu Leu His Asp Lys Gly Lys Ser He Gin

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu lie Ala Glu lie His 20 25 30

Thr Ala Glu lie Arg 35 &lt; 210 &gt; 300 &lt; 211 &gt; 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400〉 300

Leu Leu His Asp Lys Gly Lys Ser lie Gin Asp Leu Arg Arg Arg Phe 15 10 15

Phe Leu His His Leu lie Ala Glu He His Thr Ala 20 25 &lt; 210 &gt; 301 &lt; 211> 27 345 200524957 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too <400> 301

Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys 15 10 15

Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu 20 25

&lt; 210 &gt; 302 &lt; 211> 20 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory B too &lt; 400 &gt; 302

Tyr Leu Thr Gin Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gin Pro

Leu Lys Thr Pro 20 &lt; 210 &gt; 303 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory Moon 346 200524957 &lt; 400〉 303

Thr Arg Ser Ala Trp 1 5

&lt; 210〉 304 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 304

Thr Arg Ser Ala Trp 1 5

&lt; 210〉 305 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 305

Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu

Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser 20 25 30 &lt; 210 &gt; 306 &lt; 211 &gt; 33 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Description: Synthetic Victory Moon 347 200524957 &lt; 400 &gt; 306

Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp 15 10 15

His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Arg • 20 25 30 ‘His

&lt; 210〉 307 &lt; 211〉 34 &lt; 212 &gt; PRT φ &lt; 213 &gt; artificial sequence ’&lt; 220〉 &lt; 223 &gt; description of artificial sequence: victory of synthesis)! too &lt; 400 &gt; 307

Thr Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Glu Asn Asn Arg Arg 15 10 15

Thr His His Met Gin Leu Met lie Ser Leu Phe Lys Ser Pro Leu Leu 20 25 30

Leu Leu, &lt; 210> 308 &lt; 211 &gt; 31 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic tsukitsuki &lt; 400 &gt; 308

Met lie Pro Ala Lys Asp Met Ala Lys Val Met lie Val Met Leu Ala 348 200524957 15 10 15 lie Arg Phe Leu Thr Lys Ser Asp Gly Lys Ser Val Lys Lys Arg 20 25 30-&lt; 210 &gt; 309

&lt; 211〉 27 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory φ &lt; 400> 309

Thr Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Gly Lys Gin Gin Lys 15 10 15

Asn Thr Ser Tyr Ala Thr Asn Asp Leu lie lie 20 25 &lt; 210 &gt; 310 &lt; 211〉 30 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; Peptide. &Lt; 400> 310

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe • 15 10 15

Gly Ala lie Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30

&lt; 210 &gt; 311 &lt; 211 &gt; 30 &lt; 212> PRT 349 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 3 too &lt; 400 &gt; 311 * Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu 1 5 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30 &lt; 210〉 312 • &lt; 211 &gt; 25

&lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 312

Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys Leu Gin Thr Tyr Pro 15 10 15

Arg Thr Asn Thr Gly Ser Asn Thr Tyr

&lt; 210〉 313-&lt; 211〉 24 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400> 313

Leu Gly Arg Leu Ser Gin Glu Leu His Arg Leu Gin Thr Tyr Pro Arg 15 10 15 350 200524957

Thr Asn Thr Gly Ser Asn Thr Tyr 20 &lt; 210〉 314 &lt; 211〉 25 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Victory 0 太 # &lt; 400〉 314

Ala Thr Gin Arg Leu Ala Asn Glu Leu Val Arg Leu Gin Thr Tyr Pro 15 10 15

Arg Thr Asn Val Gly Ser Asn Thr Tyr 20 25 &lt; 210 &gt; 315 &lt; 211〉 29 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence

&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 315

Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe Gly 15 10 15

Ala lie Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr 20 25 &lt; 210〉 316 &lt; 211〉 37 351 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence : Satsuki Katsuyuki &lt; 400〉 316

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15 lie Arg Ser Ser Asn Asn Leu Gly Ala lie Leu Ser Pro Thr Asn Val 20 25 30

Gly Ser Asn Thr Tyr 35 &lt; 210〉 317 &lt; 211〉 37 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400 &gt; 317

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15 • Val His Ser Ser Asn Asn Phe Gly Ala lie Leu Ser Thr Asn Val 20 25 30 9

Gly Ser Asn Thr Tyr 35 &lt; 210 &gt; 318 &lt; 211 &gt; 37 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence 352 200524957 &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 〉 318

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15

Val His Ser Ser Asn Asn Phe Gly Ala lie Leu Ser Ser Thr Asn Val ^ 20 25 30

Gly Ser Asn Thr Tyr 35 • &lt; 210〉 319 &lt; 211〉 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 319

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala 1 5 10 ® &lt; 210 &gt; 320 &lt; 211 &gt; 10. &Lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation: Satsuki Katsuyuki &lt; 400 &gt; 320

Ser Asn Asn Phe Gly Ala lie Leu Ser Ser 1 5 10 353 200524957 &lt; 210 &gt; 321 &lt; 211〉 37 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory Moon &lt; 400> 321

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val

Gly Ser Asn Thr Tyr 35 &lt; 210 &gt; 322 &lt; 211 &gt; 30 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Satsuki Tsutsuki &lt; 400 &gt; 322

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu 15 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30 &lt; 210〉 323 &lt; 211〉 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 354 200524957 &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 323

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe 15 10 15

Gly Ala lie Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30

&lt; 210 &gt; 324 &lt; 211〉 30 • &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 324

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu 15 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30 Φ &lt; 210 &gt; 325 &lt; 211〉 25. &Lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyuki &lt; 400〉 325

Val Leu Gly Lys Leu Ser Gin Glu Leu His Lys Leu Gin Thr Tyr Pro 15 10 15 355 200524957

Arg Thr Asn Thr Gly Ser Asn Thr Tyr 20 25 &lt; 210 &gt; 326 &lt; 211〉 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta ⑩ &lt; 400〉 326

Leu Gly Arg Leu Ser Gin Glu Leu His Arg Leu Gin Thr Tyr Pro Arg 15 10 15

Thr Asn Thr Gly Ser Asn Thr Tyr 20 &lt; 210 &gt; 327 &lt; 211〉 25 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Synthetic Katsuyuki * &lt; 400> 327

Ala Thr Gin Arg Leu Ala Asn Glu Leu Val Arg Leu Gin Thr Tyr Pro 1 5 10 15

Arg Thr Asn Val Gly Ser Asn Thr Tyr 20 25

&lt; 210 &gt; 328 &lt; 211〉 29 &lt; 212 &gt; PRT 356 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic victory limb: &lt; 400> 328 'Thr Gin Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe Gly 15 10 15

Ala lie Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr 20 25 &lt; 210〉 329 ® &lt; 211 &gt; 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Katsuyuki Katsuyuki &lt; 400 &gt; 329

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15 lie Arg Ser Ser Asn Asn Leu Gly Ala He Leu Ser Pro Thr Asn Val

Gly Ser Asn Thr Tyr 35 &lt; 210 &gt; 330 &lt; 211> 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: 357 200524957 &lt; 400 &gt; 330

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15

Val His Ser Ser Asn Asn Phe Gly Ala lie Leu Ser Ser Thr Asn Val 20 25 30 • Gly Ser Asn Thr Tyr 35

&lt; 210〉 331 &lt; 211〉 37 φ &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Satsuki Taito &lt; 400 &gt; 331

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu 15 10 15

Val His Ser Ser Asn Asn Phe Gly Ala He Leu Ser Ser Thr Asn Val 20 25 30

Gly Ser Asn Thr Tyr 35 &lt; 210 &gt; 332 • &lt; 211〉 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki Tai &lt; 400 &gt; 332 358 200524957

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala 1 5 10

&lt; 210> 333 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 333

Ser Asn Asn Phe Gly Ala lie Leu Ser Ser

&lt; 210 &gt; 334 &lt; 211> 37 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 334

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gin Arg Leu Ala Asn Phe Leu

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val • 20 25 30

Gly Ser Asn Thr Tyr 35 &lt; 210〉 335 &lt; 211〉 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence 359 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 335

Ala Thr Gin Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu 15 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr 20 25 30 &lt; 210〉 336 &lt; 211〉 28 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Zodiac B &lt; 400> 336

Ser Gin Gly Thr Phe Thr Ser Glu Tyr Ser Lys Tyr Leu Asp Ser Arg 15 10 15

Arg Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr 20 25

&lt; 210 &gt; 337 &lt; 212〉 PRT. &lt; 213 &gt; Artificial sequence * &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400> 337

His Gly Glu Gly Thr Ser Asp Leu Ser Lys Gin Met Glu Glu Ala Arg 15 10 15

Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro 360 200524957 20 25 30

Pro Pro Ser 35

&lt; 210 &gt; 338 &lt; 211 &gt; 29 &lt; 212 &gt; PRT • &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too Φ &lt; 400 &gt; 338

His Ser Gin Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 15 10 15

Arg Arg Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr 20 25 &lt; 210 &gt; 339 &lt; 211> 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too. &lt; 400> 339

Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr 1 5 10 &lt; 210 &gt; 340 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 361 &lt; 220〉 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuyuki Kazuyuki <400> 340

Phe Val Gin Trp Leu Met Asn Thr 1 5 &lt; 210〉 341 • &lt; 211〉 28 &lt; 212〉 PRT &lt; 213〉 Artificial Sequences &lt; 220 &gt; _ &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Moon Too &lt; 400 &gt; 341

Ser Gin Gly Thr Phe Thr Ser Glu Tyr Ser Lys Tyr Leu Asp Ser Arg 15 10 15

Arg Ala Gin Asp Phe Val Gin Trp Leu Met Asn Thr 20 25

&lt; 210〉 342 &lt; 211〉 36 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Moon &quot; &lt; 400〉 342

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 15 10 15

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe He Ala Trp Leu 20 25 30

Val Lys Gly Arg 362 200524957 35 &lt; 210 &gt; 343 &lt; 211 &gt; 37 &lt; 212> 343

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe lie Ala Trp Leu 20 25 30

Val Lys Gly Arg Gly 35 &lt; 210〉 344 &lt; 211〉 30 &lt; 212〉 PRT &lt; 213〉 artificial sequence

&lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 4〇〇 &gt; 344 &quot; His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 15 10 15

Gin Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg 20 25 30 &lt; 210 &gt; 345 &lt; 211〉 33 363 200524957

&lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400 &gt; 345

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr lie Leu Asp Asn 15 10 15

Leu Ala Thr Arg Asp Phe lie Asn Trp Leu lie Gin Thr Lys lie Thr 20 25 30

Asp &lt; 210〉 346 &lt; 211〉 34 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400> 346

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr He Leu Asp Asn 15 10 15. Leu Ala Ala Arg Asp Phe lie Asn Trp Leu lie Gin Thr Lys lie Thr 20 25 30

Asp Arg &lt; 210 &gt; 347 &lt; 211> 37 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 364 200524957 &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 347

His Ser Glu Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 15 10 15

Arg Arg Ala Glu Asp Phe Val Glu Trp Leu Met Asn Thr Lys Arg Asn 20 25 30

Lys Asn Asn lie Ala 35

&lt; 210> 348 &lt; 211> 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 348

His Ser Glu Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 15 10 15

Arg Arg Ala Glu Asp Phe Val Glu Trp Leu Met Asn Thr Lys Arg Asn 20 25 30

Lys Asn Asn lie Ala 35 &lt; 210〉 349 &lt; 211 &gt; 39 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 365 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 349

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser 35 &lt; 210> 350 Φ &lt; 211 &gt; 34 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400〉 350

His Ala Asp Gly Thr Leu Thr Ser Asp He Ser Ser Phe Leu Glu Lys 15 10 15

Gin Ala Thr Lys Glu Phe lie Ala Trp Leu Val Ser Gly Arg Gly Arg

Arg Gin • &lt; 210 &gt; 351 &lt; 211〉 29 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: synthetic peptide 366 200524957 &lt; 400〉 351

His Ser Gin Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 15 10 15

Lys Lys Ala Gin Glu Phe Val Gin Trp Leu Met Asn Thr 20 25 &lt; 210> 352 &lt; 211> 39 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> 0 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory &lt; 400 &gt; 352

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe He Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser 35 &lt; 210〉 353 ® &lt; 211 &gt; 33 &lt; 212〉 PRT, &lt; 213 &gt; Artificial Sequence • &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 353

His Ala Asp Gly Ser Phe Thr Ser Asp lie Asn Lys Val Leu Asp Thr 15 10 15 lie Ala Ala Lys Glu Phe Leu Asn Trp Leu lie Ser Thr Lys Val Thr 20 25 30 367 200524957

Glu &lt; 210 &gt; 354-&lt; 211〉 36

&lt; 212 &gt; PRT — &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki _ &lt; 400> 354

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 15 10 15

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe lie Ala Trp Leu 20 25 30

Val Lys Gly Arg 35

&lt; 210 &gt; 355 &lt; 211〉 30 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence-&lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon 9 &lt; 400 &gt; 355

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 15 10 15

Gin Ala Ala Lys Glu Phe lie Ala Trp Leu Val Lys Gly Arg 20 25 30 368 200524957 &lt; 210 &gt; 356 &lt; 211〉 19 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyoshi &lt; 400〉 356

Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe lie Ala Trp Leu Val 15 10 15

Xaa Gly Arg

&lt; 210 &gt; 357 &lt; 211 &gt; 4 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta

&lt; 400 &gt; 357 Ser Asp Val Ser 1 &lt; 210 &gt; 358. &lt; 211〉 5 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon M &lt; 400> 358

Thr Ser Asp Val Ser 1 5 369 200524957 &lt; 210 &gt; 359 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Tsukitsu Λ &lt; 400 &gt; 359

Phe Thr Ser Asp Val Ser 1 5 • &lt; 210〉 360 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuki Taisho &lt; 400〉 360

Thr Phe Thr Ser Asp Val Ser 1 5 &lt; 210〉 361 ® &lt; 211 &gt; 8 &lt; 212〉 PRT. &Lt; 213 &gt; Artificial Sequence- &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence M &lt; 400> 361

Gly Thr Phe Thr Ser Asp Val Ser 1 5 &lt; 210 &gt; 362 200524957 &lt; 211 &gt; 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 362

Glu Gly Thr Phe Thr Ser Asp Val Ser 1 5

&lt; 210〉 363 &lt; 211〉 10 ♦ &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 363

Ala Glu Gly Thr Phe Thr Ser Asp Val Ser 1 5 10

&lt; 210 &gt; 364 &lt; 211> 39 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence-&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 364

His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 371 200524957

Ser Gly Ala Pro Pro Pro Ser 35 &lt; 210〉 365 &lt; 211〉 39 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Artificial sequence description: Synthetic victory &lt; 400 &gt; 365

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu ® 1 5 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser 35 &lt; 210〉 366 &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213〉 Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400〉 366 ** His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Ala Val Arg Leu Phe He Glu Trp Leu Lys Asn Gly Gly Pro Tyr 20 25 30 &lt; 210 &gt; 367 &lt; 211〉 31 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence 372 200524957 &lt; 220〉 &lt; 223 &gt; Artificial Explanation of sequence: Synthetic victory: &lt; 400 &gt; 367

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15-Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Tyr 20 25 30-&lt; 210〉 368 &lt; 211 &gt; 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 368

Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Met lie Glu 15 10 15

Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro 20 25 30

&lt; 210> 369 &lt; 211> 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta &lt; 400 &gt; 369

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 15 10 15

Ser Ser Tyr Leu Glu Gly Gin Ala Ala Lys Glu Phe He Ala Trp Leu 20 25 30

Val Lys Gly Arg Lys 35 &lt; 210 &gt; 370 373 200524957 &lt; 211 &gt; 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Zodiac Moon &lt; 400 &gt; 370-His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 15 10 15 m

Gin Ala Ala Lys Glu Phe lie Ala Trp Leu Val Lys Gly Arg Lys 20 25 30 &lt; 210〉 371 Φ &lt; 211 &gt; 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Description: Synthetic Tsukiyuki &lt; 400> 371

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser Lys 35 40. &Lt; 210 &gt; 372 &lt; 211〉 40 • &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Too &lt; 400 &gt; 372

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15 374 200524957

Glu Ala Val Arg Leu Phe He Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Pro Ser Lys 35 40-&lt; 210〉 373

&lt; 211〉 40 * &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsutsuki &lt; 400> 373 His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu 15 10 15

Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30

Ser Gly Ala Pro Pro Ser Lys 35 40

&lt; 210 &gt; 374 &lt; 211 &gt; 31 &lt; 212> PRT φ &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki • &lt; 400> 374

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Glu Met Glu Glu * 15 10 15

Glu Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Tyr 20 25 30

&lt; 210 &gt; 375 &lt; 211〉 30 &lt; 212 &gt; PRT 375 200524957 &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 375

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Glu Met Glu Glu 15 10 15

Glu Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Tyr ^ 20 25 30

&lt; 210 &gt; 376 &lt; 211〉 29 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 376

Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe lie Glu 15 10 15

Trp Leu Lys Gly Gly Pro Ser Ser Gly Pro Pro Pro Ser 20 25

&lt; 210 &gt; 377 &lt; 211 &gt; 31 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon • &lt; 400 &gt; 377

Glu Ala Glu Asp Leu Gin Val Gly Gin Val Glu Leu Gly Gly Gly Pro 15 10 15

Gly Ala Gly Ser Leu Gin Pro Leu Ala Leu Glu Gly Ser Leu Gin 20 25 30 &lt; 210 &gt; 378 376 200524957 &lt; 211 &gt; 32 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Explanation of the sequence: Synthesis of Victory Moon <400> 378 • Tyr Glu Ala Glu Asp Leu Gin Val Gly Gin Val Glu Leu Gly Gly Gly 15 10 15

Pro Gly Ala Gly Ser Leu Gin Pro Leu Ala Leu Glu Gly Ser Leu Gin 20 25 30

&lt; 210 &gt; 379 &lt; 211 &gt; 51 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 379

Gly lie Val Glu Gin Cys Cys Thr Ser lie Cys Ser Leu Tyr Gin Leu 15 10 15

Glu Asn Tyr Cys Asn Phe Val Asn Gin His Leu Cys Gly Ser His Leu

Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr 35 40 45

Pro Lys Thr 50 &lt; 210〉 380 &lt; 211〉 16 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 377 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki Tai &lt; 400 &gt; 380

Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg Tyr 15 10 15 &lt; 210 &gt; 381 ^ &lt; 211 &gt; 35

^ &lt; 212 &gt; PRT * &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 381

Arg Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg ® 1 5 10 15

Tyr Pro Val Gly Lys Phe Phe Gin Tyr Asp Thr Trp Lys Gin Ser Thr 20 25 30

Gin Arg Leu 35 &lt; 210 &gt; 382 &lt; 211〉 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence • &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory too &lt; 400> 382 sickle

Gly Leu Pro Ala Leu Leu Arg Ala Arg Arg Gly His Val Leu Ala Lys 15 10 15

Glu Leu Glu Ala Phe Arg Glu Ala 20 &lt; 210 &gt; 383 &lt; 211〉 36 378 200524957 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 383

Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp 15 10 15

Met Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr lie Asn Leu Leu Thr 20 25 30

Arg Pro Arg Tyr 35

&lt; 210 &gt; 384 &lt; 211 &gt; 39 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki too &lt; 4〇〇 &gt; 384

Pro Asp Lys Asp Phe lie Val Asn Pro Ser Asp Leu Val Leu Asp Asn 15 10 15

Lys Ala Ala Leu Arg Asp Tyr Leu Arg Gin lie Asn Glu Tyr Phe Ala

He He Gly Arg Pro Arg Phe 35 &lt; 210 &gt; 385 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 385 Phe Met Arg 379 200524957 &lt; 210 &gt; 386 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 386

Cys Trp Arg Tyr Cys Trp Arg Tyr 1 5 &lt; 210> 387 • &lt; 211 &gt; 36 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 387

Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp 15 10 15

Met Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr lie Asn Leu lie Thr 20 25 30

Arg Gin Arg Tyr 35 &quot; &lt; 210 &gt; 388 &lt; 211〉 24 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 388

Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp 1 5 10 15 380 200524957

Met Ala Arg Tyr Tyr Ser Ala Leu 20

&lt; 210 &gt; 389 &lt; 211〉 8 &lt; 212 &gt; PRT Arg Leu Arg Tyr 1 5 • &lt; 210 &gt; 390 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 390

Gly Pro Ser Gin Pro Thr Tyr Pro Gly Asp Asp Ala Pro Val Glu Asp 15 10 15

Leu lie Arg Phe Tyr Asp Asn Leu Gin Gin Tyr Leu Asn Val Val Thr

Arg His Arg Tyr 35 &lt; 210> 391 &lt; 211 &gt; 36 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 391

Ala Pro Leu Glu Pro Val Tyr Pro Gly Asp Asn Ala Thr Pro Glu Gin 381 200524957 15 10 15

Met Ala Gin Tyr Ala Ala Asp Leu Arg Arg Tyr lie Asn Met Leu Thr 20 25 30

Arg Pro Arg Tyr-35 ^ &lt; 210〉 392 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 392

Leu Thr Arg Pro Arg Tyr 1 5 &lt; 210〉 393 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Artificial Sequence Explanation: Synthetic Victory &lt; 400 &gt; 393

Leu Thr Arg Pro Arg Tyr

&lt; 210〉 394 &lt; 211〉 36 &lt; 212〉 PRT _ &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223〉 Explanation of artificial sequence: Satsuki Katsuta &lt; 4〇〇 &gt; 394

Ala Pro Ser Glu Pro His His Pro Gly Asp Gin Ala Thr Gin Asp Gin 15 10 15

Leu Ala Gin Tyr Tyr Ser Asp Leu Tyr Gin Tyr lie Thr Phe Val Thr 382 200524957 20 25 30

Arg Pro Arg Phe 35 &lt; 210〉 395 &lt; &lt; 211 &gt; 36 &lt; 212〉 PRT ^ &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too & 400 〉 395

Ala Pro Leu Glu Pro Met Tyr Pro Gly Asp Tyr Ala Thr His Glu Gin ® 1 5 10 15

Arg Ala Gin Tyr Glu Thr Gin Leu Arg Arg Tyr lie Asn Thr Leu Thr 20 25 30

Arg Pro Arg Tyr 35 &lt; 210〉 396 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400〉 396 '' Tyr Pro Pro Lys Pro Glu Asn Pro Gly Glu Asp Ala Pro Pro Glu Glu 15 10 15

Leu Ala Lys Tyr Tyr Thr Ala Leu Arg His Tyr lie Asn Leu lie Thr 20 25 30

Arg Gin Arg Tyr 35 &lt; 210 &gt; 397 383 200524957 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400〉 397

Tyr Pro He Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 20 25 30

Arg Gin Arg Tyr &lt; 210〉 398 &lt; 211〉 34 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 398 lie Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn 15 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gin 20 25 30

Arg Tyr &lt; 210〉 399 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 399 384 200524957

Tyr Pro Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15

Leu Ser Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 20 25 30-Arg Gin Arg Tyr 35 ^ &lt; 210 &gt; 400 &lt; 211〉 36 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &Lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &400; 400

Tyr Pro lie Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Leu Thr 20 25 30

Arg Pro Arg Tyr 35

&lt; 210> 401 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400> 401

Glu Gin Asp Tyr Thr Gly Trp Met Asp Phe 1 5 10 &lt; 210〉 402 &lt; 211〉 33 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 385 200524957 &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthesis Victory Limb: &lt; 400 &gt; 402

Lys Ala Pro Ser Gly Arg Met Ser lie Val Lys Asn Leu Gin Asn Leu 15 10 15

Asp Pro Ser His Arg lie Ser Asp Arg Asp Tyr Met Gly Trp Met Asp 20 25 30

Phe &lt; 210 &gt; 403 &lt; 211〉 4

φ &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400> 403 Asp Tyr Met Gly 1

&lt; 210> 404 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuta &lt; 400 &gt; 404

Asp Tyr Met Gly Trp Met Asp Phe 1 5 &lt; 210> 405 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory β too &lt; 400 &gt; 405 386 200524957

Asp Tyr Met Gly Trp Met Asp Phe 1 5 &lt; 210> 406 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence w &lt; 400 &gt; 406

Tyr Met Gly Trp Met Asp Phe 1 5 &lt; 210 &gt; 407 Φ &lt; 211 &gt; 4 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400〉 407 Trp Met Asp Phe 1

&lt; 210 &gt; 408 &lt; 211 &gt; 33 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 408

Lys Ala Pro Ser Gly Arg Val Ser Met lie Lys Asn Leu Gin Ser Leu 15 10 15

Asp Pro Ser His Arg lie Ser Asp Arg Asp Tyr Met Gly Trp Met Asp 20 25 30 387 200524957

Phe &lt; 210 &gt; 409 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • &lt; 223〉 Description of Artificial Sequence: Synthetic Winner: &lt; 400〉 409 &lt; 210〉 410 φ &lt; 211 〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 410

Ser Ala Glu Glu Tyr Glu Tyr Pro Ser 1 5

&lt; 210〉 411 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 411

Asp Tyr Met Gly Trp 1 5 &lt; 210 &gt; 412 388 200524957 &lt; 211 &gt; 6 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400 &gt; 412

Asp Tyr Met Gly Trp Met 1 5 &lt; 210> 413 &lt; 211 &gt; 9

• &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400> 413

Val Pro Val Glu Ala Val Asp Pro Met 1 5

&lt; 210 &gt; 414 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 4〇〇 &gt; 414 &lt; 210> 415 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence 200524957 &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 415

Asp Tyr Met Gly Trp Met Asp Phe 1 5 &lt; 210〉 416 &lt; 211〉 23 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Peptide &lt; 400〉 416

Met Lys Val Ala lie lie Phe Leu Leu Ser Ala Leu Ala Leu Leu Asn 1 5 10 15

Leu Ala Gly Asn Thr Thr Ala 20

&lt; 210〉 417 &lt; 211〉 27 &lt; 212〉 PRT φ &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 417

Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro 15 10 15

Arg Gly Asn His Trp Ala Val Gly His Leu Met 20 25 390 200524957 &lt; 210〉 418 &lt; 211 &gt; 16 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223 &gt; Explanation of Artificial Sequence: Katsuyuki Kazuyuki ^ &lt; 400 &gt; 418

Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro 15 10 15 &lt; 210〉 419 ® &lt; 211 &gt; 27 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223〉 Artificial Explanation of sequence: synthetic peptide &lt; 400 &gt; 419

Ala Pro Val Ser Val Gly Gly Gly Thr Val Leu Ala Lys Met Tyr Pro 15 10 15

Arg Gly Asn His Trp Ala Val Gly His Leu Met

&lt; 210〉 420-&lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 420

Met Tyr Pro Arg Gly Asn His Trp Ala Val Gly His Leu Met 391 200524957 1 5 10 &lt; 210〉 421 &lt; 211〉 36 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence- &lt; 220 &gt; &lt; 223 &gt; Artificial Explanation of sequence: Synthetic victory: # &lt; 400 &gt; 421

Phe Leu Pro His Val Phe Ala Glu Leu Ser Asp Arg Lys Gly Phe Val 15 10 15 • Gin Gly Asn Gly Ala Val Glu Ala Leu His Asp His Phe Tyr Pro Asp 20 25 30

Trp Met Asp Phe 35 &lt; 210 &gt; 422 &lt; 211 &gt; 17 &lt; 212〉 PRT &lt; 213〉 artificial sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 422

Glu Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp 15 10 15

Phe &lt; 210> 423 &lt; 211> 34 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 392 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 423

Glu Leu Gly Pro Gin Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys 15 10 15

Lys Gin Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met 20 25 30

Asp Phe Φ &lt; 210 &gt; 424 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400> 424

Glu Arg Pro Pro Met Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp 15 10 15

&lt; 210 &gt; 425 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 425 393 200524957

Ala Trp Met Asp Phe 1 5 &lt; 210〉 426 &lt; 211 &gt; 42 &lt; 212〉 PRT ^ &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400 〉 426

Tyr Ala Glu Gly Thr Phe lie Ser Asp Tyr Ser lie Ala Met Asp Lys • 1 5 10 15 lie His Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys Gly Lys 20 25 30

Lys Asn Asp Trp Lys His Asn lie Thr Gin 35 40 &lt; 210〉 427 &lt; 211〉 42 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence

&lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400> 427

Tyr Ala Glu Gly Thr Phe He Ser Asp Tyr Ser lie Ala Met Asp Lys 15 10 15 lie Arg Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys Gly Lys 20 25 30

Lys Ser Asp Trp Lys His Asn He Thr Gin 35 40 394 200524957 &lt; 210 &gt; 428 &lt; 211〉 30 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence, &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthesis Victory: &lt; 400 &gt; 428

Tyr Ala Glu Gly Thr Phe lie Ser Asp Tyr Ser lie Ala Met Asp Lys 15 10 15 Hit lie Arg Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys 20 25 30 &lt; 210〉 429 &lt; 211〉 30 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400> 429

Tyr Ala Glu Gly Thr Phe lie Ser Asp Tyr Ser lie Ala Met Asp Lys

He Arg Gin Gin Asp Phe Val Asn Trp Leu Leu Ala Gin Lys 20 25 30 &lt; 210 &gt; 430 &lt; 211 &gt; 22 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence ： Synthetic victory 0 395 200524957 &lt; 400〉 430

Phe Val Pro He Phe Thr His Ser Glu Leu Gin Lys lie Arg Glu Lys 15 10 15

Glu Arg Asn Lys Gly Gin 20 &lt; 210〉 431 • &lt; 211 &gt; 22 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 0 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 431

Phe Val Pro lie Phe Thr Tyr Gly Glu Leu Gin Arg Met Gin Glu Lys 15 10 15

Glu Arg Asn Lys Gly Gin 20

&lt; 210〉 432 &lt; 211〉 22 &lt; 212〉 PRT _ &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400 &gt; 432

Phe Val Pro lie Phe Thr Tyr Gly Glu Leu Gin Arg Leu Gin Glu Lys 15 10 15

Glu Arg Asn Lys Gly Gin 20 396 200524957 &lt; 210 &gt; 433 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 # &lt; 223 &gt; Explanation of Artificial Sequence: Katsuyuki Katsuta • &lt; 400〉 433

Phe Val Pro He Phe Thr Tyr Gly Glu Leu Arg Leu Gin Glu Lys Glu 15 10 15

Arg Asn Lys Gly Gin

&lt; 210〉 434 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory)} &lt; 4〇〇 &gt; 434

lie Ala Arg Arg His Pro Tyr Phe Leu

&lt; 210〉 435 &lt; 211〉 27 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 435

His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Glu Ser 397 200524957 15 10 15

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val 20 25

. &lt; 210〉 436 &lt; 211〉 27 »&lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory

&lt; 400〉 436

His Ser Asp Gly Leu Phe Thr Ser Glu Tyr Ser Lys Met Arg Gly Asn 15 10 15

Ala Gin Val Gin Lys Phe He Gin Asn Leu Met 20 25 &lt; 210 &gt; 437 &lt; 211 &gt; 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki, &lt; 400 &gt; 437

His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Glu Gly 15 10 15

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val 20 25 &lt; 210 &gt; 438 398 200524957 &lt; 211〉 27 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis Katsuyuki

Hr &lt; 400 &gt; 438 ^ His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Asp Ser 15 10 15

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val 20 25

&lt; 210 &gt; 439 &lt; 211> 27 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 439

His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Gin Asp Ser 15 10 15

Ala Arg Leu Gin Arg Leu Leu Gin Gly Leu Val 20 25 ♦ &lt; 210〉 440 &lt; 211〉 26 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223> description of artificial sequence: synthesized Winning limb: 399 200524957 &lt; 4〇〇 &gt; 440

Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Asp Ser Ala 15 10 15

Arg Leu Gin Arg Leu Leu Gly Gly Leu Val 20 25 e &lt; 210〉 441 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence ^ &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winners: &lt; 400〉 441

Ala Ala Met Leu Ala Ser Gin Thr Glu Ala Phe Val Pro lie Phe Thr 15 10 15

Tyr Gly Glu Leu Gin Arg Met Gin Glu Lys Glu Arg Asn Lys Gly Gin 20 25 30 &lt; 210〉 442 &lt; 211〉 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence

&lt; 220〉% &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta, 〈400〉 442

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Arg Gin 15 10 15

Leu Ala Val Arg Arg Tyr Leu Asn Ser lie Leu Asn 20 25 &lt; 210> 443 400 200524957 &lt; 211 &gt; 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuyuki Kazuyuki: 400 &gt; 443

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Arg Gin 15 10 15

Leu Ala Val Arg Arg Tyr Leu Asn Ser lie Leu Asn Gly Lys Arg 20 25 30 &lt; 210> 444 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory 0 too &lt; 400 &gt; 444

Met Ala Val Lys Lys Tyr Leu Asn Ser lie Leu Asn 1 5 10 &lt; 210〉 445 &lt; 211〉 27 &lt; 212〉 PRT &lt; 213: Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tsukitsu Tsuki &lt; 4〇〇 &gt; 445

His Ala Asp Gly Val Phe Thr Ser Asp Phe Ser Arg Leu Leu Gly Gin 15 10 15 401 200524957

Leu Ser Ala Lys Lys Tyr Leu Glu Ser Leu lie 20 25 &lt; 210 &gt; 446 &lt; 211〉 27 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Yuetai &lt; 400 &gt; 446

His Ala Asp Gly Val Phe Thr Ser Asp Tyr Ser Arg Leu Leu Gly Gin

lie Ser Ala Lys Lys Tyr Leu Glu Ser Leu He 20 25 &lt; 210〉 447 &lt; 211〉 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;

&lt; 223> Explanation of artificial sequence: Synthetic victory fl 之 &lt; 4〇〇 &gt; 447

His Ala Asp Gly Val Phe Thr Ser Asp Phe Ser Lys Leu Leu Gly Gin 15 10 15

Leu Ser Ala Lys Lys Tyr Leu Glu Ser Leu Met 20 25

&lt; 210> 448 &lt; 211 &gt; 42 &lt; 212> PRT &lt; 213 &gt; artificial sequence ’402

200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400〉 448

His Ala Asp Gly Val Phe Thr Ser Asp Phe Ser Lys Leu Leu Gly Gin 15 10 15 ～ Leu Ser Ala Lys Lys Tyr Leu Glu Ser Leu Met Gly Lys Arg Val Ser * 20 25 30

Ser Asn He Ser Glu Asp Pro Val Pro Val 35 40 &lt; 210〉 449 &lt; 211 &gt; 12 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon Too &lt; 4〇〇 &gt; 449

Val Ser Ser Asn lie Ser Glu Asp Pro Val Pro Val 1 5 10 &lt; 210 &gt; 450 &lt; 211 &gt; 15 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory Moon too <400> 450

Ser Ser Glu Gly Glu Ser Pro Asp Phe Pro Glu Glu Leu Glu Lys 15 10 15 403 200524957 &lt; 210 &gt; 451 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Artificial Explanation of Sequence: Synthetic Victory &lt; 400 &gt; 451

Cys Ser Cys Asn Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp lie lie Trp

&lt; 210 &gt; 452 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 452

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Ser Arg Phe Arg Lys Gin

Met Ala Val Lys Lys Tyr Leu Asn Ser Val Leu Thr 20 25 &lt; 210 &gt; 453 &lt; 211〉 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too 404 200524957 &lt; 400 &gt; 453

His Ser Asp Ala Leu Phe Thr Asp Thr Tyr Thr Arg Leu Arg Lys Gin 15 10 15

Met Ala Met Lys Lys Tyr Leu Asn Ser Val Leu Asn 20 25 &lt; 210〉 454 &lt; 211〉 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • &lt; 223> Explanation of Artificial Sequence: Synthesis臓 &lt; 4〇〇 &gt; 454

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser lie Leu Asn 20 25

&lt; 210〉 455 &lt; 211〉 28 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 455

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser lie Leu Asn 20 25 405 200524957 &lt; 210 &gt; 456 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Katsuyuki Katsuyuki &lt; 400 &gt; 456

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg 1 5 10 &lt; 210> 457 W &lt; 211 &gt; 19

&lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400> 457

Tyr Thr Arg Leu Arg Lys Gin Met Ala Val Lys Lys Tyr Leu Asn Ser

He Leu Asn &lt; 210〉 458 &lt; 211 &gt; 18 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki 406

200524957 &lt; 400〉 458

Thr Arg Leu Arg Lys Gin Met Ala Val Lys Lys Tyr Leu Asn Ser lie 15 10 15

Leu Asn &lt; 210 &gt; 459 &lt; 211〉 27 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 459

His Ser Asp Ala Val Phe Thr Asp Asn Ser Arg Phe Arg Lys Gin Met 15 10 15

Ala Ala Lys Lys Tyr Leu Asn Ser Val Leu Ala 20 25 &lt; 210〉 460 &lt; 211〉 23 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Tsuki &lt; 400> 460

Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin Met Ala Val Lys Lys 15 10 15

Tyr Leu Asn Ser lie Leu Asn 20 407 200524957 &lt; 210 &gt; 461 &lt; 211〉 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400〉 461

Lys Pro Arg Arg Pro Tyr Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser lie Leu Asn 20 25 &lt; 210〉 462 &lt; 211〉 29 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence · Synthesis Victory peptide &lt; 400 &gt; 462

Tyr Phe Asp Ala lie Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gin

Leu Ser Ala Arg Lys Leu Leu Gin Asp lie Met Ser Arg 20 25 &lt; 210> 463 &lt; 211 &gt; 28 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory Moon 408 200524957 &lt; 400 &gt; 463

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gin 15 10 15

Leu Ala Val Lys Lys Tyr Leu Asn Ser He Leu Asn 20 25 &lt; 210〉 464 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory)} &lt; 4〇〇 &gt; 464

Leu Met Tyr Pro Thr Tyr Leu Lys 1 5 &lt; 210 &gt; 465 &lt; 211 &gt; 29 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> φ &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 465 &quot; Met Met Arg Asp Ser Gly Cys Phe Gly Arg Arg lie Asp Arg lie Gly 15 10 15

Ser Leu Ser Gly Met Gly Cys Asn Gly Ser Arg Lys Asn 20 25

&lt; 210> 466 &lt; 211 &gt; 15 &lt; 212> PRT 409

200524957 &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400> 466

Gly Phe He Trp Gly Asn He Phe Gly His Tyr Ser Gly Asp Phe 15 10 15 &lt; 210 &gt; 467 &lt; 211 &gt; 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Artificial Sequences Explanation: Synthetic Victory Moon <400> 467

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg 1 5 10 &lt; 210 &gt; 468 &lt; 211〉 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 468

Ser Ser Asp Cys Phe Gly Ser Arg lie Asp Arg He Gly Ala Gin Ser 15 10 15

Gly Met Gly Cys Gly Arg Arg Phe 20 &lt; 210> 469 &lt; 211 &gt; 20 410 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence &lt; 400 &gt; 469

Cys Phe Gly Ser Arg lie Asp Arg He Gly Ala Gin Ser Gly Met Gly 15 10 15

Cys Gly Arg Phe 20 &lt; 210 &gt; 470 &lt; 211 &gt; 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400〉 470

Cys Phe Gly Ser Arg He Asp Arg He Gly Ala Gin Ser Gly Met Gly 15 10 15

Cys Gly Arg Arg Phe 20 &lt; 210 &gt; 471 &lt; 211〉 24 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsukitsu &lt; 400 &gt; 471 411 200524957

Ser Ser Asp Cys Phe Gly Ser Arg lie Asp Arg He Gly Ala Gin Ser 15 10 15

Gly Met Gly Cys Gly Arg Arg Phe 20 &lt; 210〉 472 &lt; 211 &gt; 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400〉 472

Ala Pro Arg Ser Met Arg Arg Ser Ser Asp Cys Phe Gly Ser Arg lie 15 10 15

Asp Arg lie Gly Ala Gin Ser Gly Met Gly Cys Gly Arg Phe 20 25 30 &lt; 210 &gt; 473 &lt; 211 &gt; 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence : Synthetic victory 0 too &lt; 400 &gt; 473

Ser Ser Cys Phe Gly Gly Arg Met Asp Arg He Gly Ala Gin Ser Gly 15 10 15

Leu Gly Cys Asn Ser Phe Arg Tyr 20 &lt; 210 &gt; 474 &lt; 211〉 17 412 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence &lt; 4〇〇> 474

Cys Phe Gly Gly Arg Met Asp Arg lie Gly Ala Gin Ser Gly Leu Gly 15 10 15

Cys &lt; 210〉 475 &lt; 211〉 22 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 475

Cys Phe Gly Gly Arg Met Asp Arg lie Gly Ala Gin Ser Gly Leu Gly 15 10 15

Cys Asn Ser Phe Arg Tyr 20 &lt; 210〉 476 &lt; 211 &gt; 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 476

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly 1 5 10 15 413 200524957

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt; 210〉 477 &lt; 211〉 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Katsuki fl &lt; 4〇〇> 477

Arg Cys Gly Gly Arg He Asp Arg He Arg Cys 1 5 10 &lt; 210〉 478 &lt; 211〉 26 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 4〇〇 &gt; 478

Arg Arg Ser Ser Cys Phe Gly Gly Arg He Asp Arg lie Gly Ala Gin 15 10 15

Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt; 210〉 479 &lt; 211〉 26 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 414 200524957 &lt; 4〇〇 &gt; 479

Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg He Gly Ala Gin 15 10 15

Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt; 210 &gt; 480 &lt; 211 &gt; 25 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence Too &lt; 400 &gt; 480

Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly Ala Gin Ser 15 10 15

Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt; 210 &gt; 481 &lt; 211 &gt; 23 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 481

Ser Ser Cys Phe Gly Gly Arg Met Asp Arg He Gly Ala Gin Ser Gly 15 10 15

Leu Gly Cys Asn Ser Phe Arg 415 20 200524957 &lt; 210 &gt; 482 &lt; 211 &gt; 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220> • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Rib : &Lt; 400 &gt; 482

Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Gly Lys Leu Asp Arg lie Gly 15 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys 20 25 &lt; 210 &gt; 483 &lt; 211〉 21 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory Peptide &lt; 400 &gt; 483 · — Ser Ser Cys Phe Gly Gly Gly Arg lie Asp Arg lie Gly Ala Gin Ser Gly 15 10 15

Leu Gly Cys Asn Ser 20 &lt; 210> 484 &lt; 211> 23 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence 416 &lt; 220〉 200524957 &lt; 223> Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 484

Ser Ser Cys Phe Gly Gly Arg He Asp Arg lie Gly Ala Gin Ser Gly 15 10 15

Leu Gly Cys Asn Ser Phe Arg 20 &lt; 210 &gt; 485, &lt; 211〉 24 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 485

Ser Ser Cys Phe Gly Gly Arg He Asp Arg He Gly Ala Gin Ser Gly 15 10 15

Leu Gly Cys Asn Ser Phe Arg Tyr 20 &lt; 210 &gt; 486 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon &lt; 400 &gt; 486

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg lie Asp Arg lie Gly 15 10 15

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 417 200524957 &lt; 210 &gt; 487 &lt; 211 &gt; 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Artificial sequence description: Katsuyuki Kazuyuki &lt; 400 &gt; 487

Arg Ser Ser Cys Phe Gly Gly Arg lie Asp Arg He Gly Ala Gin Ser 15 10 15

Gly Leu Gly Cys Asn Ser Phe Arg 20 &lt; 210 &gt; 488 &lt; 211〉 25 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl too &lt; 400 &gt; 488

Arg Ser Ser Cys Phe Gly Gly Arg lie Asp Arg He Gly Ala Gin Ser L 1 5 10 15 _ Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt; 210〉 489 &lt; 211 &gt; 56 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide 418 200524957 &lt; 400〉 489

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly 15 10 15

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Ser Leu Arg Arg 20 25 30

Ser Ser Cys Phe Gly Gly Arg Met Asp Arg He Gly Ala Gin Ser Gly 35 40 45

Leu Gly Cys Asn Ser Phe Arg Tyr 50 55 &lt; 210〉 490 &lt; 211 &gt; 32 &lt; 212 &gt; PRT &lt; 213> Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 490

Ala Gly Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg lie 15 10 15

Asp Arg lie Gly Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 30 &lt; 210 &gt; 491 &lt; 211> 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Description: Synthetic Winner: &lt; 400 &gt; 491

Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Gly Lys Leu Asp Arg lie Gly 419 200524957 15 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys 20 25 &lt; 210〉 492-&lt; 211〉 16 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Peptide

&lt; 400 &gt; 492

Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys 15 10 15 &lt; 210〉 493 &lt; 211〉 15 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; artificial sequence Explanation: The synthesis of victory over the moon · _ &lt; 400〉 493

Arg Ser Ser Cys Phe Gly Gly Arg He Asp Arg lie Gly Ala Cys. 15 10 15 &lt; 210〉 494 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Artificial sequence Description: Synthetic Victory Moon 420 200524957 &lt; 4〇〇 &gt; 494

Ser Phe Gly Gly Arg lie Asp Arg lie Gly Ala Gin Ser Gly Leu Gly 15 10 15

Asn Ser Phe Arg Tyr 20 &lt; 210 &gt; 495 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 495

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg lie Gly 15 10 15

Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 &lt; 210〉 496 &lt; 211〉 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 496

Phe Ala Gly Arg lie Asp Arg lie Gly Ala Gin Ser Gly Leu Gly Cys 15 10 15

Asn Ser Phe Arg Tyr 20 421 200524957

&lt; 210 &gt; 497 &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400> 497

Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg 1 5 10 &lt; 210 &gt; 498 &lt; 211 &gt; 30 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Victory of synthesis fl too <400> 498

Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys 15 10 15

Asn Leu Leu Asp His Leu Glu Glu Lys Met Pro Leu Glu Asp 20 25 30 &lt; 210 &gt; 499 &lt; 211〉 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 4〇〇 &gt; 499 422 200524957

Glu Val Val Pro Pro Gin Val Leu Ser Glu Pro Asn Glu Glu Ala Gly 15 10 15

Ala Ala Leu Ser Pro Leu Pro Glu Val Pro Pro Trp Thr Gly Glu Val 20 25 30-Ser Pro Ala Gin Arg 35 &lt; 210 &gt; 500 &lt; 211〉 20 &lt; 212> PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &400; 500

Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu 15 10 15

Thr Ala Pro Arg 20 &lt; 210 &gt; 501 &lt; 211> 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400> 501

Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Gly Lys Leu Asp Arg lie Gly 15 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys 423 200524957 20 25 &lt; 210 &gt; 502 &lt; 211 &gt; 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Victory over synthesis B too <400> 502

Tyr Ser Ser Cys Phe Gly Gly Arg He Asp Arg He Gly Ala Gin Ser 15 10 15

Gly Leu Gly Cys Asn Ser Phe Arg 20 &lt; 210〉 503 &lt; 211 &gt; 21 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 503

Tyr Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu 15 10 15

Leu Thr Ala Pro Arg 20 &lt; 210 &gt; 504 &lt; 211> 32 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 424 200524957 &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Synthetic I-S S &lt; 400 &gt; 504

Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met 15 10 15

Asp Arg He Gly Ala Gin Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 30 &lt; 210〉 505 &lt; 211〉 24 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory 0 too <400> 505

Tyr Ser Ser Cys Phe Gly Gly Arg lie Asp Arg lie Gly Ala Gin Ser 15 10 15

Gly Leu Gly Cys Asn Ser Phe Arg 20 &lt; 210 &gt; 506 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequences: Synthetic Victory fl too &lt; 400〉 506

Ser Phe Asn Ser Cys Phe Gly Asn Arg He Glu Arg lie Gly Ser Trp 15 10 15 425 200524957

Ser Gly Leu Gly Cys Asn Asn Val Lys Thr Gly Asn Lys Lys Arg lie 20 25 30

Phe Gly Asn 35 &lt; 210〉 507 &lt; 211〉 32 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuki Tsutsuki &lt; 400> 507

Ser Pro Lys Met Met His Lys Ser Gly Cys Phe Gly Arg Arg Leu Asp 15 10 15

Arg lie Gly Ser Leu Ser Gly Leu Gly Cys Asn Val Leu Arg Lys Tyr 20 25 30 &lt; 210 &gt; 508 &lt; 211 &gt; 22 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Description: Synthetic Tsukiyuki &lt; 400 &gt; 508

Gly Trp Asn Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg He Gly Ser 15 10 15

Leu Ser Gly Leu Gly Cys 20 426 200524957 &lt; 210〉 509 &lt; 211〉 32 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuta &lt; 400〉 509 »Ser Pro Lys Met Val Gin Gly Ser Gly Cys Phe Gly Arg Lys Met Asp 15 10 15

Arg lie Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His 20 25 30 &lt; 210〉 510 &lt; 211〉 45 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Artificial Sequence Explanation: Synthetic victory 0 too <400> 510

Ser Gin Gly Ser Thr Leu Arg Val Gin Gin Arg Pro Gin Asn Ser Lys ^ 1 5 10 15. Val Thr His lie Ser Ser Cys Phe Gly His Lys He Asp Arg lie Gly 20 25 30

Ser Val Ser Arg Leu Gly Cys Asn Ala Leu Lys Leu Leu 35 40 45 &lt; 210 &gt; 511 &lt; 211〉 26

&lt; 212 &gt; PRT 427 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic I limb: &lt; 400> 511

Asp Ser Gly Cys Phe Gly Arg Arg Leu Asp Arg He Gly Ser Leu Ser 15 10 15

Gly Leu Gly Cys Asn Val Leu Arg Arg Tyr 20 25 &lt; 210 &gt; 512 &lt; 211 &gt; 32 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Description of Artificial Sequences: Synthesizer fl too &lt; 400 &gt; 512

Ser Pro Lys Thr Met Arg Asp Ser Gly Cys Phe Gly Arg Arg Leu Asp 15 10 15

Arg lie Gly Ser Leu Ser Gly Leu Gly Cys Asn Val Leu Arg Arg Tyr 20 25 30 &lt; 210〉 513 &lt; 211 &gt; 32 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; artificial sequence Explanation: Synthetic victory 0 too <400> 513

Asn Ser Lys Met Ala His Ser Ser Ser Cys Phe Gly Gin Lys lie Asp 428 200524957 15 10 15

Arg lie Gly Ala Val Ser Arg Leu Gly Cys Asp Gly Leu Arg Leu Phe 20 25 30 &lt; 210〉 514-&lt; 211 &gt; 45 &lt; 212 &gt; PRT * &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over Tsukita

&lt; 400 &gt; 514

Ser Gin Asp Ser Ala Phe Arg lie Gin Glu Arg Leu Arg Asn Ser Lys 15 10 15

Met Ala His Ser Ser Ser Cys Phe Gly Gin Lys lie Asp Arg lie Gly 20 25 30

Ala Val Ser Arg Leu Gly Cys Asp Gly Leu Arg Leu Phe 35 40 45

&lt; 210 &gt; 515 &lt; 211〉 33 # &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 515

Tyr Ser Pro Lys Met Val Gin Gly Ser Gly Cys Phe Gly Arg Lys Met 15 10 15

Asp Arg Leu Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg 20 25 30 429 200524957

His &lt; 210〉 516 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic wins too &lt; 400 &gt; 516

Ser Pro Lys Met Val Gin Gly Ser Gly Cys Phe Gly Arg Lys Met Asp 15 10 15

Arg lie Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His 20 25 30 &lt; 210 &gt; 517 &lt; 211〉 22 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Artificial Sequence Description: Synthetic Winner: &lt; 400 &gt; 517

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg lie Gly Ser 15 10 15

Met Ser Gly Leu Gly Cys 20 &lt; 210〉 518 &lt; 211〉 22 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 430 200524957 &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 518

Gly Leu Ser Arg Ser Cys Phe Gly Val Lys Leu Asp Arg lie Gly Ser 15 10 15

Met Ser Gly Leu Gly Cys 20 &lt; 210> 519 &lt; 211 &gt; 53 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory B too &lt; 400 &gt; 519

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu 15 10 15

Gin Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys Gly 20 25 30

Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg He Gly Ser Met 35 40 45

Ser Gly Leu Gly Cys 50 &lt; 210 &gt; 520 &lt; 211〉 53 &lt; 212〉 PRT &lt; 213> Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Artificial Sequences Description: Synthetic Victory Moon 431 200524957 &lt; 400 &gt; 520

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu 15 10 15

His Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Gly Asn Lys Lys Gly 20 25 30

Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg He Gly Ser Met 35 40 45

Ser Gly Leu Gly Cys 50 &lt; 210 &gt; 521 &lt; 211〉 27 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 521

Lys Pro Gly Thr Pro Pro Lys Val Pro Arg Thr Pro Pro Gly Glu Glu 15 10 15

Leu Ala Glu Pro Gin Ala Ala Gly Gly Asn Gin 20 25 &lt; 210〉 522 &lt; 211〉 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl too &lt; 400 &gt; 522

Gly Asp Lys Thr Pro Gly Gly Gly Gly Gly Ala Asn Leu Lys Gly Asp Arg 15 10 15

Ser Arg Leu Leu Arg 20 432 200524957 &lt; 210 &gt; 523 &lt; 211〉 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 523

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg lie Gly Ser 1 5 10 15

Met Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25

&lt; 210> 524 &lt; 211 &gt; 23 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory too &lt; 400 &gt; 524

Tyr Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg lie Gly 15 10 15

Ser Met Ser Gly Leu Gly Cys 20 &lt; 210 &gt; 525 φ &lt; 211 &gt; 7-&lt; 212 &gt; PRT ^ &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400〉 525

Asp Ala Phe Val Ala Leu Met 1 5

&lt; 210 &gt; 526 &lt; 211〉 7 &lt; 212 &gt; PRT 433 200524957 &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400〉 526

Asp Ala Phe Val Ala Leu Met 1 5 &lt; 210〉 527 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 527

Glu Pro Ser Lys Asp Ala Phe lie Gly Leu Met 1 5 10 &lt; 210 &gt; 528 &lt; 211 &gt; 9 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 528

Gly Pro Ser Gly Phe Tyr Gly Val Arg 1 5 &lt; 210 &gt; 529 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400〉 529

Ala Pro Leu Ser Gly Phe Tyr Gly Val Arg 1 5 10 &lt; 210 &gt; 530 &lt; 211 &gt; 7 434 200524957 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory too <400> 530

Asp Ser Phe Val Gly Leu Met _ 1 5 &gt; &lt; 210〉 531 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence

&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory flfl &lt; 400 &gt; 531

His Lys Thr Asp Ser Phe Val Gly Leu Met 1 5 10 &lt; 210> 532 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &400; 532 • His Lys lie Asn Ser Phe Val Gly Leu Met 1 5 10 ^ &lt; 210> 533 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400〉 533

Tyr His Lys Thr Asp Ser Phe Val Gly Leu Met 1 5 10 435 200524957 &lt; 210 &gt; 534 &lt; 211 &gt; 10 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too <400> 534

His Lys Thr Asp Ser Tyr Val Gly Leu Met 1 5 10 &lt; 210 &gt; 535 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory B too &lt; 400 &gt; 535

Lys Asp Ser Phe Val Gly Met 1 5 &lt; 210 &gt; 536 &lt; 211> 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Katsuyuki Katsuta &lt; 400〉 536

Arg Ala Trp Phe Pro Pro 1 5 &lt; 210 &gt; 537 436 200524957 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 537

Ala Ala Trp Phe Pro Pro 1 5 &lt; 210 &gt; 538 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 538

Ala Ala Trp Phe Pro Pro 1 5 &lt; 210〉 539 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400 &gt; 539

Asp Ser Phe Val Ala Leu Met 1 5 &lt; 210〉 540 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400 &gt; 540

Asp Ser Phe Val Gly Leu 1 5 &lt; 210 &gt; 541 &lt; 211 &gt; 7 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 〉 541

Asp Ser Phe Trp Ala Leu Met 1 5 &lt; 210〉 542 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 542

Asp Tyr Trp Val Trp Trp Arg 1 5 &lt; 210 &gt; 543 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 543

Asp Tyr Trp Val Trp Trp Lys 1 5 &lt; 210> 544 &lt; 211 &gt; 10 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223> Explanation of artificial sequence: Synthetic victory I too &lt; 400 &gt; 544

Asp Met His Asp Phe Phe Val Gly Leu Met 1 5 10 &lt; 210〉 545 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220>

&lt; 223〉 Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400〉 545

Asp Met His Asp Phe Phe Gly Leu Met 1 5 &lt; 210 &gt; 546 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 546

Asp Met His Asp Phe Phe Pro Gly Leu Met

&lt; 210> 547 &lt; 211 &gt; 11 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki too &lt; 400 &gt; 547

Tyr Asp Met His Asp Phe Phe Val Gly Leu Met 1 5 10 439 200524957 &lt; 210〉 548 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic victory: &lt; 400 &gt; 548

Asp Pro His Asp Phe Trp Val Trp Leu 1 5

&lt; 210〉 549 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: synthetic peptide &lt; 400> 549

Gly Asn Leu Trp Ala Thr Gly His Phe Met 1 5 10 &lt; 210 &gt; 550 &lt; 211〉 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 550 &quot; Leu Ser Trp Asp Leu Pro Glu Pro Arg Ser Arg Ala Gly Lys lie Arg 15 10 15

Val His Pro Arg Gly Asn Leu Trp Ala Thr Gly His Phe Met 20 25 30 &lt; 210〉 551 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 440 200524957 &lt; 223 &gt; Artificial Sequence Description: Synthesis of β to Tai &lt; 400> 551

Ala Pro Leu Ser Trp Asp Leu Pro Glu Pro Arg Ser Arg Ala Gly Lys 15 10 15 lie Arg Val His Pro Arg Gly Asn Leu Trp Ala Thr Gly His Phe Met 20 25 30 &lt; 210〉 552 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequences: Synthesis of Katsuyuki &lt; 400〉 552

Cys Tyr Trp Val Cys 1 5 &lt; 210〉 553 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 553

Gly Asn His Trp Ala Val Gly His Leu Met 1 5 10 &lt; 210〉 554 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 554

Lys lie Pro Tyr lie Leu 1 5 441 200524957 &lt; 210 &gt; 555 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 555

Tyr Phe Leu Phe Arg Pro Arg Asn 1 5

&lt; 210 &gt; 556 &lt; 211 &gt; 25 &lt; 212 &gt; PRT call &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400〉 556

Phe Lys Val Asp Glu Glu Phe Gin Gly Pro lie Val Ser Gin Asn Arg 15 10 15

Arg Tyr Phe Leu Phe Arg Pro Arg Asn 20 25 &lt; 210 &gt; 557 • &lt; 211〉 23

'&lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence ^ &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 557

Tyr Lys Val Asn Glu Tyr Gin Gly Pro Val Ala Pro Ser Gly Gly Phe 15 10 15

Phe Leu Phe Arg Pro Arg Asn 20 442 200524957 &lt; 210 &gt; 558 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400〉 558

Asp Ala Gly His Gly Gin He Ser His Lys Arg His Lys Thr Asp Ser 15 10 15

Phe Val Gly Leu Met 20

&lt; 210> 559 &lt; 211 &gt; 10 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 559

Pro Asn Pro Asp Glu Phe Val Gly Leu Met 1 5 10

&lt; 210 &gt; 560 &lt; 211 &gt; 9 &lt; 212〉 PRT # &lt; 213 &gt; Artificial sequence &lt; 220 &gt; ^ &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400> 560

Glu Leu Trp Ala Val Gly Ser Phe Met 1 5 &lt; 210 &gt; 561 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 443 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic β Ichigetsu &lt; 400 &gt; 561

Glu Leu Trp Ala Val Gly Ser Leu Met 1 5 &lt; 210〉 562 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 562

Glu Ala Asp Pro Asn Lys Phe Tyr Gly Leu Met 1 5 10 &lt; 210〉 563 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Peptide &lt; 400> 563

Glu Ala Asp Pro Asn Lys Phe Tyr 1 5 &lt; 210> 564 &lt; 211 &gt; 18 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400 &gt; 564

Ser Pro Ser Asn Ser Lys Cys Pro Asp Gly Pro Asp Cys Phe Val Gly 15 10 15

Leu Met 444 200524957 &lt; 210 &gt; 565 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Satsuki Katsuta &lt; 400〉 565

Asp Phe Gly Leu Met 1 5

&lt; 210〉 566 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too &lt; 400〉 566

Asp Asp Phe Gly Leu Met 1 5 &lt; 210 &gt; 567 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: • &lt; 400 &gt; 567 'Gly Ser His Trp Ala Val Gly His Leu Met 1 5 10 &lt; 210 &gt; 568 &lt; 211〉 23 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 568

Gly Lys Arg Asp Ala Asp Ser Ser lie Glu Lys Gin Val Ala Leu Leu 445

200524957 15 10 15

Lys Ala Leu Tyr Gly His Gly 20 &lt; 210 &gt; 569 &lt; 211 &gt; 19 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 〉 569

Ala Leu Asn Ser Val Ala Tyr Glu Arg Ser Ala Met Gin Asn Tyr Glu 15 10 15

Arg Arg Arg &lt; 210〉 570 &lt; 211 &gt; 17 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 570

Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly He Cys Tyr Arg Arg Cys 15 10 15

Arg &lt; 210> 571 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 446 200524957 &lt; 400 &gt; 571

Glu Gly Lys Arg Pro Trp lie Leu 1 5 &lt; 210〉 572 &lt; 211〉 25 &lt; 212〉 PRT &lt; 213> Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt;; 400 &gt; 572

Met Leu Thr Lys Phe Glu Thr Lys Ser Ala Arg Val Lys Gly Leu Ser

Phe His Pro Lys Arg Pro Trp lie Leu 20 25 &lt; 210〉 573 &lt; 211 &gt; 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuta &lt; 400〉 573 spring Asp Met His Asp Phe Phe Val Gly Leu Met 1 5 10 &lt; 210 &gt; 574 &lt; 211〉 10 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; of artificial sequence Explanation: Synthetic Victory Moon too <400; 574

His Lys Thr Asp Ser Phe Val Gly Leu Met 1 5 10 447 200524957 &lt; 210> 575 &lt; 211 &gt; 24 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tokiyuki &lt; 400 &gt; 575

Asp Ala Asp Ser Ser lie Glu Lys Gin Val Ala Leu Leu Lys Ala Leu 1 5 10 15

Tyr Gly His Gly Gin lie Ser His 20

&lt; 210 &gt; 576 &lt; 211> 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 576

Glu Gin Trp Phe Trp Trp Met 1 5 &lt; 210 &gt; 577 &lt; 211〉 5 φ &lt; 212〉 PRT ~ &lt; 213 &gt; Artificial Sequence I &lt; 220> '&lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Tsuki &lt; 400> 577

Arg Phe Phe Leu Met 1 5 &lt; 210 &gt; 578 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 448 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 578

Arg Pro Arg Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt; 210 &gt; 579 &lt; 211 &gt; 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Win 0 Too <400> 579

Arg Trp Phe Trp Leu Met 1 5 &lt; 210 &gt; 580 &lt; 211〉 2 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Rib: &lt; 400 &gt; 580 Trp Met 1 φ &lt; 210 &gt; 581 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400〉 581

Arg Phe Phe Leu Met 1 5 &lt; 210 &gt; 582 449 200524957 &lt; 211 &gt; 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 582

Arg Trp Phe Trp Leu Met 1 5 _ &lt; 210〉 583 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; Xin &lt; 223 &gt; Reward of Artificial Sequence: Synthetic Victory Peptide &lt; 400〉 583

Ala Gin Gin Phe Phe Gly Leu Met 1 5 &lt; 210 &gt; 584 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt;; 400 &gt; 584

Tyr Phe Phe His Leu Met 1 5 &lt; 210 &gt; 585 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B too &lt; 400 &gt; 585

Arg Pro Lys Pro Gin Gin Phe Tyr Gly Leu Met 1 5 10 450 200524957 &lt; 210 &gt; 586 &lt; 211 &gt; 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide. &Lt; 400 &gt; 586

Arg Pro Lys Pro Gin Gin Phe Phe Leu Met-1 5 10

&lt; 210 &gt; 587 &lt; 211〉 11 &lt; 212 &gt; PRT φ &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223〉 description of artificial sequence: Katsuyuki Katsuta &lt; 400 &gt; 587

Arg Pro Lys Pro Gin Gin Phe Phe His Leu Met 1 5 10 &lt; 210 &gt; 588 &lt; 211> 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Win

&lt; 400 &gt; 588

Arg Pro Lys Pro Gin Gin Phe Phe Trp Leu Met 1 5 10 &lt; 210 &gt; 589 &lt; 211 &gt; 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 589 451 200524957

Arg Pro Lys Pro Gin Gin Trp Phe Trp Leu Met 1 5 10 &lt; 210 &gt; 590 &lt; 211> 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 590

Arg Pro Lys Pro Phe Gin Trp Phe Trp Leu Leu 1 5 10

&lt; 210> 591 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 591

Arg Pro Lys Pro Gin Gin Phe Phe Pro Leu Met 1 5 10

&lt; 210> 592 &lt; 211 &gt; 8 &lt; 212 &gt; PRT φ &lt; 213 &gt; artificial sequence ‘&lt; 220〉 &lt; 223> Explanation of artificial sequence: Synthetic victory moon too ~ &lt; 400 &gt; 592

Pro Gin Gin Phe Phe Gly Leu Met 1 5 &lt; 210〉 593 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 452 200524957 &lt; 223 &gt; Explanation of Artificial Sequence fl: Too &lt; 400 &gt; 593

Gin Phe Phe Leu Met 1 5 &lt; 210 &gt; 594 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 594

Gin Phe Phe Leu Met 1 5 &lt; 210 &gt; 595 &lt; 211> 6 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 595

Gin Phe Phe Gly Leu Met 1 5 &lt; 210〉 596 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too & 400 〉 596

Gin Gin Phe Phe Gly Leu Met 1 5

&lt; 210 &gt; 597 &lt; 211 &gt; 6 &lt; 212 &gt; PRT 200524957 &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 597

Gin Phe Phe Gly Leu Met 1 5 &lt; 210 &gt; 598 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuta &lt; 400 &gt; 598

Arg Pro Lys Pro Gin Gin Phe Phe Leu Met 1 5 10 &lt; 210 &gt; 599 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Tsuki &lt; 400> 599

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu 1 5 10

&lt; 210> 600 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 600

Pro Gin Gin Phe Phe Gly Leu Met 1 5 &lt; 210 &gt; 601 454 200524957 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence Too &lt; 400 &gt; 601

Glu Phe Phe Gly Leu Met. 1 5-&lt; 210〉 602 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence &lt; 400〉 602

Glu Phe Phe Pro Leu Met 1 5 &lt; 210〉 603 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuki Tsukita &lt; 400 〉 603 • Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu 1 5 10 &lt; 210〉 604 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: The victory of synthesis fl too <400> 604

Phe Phe Gly Leu Met 1 5 455 200524957 &lt; 210〉 605 &lt; 211〉 11 &lt; 212 &gt; PRT &lt; 213〉 artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Satsuki Katsuta, &lt; 400 &gt; 605

Arg Pro Lys Pro Gin Gin Phe Phe Pro Leu Met • 1 5 10 &lt; 210 &gt; 606 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tokiyuki &lt; 400 &gt; 606

Phe Phe Pro Leu Met 1 5 &lt; 210〉 607 &lt; 211> 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 # &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 607 v Gin Gin Phe Phe Gly Leu Met 1 5 &lt; 210〉 608 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: 0 &lt; 400 &gt; 608 456 200524957

Arg Pro Lys Pro Gin Gin Phe Phe Leu Met 1 5 10 &lt; 210〉 609 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 _ &lt; 223〉 Explanation of Artificial Sequence: Synthetic Katsuki Taiichi &lt; 400〉 609

Glu Phe Phe Pro Leu Met 1 5 &lt; 210〉 610 ® &lt; 211 &gt; 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Satsuki Katsuta &lt; 400〉 610

Arg Pro Lys Pro Gin Gin Trp Phe Trp Leu Leu 1 5 10

&lt; 210〉 611 &lt; 211〉 9 &lt; 212〉 PRT φ &lt; 213 &gt; Artificial Sequence &quot; &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki ~ &400; 611

Lys Pro Pro Phe Asn Trp Phe Trp Leu 1 5 &lt; 210〉 612 &lt; 211 &gt; 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 457 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 612

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt; 210〉 613 &lt; 211 &gt; 11 &lt; 212〉 PRT I &lt; 213 &gt; Artificial Sequence ^ &lt; 220〉 I &lt; 223〉 Explanation of Artificial Sequence : Synthetic Victory 0 Too <400> 613

Lys Pro Arg Pro Gin Gin Phe lie Gly Leu Met 1 5 10 &lt; 210〉 614 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 614

Lys Pro Arg Pro His Gin Phe Phe Gly Leu Met 1 5 10 &lt; 210 &gt; 615 • &lt; 211〉 3

'&lt; 212〉 PRT &lt; 213〉 Artificial sequence' &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb:

&lt; 400〉 615 Gin Trp Phe &lt; 210〉 616 &lt; 211 &gt; 14 &lt; 212〉 PRT 458 200524957 &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 616

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met Gly Lys Arg 1 5 10 • &lt; 210〉 617

&lt; 211〉 4 ^ &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: φ &lt; 400> 617

Arg Pro Lys Pro 1 &lt; 210〉 618 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 618

Arg Pro Lys Pro Gin Gin

&lt; 210> 619 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory fl too &lt; 400> 619

Arg Pro Lys Pro Gin Gin Phe 1 5 &lt; 210 &gt; 620 459 200524957 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: 0 &lt; 400 &gt; 620

Arg Pro Lys Pro Gin Gin Phe Phe Gly 1 5 &lt; 210 &gt; 621 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 621

Pro Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt; 210〉 622 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 622

Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 &lt; 210 &gt; 623 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence &lt; 400〉 623 Phe Gly Leu Met 1 460 200524957 &lt; 210〉 624 &lt; 211〉 3 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B Too &lt; 400 &gt; 624 Gly Leu Met

&lt; 210 &gt; 625 &lt; 211 &gt; 11 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 625

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met 1 5 10 &lt; 210 &gt; 626 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; φ &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory '&lt; 400> 626

Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu Met '1 5 10 &lt; 210〉 627 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tokiyuki &lt; 40〇 &gt; 627 461 200524957

Arg Pro Lys Pro Gin Gin Phe Tyr Gly Leu 1 5 10 &lt; 210 &gt; 628 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence ^ &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki too— &lt; 400 &gt; 628

Asp Arg Val Tyr He His Ala 1 5 φ &lt; 210〉 629 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 629

Ala Pro Gly Asp Arg lie Tyr Val His Pro Phe 1 5 10

&lt; 210〉 630 &lt; 211〉 7 &lt; 212 &gt; PRT • &lt; 213〉 Artificial sequence &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory) too &lt; 400 &gt; 630

Gly Val Tyr Val His Pro Val 1 5 &lt; 210> 631 &lt; 211 &gt; 15 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence 462 200524957 &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: 0 &lt; 400 &gt; 631

Glu Asn Gly Leu Pro Val His Leu Asp Gin Ser lie Phe Arg Arg 15 10 15 &lt; 210 &gt; 632 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation: Synthetic Victory &lt; 400〉 632

Glu Asn Gly Leu Pro Val His Leu Asp Gin Ser lie Phe Arg Arg 15 10 15 &lt; 210 &gt; 633 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation: Synthetic Victory Limb: &lt; 400〉 633

Gly Leu Pro Pro Arg Pro Lyslie Pro Pro 1 5 10 • &lt; 210〉 634 &lt; 211 &gt; 10 &lt; 212〉 PRT "&lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory: &lt; 4〇〇 &gt; 634

Gly Leu Pro Pro Gly Pro Pro lie Pro Pro 1 5 10 &lt; 210 &gt; 635 &lt; 211〉 8 463 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis Tokiyuki &lt; 400 &gt; 635

Arg Pro Gly Phe Ser Pro Phe Arg 1 5 &lt; 210> 636 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213> artificial sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthetic Ikiyuki &lt; 400> 636

Arg Pro Gly Phe Ser Pro Phe Arg 1 5 &lt; 210> 637 &lt; 211 &gt; 10 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 637

Asp Arg Val Tyr lie His Pro Phe His Leu

&lt; 210 &gt; 638 &lt; 211 &gt; 3 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223> Description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 638 Gly Gly Gly 464 200524957 &lt; 210 &gt; 639 &lt; 211> 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 639

Asp Arg Val Tyr He His Pro 1 5

&lt; 210〉 640 &lt; 211〉 7 &lt; 212 &gt; PRT Φ &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: synthetic peptide &lt; 400> 640

Cys Tyr Trp Lys Val Cys Thr 1 5 &lt; 210> 641 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400> 641

Asp Arg Val Tyr lie His Pro Phe 1 5 &lt; 210 &gt; 642 &lt; 211 &gt; 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt;; 400〉 642

Glu Gly Val Tyr Val His Pro Val 200524957 1 5 &lt; 210 &gt; 643 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt;; 400 &gt; 643 Asp Arg Val Tyr 1 &lt; 210> 644 &lt; 211 &gt; 6 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 644

Val Tyr He His Pro Phe 1 5 &lt; 210> 645 &lt; 211> 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 645

Tyr He His Pro Phe 1 5 &lt; 210 &gt; 646 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu 200524957 &lt; 400 〉 646 lie His Pro Phe 1 &lt; 210〉 647 &lt; 211〉 7 &lt; 212〉 PRT-&lt; 213 &gt; Artificial Sequence &lt; 220〉 — &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 〉 647

Arg Val Tyr He His Pro Phe 1 5

&lt; 210 &gt; 648 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 648

Arg Val Tyr He His Pro lie 1 5

&lt; 210〉 649 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory: &lt; 400〉 649

Pro Thr His lie Lys Trp Gly Asp 1 5 &lt; 210 &gt; 650 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 200524957 &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic winning ribs: &lt; 400〉 650

Glu Trp Pro Arg Pro Gin He Pro Pro 1 5 &lt; 210 &gt; 651 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 651

Asn Arg Val Tyr Val His Pro Phe His Leu 1 5 10 &lt; 210 &gt; 652 &lt; 211 &gt; 10 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 652

Asn Arg Val Tyr Val His Pro Phe Asn Leu 1 5 10 # &lt; 210 &gt; 653

&lt; 211〉 10, ‘&lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400〉 653

Asn Arg Val Tyr Val His Pro Phe Gly Leu 1 5 10 &lt; 210〉 654 &lt; 211〉 7 468 200524957 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory 0 too &lt; 400 &gt; 654

Asn Arg Val Tyr Val His Pro 1 5 &lt; 210〉 655 ~ &211; 211> 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400〉 655

Asn Arg Val Tyr Val His Pro Phe 1 5 &lt; 210> 656 &lt; 211 &gt; 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 656

Arg Val Tyr lie His Pro Phe His Leu 1 5 * &lt; 210〉 657 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon M &lt; 400> 657

Tyr Lys Arg His Pro He 1 5 469 200524957 &lt; 210 &gt; 658 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 658

Asp Arg Val Tyr lie Phe Pro Phe-1 5

&lt; 210〉 659 &lt; 211〉 13 &lt; 212〉 PRT ® &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400〉 659

Asp Arg Val Tyr He His Pro Phe His Leu Val lie His 1 5 10 &lt; 210〉 660 &lt; 211 &gt; 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; φ &lt; 223 &gt; Explanation of Artificial Sequence : Synthetic Victory '&lt; 400〉 660

Asp Arg Val Tyr He His Pro Phe His Leu Val lie His Asn ^ 1 5 10 &lt; 210〉 661 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation: Satsuki Katsuyuki &lt; 400 &gt; 661 470 200524957

Asp Arg Val Tyr lie His Pro Phe His Leu Leu Val Tyr Ser 1 5 10 &lt; 210> 662 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence : The victory of synthesis fl too &lt; 400 &gt; 662

Arg Val Tyr lie His Pro Phe 1 5

&lt; 210〉 663 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 663

Arg Val Tyr He His Pro 1 5

&lt; 210〉 664 &lt; 211〉 7 &lt; 212 &gt; PRT φ &lt; 213 &gt; artificial sequence 1 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B too * &lt; 400 &gt; 664

Arg Val Tyr lie His Pro Ala 1 5 &lt; 210 &gt; 665 &lt; 211 &gt; 7 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 22〇 &gt; 471 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory B too &lt; 400 &gt; 665

Arg Val Tyr He His Pro He 1 5 &lt; 210 &gt; 666 &lt; 211〉 7 &lt; 212 &gt; PRT ~ &lt; 213 &gt; artificial sequence ^ &lt; 220> '&lt; 223 &gt; Explanation of artificial sequence: the moon of synthesis Too &lt; 400 &gt; 666

Arg Val Tyr lie His Pro Thr

&lt; 210 &gt; 667 &lt; 211> 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic victory fl too &lt; 400〉 667

Arg Val Tyr He His Pro Phe 1 5 &lt; 210〉 668 • &lt; 211〉 7

* &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 668

Arg Val Tyr Val His Pro Ala 1 5

&lt; 210 &gt; 669 &lt; 211 &gt; 6 &lt; 212 &gt; PRT 200524957 &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400> 669

Val Tyr lie His Pro lie 1 5-"210> 67 &lt; 211> 14-&lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory moon too φ &lt; 400〉 670

Asp Arg Val Tyr He His Pro Phe His Leu Val lie His Ser 1 5 10 &lt; 210〉 671 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence : Synthetic victory 0 too &lt; 400 &gt; 671

Arg Val Tyr Val His Pro Phe

&lt; 210 &gt; 672 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400〉 672

Asp Arg Val Tyr Val His Pro Phe 1 5 &lt; 210 &gt; 673 473 200524957 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl Too &lt; 400 &gt; 673

Asp Arg Val Tyr Val His Pro Phe 1 5

&lt; 210> 674 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400> 674

Asp Arg Val Tyr Val His Pro Phe His Leu 1 5 10 &lt; 210 &gt; 675 &lt; 211 &gt; 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 675 Lu Asp Arg Val Tyr Val His Pro Phe Asn Leu '1 5 10 皤 &lt; 210〉 676 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223> Explanation of artificial sequence: Synthetic victory 0 too <400> 676

Asp Arg Val Tyr Val His Pro Phe Ser Leu 1 5 10 474 200524957 &lt; 210〉 677 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory- &400; 677

Asp Arg Val Tyr Val His Pro Phe His Leu 1 5 10

&lt; 210 &gt; 678 &lt; 211〉 14 φ &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsutsuki &lt; 400> 678

Asp Arg Val Tyr lie His Pro Phe His Leu Val He His Asn 1 5 10 &lt; 210〉 679 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉. &Lt; 223 &gt; Artificial Sequence Explanation: Synthetic peptide &lt; 400 &gt; 679. Asp Arg Val Tyr lie His Pro Phe His Leu Leu Val Tyr Ser 1 5 10 &lt; 210 &gt; 680 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 680 475 200524957

Pro His Pro Phe His Phe Phe Val Tyr Lys 1 5 10 &lt; 210 &gt; 681 &lt; 211〉 14 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence- &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki-&lt; 400 &gt; 681

Asp Arg Val Tyr lie His Pro Phe His Leu Leu Tyr Tyr Ser 1 5 10 钃 I &lt; 210 &gt; 682 &lt; 211〉 14 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400〉 682

Asp Arg Val Tyr lie His Pro Cys His Leu Leu Tyr Tyr Ser 1 5 10

&lt; 210〉 683 &lt; 211〉 14 &lt; 212 &gt; PRT · _ &lt; 213〉 Artificial sequence &lt; 220〉. &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 683

Asp Arg Val Tyr lie His Pro Leu His Leu Leu Tyr Tyr Ser 1 5 10 &lt; 210 &gt; 684 &lt; 211 &gt; 14 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220 &gt; 476 200524957 &lt; 223 &gt; Artificial sequence Explanation: Synthetic Victory: &lt; 400〉 684

Asp Arg Val Tyr lie His Pro Val His Leu Leu Tyr Tyr Ser 1 5 10 &lt; 210 &gt; 685 &lt; 211〉 38. &Lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 1 &lt; 220> &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyuki &lt; 400> 685

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His

Leu Asp lie lie Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Arg Ser 35 &lt; 210 &gt; 686 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 · &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400 &gt; 686 -lie Asn Thr Pro Glu Gin Thr Val Pro Tyr Gly Leu Ser Asn Tyr Arg 15 10 15

Gly Ser Phe Arg 20 &lt; 210 &gt; 687 &lt; 211〉 18 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence 477 200524957 &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 687

Val Asn Thr Pro Glu Arg Val Val Pro Tyr Gly Leu Gly Ser Pro Ser 15 10 15

Arg Ser &lt; 210 &gt; 688-&lt; 211 &gt; 39 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> φ &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 688

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp lie lie Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Ser Arg Ser 35

&lt; 210 &gt; 689 &lt; 211 &gt; 18 W &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence-&lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 689

Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Ser 15 10 15

Arg Ser &lt; 210> 690 &lt; 211 &gt; 20 478 200524957 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 690

He He Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly 15 10 15

Ser Pro Arg Ser-20 &lt; 210〉 691 &lt; 211〉 17 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 691

Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Arg 15 10 15

Ser

&lt; 210〉 692 &lt; 211〉 37 &lt; 212 &gt; PRT • &lt; 213〉 Artificial sequence &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400〉 692

Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp lie lie Trp Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly 20 25 30

Leu Gly Asn Pro Pro 35 479 200524957 &lt; 210 &gt; 693 &lt; 211〉 16 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory B too &lt; 400 &gt; 693

Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly Leu Gly Asn Pro Pro 15 10 15 &lt; 210〉 694 φ &lt; 211〉 41 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; artificial Explanation of sequence: Synthetic Victory B too <400> 694

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 15 10 15

Leu Asp He lie Trp lie Asn Thr Pro Glu Gin Thr Val Pro Tyr Gly 20 25 30

Leu Ser Asn Tyr Arg Gly Ser Phe Arg 35 40 • &lt; 210〉 695 &lt; 211〉 39 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl M &lt; 400> 695

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15 480 200524957

Leu Asp lie lie Trp Val Asn Thr Pro Glu His He Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Ser Arg Ser 35 &lt; 210> 696 &lt; 211 &gt; 18 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

A &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Synthetic tsukiyuki &lt; 400> 696

Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Ser

Arg Ser &lt; 210〉 697 &lt; 211〉 39 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 697

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His

Leu Asp He He Trp Val Asn Thr Pro Glu Arg Val Val Pro Tyr Gly 20 25 30

Leu Gly Ser Pro Ser Arg Ser 35 &lt; 210 &gt; 698 &lt; 211〉 38 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 481 200524957 &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tai &lt;; 400 &gt; 698

Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp He lie Trp Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly-20 25 30 u Leu Gly Asn Pro Pro Arg 35 &lt; 210 &gt; 699 φ &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 699

Val Asn Thr Pro Glu Gin Thr Ala Pro Tyr Gly Leu Gly Asn Pro Pro 15 10 15

Arg

&lt; 210〉 700 &lt; 211〉 41 ® &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence _ &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 8 too &lt; 400〉 700

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 15 10 15

Leu Asp lie lie Trp lie Asn Thr Pro Glu Gin Thr Val Pro Tyr Gly 20 25 30

Leu Ser Asn His Arg Gly Ser Leu Arg 482 200524957 35 40 &lt; 210 &gt; 701 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner &lt; 400〉 701 ^ Cys Gin Cys Ala Ser Gin Lys Asp Lys Lys Trp Ser Tyr Cys Gin Ala 15 10 15

Gly Lys Glu lie

&lt; 210 &gt; 702 &lt; 211> 21 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic tsukiyuki &lt; 400> 702

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp lie He Trp 20 &lt; 210 &gt; 703 &lt; 211 &gt; 15 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 703

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys 15 10 15 483 200524957 &lt; 210 &gt; 704 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Artificial Explanation of sequence: Satsuki Katsuyuki. &Lt; 400 &gt; 704

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys-15 10 15 &lt; 210 &gt; 705 &lt; 211〉 6

φ &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 705

Trp Leu Asp lie lie Trp 1 5 &lt; 210〉 706 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 #. &Lt; 223 &gt; Explanation of Artificial Sequence ; 400 &gt; 706 e Cys Ser Ala Ser Ser Leu Met Asp Lys Glu Ala Val Tyr Phe Cys His 15 10 15

Leu Asp lie He Trp 20 &lt; 210> 707 &lt; 211> 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 484 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 707

Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Asp His Leu 15 10 15

Asp lie lie Trp 20

&lt; 210 &gt; 708 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400> 708

Ala Ser Ala Ser Ser Leu Met Asp Lys Glu Ala Val Tyr Phe Ala His 15 10 15

Leu Asp lie lie Trp 20 &lt; 210 &gt; 709 &lt; 211> 16 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence • &lt; 220 &gt; '&lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400 〉 709

Leu Met Asp Lys Glu Ala Val Tyr Phe Ala His Leu Asp lie He Trp 15 10 15 &lt; 210 &gt; 710 &lt; 211> 21 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; artificial sequence Explanation: Synthetic Victory Moon 485 200524957 &lt; 400〉 710

Cys Ala Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 15 10 15

Leu Asp lie lie Trp 20

-&lt; 210 &gt; 711 &lt; 211> 20 '&lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223> description of artificial sequence: Synthetic victory moon too φ &lt; 400 &gt; 711

Cys Ser Ala Ser Ser Leu Asp Lys Glu Ala Val Tyr Phe Cys His Leu 15 10 15

Ala lie lie Trp 20 &lt; 210 &gt; 712 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 712

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asn lie He Trp 20 &lt; 210 &gt; 713 &lt; 211> 15 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 486 200524957 &lt; 223 &gt; description of artificial sequence: victory of synthesis: &lt; 400 &gt; 713

Asn Trp His Gly Thr Ala Pro Asp Trp Phe Phe Asn Tyr Tyr Trp 15 10 15 &lt; 210 &gt; 714 &lt; 211 &gt; 14. &Lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220〉 &lt; 223 &gt; Artificial Explanation of the sequence: Katsuyuki Katsuta &lt; 400 &gt; 714

Asp Glu Glu Ala Val Tyr Phe Ala His Leu Asp lie He Trp

&lt; 210〉 715 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic victory 0 too &lt; 400〉 715

His Leu Asp He lie Trp 1 5 &lt; 210〉 716 ·. &Lt; 211〉 23 &lt; 212〉 PRT-&lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; &lt; 400 &gt; 716

His Leu Asp lie He Trp Val Asn Thr Pro Glu His Val Val Pro Tyr 1 5 10 15

Gly Leu Gly Ser Pro Arg Ser 20 487 200524957 &lt; 210 &gt; 717 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 717 -Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His 15 10 15

Leu Asp He lie Trp 20 Φ &lt; 210 &gt; 718 &lt; 211〉 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl too &400; 718

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His 15 10 15

Leu Asp lie lie Trp 20 &lt; 210〉 719 • &lt; 211〉 16 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 719

Ser Leu Lys Asp Leu Phe Pro Ala Lys Ala Ala Asp Arg Arg Asp Arg 15 10 15 &lt; 210 &gt; 720 488 200524957 &lt; 211〉 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning ribs: &lt; 400 &gt; 720 Leu Trp Trp 1

&lt; 210 &gt; 721 &lt; 211 &gt; 4 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400> 721

Met Leu Met Trp &lt; 210〉 722 &lt; 211〉 1 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsukita &lt; 400〉 722

Arg &lt; 210 &gt; 723 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory lt &lt; 400 &gt; 723

Asp Pro lie Leu Trp 200524957 &lt; 210〉 724 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400 &gt; 724 ** Ser Pro Val Leu Trp 1 5 &lt; 210〉 725 φ &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 725

Leu Asp lie lie Trp 1 5

&lt; 210 &gt; 726 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; Synthetic winning rib: &lt; 223 &gt; Explanation of artificial sequence &lt; 400> 726

Leu Asplie He Trp 1 5 &lt; 210 &gt; 727 &lt; 211 &gt; 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide 200524957 &lt; 400> 727

Cys Ser Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Asn Phe Cys His 15 10 15

Gin Asp Val lie Trp 20 &lt; 210 &gt; 728 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223〉 An explanation of the artificial sequence: Synthetic Birth Moon &lt; 400 &gt; 728

Cys Ser Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Tyr Phe Cys His 15 10 15

Gin Asp Val lie Trp 20 &lt; 210〉 729 &lt; 211〉 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory moon too φ &lt; 400〉 729

Cys Thr Cys Asn Asp Met Thr Asp Glu Glu Cys Leu Asn Phe Cys His 15 10 15

Gin Asp Val lie Trp 20 &lt; 210> 730 &lt; 211 &gt; 16 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; 491 200524957 &lt; 223 &gt; Description of Artificial Sequences: Synthetic Katsuki Tsukita &lt; 400 &gt; 730

Gly Asn Trp His Gly Thr Ala Pro Asp Trp Phe Phe Asn Tyr Tyr Trp 15 10 15 &lt; 210 &gt; 731 &lt; 211〉 6 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence '&lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Satsuki Katsuyuki &lt; 400 &gt; 731

His Leu Asp lie lie Trp 1 5 &lt; 210> 732 &lt; 211 &gt; 45 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl too &lt; 400 &gt; 732

Thr Leu Asp Glu Glu Asp Leu Val Asp Ser Leu Ser Glu Gly Asp Ala 15 10 15

Tyr Thr Asn Gly Leu Gin Val Asn Phe His Ser Pro Arg Ser Gly Gin 20 25 30

Arg Cys Trp Ala Ala Arg Thr Gin Val Glu Lys Arg Leu 35 40 45 &lt; 210〉 733 &lt; 211〉 16 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide 492 200524957 &lt; 400 &gt; 733

Cys Pro Pro Gly Ser Pro Met Asn Pro His His Lys Cys Glu Val Trp 15 10 15

&lt; 210〉 734 &lt; 211〉 5 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; • &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Ichigotsuki &lt; 400> 734

Asp Pro Val Leu Trp

&lt; 210〉 735 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213〉 artificial sequence &lt; 220 &gt; &lt; 223〉 description of artificial sequence: synthetic Ikiyuki too &lt; 400〉 735

Glu Ala He Trp Leu 1 5

&lt; 210〉 736 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; Synthetic victory &lt; 223 &gt; Explanation of artificial sequence &lt; 400> 736

Ala Val Leu Trp &lt; 210 &gt; 737 &lt; 211〉 3 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence 493 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuki Taito &lt; 400 &gt; 737 Leu Trp Trp 1 &lt; 210 &gt; 738 &lt; 211〉 2 &lt; 212〉 PRT '&lt; 213〉 Artificial sequence &lt; 220 &gt; ^ &lt; 223〉 Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400> 738 Leu Trp &lt; 210〉 739 &lt; 211〉 3 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb: &lt; 400〉 739 Leu Trp Tyr 1 &lt; 210 &gt; 740 &lt; 211 &gt; 6 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 740

Leu Trp Ala Ala Tyr Phe 1 5

&lt; 210 &gt; 741 &lt; 211 &gt; 16 &lt; 212 &gt; PRT 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400> 741

Gly Asn Trp His Gly Thr Ser Pro Asp Trp Phe Pn Asn Tyr Tyr Trp 15 10 15 • &lt; 210〉 742 &lt; 211〉 14 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too φ &lt; 400> 742

Asp Lys Glu Ala Val Tyr Phe Ala His Leu Asp He lie Trp 1 5 10 &lt; 210〉 743 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400〉 743

Cys Thr Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Tyr Phe Cys His 15 10 15

Gin Asp lie lie Trp 20 &lt; 210> 744 &lt; 211 &gt; 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 4〇〇 &gt; 744

Cys Thr Cys Lys Asp Met Thr Asp Glu Glu Cys Leu Asn Phe Cys His 495 200524957 1 5

Gin Asp Val lie Trp 20

&lt; 210> 745 &lt; 211 &gt; 7 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 745

Tyr Pro Phe Val Glu Pro lie 1 5 &lt; 210 &gt; 746 &lt; 211 &gt; 3 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400〉 746 Tyr Pro Phe &lt; 210 &gt; 747 &lt; 211> 3. &Lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too & 400 〉 747 Tyr Pro Phe &lt; 210 &gt; 748 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213> Artificial sequence 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B too &lt; 4〇〇 &gt; 748

Tyr Pro Phe Pro Gly Pro lie 1 5 &lt; 210〉 749. &Lt; 211 &gt; 4 &lt; 212〉 PRT-&lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory)} M &lt; 400> 749

Tyr Pro Phe Pro &lt; 210 &gt; 750 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 8 too &lt; 400〉 750

Tyr Pro Phe Pro Gly 1 5 &lt; 210 &gt; 751 &lt; 211〉 5. &Lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Artificial Sequence Explanation: Katsuyuki Katsuta &lt; 400 &gt; 751

Tyr Pro Phe Pro Gly 1 5 &lt; 210> 752 &lt; 211 &gt; 5 200524957 &lt; 212 &gt; PRT &lt; 213> artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Synthetic Victory &lt; 400 &gt; 752

Tyr Pro Phe Pro Gly 1 5 &lt; 210〉 753. &Lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 φ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic peptide W &lt; 400 &gt; 753

Tyr Pro Phe Val Glu Pro lie 1 5 &lt; 210〉 754 &lt; 211〉 2 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 754 Tyr Phe

^ &lt; 210 &gt; 755 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223〉 description of artificial sequence: Synthetic Katsuyuki too &lt; 400〉 755 Tyr Phe Tyr 200524957 &lt; 210> 756 &lt; 211 &gt; 3 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400 &gt; 756 Tyr Phe Tyr

&lt; 210 &gt; 757 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 757

Tyr Phe Pro Tyr &lt; 210 &gt; 758 &lt; 211 &gt; 3 &lt; 212> PRT &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory) Too φ &lt; 400 &gt; 758 Tyr Phe Pro &lt; 210 &gt; 759 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic Victory C &lt; 400 &gt; 759

Tyr Phe Pro 200524957 &lt; 210 &gt; 760 &lt; 211 &gt; 3 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; Synthetic tsukiyuki_ &lt; 223> Explanation of artificial sequence &lt; 400 &gt; 760 Tyr Phe Pro

&lt; 210 &gt; 761 &lt; 211 &gt; 4 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400> 761

Tyr Phe Pro Gly &lt; 210 &gt; 762 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence • &lt; 220〉 e &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400〉 762 Tyr Phe Pro Gly 1 &lt; 210 &gt; 763 &lt; 211 &gt; 4 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: synthetic peptide 200524957 &lt; 400 &gt; 763 Tyr Phe Pro Gly 1 &lt; 210 &gt; 764 &lt; 211 &gt; 5 &lt; 212 &gt; PRT-&lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Jitai &lt; 400〉 764

Tyr Phe Pro Gly Pro 1 5 &lt; 210 &gt; 765 &lt; 211〉 3 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 765 Tyr Phe Pro 1

&lt; 210 &gt; 766 &lt; 211〉 6 ^ &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400〉 766

Pro Phe Pro Gly Pro lie 1 5 &lt; 21〇 &gt; 767 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: 8 &lt; 400〉 767

Pro Phe Pro Gly Pro He 1 5 &lt; 210 &gt; 768 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence. &Lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsukitsu &lt; 400〉 768

Tyr Pro Val Pro &lt; 210 &gt; 769 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 8 too &lt; 400 &gt; 769

Tyr Pro Phe Pro &lt; 210 &gt; 770 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 770 Tyr Pro Phe Pro 1

&lt; 210 &gt; 771 &lt; 211〉 3 &lt; 212 &gt; PRT 200524957 &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Ikutsuki &lt; 400 &gt; 771 Tyr Pro Pro &lt; 210> 772 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory® &lt; 400> 772

Tyr Ala Phe Gly Tyr Pro Ser 1 5 &lt; 210 &gt; 773 &lt; 211〉 3 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400 &gt; 773 Tyr Arg Phe

&lt; 210 &gt; 774 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory fl 太 &lt; 400〉 774

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn 15 10 15 503 200524957

Gin Lys Arg Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr 20 25 30 &lt; 210〉 775 &lt; 211〉 17 &lt; 212〉 PRT. &Lt; 213 &gt; Artificial Sequences &lt; 220 &gt;-&lt; 223〉 Explanation of artificial sequence: Katsuyuki Katsuyuki <400> 775

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn

Gin &lt; 210 &gt; 776 &lt; 211〉 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 776

Tyr Gly Phe Leu Arg He Arg Pro Lys Leu Lys

&lt; 210〉 777 &lt; 211〉 17 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 777

Tyr Ala Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn 15 10 15 504 200524957

Gin &lt; 210 &gt; 778 &lt; 211 &gt; 17 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic tsukitsutsuki. &Lt; 400 &gt; 778

Tyr Ala Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn 15 10 15

&lt; 210〉 779 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 779

Tyr Ala Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn 15 10 15 Lu Gin • &lt; 210 &gt; 780 &lt; 211〉 12 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Katsuyuki Katsuta &lt; 400 &gt; 780

Tyr Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys 1 5 10 505 200524957 &lt; 210 &gt; 781 &lt; 211 &gt; 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence : Synthetic Victory &lt; 400 &gt; 781

Tyr Gly Phe Leu Arg Arg lie Arg 1 5

&lt; 210 &gt; 782 &lt; 211 &gt; 12 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223> description of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 782

Tyr Gly Gly Phe Leu Arg lie Arg Pro Lys Leu Lys 1 5 10 &lt; 210 &gt; 783 &lt; 211〉 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory fl too # &lt; 400 &gt; 783

Tyr Gly Gly Phe Leu Arg Arg Arg Pro Lys Leu Lys. 1 5 10 &lt; 210〉 784 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuyuki Kazuyuki <400> 784

Gly Gly Phe Leu Arg Arg He 506 200524957 1 5 &lt; 210 &gt; 785 &lt; 211〉 12 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 _ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon Too &lt; 400 &gt; 785 »Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu 1 5 10 &lt; 210 &gt; 786 • &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223> Explanation of the artificial sequence: Katsuyuki Katsuta &lt; 400 &gt; 786

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys 1 5 10 &lt; 210〉 787 &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213〉 artificial sequence ❿ &lt; 220〉 &quot; &lt; 223 &gt; artificial sequence Explanation: Synthetic victory. &Lt; 400 &gt; 787

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys 1 5 10 &lt; 210> 788 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic peptide 507 200524957 &lt; 400 &gt; 788

Tyr Gly Gly Gly Phe Leu Arg Arg lie Arg Pro 1 5 10 &lt; 210 &gt; 789 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223> Explanation of artificial sequence: Synthetic victory Yuetai &lt; 400 &gt; 789

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Arg Leu Arg Gly 1 5 10

&lt; 210 &gt; 790 &lt; 211 &gt; 16 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 790

Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15 &lt; 210〉 791 &lt; 211〉 16 φ &lt; 212〉 PRT ~ &lt; 213 &gt; Artificial Sequences &lt; 220〉 ^ &lt; 223 &gt; Explanation of artificial sequence: Katsuyuki Katsuyuki &lt; 400 &gt; 791

Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15 &lt; 210> 792 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 508 200524957 &lt; 220> &lt; 223 &gt; Explanation of the artificial sequence: Synthetic Katsuyuki &lt; 400> 792

Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu 1 5 10 &lt; 210〉 793 ^ &lt; 211 &gt; 15 &lt; 212〉 PRT-&lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Victory of Synthesis B too <400> 793

Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15 &lt; 210〉 794 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation: Synthetic Victory B too &lt; 4〇〇 &gt; 794

Gly Phe Leu Arg Arg lie φ &lt; 210 &gt; 795 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 795

Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys 1 5 10 &lt; 210 &gt; 796 &lt; 211 &gt; 15 509 200524957

&lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 796

Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15 &lt; 210〉 797-&lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> φ &lt; 223 &gt; artificial Explanation of Sequence: Synthetic Victory &lt; 400> 797

Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 10 &lt; 210 &gt; 798 &lt; 211〉 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 798 lie Arg Pro Lys Leu Lys Trp Asp Asn Gin

&lt; 210 &gt; 799 &lt; 211 &gt; 12 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 799

Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 10 510 200524957 &lt; 210 &gt; 800 &lt; 211〉 16 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence ： Synthetic peptide <400> 800 .Tyr Pro Phe Pro Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn Gin 15 10 15

&lt; 210 &gt; 801 &lt; 211〉 9 &lt; 212〉 PRT φ &lt; 213 &gt; artificial sequence — &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 801

Arg Pro Lys Leu Lys Trp Asp Asn Gin 1 5 &lt; 210 &gt; 802 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: • &lt; &gt; 802

Lys Trp Asp Asn Gin • 1 5 &lt; 210〉 803 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223〉 Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 803

Tyr Gly Gly Phe Leu Arg Arg lie Arg Pro Lys Leu Lys Trp Asp Asn 511 200524957 10 15

Gin &lt; 210 &gt; 804 &lt; 211〉 13 &lt; 212〉 PRT ^ &lt; 213 &gt; Artificial Sequence &lt; 220〉-&lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 804

Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr 1 5 10

&lt; 210 &gt; 805 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400 &gt; 805

Tyr Gly Gly Phe Leu Arg Arg Gin Phe 1 5 &lt; 21〇 &gt; 806

&lt; 211〉 29 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 806

Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr Arg Ser Gin 15 10 15

Glu Asp Pro Asn Ala Tyr Ser Gly Glu Leu Phe Asp Ala 20 25 &lt; 210 &gt; 807 &lt; 211〉 10 512 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 807

Tyr Gly Gly Phe Leu Arg Lys Tyr Pro Lys 1 5 10 &lt; 210 &gt; 808 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 808

Tyr Gly Gly Gly Phe Leu Arg Lys Tyr Pro 1 5 &lt; 210〉 809 &lt; 211 &gt; 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 809

Tyr Gly Gly Phe Leu Arg Arg He Arg Pro Lys Leu Lys

&lt; 210> 810 &lt; 211 &gt; 7 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 810

Tyr Gly Gly Phe Leu Arg Phe 1 5 513 200524957 &lt; 210〉 811 &lt; 211 &gt; 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: 0 &lt; 400 &gt; 811

Tyr Gly Gly Phe Leu Arg Phe 1 5

&lt; 210 &gt; 812 &lt; 211 &gt; 29 &lt; 212 &gt; PRT spring &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B too &lt; 400> 812

Tyr Gly Gly Phe Leu Arg Arg Gin Phe Lys Val Val Thr Arg Ser Gin 15 10 15

Glu Asp Pro Asn Ala Tyr Tyr Glu Glu Leu Phe Asp Val 20 25

&lt; 210 &gt; 813 &lt; 211〉 31 • &lt; 212 &gt; PRT &gt; &lt; 213 &gt; Artificial sequence &lt; 220〉 I &lt; 223〉 Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400〉 813

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala His Lys Lys Gly Gin 20 25 30 &lt; 210〉 814 514 200524957 &lt; 211〉 27 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Artificial Explanation of the sequence: Synthesis of Tsukiyuki &lt; 400 &gt; 814

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr -15 10 15 • Leu Phe Lys Asn Ala lie lie Lys Asn Ala His 20 25 &lt; 210 &gt; 815 • &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400> 815

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 30 &lt; 210 &gt; 816 · _ &lt; 211〉 26 &lt; 212〉 PRT-&lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: The synthesis of Katsuyuki &lt; 400 &gt; 816

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala 20 25 515 200524957 &lt; 210 &gt; 817 &lt; 211〉 27 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223> Description of artificial sequence: Synthetic Katsuyuki &lt; 400> 817

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr 20 25

&lt; 210〉 818 &lt; 211〉 17 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 818

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu &lt; 210 &gt; 819 φ &lt; 211 &gt; 16

* &lt; 212 &gt; PRT • &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 819

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

&lt; 210> 820 &lt; 211 &gt; 16 &lt; 212 &gt; PRT 516 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 820

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15-&lt; 210〉 821 &lt; 211 &gt; 11 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Katsuyuki of synthesis φ &lt; 400 &gt; 821

Tyr Gly Gly Phe Leu Arg Lys Tyr Arg Pro Lys 1 5 10 &lt; 210 &gt; 822 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Wins: &lt; 400 &gt; 822

Tyr Gly Gly Phe Leu Arg Lys 1 5

&lt; 210 &gt; 823 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400〉 823

Tyr Gly Gly Phe Leu Arg Lys Arg 1 5 &lt; 210〉 824 517 200524957 &lt; 211 &gt; 31 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory : &lt; 400〉 824

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala His Lys Lys Gly Gin 20 25 30

&lt; 210 &gt; 825 &lt; 211> 27 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400 &gt; 825

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala His 20 25 • &lt; 210〉 826 ~ &lt; 211〉 31 &lt; 212〉 PRT * &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: The victory of synthesis fl too <400> 826

Tyr Gly Gly Phe Met Ser Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala His Lys Lys Gly Gin 20 25 30 518 200524957 &lt; 210 &gt; 827 &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223〉 artificial Explanation of sequence: Synthetic victory fl too &lt; 400 &gt; 827

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 30

&lt; 210 &gt; 828 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 828

Tyr Gly Gly Phe Met Thr Leu Phe Lys Asn Ala lie lie Lys Asn Ala 15 10 15

Tyr Lys Lys Gly Glu 20

&lt; 210 &gt; 829 &lt; 211〉 26 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsukitsu &lt; 400 &gt; 829

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15 519 200524957

Leu Phe Lys Asn Ala lie lie Lys Asn Ala 20 25 &lt; 210 &gt; 830 &lt; 211〉 27 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • Description of &lt; 223 &gt; Artificial Sequence: Synthetic Victory Peptide, &lt; 400 &gt; 830

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr 20 25 &lt; 210 &gt; 831 &lt; 211 &gt; 26 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 831

Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr Leu Phe Lys Asn Ala 15 10 15 lie He Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 &lt; 210 &gt; 832 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400> 832

Phe Lys Asn Ala lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 1 5 10 520 200524957 &lt; 210 &gt; 833 &lt; 211 &gt; 31 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; description of artificial sequence : The victory of synthesis. &lt; 400〉 833

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 1 5 10 15

Leu Phe Lys Asn Ala lie Val Lys Asn Ala His Lys Lys Gly Gin 20 25 30

&lt; 210 &gt; 834 &lt; 211> 31 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 834

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu Phe Lys Asn Ala lie lie Lys Asn Val His Lys Lys Gly Gin 20 25 30. &Lt; 210 &gt; 835 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213〉 artificial sequence &lt; 220〉 &lt; 223 &gt; artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 835

Glu Leu Ala Gly Ala Pro Pro Glu Pro Ala 1 5 10 521 200524957 &lt; 210 &gt; 836 &lt; 211 &gt; 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis Tsukitsu Tsuki &lt; 400 &gt; 836 Tyr Gly Gly Phe 1

&lt; 210 &gt; 837 &lt; 211 &gt; 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 837

Tyr Gly Gly Phe Met Thr Ser Glu Lys 1 5 &lt; 210 &gt; 838 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence &lt; 400 &gt; 838 • Lys Lys Gly Glu &lt; 210 &gt; 839 &lt; 211 &gt; 31 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 22〇 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B Too &lt; 400 &gt; 839

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15 522 200524957

Leu Phe Lys Asn Ala lie lie Lys Asn Ala Tyr Lys Lys Gly Glu 20 25 30 &lt; 210 &gt; 840 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Artificial Sequences Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 840

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15

Leu &lt; 210 &gt; 841 &lt; 211〉 1 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: &lt; 400 &gt; 841 Tyr: Synthetic victory 0 to 1 &lt; 210> 842 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence:: Synthetic Katsuta &lt; 400 &gt; 842

Tyr Gly Phe Met Thr Ser Glu Lys 1 5 &lt; 210 &gt; 843 &lt; 211 &gt; 8 523 200524957 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning ribs : &lt; 400 &gt; 843

Tyr Gly Phe Met Thr Ser Glu Lys 1 5 &lt; 210 &gt; 844 # &lt; 211 &gt; 16 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 844

Tyr Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr Leu 15 10 15 &lt; 210> 845 &lt; 211 &gt; 16 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; artificial sequence Explanation: Synthetic Victory Limb: &lt; 400 &gt; 845

Gly Gly Phe Met Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr Leu

&lt; 210〉 846 &lt; 211〉 31 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: victory of synthesis) i too &lt; 400〉 846

Tyr Gly Gly Phe Leu Thr Ser Glu Lys Ser Gin Thr Pro Leu Val Thr 15 10 15 524 200524957

Leu Phe Lys Asn Ala lie lie Lys Asn Ala His Lys Lys Gly Gin 20 25 30 &lt; 210 &gt; 847 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220〉 &lt; 223〉 Artificial Sequence Explanation: The synthesis of the birth month too ^ &lt; 400 &gt; 847

Tyr Gly Gly Gly Phe Met Lys 1 5 φ &lt; 210 &gt; 848 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 848

Tyr Gly Gly Phe Met Lys Lys 1 5

&lt; 210 &gt; 849 &lt; 211〉 7 &lt; 212 &gt; PRT • &lt; 213〉 Artificial sequence &lt; 220〉-&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 849

Tyr Gly Gly Gly Phe Met Lys Arg 1 5 &lt; 210 &gt; 850 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 525 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 850

Tyr Gly Gly Gly Phe Met Arg Arg Val 1 5 &lt; 210〉 851 &lt; 211〉 8-&lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory B M &lt; 400> 851

Ala Ala Ala Tyr Gly Gly Phe Met

&lt; 210 &gt; 852 &lt; 211 &gt; 26 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic victory fl too &lt; 400> 852

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val 15 10 15

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu 20 25-&lt; 210 &gt; 853 &lt; 211〉 26 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Tsuki &lt; 400> 853

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val 15 10 15 526 200524957

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu 20 25 &lt; 210 &gt; 854 &lt; 211〉 12 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence. &Lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Tsuki- &lt; 400 &gt; 854

Tyr Gly Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu 1 5 10 with &lt; 210 &gt; 855 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Victory of synthesis fl too &lt; 400 &gt; 855

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu 1 5 10

&lt; 210 &gt; 856 &lt; 211 &gt; 22 &lt; 212〉 PRT · &lt; 213〉 Artificial sequence &lt; 220 &gt;-&lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuta &lt; 400 &gt; 856

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp 15 10 15

Tyr Gin Lys Arg Tyr Gly 20 &lt; 210 &gt; 857 &lt; 211〉 3 527 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 857 Phe Ala Arg &lt; 210 &gt; 858 &lt; 211〉 5 # &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> Katsuta Katsuta

&lt; 223 &gt; Explanation of artificial sequence &lt; 400 &gt; 858

Tyr Ala Gly Phe Gly 1 5 &lt; 210 &gt; 859 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 859

Tyr Ala Gly Phe Leu

&lt; 210 &gt; 860 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 860

Tyr Ala Gly Phe Met 200524957 &lt; 210 &gt; 861 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki Tai &lt; 400 &gt; 861 Tyr Gly Phe Leu

&lt; 210 &gt; 862 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 862

Tyr Gly Phe Leu Arg 1 5 &lt; 210 &gt; 863 &lt; 211> 2 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; φ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400 &gt; 863 Gly Phe _ 1 &lt; 210〉 864 &lt; 211〉 2 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 864 200524957

Gly Phe 1 &lt; 210 &gt; 865 &lt; 211 &gt; 4 &lt; 212> PRT &lt; 213 &gt; artificial sequence:. &Lt; 220 &gt; &lt; 223 &gt; artificial sequence description: Synthetic tsukitsuta-&lt; 400 &gt; 865

Gly Gly Phe Leu φ &lt; 210 &gt; 866 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223 &gt; Description of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 866 Tyr Gly Phe &lt; 210〉 867 &lt; 211〉 3 &lt; 212〉 PRT • &lt; 213〉 Artificial sequence &lt; 220〉. &lt; 223 &gt; Artificial sequence description: Satsuki Katsuta &lt; 400〉 867 Tyr Gly Phe 1 &lt; 210 &gt; 868 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; 200524957 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory flfl &400; 868 Phe Leu Arg 1 &lt; 210 &gt; 869 &lt; 211> 3. &Lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence- &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 869 Tyr Gly Phe

&lt; 210 &gt; 870 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 870

Tyr Gly Gly Phe Leu 1 5 &lt; 210 &gt; 871 &lt; 211 &gt; 5 &lt; 212 &gt; PRT. &Lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 871

Tyr Gly Gly Phe Leu 1 5

&lt; 210 &gt; 872 &lt; 211〉 5 &lt; 212> PRT 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 872

Tyr Gly Gly Phe Leu 1 5. &Lt; 210 &gt; 873 &lt; 211 &gt; 5-&lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 8 Too φ &lt; 400 &gt; 873

Tyr Ala Gly Phe Leu 1 5 &lt; 210 &gt; 874 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 874

Tyr Ser Gly Phe Leu Thr

&lt; 210 &gt; 875 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400〉 875

Tyr Thr Gly Phe Leu Thr 1 5 &lt; 210 &gt; 876 200524957 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon &lt; 400 &gt; 876

Tyr Gly Gly Ghe Phe Leu Lys 1 5-&lt; 210 &gt; 877 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence φ &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Btai &lt; 400 &gt; 877

Tyr Gly Gly Gly Phe Met Arg 1 5 &lt; 210 &gt; 878 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223> Artificial Sequence Explanation: Katsuyuki Katsuta &lt; 400 &gt; 878

Tyr Gly Gly Gly Phe Met Arg Arg 1 5 210 &lt; 210 &gt; 879 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt;; 400 &gt; 879

Tyr Gly Gly Gly Phe Met Arg Arg Val Gly 200524957 &lt; 210 &gt; 880 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory β too &lt; 400 &gt; 880

Tyr Gly Gly Phe Met Arg Gly Leu

&lt; 210 &gt; 881 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic victory 0 too &lt; 400> 881

Tyr Gly Gly Ghe Pet Met Arg Phe 1 5 &lt; 210 &gt; 882 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223> Explanation of Artificial Sequence

&lt; 400 &gt; 882 # Tyr Gly Gly Phe Met 1 5 &lt; 210 &gt; 883 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Yuetai 200524957 &lt; 400 &gt; 883

Tyr Gly Gly Phe Met 1 5 &lt; 210 &gt; 884 &lt; 211〉 5 &lt; 212 &gt; PRT-&lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory)} 太 &lt; 400 &gt; 884

Tyr Ala Gly Phe Met

&lt; 210〉 885 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 885

Tyr Ala Gly Phe Met 1 5 &lt; 210 &gt; 886 &lt; 211〉 7

· _ &Lt; 212〉 PRT &lt; 213〉 Artificial sequence ‘· &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 886

Tyr Gly Gly Gly Phe Met Arg Phe 1 5 &lt; 210 &gt; 887 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 200524957 &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 887

Tyr Gly Gly Phe Met 1 5 &lt; 210 &gt; 888-&lt; 211〉 5 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223> Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 888

Tyr Ala Gly Phe Met 1 5 &lt; 210 &gt; 889 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223> Artificial Sequence Explanation: Synthetic Katsuyuki &lt; 400 &gt; 889 Tyr Gly Phe Pro 1

&lt; 210 &gt; 890 &lt; 211〉 4 ^ &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 890

Tyr Gly Phe Met &lt; 210 &gt; 891 &lt; 211 &gt; 8 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400〉 891

Tyr Gly Gly Phe Met Arg Arg Val 1 5 &lt; 210 &gt; 892, &lt; 211〉 31 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223〉 An explanation of the artificial sequence: Synthetic Katsuta &lt; 400〉 892

Phe Ala Glu Pro Leu Pro Ser Glu Glu Glu Gly Glu Ser Tyr Ser Lys 15 10 15

Glu Val Pro Glu Met Glu Lys Arg Tyr Gly Gly Phe Met Arg Phe 20 25 30 &lt; 210〉 893 &lt; 211 &gt; 25 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; of artificial sequence Explanation: Synthetic Victory Moon too φ &lt; 400 &gt; 893

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp 15 10 15 Tournament

Tyr Gin Lys Arg Tyr Gly Gly Phe Leu 20 25 &lt; 210〉 894 &lt; 211 &gt; 34 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 537 200524957 &lt; 220> &lt; 223 &gt; Description of artificial sequence: victory of synthesis Tsuki &lt; 400> 894

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val 15 10 15

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu Gly Lys Arg Tyr Gly Gly 20 25 30

Phe Met

&lt; 210 &gt; 895 &lt; 211 &gt; 19 φ &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki &lt; 400〉 895

Ser Ser Glu Val Ala Gly Glu Gly Asp Gly Asp Ser Met Gly His Glu 15 10 15

Asp Leu Tyr

&lt; 210 &gt; 896 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory B too &lt; 400 &gt; 896

Leu Val Val Tyr Pro Trp 1 5 &lt; 210〉 897 &lt; 211〉 2 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 538 200524957 &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 897 Pro Gly 1 &lt; 210 &gt; 898-&lt; 211 &gt; 4 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220〉 Synthetic Victory: &lt; 223〉 Explanation of Artificial Sequence

&lt; 400 &gt; 898 Tyr Pro Phe Pro &lt; 210〉 899 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta Synthesis &lt; 400 &gt; 899

Tyr Pro Phe Pro Pro 1 5 &lt; 210〉 900 &lt; 211 &gt; 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 Synthetic victory: &lt; 223 &gt; Explanation of artificial sequence &lt; 400〉 900

Tyr Pro Pro Pro &lt; 210 &gt; 901 &lt; 211 &gt; 6 &lt; 212 &gt; PRT 200524957 &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223〉 Artificial sequence description: Synthetic tsukiyuki &lt; 400> 901

Arg Tyr Leu Gly Tyr Leu 1 5-&lt; 210〉 902 &lt; 211〉 8 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: φ &lt; 400〉 902

Ala Ala Ala Tyr Gly Gly Phe Leu 1 5 &lt; 210〉 903 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta &lt;; 400> 903

Ala Ala Ala Tyr Gly Gly Phe Leu

&lt; 210〉 904-&lt; 211 &gt; 18 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki &lt; 400> 904

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp 15 10 15

Tyr Gin 540 200524957 &lt; 210〉 905 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt;. &Lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 905 • Tyr Pro Phe Pro Pro Leu 1 5 &lt; 210〉 906

I &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 906

Tyr Val Pro Phe Pro Pro Phe 1 5 &lt; 210〉 907 &lt; 211〉 2 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence φ &lt; 220〉 '&lt; 223 &gt; Explanation of Artificial Sequence β &lt; 400 &gt; 907 Trp Gly &lt; 210 &gt; 908 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuta 541 200524957 &lt; 400 &gt; 908 Tyr Arg Phe Lys 1 &lt; 210〉 909 &lt; 211〉 7 &lt; 212 &gt; PRT-&lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta &lt;; 400> 909

Tyr Met Phe His Leu Met Asp

&lt; 210〉 910 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400> 910

Tyr Ala Phe Asp Val Val Gly 1 5

&lt; 210> 911 &lt; 211 &gt; 7 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 911

Tyr Ala Phe Glu Val Val Gly 1 5 &lt; 210 &gt; 912 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence 200524957 &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt;; 400〉 912

Tyr Pro Trp Phe &lt; 210〉 913

* &lt; 211〉 5 &lt; 212〉 PRT e &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuta &lt; 400〉 913 • I Tyr Pro Trp Phe Phe 1 5 &lt; 210〉 914 &lt; 211 &gt; 2 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400〉 914 Tyr Arg 1 ·-&lt; 210〉 915 &lt; 211〉 1 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 915

Tyr &lt; 210〉 916 &lt; 211〉 2 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400〉 916 Leu Gly

&lt; 210 &gt; 917 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400> 917

Pro Gin Arg Phe &lt; 210 &gt; 918 &lt; 211 &gt; 18 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Artificial Sequence Explanation: Synthetic Victory Rib: &lt; 400 &gt; 918

Ala Gly Glu Gly Leu Ser Ser Pro Phe Trp Ser Leu Ala Ala Pro Gin &quot; 15 10 15

Arg Phe &lt; 210 &gt; 919 &lt; 211 &gt; 17 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: synthetic peptide 544 200524957 &lt; 400> 919

Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn 15 10 15

Gin-&lt; 210〉 920 &lt; 211〉 3 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Rib: φ &lt; 400〉 920 Tyr Phe Phe &lt; 210 &gt; 921 &lt; 211〉 4 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 921

Tyr Pro Leu Gly

&lt; 210 &gt; 922-&lt; 211〉 4 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400> 922

Tyr Pro Trp Gly &lt; 210 &gt; 923 545 200524957 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 923

Val Val Tyr Pro Trp Thr Gin 1 5 &lt; 210〉 924 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence Call &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 924

Leu Val Val Tyr Pro Trp Thr Gin Arg 1 5 &lt; 210> 925 &lt; 211 &gt; 2 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence_ &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &400; 925 Pro Leu 1 &lt; 210〉 926 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 〉 Explanation of the artificial sequence: Satsuki Katsuta &lt; 400〉 926

Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn 15 10 15 546 200524957

Gin &lt; 210> 927 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence * &lt; 220 &gt;. &Lt; 223 &gt; Description of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 927

Tyr Gly Gly Gly Phe Met Arg Arg Val 1 5 &lt; 210〉 928 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400〉 928

Ala Lys Ser Gin Gly Gly Ser Asn 1 5 &lt; 210 &gt; 929 &lt; 211〉 8

• &lt; 212〉 PRT ‘&lt; 213 &gt; artificial sequence &lt; 220〉 I &lt; 223 &gt; description of artificial sequence: Synthetic victory 0 too &lt; 400〉 929

Leu Glu Asp Gly Pro Lys Phe Leu 1 5

&lt; 210〉 930 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 200524957 &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic Katsuki Tsukita &lt; 400〉 930

Arg Lys Asp Val Tyr 1 5 &lt; 210 &gt; 931 • &lt; 211〉 13 &lt; 212〉 PRT &gt; &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory)} &lt; 400〉 931

Gly Glu Gin Arg Lys Asp Val Tyr Val Gin Leu Tyr Leu 1 5 10 &lt; 210 &gt; 932 &lt; 211 &gt; 28 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Katsuyuki Katsuyuki &lt; 400 &gt; 932

Ser Asp Ala Ala Val Asp Thr Ser Ser Glu He Thr Thr Lys Asp Leu 15 10 15

Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn 20 25 * &lt; 210 &gt; 933 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223> description of artificial sequence: Synthesis Victory 0 too <400> 933

Tyr Gin Ala Lys Ser Gin Gly Gly Ser Asn 1 5 10 548 200524957 &lt; 210〉 934 &lt; 211〉 28 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory) too &lt; 400 &gt; 934 .Ser Asp Ala Ala Val Asp Thr Ser Ser Glu lie Thr Lys Asp Leu 15 10 15

Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn 20 25 • &lt; 210 &gt; 935 &lt; 211〉 52 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Synthesis Victory &lt; 400 &gt; 935

Tyr Arg Gin Ser Met Asn Asn Phe Gin Gly Leu Arg Ser Phe Gly Cys 15 10 15

Arg Phe Gly Thr Cys Thr Val Gin Lys Leu Ala His Gin lie Tyr Gin 20 25 30

Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys lie Ser 35 40 45 .Pro Gin Gly Tyr 50 &lt; 210 &gt; 936 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 40〇 &gt; 936 549 200524957

Tyr Arg Gin Ser Met Asn Asn Phe Gin Gly Leu Arg 1 5 10 &lt; 210〉 937 &lt; 211 &gt; 37 &lt; 212〉 PRT _ &lt; 213 &gt; Artificial Sequence &lt; 220〉. &Lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 937

Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr Val Gin Lys Leu Ala His 15 10 15

Gin lie Tyr Phe Thr Asp Lys Asp Asn Val Ala Pro Arg Ser Lys lie 20 25 30

Ser Pro Gin Gly Tyr 35 &lt; 210 &gt; 938 &lt; 211 &gt; 31 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory moon too φ &lt; 400 &gt; 938

Thr Val Gin Lys Leu Ala His Gin lie Tyr Gin Phe Thr Asp Lys Asp 15 10 15

Lys Asp Asn Val Ala Pro Arg Ser Lys lie Ser Pro Gin Gly Tyr 20 25 30 &lt; 210 &gt; 939 &lt; 211 &gt; 48 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220〉 &lt; 223 &gt; Description: Synthetic peptide 550 200524957 &lt; 400 &gt; 939

Glu Leu Arg Met Ser Ser Ser Tyr Pro Thr Gly Leu Ala Asp Val Lys 15 10 15

Ala Gly Pro Ala Gin Thr Leu lie Arg Pro Gin Asp Met Lys Gly Ala 20 25 30

Ser Arg Ser Pro Glu Asp Ser Ser Pro Asp Ala Ala Arg He Arg Val 35 40 45 &lt; 210〉 940

&lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory I too &lt; 400 &gt; 940

Ser Leu Pro Glu Ala Gly Pro Gly Arg Thr Leu Val Ser Ser Lys Pro 15 10 15

Gin Ala His Gly Ala Pro Ala Pro Pro Ser Gly Ser Ala Pro His Phe 20 25 30

Leu

&lt; 210> 941 &lt; 211 &gt; 52 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400> 941

Tyr Arg Gin Ser Met Asn Phe Gin Gly Leu Arg Ser Phe Gly Cys Arg 15 10 15

Phe Gly Thr Cys Thr Val Gin Lys Leu Ala His Gin lie Tyr Gin Phe 20 25 30 551 200524957

Thr Asp Lys Asp Gly Val Ala Pro Arg Ser Lys lie Ser Lys He Ser 35 40 45

Pro Gin Gly Tyr 50-&lt; 210〉 942 &lt; 211〉 20 e &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon φ &lt; 400 &gt; 942

Ala Arg Leu Asp Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp 15 10 15

Ala Leu Ser Arg 20 &lt; 210〉 943 &lt; 211 &gt; 53 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉

&lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400> 943

Tyr Arg Gin Ser Met Asn Gin Gly Ser Arg Ser Thr Gly Cys Arg Phe 15 10 15

Gly Thr Cys Thr Met Gin Lys Leu Ala His Gin lie Tyr Gin lie Tyr 20 25 30

Gin Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg Asn Lys He 35 40 45

Ser Pro Gin Gly Tyr 50 552 200524957 &lt; 210 &gt; 944 &lt; 211〉 40 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory ^ &lt; 4 〇〇 &gt; 944

Ser Thr Gly Cys Arg Phe Gly Thr Cys Thr Met Gin Lys Leu Ala His • 15 10 15

Gin He Tyr Gin Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg 20 25 30 钃 ^ Asn Lys lie Ser Pro Gin Gly Tyr 35 40 &lt; 210〉 945 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb: &lt; 400> 945

Ala Arg Leu Asp Thr Ser Ser Gin Phe Arg Lys Lys Trp Asn Lys Trp 15 10 15

-Ala Leu Ser Arg 20 &lt; 210〉 946 &lt; 211 &gt; 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400> 946

Ala Pro Ser Gly Ala Gin Arg Leu Tyr Gly Phe Gly Leu 1 5 10 553 200524957 &lt; 210 &gt; 947 &lt; 211〉 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Satsuki Katsuyuki • &lt; 400〉 947

Gly Asp Gly Arg Leu Tyr Ala Phe Gly Leu # 1 5 10 &lt; 210 &gt; 948 &lt; 211〉 9

• &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 948

Gly Gly Ser Leu Tyr Ser Phe Gly Leu 1 5 &lt; 210〉 949 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 949

Asp Arg Leu Tyr Ser Phe Gly Leu 1 5 &lt; 210〉 950 &lt; 211〉 17 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223> Explanation of Artificial Sequences: Synthetic Victory &lt; 400〉 950 554 200524957

Val His His Gin Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn 15 10 15

Lys &lt; 210 &gt; 951 &lt; 211〉 11 &lt; 212〉 PRT ~ &lt; 213 &gt; Artificial Sequence. &Lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuta &lt; 400 &gt; 951

Gly Ser Asn Lys Gly Ala He He Gly Leu Met

&lt; 210〉 952 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 952

Arg Glu Arg Met Ser 1 5

&lt; 210〉 953 φ &lt; 211 &gt; 17 ~ &212; 212> PRT _ &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400〉 953

Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gin Val 15 10 15

Met &lt; 210〉 954 &lt; 211〉 43 555 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400〉 954

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15. Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He lie 20 25 30

Gly Leu Met Val Gly Gly Val Val He Ala Thr

&lt; 210〉 955 &lt; 211〉 42 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Ult &lt; 400 &gt; 955

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie

Gly Leu Met Val Gly Gly Val Val lie Ala 35 40 &lt; 210 &gt; 956 &lt; 211 &gt; 40 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence Too &lt; 400 &gt; 956

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 556 200524957 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt; 210〉 957 9 &lt; 211 &gt; 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; Ringer &223; Explanation of Artificial Sequences: Synthetic Dirty &lt; 400 &gt; 957

Tyr Glu Val His His Gin Lys Leu Val Phe Phe 1 5 10 &lt; 210〉 958 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 958 • Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met-1 5 10 &lt; 210〉 959 &lt; 211〉 28 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &223; Explanation of artificial sequence: Synthetic victory 0 too &400; 959

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 1 5 10 15 557 200524957

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 20 25 &lt; 210〉 960 &lt; 211〉 40 &lt; 212 &gt; PRT ^ &lt; 213 &gt; Artificial Sequence- &lt; 220〉. &Lt; 223〉 Explanation of Artificial Sequence ： Synthetic victory B too <400> 960

Val Val Gly Gly Val Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 15 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gin His His Val Glu Tyr Gly 20 25 30

Ser Asp His Arg Phe Glu Ala Asp 35 40 &lt; 210> 961 &lt; 211 &gt; 42 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta

&lt; 400〉 961

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val lie Ala 35 40 &lt; 210 &gt; 962 &lt; 211 &gt; 40 558 200524957 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Win 0 too &lt; 400 &gt; 962

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40

&lt; 210> 963 &lt; 211> 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: synthetic peptide &lt; 400 &gt; 963

Tyr Glu Val His His Gin Lys Leu Val Phe Phe 1 5 10

&lt; 210〉 964 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223〉 Explanation of artificial sequence: Synthetic victory &lt; 400〉 964

Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met 1 5 10 &lt; 210 &gt; 965 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 559 200524957 &lt; 220 &gt; &lt; 223〉 artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 965

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 20 25

&lt; 210 &gt; 966 &lt; 211〉 40 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 966

Val Val Gly Gly Val Met Leu Gly He lie Ala Gly Lys Asn Ser Gly 15 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gin His His Val Glu Tyr Gly 20 25 30

Ser Asp His Arg Phe Glu Ala Asp 35 40 &lt; 210〉 967 • &lt; 211〉 42 ^ &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 Too &lt; 400 &gt; 967

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val lie Ala 560 200524957 35 40 &lt; 210 &gt; 968 &lt; 211〉 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> ^ &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victorious Moon too. &Lt; 400 &gt; 968

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt; 210 &gt; 969 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 Too &lt; 400 &gt; 969 Lu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu '1 5 10 &lt; 210 &gt; 970 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; artificial Explanation of sequence: Synthetic tsukiyoshi &lt; 400〉 970 lie lie Gly Leu Met 1 5 561 200524957 &lt; 210〉 971 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223> Explanation of the artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 971 lie Gly Leu Met

&lt; 210 &gt; 972 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 972

Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 1 5 10 &lt; 210〉 973 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400〉 973

Asn Trp Cys Lys Arg Gly Arg Lys Gin Cys Lys Thr His Pro His 15 10 15 &lt; 210> 974 &lt; 211 &gt; 20 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation: Synthetic Victory Limb: &lt; 400 &gt; 974 562 200524957

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg 15 10 15

His Leu Ser Lys 20 &lt; 210〉 975 &lt; 211 &gt; 38 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉

&lt; 223〉 Explanation of the artificial sequence: Synthetic Victory Moon &lt; 400〉 975

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly 35 &lt; 210〉 976 &lt; 211〉 28 &lt; 212〉 PRT &lt; 213〉 Artificial sequence φ &lt; 220 &gt; * &lt; 223〉 Explanation of artificial sequence: Satsuki Katsuyuki_ &lt; 400〉 976

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 20 25 &lt; 210〉 977 &lt; 211 &gt; 16 &lt; 212 &gt; PRT &lt; 213〉 artificial sequence 563 200524957 &lt; 220〉 &lt; 223 &gt; description of the artificial sequence: Katsuyuki Katsuta &lt; 400 &gt; 977

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 15 10 15 &lt; 210 &gt; 978-&lt; 211〉 40 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Synthetic Life 0 too <400> 978 钃 ^ Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He lie 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40

&lt; 210〉 979 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400〉 979

His Asp Ser Gly Tyr Glu Val His His Gin Lys Leu Val Phe Phe Ala 15 10 15

Gin Asp Val Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met Val Gly 20 25 30

Gly Val Val 35 564 200524957 &lt; 210 &gt; 980 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki- &lt; 400 &gt; 980

Glu Gin Val Thr Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala ^ 15 10 15

Val Ala Gin Lys Thr Val Glu Gly Ala Gly Ser lie Ala Ala Ala Thr 20 25 30 ♦ Gly Phe Val 35 &lt; 210 &gt; 981 &lt; 211〉 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &400; 981

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 15 10 15

Gly Leu Met Val Gly Gly Val Val 20 &lt; 210 &gt; 982 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 982

Gly Tyr Val lie He Lys Pro Leu Val Trp Val 1 5 10 565 200524957 &lt; 210 &gt; 983 &lt; 211 &gt; 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too-&lt; 400 &gt; 983

Val His His Gin Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn 1 5 10 15

Lys

&lt; 210 &gt; 984 &lt; 211> 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223> Description of artificial sequence: Satsuki Katsuta &lt; 4〇〇 &gt; 984

Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met 1 5 10

&lt; 210 &gt; 985 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400> 985

Arg Glu Arg Met Ser 1 5 &lt; 210> 986 &lt; 211 &gt; 17 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 566 200524957 &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 986

Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gin Val 15 10 15 -Met

&lt; 210 &gt; 987 &lt; 211> 43 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 987

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val lie Ala Thr 35 40

&lt; 210 &gt; 988 &lt; 211 &gt; 42 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 988

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He lie 20 25 30 567 200524957

Gly Leu Met Val Gly Gly Val Val lie Ala 35 40 &lt; 210 &gt; 989 &lt; 211〉 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon Too &lt; 400 &gt; 989

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt; 210〉 990 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 φ &lt; 223 &gt; Description of Artificial Sequence &lt; 400〉 990

Tyr Glu Val His His Gin Lys Leu Val Phe Phe ^ 1 5 10 &lt; 210 &gt; 991 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Winner: &lt; 400〉 991

Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met 568 200524957 1 5 10 &lt; 210〉 992 &lt; 211〉 28 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223 &gt; Artificial Explanation of sequence: Synthetic victory fl too <400> 992

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys # 20 25 &lt; 210〉 993 &lt; 211〉 40 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Winner: &lt; 400 &gt; 993

Val Val Gly Gly Val Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 15 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gin His His Val Glu Tyr Gly 20 25 30

Ser Asp His Arg Phe Glu Ala Asp 35 40 &lt; 210> 994 &lt; 211 &gt; 42 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 4〇〇〉 994 569 200524957

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val lie Ala-35 40 Λ &lt; 210 &gt; 995 &lt; 211〉 40 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory fl &lt; 400> 995

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie He 20 25 30

Gly Leu Met Val Gly Gly Val Val 35 40 &lt; 210 &gt; 996 ·· &lt; 211〉 11 &lt; 212〉 PRT Yuetai &lt; 400〉 996

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu 1 5 10 &lt; 210 &gt; 997 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence 570 200524957 &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: The victory of synthesis 0 too <400> 997 lie He Gly Leu Met 1 5 &lt; 210 &gt; 998 '&lt; 211> 4 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; of artificial sequence Description: Synthetic Tsukiyoshi &lt; 400 &gt; 998 _ lie Gly Leu Met &lt; 210〉 999 &lt; 211〉 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence : Victory of Synthesis fl too <400> 999

Met Leu Gly lie lie Ala Gly Lys Asn Ser Gly 1 5 10

-&210; 1000 &lt; 211 &gt; 15 &gt; &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1000

Asn Trp Cys Lys Arg Gly Arg Lys Gin Cys Lys Thr His Pro His 15 10 15 &lt; 210〉 1001 &lt; 211 &gt; 20 571 200524957 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Artificial Explanation of the sequence: Katsuyuki Kazuyuki <400> 1001

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg 15 10 15

His Leu Ser Lys • 20

&lt; 210 &gt; 1002 &lt; 211〉 38 φ &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: synthetic peptide &lt; 400 &gt; 1002

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He lie 20 25 30

Gly Leu Met Val Gly Gly

&lt; 210 &gt; 1003 • &lt; 211〉 28 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 1003

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 572 200524957 20 25 &lt; 210〉 1004 &lt; 211 &gt; 16 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉-&lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 1004

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gin Val His His Gin Lys 15 10 15 &lt; 210〉 1005 Φ &lt; 211〉 40 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Explanation of sequence: Synthetic victory: &lt; 400 &gt; 1005

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gin Lys 15 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala lie lie 20 25 30

Gly Leu Met Val Gly Gly Val Val

&lt; 210 &gt; 1006-&lt; 211> 35 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 1006

His Asp Ser Gly Tyr Glu Val His His Gin Lys Leu Val Phe Phe Ala 15 10 15

Gin Asp Val Gly Ser Asn Lys Gly Ala lie lie Gly Leu Met Val Gly 573 200524957 20 25 30

Gly Val Val 35 &lt; 210〉 1007 &lt; 211〉 35-&212; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory)! Too &lt; 400 &gt; 1007

Glu Gin Val Thr Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala

Val Ala Gin Lys Thr Val Glu Gly Ala Gly Ser lie Ala Ala Ala Thr 20 25 30

Gly Phe Val 35 &lt; 210 &gt; 1008 &lt; 211> 24 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 1008

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala He He 15 10 15

Gly Leu Met Val Gly Gly Val Val 20 &lt; 210 &gt; 1009 &lt; 211 &gt; 11 &lt; 212> &lt; 400〉 1009

Gly Tyr Val lie lie Lys Pro Leu Val Trp Val 1 5 10 &lt; 210 &gt; 1010 • &lt; 211〉 63 &lt; 212〉 PRT '&lt; 213〉 artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthetic victory moon too # &lt; 400〉 1010

Arg Leu Glu Lys Arg Asp Val Lys Ala Val Cys Ser Gin Glu Ala Met 15 10 15

Thr Gly Pro Cys Arg Ala Val Met Pro Arg Trp Tyr Phe Asp Leu Ser 20 25 30

Lys Gly Lys Cys Val Arg Phe lie Tyr Gly Gly Cys Gly Gly Asn Arg 35 40 45

Asn Asn Phe Glu Ser Glu Asp Tyr Cys Met Ala Val Cys Lys Ala 50 55 60

&lt; 210 &gt; 1011 &lt; 211〉 39 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Katsuyuki Katsuta &lt; 400 &gt; 1011

Asn Ser Ser Cys Gly Glu Gly Asn His Leu Pro Thr Thr Pro Cys Tyr 15 10 15

Leu Gin Trp Gly Thr His Arg Glu Phe Leu Arg Arg Phe Ser He Trp 20 25 30 575 200524957

Asn His Gly His Leu His Met 35 &lt; 210 &gt; 1012 &lt; 211〉 39 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence • &lt; 220〉 _ &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1012

Ala Gly Arg Gly Lys Gin Gly Gly Lys Val Arg Ala Lys Ala Lys Thr 15 10 15 • Arg Ser Ser Arg Ala Gly Leu Gin Phe Pro Val Gly Arg Val His Arg 20 25 30

Leu Leu Arg Lys Gly Asn Tyr 35 &lt; 210〉 1013 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220>

&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 1013

Thr Arg Ser Ser Arg Ala Gly Leu Gin Phe Pro Val Gly Arg Val His 15 10 15

Arg Leu Leu Arg Lys 20 &lt; 210 &gt; 1014 &lt; 211> 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: 576 200524957 &lt; 400 &gt; 1014

Lys Trp Lys Leu Phe Lys Lys lie Glu Lys Val Gly Gin Asn He Arg 15 10 15

Asp Gly lie He Lys Ala Gly Pro Ala Val Ala Val Val Gly Gin Ala 20 25 30

Thr Gin He Ala Lys a 35

&lt; 210 &gt; 1015 &lt; 211> 32 &lt; 212 &gt; PRT call &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 1015

Ser Trp Leu Ser Lys Thr Ala Lys Lys Leu Glu Asn Ser Ala Lys Lys 15 10 15

Arg He Ser Glu Gly lie Ala lie Ala lie Gin Gly Gly Pro Arg Cys 20 25 30

&lt; 210 &gt; 1016 &lt; 211〉 31 • &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; ^ &lt; 223> Description of artificial sequence: Katsuyuki Katsuta &lt; 400 &gt; 1016

Gly lie Met Ser lie Val Lys Asp Val Ala Lys Asn Ala Ala Lys Gly 15 10 15

Ala Leu Ser Thr Leu Ser Thr Leu Ser Cys Lys Leu Ala Lys Thr 20 25 30 &lt; 210 &gt; 1017 &lt; 211 &gt; 24 577 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223〉 Artificial Explanation of the sequence: Katsuyuki Kazuyuki <400> 1017

Phe Leu Gly Ala Leu Phe Lys Val Ala Ser Lys Val Leu Pro Ser Val 15 10 15

Lys Cys Ala lie Thr Lys Lys Cys 20

&lt; 210〉 1018 &lt; 211 &gt; 13 &lt; 212〉 PRT • &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory moon too &lt; 400 &gt; 1018 lie Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg 1 5 10 &lt; 210〉 1019 &lt; 211 &gt; 18 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 φ &lt; 223> Explanation of Artificial Sequence: Synthetic Victory zero. &lt; 400〉 1019

Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val • 15 10 15

Gly Arg &lt; 210〉 1020 &lt; 211〉 18 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 578 200524957 &lt; 400〉 1020

Arg Arg Trp Cys Tyr Arg Lys Cys Tyr Lys Gly Tyr Cys Tyr Arg Lys 15 10 15

Cys Arg &lt; 210> 1021-&lt; 211 &gt; 35 &lt; 212 &gt; PRT I &lt; 2 丨 3 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400> 1021 • Arg Trp Lys lie Phe Lys Lys lie Glu Lys Val Gly Gin Asn lie Arg 15 10 15

Asp Gly lie Val Lys Ala Gly Pro Ala Val Ala Val Val Gly Gin Ala 20 25 30

Ala Thr lie 35

&lt; 210 &gt; 1022 &lt; 211〉 12 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400 &gt; 1022

Arg Leu Cys Arg lie Val Val lie Arg Val Cys Arg 1 5 10 &lt; 210〉 1023 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223〉 Explanation of artificial sequence: Synthesis Peptide 579 200524957 &lt; 400〉 1023

Thr Arg Ser Ser Arg Ala Gly Leu Gin Phe Pro Val Gly Arg Val His 15 10 15

Arg Leu Leu Arg Lys 20 &lt; 210 &gt; 1024 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 1024

Tyr Pro Pro Gly Pro Leu Ala Pro Pro Gin Pro Phe Gly Pro 1 5 10 &lt; 210〉 1025 &lt; 211 &gt; 22 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence : Synthetic victory 0 too &lt; 400 &gt; 1025

Val Asn Pro Gly Val Val Val Arg He Ser Gin Lys Gly Leu Asp Tyr 15 10 15

Ala Ser Gin Gin Gly Arg 20 &lt; 210 &gt; 1026 &lt; 211 &gt; 15 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Synthetic peptide &lt; 40〇 &gt; 1026 580 200524957

Ala Asp Val Leu Thr Thr Gly Ala Gly Asn Pro Val Gly Asp Lys 15 10 15 &lt; 210 &gt; 1027 &lt; 211〉 42 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation: Synthetic victory 0 too &lt; 400 &gt; 1027

Met Ala Ala Val Ser Met Ser Val Ala Leu Arg Gin Ala Leu Trp Gly

Arg Arg Val Ala Thr Val Ala Ala Val Ser Val Ser Lys Val Ser Thr 20 25 30

Arg Ser Leu Ser Thr Ser Thr Trp Arg Leu 35 40 &lt; 210 &gt; 1028 &lt; 211〉 23 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> φ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Status &quot; &lt; 400 &gt; 1028

Gly lie Gly Lys Phe Lys His Ser Ala Gly Lys Phe Gly Lys Ala Phe ^ 15 10 15

Val Gly Glu lie Met Lys Ser 20 &lt; 210 &gt; 1029 &lt; 211〉 29 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 581 200524957 &lt; 223> Explanation of Artificial Sequence: Katsuta Katsuta ; 400 &gt; 1029

Leu Arg Asp Leu Val Ser Tyr Cys Arg Ala Arg Gly Lys Gly Arg Glu 15 10 15

Arg Met Asn Gly Thr Arg Lys Gly His Leu Leu Tyr Met 20 25 &lt; 210〉 1030 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223〉 Recitation of Artificial Sequence: Synthetic dirty &lt; 400 &gt; 1030 Ser Gin Asn Tyr &lt; 210 &gt; 1031 &lt; 211 &gt; 12 &lt; 212〉 PRT &lt; 213> Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory : &Lt; 400 &gt; 1031

Arg Leu Cys Arg lie Val Val lie Arg Val Cys Arg 1 5 10 &lt; 210 &gt; 1032 &lt; 211〉 25 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory Moon too <400> 1032

Asn Gin Gly Arg His Phe Cys Gly Gly Ala Leu lie His Ala Arg Phe 1 5 10 15 582 200524957

Val Met Thr Ala Ala Ser Cys Phe Gin 20 25 &lt; 210 &gt; 1033 &lt; 211〉 2 &lt; 212〉 PRT-&lt; 213 &gt; Artificial Sequence &lt; 220〉 / &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic victory )} &Lt; 400〉 1033 Pro Phe

&lt; 210〉 1034 &lt; 211〉 18 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1034

Cys Asn Leu Ala Val Ala Ala Ala Ser His lie Tyr Gin Asn Gin Phe 15 10 15

Val Gin &lt; 210〉 1035 &lt; 211〉 19 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 1035

Tyr Arg Val Arg Phe Leu Ala Lys Glu Asn Val Thr Gin Asp Ala Glu 15 10 15

Asp Asn Cys 583 200524957 &lt; 210〉 1036 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 Too &lt; 400 &gt; 1036- Lys Trp Lys Leu Phe Lys Lys He Gly Ala Val Leu Lys Val Leu 15 10 15

&lt; 210〉 1037 &lt; 211 &gt; 35 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400〉 1037

Lys Trp Lys Val Phe Lys Lys lie Glu Lys Met Gly Arg Asn lie Arg 15 10 15

Asn Gly He Val Lys Ala Gly Pro Ala lie Ala Val Leu Gly Glu Ala 20 25 30

Lys Ala Leu 35 &lt; 210〉 1038

&lt; 211 &gt; 12 ^ &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1038

Thr Tyr lie Cys Glu Val Glu Asp Gin Lys Glu Glu 1 5 10 &lt; 210〉 1039 &lt; 211〉 29 584 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence : Synthetic Victory Rib: &lt; 400 &gt; 1039

Cys Tyr Cys Arg He Pro Ala Cys He Ala Gly Glu Arg Arg Tyr Gly 15 10 15

Thr Cys lie Tyr Gin Gly Arg Leu Trp Ala Phe Cys Cys 20 25

&lt; 210 &gt; 1040 &lt; 211> 34 ® &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic Satsuki Taito &lt; 400 &gt; 1040

Ala Leu Trp Lys Thr Met Leu Lys Lys Leu Gly Thr Met Ala Leu His 15 10 15

Ala Gly Lys Ala Ala Leu Gly Ala Ala Ala Asp Thr lie Ser Gin Gly 20 25 30

Thr Gin

• &lt; 210〉 1041 &lt; 211 &gt; 24 '' &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Synthetic Katsuyuki &lt; 400〉 1041

Gly Val Leu Ser Asn Val lie Gly Tyr Leu Lys Lys Leu Gly Thr Gly 15 10 15

Ala Leu Asn Ala Val Leu Lys Gin 20 585 200524957 &lt; 210 &gt; 1042 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400〉 1042 Val Glu Pro He Pro Tyr 1 5

&lt; 210〉 1043 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1043

Arg Arg Trp Gin Trp Arg Met Lys Lys Leu Gly 1 5 10 &lt; 210 &gt; 1044 &lt; 211> 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Win 0 Too <400> 1044

Asp Ala Glu Ala Val Gly Pro Glu Ala Phe Ala Asp Gin Asp Leu Asp 15 10 15

Glu Arg Glu Val Arg 20 &lt; 210> 1045 &lt; 211 &gt; 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; 586 200524957 &lt; 223 &gt; Explanation of Artificial Sequences: Satsuki Katsuta &lt; 400 &gt; 1045

Ser lie Gly Ser Leu Ala Lys 1 5 &lt; 210〉 1046 &lt; 211〉 23 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl too &lt; 400 &gt; 1046

Gly He Gly Lys Phe Leu His Ser Ala Gly Lys Phe Gly Lys Ala Phe 15 10 15

Val Gly Glu He Met Lys Ser 20 &lt; 210〉 1047 &lt; 211〉 23 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory fl too & 400 〉 1047

Gly lie Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe

Val Gly Glu He Met Asn Ser 20 &lt; 210〉 1048 &lt; 211 &gt; 27 &lt; 212〉 PRT &lt; 213> Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki Tai &lt; 400 &gt; 1048

Tyr Leu Val Leu Phe Phe Tyr Pro Leu Asp Phe Thr Phe Val Cys Pro 587 200524957 15 10 15

Thr Glu lie lie Cys Pro Thr Glu lie lie Gly 20 25 &lt; 210 &gt; 1049 &lt; 211 &gt; 15 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence '&lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory fl &lt; 400> 1049

Leu Val Gin Ala Phe Gin Gly Lys Val Asn Val Phe Leu Gin Phe

&lt; 210 &gt; 1050 &lt; 211 &gt; 19 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1050

Gly Leu Phe lie He Asp Tyr Thr Asp Glu Met Gly Glu Val Pro Ala 15 10 15

Gly Gly Lys

&lt; 210> 1051 &lt; 211 &gt; 4 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400> 1051 Asp Glu Val Asp 1 &lt; 210 &gt; 1052 &lt; 211〉 4 588 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223〉 Description of artificial sequence: Synthetic Katsuyuki too &lt; 400〉 1052 Asp Glu Val Asp &lt; 210 &gt; 1053 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> # &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 1053 Val Ala Asp 1 &lt; 210 &gt; 1054 &lt; 211〉 3 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400〉 1054 Val Ala Asp • &lt; 210〉 1055 &lt; 211〉 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223> Explanation of the artificial sequence: Synthesis of Katsuyuki too <400> 1055

Asp Pro Met Ser Ser Thr Tyr lie Glu Glu Leu Gly Lys Arg Glu Val 15 10 15 5 &lt; S9 200524957

Thr lie Pro Pro Lys Tyr Arg Glu Leu Leu Ala 20 25 &lt; 210 &gt; 1056 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt;, &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1056 Val Ala Asp Met

&lt; 210〉 1057 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400〉 1057

Asp Glu Val Asp

&lt; 210 &gt; 1058 &lt; 211〉 20 • &lt; 212 &gt; PRT ^ &lt; 213 &gt; Artificial sequence &lt; 220〉 '&lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1058

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 15 10 15

Tyr Val Ala Asp 20 &lt; 210〉 1059 &lt; 211〉 7 590 200524957 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 1059

Tyr Val Ala Asp Ala Pro Lys 1 5

&lt; 210〉 1060 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 1060

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 15 10 15

Asp Glu Val Asp 20 &lt; 210〉 1061 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 _ &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 1061 Tyr Val Ala Asp &lt; 210 &gt; 1062 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 1062 591 200524957

Tyr Val Ala Asp 1 &lt; 210 &gt; 1063 &lt; 211 &gt; 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; _ &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400> 1063 Tyr Val Ala Asp &lt; 210 &gt; 1064 〇 &lt; 211〉 2 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1064 Val Phe 1

&lt; 210〉 1065 &lt; 211〉 3 &lt; 212 &gt; PRT φ &lt; 213 &gt; Artificial Sequence- &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: '&lt; 400 &gt; 1065 Leu Leu Leu 1 &lt; 210 &gt; 1066 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 200524957 &lt; 400 &gt; 1066 Tyr Val Ala Asp 1 &lt; 210 &gt; 1067 &lt; 211 &gt; 4 &lt; 212〉 PRT ~ &lt; 213 &gt; Artificial Sequence_ &lt; 220〉 ~ &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400〉 1067 Val Glu lie Asp 1 Ο &lt; 210 &gt; 1068 &lt; 211〉 1 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400> 1068

Asp

&lt; 210 &gt; 1069 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 1069

Asp Glu Val Asp Ala Pro Lys 1 5 &lt; 210 &gt; 1070 &lt; 211 &gt; 21 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 1070

Asp Met Phe Ser Asp Gly Asn Phe Asn Trp Val Arg Val Val Ala Leu 15 10 15

Phe Tyr Phe Ala Ser • 20 ^ &lt; 210 &gt; 1071 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence 〇 &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 1071

Ala Asn Arg Leu Phe Gly Glu Lys 1 5 &lt; 210 &gt; 1072 &lt; 211〉 19 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220>

&lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 1072

Gly Gly Gly Gly Asp lie His Gin Gly Phe Gin Ser Leu Leu Thr Glu 15 10 15

Val Asn Lys &lt; 210 &gt; 1073 &lt; 211〉 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400> 1073 594 200524957

Gly Asn Thr Ala Ala Gin Met Ala Gin lie Leu Ser Phe Asn 1 5 10 &lt; 210〉 1074 &lt; 211 &gt; 25 &lt; 212〉 PRT &lt; 213〉 artificial sequence "&lt; 220〉 # &lt; 223 &gt; artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 1074

Gin Gly Leu Trp Leu Met Asn Val Leu Arg Val Gly Trp His His His 15 10 15

Leu Gin Pro Arg Thr Val Pro Glu Asn 20 25 &lt; 210 &gt; 1075 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 1075

Thr Gly His Gly Gly Pro Gin Phe Val Ala Asp His Pro Phe Leu Phe 15 10 15

* Leu lie Met His Lys lie Thr Asn Cys lie Leu Phe Phe Gly Arg Phe 20 25 30

Ser Ser Pro 35 &lt; 210〉 1076 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon &lt; 400> 1076 595 200524957

Ala Pro Arg Leu Arg Phe Tyr Ser Leu 1 5 &lt; 210〉 1077 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 1077

Ala Pro Arg Leu Arg Phe Tyr Ser 1 5 o &lt; 210 &gt; 1078 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 1078

Ala Pro Arg Leu Arg Phe Tyr

&lt; 21〇 &gt; 1079 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1079 Arg Leu Arg Phe His 1 5 &lt; 210 &gt; 1080 &lt; 211> 5 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 596 200524957 &lt; 223 &gt; Description of artificial sequence: Synthetic I Health Fl &lt; 400 &gt; 1080 Arg Leu Arg Phe Asp 1 5 &lt; 210 &gt; 1081 &lt; 211〉 23, &lt; 212〉 PRT &gt; &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400 &gt; 1081

Leu Lys Lys Tyr Lys Val Pro Gin Leu Glu lie Val Pro Asn Ser Ala O 1 5 10 15

Glu Glu Arg Leu His Ser Met 20 &lt; 210 &gt; 1082 &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1082

Gin Lys Leu Gly Asn Gin Trp Ala Val Gly His Leu Met 1 5 10 &lt; 210 &gt; 1083 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Rib: &lt; 400 &gt; 1083

Trp Ala Val Gly His Leu Met 1 5 597 200524957 &lt; 210〉 1084 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Synthetic Victory &lt;; 400〉 1084

Glu Gin Arg Leu Gly Asn Gin Trp Ala Val Gly His Leu Met 1 5 10 &lt; 210 &gt; 1085 &lt; 211 &gt; 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 1085

Glu Gin Arg Leu Gly Asn Gin Trp Ala Val Gly His Leu Leu 1 5 10 &lt; 210〉 1086 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 1086

Phe Gin Trp Ala Val Gly His Leu 1 5 &lt; 210 &gt; 1087 &lt; 211 &gt; 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400 &gt; 1087

Gin Arg Leu Gly Asn Gin Trp Ala Val Gly Phe Leu Met 1 5 10 598 200524957 &lt; 210 &gt; 1088 &lt; 211〉 13 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory 0 too • &lt; 400〉 1088

Gin Arg Leu Gly Asn Gin Trp Ala Val Gly Phe Leu Leu ^ 1 5 10

&lt; 210 &gt; 1089 &lt; 211 &gt; 13 丨 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1089

Gin Arg Tyr Gly Asn Gin Trp Ala Val Gly His Leu Met 1 5 10 &lt; 210〉 1090 &lt; 211 &gt; 13 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence f &lt; 220> ^ · &lt; 223 &gt; artificial sequence Explanation: Synthetic Victory Moon <400> 1090 ^ Gin Arg Tyr Gly Asn Gin Trp Ala Val Gly Phe Leu Met 1 5 10 &lt; 210 &gt; 1091 &lt; 211> 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory moon 599 200524957 &lt; 400 &gt; 1091

Met Pro Leu Pro Pro His Pro Gly His Pro Gly Tyr lie Asn Phe Ser 15 10 15

Tyr Glu Val Leu Thr 20 ^ &lt; 210〉 1092 &lt; 211〉 6 1 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Flr, rJ &lt; 400〉 1092

Pro Phe Tyr Gly Pro Val 1 5 &lt; 210〉 1093 &lt; 211〉 47 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 8 too &lt; 400 &gt; 1093

Tyr Leu Tyr Gin Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu

Glu Pro Arg Arg Val Cys Leu Asn Pro Asp Cys Asp Glu Leu Ala Asp 20 25 30

His lie Gly Phe Gin Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val 35 40 45 &lt; 210 &gt; 1094 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 600 200524957 &lt; 223〉 artificial Explanation of the sequence: Satsuki Katsuta &lt; 400 &gt; 1094

Leu Val Val Tyr Pro Trp 1 5 &lt; 210〉 1095 &lt; 211〉 46 _ &lt; 212〉 PRT • # &lt; 213 &gt; Artificial Sequence ^ &lt; 220 &gt; f &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 1095

Tyr Leu Tyr Gin Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu φ 1 5 10 15

Pro Arg Arg Val Cys Leu Asn Pro Asp Cys Asp Glu Leu Ala Asp His 20 25 30 lie Gly Phe Gin Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val 35 40 45 &lt; 210〉 1096 &lt; 211〉 13 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence

&lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory rib: &lt; 400〉 1096 、 Gly Phe Gin Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val _ 1 5 10 &lt; 210 &gt; 1097 / &lt; 211 〉 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 400 &400; 1097 601 200524957

Pro Tyr Gin Glu Ala Phe Arg Arg Phe Phe Gly Pro Val 1 5 10 &lt; 210〉 1098 &lt; 211> 48 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;, &lt; 223 &gt; Explanation of Artificial Sequence : Synthesis of Victory Moon ^ &lt; 400 &gt; 1098 n Val Pro He Tyr Glu Lys Lys Tyr Gly Gin Val Pro Met Cys Asp Ala 15 10 15 • Gly Glu Gin Cys Ala Val Arg Lys Gly Ala Arg lie Gly Lys Leu Cys 20 25 30

Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu 35 40 45 &lt; 210 &gt; 1099 &lt; 211〉 48 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Description: Victory of Synthesis &lt; 400〉 1099 ^ Val Pro lie Tyr Glu Lys Lys Tyr Gly Gin Val Pro Met Cys Asp Ala 15 10 15 λ Gly Glu Gin Cys Ala Val Arg Lys Gly Ala Arg lie Gly Lys Leu Cys, 20 25 30

Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu 35 40 45 &lt; 210 &gt; 1100 &lt; 211 &gt; 48 602 200524957 &lt; 212> PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb: &lt; 400〉 1100

Val Pro lie Tyr Glu Lys Lys Tyr Gly Gin Val Pro Met Cys Asp Ala 15 10 15

Gly Glu Gin Cys Ala Val Arg Lys Gly Ala Arg lie Gly Lys Leu Cys 20 25 30

Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu 35 40 45

&lt; 210> 1101 &lt; 211 &gt; 28 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 1101

Ala Gly Ala Thr Val Gin Val Thr Leu Asp Gly Val Pro Ala Ala Ala 15 10 15

Pro Gly Gin Pro Ala Gin Leu Gin Leu Asn Ala Thr

&lt; 210 &gt; 1102 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213〉 artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: synthetic peptide &lt; 400> 1102 Phe Leu Phe Leu Phe 1 5 &lt; 210 &gt; 1103 603 200524957 &lt; 211〉 30 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1103

Ala Cys Tyr Cys Arg He Pro Ala Cys lie Ala Gly Glu Arg Arg Tyr 15 10 15

Gly Thr Cys He Tyr Gin Gly Arg Leu Trp Ala Phe Cys Cys 20 25 30 &lt; 210 &gt; 1104 φ &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; artificial sequence Explanation: Satsuki Katsuyuki &lt; 400 &gt; 1104 Met Leu Phe

&lt; 210〉 1105 &lt; 211〉 4 &lt; 212〉 PRT • &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1105

Met Leu Phe Lys ^ 1 &lt; 210 &gt; 1106 &lt; 211> 4 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 604 200524957 &lt; 223 &gt; Description of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1106

Met Leu Phe Lys

&lt; 210〉 1107 &lt; 211〉 6 &lt; 212〉 PRT-&lt; 213〉 Artificial sequence &lt; 220〉 • &lt; 22b Explanation of artificial sequence: Synthetic victory over moon &lt; 400〉 1107

Trp His Val Ala Ala Asn

&lt; 210 &gt; 1108 &lt; 211> 25 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 1108

Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser lie lie Asp Val Tyr 15 10 15

His Lys Tyr Ser Leu lie Lys Gly Asn

&lt; 210 &gt; 1109, &lt; 211〉 19 &lt; 212〉 PRT-&lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400〉 1109

His Trp Asp Thr Thr Gin Ser Leu Lys Gin Leu Glu Glu Arg Ala Ala 15 10 15 605 200524957

Trp Asn Val &lt; 210〉 1110 &lt; 211〉 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 1110

Gly Pro Val Ser Ala Val Leu Thr Glu Leu Arg Cys Thr Cys Leu Arg 15 10 15 • Val Thr Leu Arg 20 &lt; 210〉 1111 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Synthetic Victory Moon &lt; 400〉 1111 lie Gin Arg Thr Pro Lys lie Gin Val Tyr Ser Arg His Pro Ala Glu 15 10 15

Asn Gly Lys Ser Asn 20 gas &lt; 210 &gt; 1112 &lt; 211> 11, &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 1112

Arg Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala 1 5 10 606 200524957 &lt; 210 &gt; 1113 &lt; 211〉 19 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic Victory &lt; 400> 1113

Tyr Ser Asp Asp Glu Gly Ala Ser Trp Ser Asp Leu Asp He Val Ser 15 10 15

I

Phe Ser Lys φ &lt; 210 &gt; 1114 &lt; 211〉 18 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 1114

Val Ala Arg Thr Leu Leu Val Phe Glu Val Gin Gin Pro Phe Leu Phe 15 10 15

Val Leu

&lt; 210〉 1115 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &quot; &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory: &quot; &lt; 400 &gt; 1115

Asp Phe Arg Phe Leu Arg Cys Ser Thr Arg Gin Cys Trp Asn 1 5 10

&lt; 210 &gt; 1116 &lt; 211 &gt; 10 &lt; 212 &gt; PRT 607 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400> 1116

Cys Asn Thr Gly Gin Leu Cys Pro Val Glu 1 5 10

&lt; 210 &gt; 1117 &lt; 211 &gt; 18 &lt; 212 &gt; PRT '&lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too # &lt; 400 &gt; 1117

Ser Val Asp Arg Ser Gly Asn Val His His Gin Phe Gin Lys Leu Thr 15 10 15

Leu Glu &lt; 210〉 1118 &lt; 211〉 19 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta

&lt; 400 &gt; 1118

Leu His Glu Trp Thr Lys Pro Glu Asn Leu Asp Phe He Glu Val Asn 15 10 15

Val Leu Pro &lt; 210 &gt; 1119 &lt; 211〉 29 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic peptide 608 200524957 &lt; 400> 1119

Val Leu Glu Leu Pro Tyr Gin Gly Glu Glu Leu Ser Met Val He Leu 15 10 15

Leu Pro Asp Asp lie Glu Asp Glu Ser Thr Gly Leu Lys 20 25

&lt; 210 &gt; 1120 &lt; 211 &gt; 19 &lt; 212〉 PRT ^ &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: # &lt; 400〉 1120

Thr Tyr Gly Ala Asp Leu Ala Ser Val Asp Phe Gin His Ala Ser Glu 15 10 15

Asp Ala Arg &lt; 210 &gt; 1121 &lt; 211> 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta

&lt; 400 &gt; 1121

Glu Arg Pro Pro Leu Gin Gin Pro Pro His Arg Asp 10 &lt; 210 &gt; 1122 &lt; 211 &gt; 29 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400〉 1122

Tyr Glu Arg Pro Pro Leu Gin Gin Pro Pro His Arg Asp Lys Lys Pro 15 10 15 609 200524957

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 20 25 &lt; 210 &gt; 1123 &lt; 211〉 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory over Moon &lt; 400> 1123

Ser Ala Leu Pro Leu Glu Ser Gly Pro Thr Gly Gin Asp Ser Val Gin 15 10 15

Asp Ala Thr Gly 20 &lt; 210 &gt; 1124 &lt; 211 &gt; 31 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Artificial Sequence Explanations: Synthetic Victory Moon &lt; 400> 1124

Thr Gly Leu Leu Thr Phe Leu Ala Trp Trp His Glu Trp Ala Ser Gin

Asp Ser Ser Ser Thr Ala Phe Glu Gly Gly Thr Pro Glu Leu Ser 20 25 30 &lt; 210 &gt; 1125 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation: Synthetic Tsukiyoshi &lt; 400〉 1125 Arg Gly Asp Cys 610 200524957 1 &lt; 210 &gt; 1126 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Artificial Sequence Explanation: Synthetic Victory &lt; 400〉 1126 Arg Gly Asp Ser &lt; 210〉 1127 • &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence : Synthetic Katsuyuki &lt; 400 &gt; 1127 Arg Gly Asp Val &lt; 210 &gt; 1128 &lt; 211〉 4 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence 9 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuyuki &lt; 400 &gt; 1128 ^ Arg Gly Glu Ser 1 &lt; 210 &gt; 1129 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: The victory of synthesis 呔 200524957 &lt; 400〉 1129

Gly Arg Gly Asp Ser Pro Ala 1 5 &lt; 210〉 1130 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta- &lt; 400〉 1130

Arg Gly Asp Phe Val

&lt; 210〉 1131 &lt; 211〉 12 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 1131

Pro Leu Tyr Lys Lys lie lie Lys Lys Leu Leu Ser 1 5 10

&lt; 210 &gt; 1132 &lt; 211> 49 φ &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt;-&lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1132 ^ Glu Cys Glu Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu Lys Glu 15 10 15

Gly Thr lie Cys Lys Arg Ala Arg Gly Asp Asp Met Asp Asp Tyr Cys 20 25 30

Asn Gly Lys Thr Cys Asp Cys Pro Arg Asn Pro His Lys Gly Pro Ala 612 200524957 35 40 45

Thr &lt; 210 &gt; 1133 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1133

Gly Arg Ala Asp Ser Pro Lys

&lt; 210> 1134 &lt; 211 &gt; 37 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuyuki Katsuta &lt; 400 &gt; 1134

Phe Asn Lys His Thr Glu lie lie Glu Glu Asp Thr Asn Lys Asp Lys 15 10 15

Pro Ser Tyr Gin Phe Gly Gly His Asn Ser Val Asp Phe Glu Glu Asp 20 25 30

Thr Leu Pro Lys Val 35 &lt; 210> 1135 &lt; 211 &gt; 16 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 1135

Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly Val Arg 613 200524957 15 10 15 &lt; 210〉 1136 &lt; 211 &gt; 17 &lt; 212〉 PRT &lt; 213〉 Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: synthetic peptide &lt; 400 &gt; 1136, Tyr Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly Val 15 10 15

&lt; 210 &gt; 1137 &lt; 211> 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuyuki Katsuta &lt; 400 &gt; 1137

Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg 1 5 10 • &lt; 210> 1138 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉, &lt; 223 &gt; of artificial sequence Explanation: Satsuki Katsuyuki &lt; 400 &gt; 1138

Glu Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg 1 5 10

&lt; 210〉 1139 &lt; 211〉 14 &lt; 212 &gt; PRT 614 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1139

Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg Tyr 1 5 10 &lt; 210 &gt; 1140 &lt; 211 &gt; 18 &lt; 212> PRT &lt; 213 &gt; artificial sequence

&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400> 1140

Tyr Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg 15 10 15

Gly Val &lt; 210 &gt; 1141 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223〉 Description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1141 • Trp Gin Pro Pro Arg Ala Arg lie &lt; 210 &gt; 1142 &lt; 211 &gt; 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 40〇 &gt; 1142 615 200524957

Glu lie Leu Asp Val 1 5 &lt; 210 &gt; 1143 &lt; 211> 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Artificial Sequence Explanation: Synthetic Winner: &lt; 400 &gt; 1143

Glu lie Leu Asp Val Pro Ser Thr 1 5

&lt; 210 &gt; 1144 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 4〇〇 &gt; 1144

Gly Arg Ala Asp Ser Pro 1 5

&lt; 210 &gt; 1145 &lt; 211〉 5 &lt; 212〉 PRT φ &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400〉 1145 m

Gly Arg Gly Asp Ser 1 5 嚅 &lt; 210〉 1146 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu 200524957 &lt; 400〉 1146

Gly Arg Gly Asp Ser Pro 1 5 &lt; 210 &gt; 1147 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory fl too &lt; 400 〉 1147

Gly Arg Gly Asp Ser Pro Cys

&lt; 210 &gt; 1148 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400〉 1148

Gly Arg Gly Asp Thr Pro 1 5 &lt; 210 &gt; 1149 • &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence w &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: the victory of synthesis g too, &lt; 400〉 1149

Gly Arg Gly Glu Ser 1 5 &lt; 210〉 1150 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 200524957 &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1150

Gly Arg Gly Glu Ser Pro 1 5 &lt; 210 &gt; 1151 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki too &lt; 400 &gt; 1151 • Gly Gly Asp Ser Pro 1 5 &lt; 210 &gt; 1152 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400 &gt; 1152

Gly Gin Gin His His Leu Gly Gly Ala Lys Gin Ala Gly Asp Val 15 10 15

φ &lt; 210〉 1153 &lt; 211〉 3 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;, &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl 太 &lt; 400 &gt; 1153 Gly Pro Arg &lt; 210 &gt; 1154 &lt; 211 &gt; 10 618 200524957 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400> 1154

Gly Arg Gly Asp Ser Pro Ala Ser Ser Lys 1 5 10 &lt; 210〉 1155 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213〉 artificial sequence

&lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1155

Gly Gly Arg Gly Asp Ser Pro Cys Ala 1 5 &lt; 210〉 1156 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 1156

Gly Arg Gly Asp Ser Pro 1 5 &lt; 210〉 1157 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory 0 too & 400 〉 1157

Gly Arg Gly Asp Asn Pro 1 5 619 200524957 &lt; 210 &gt; 1158 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 1158

Trp Gin Pro Pro Arg Ala Arg He 1 5 &lt; 210 &gt; 1159 &lt; 211〉 5 &lt; 212〉 PRT φ &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 1159 Tyr lie Gly Ser Arg 1 5 &lt; 210 &gt; 1160 &lt; 211〉 3 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: victory of synthesis fl Too φ &lt; 400 &gt; 1160 Leu Asp Val 1 黪 &lt; 210 &gt; 1161 • &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory S too &lt; 400 &gt; 1161

Leu Asp Val Pro Ser 200524957 1 5 &lt; 210〉 1162 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213> Artificial Sequences &lt; 220 &gt; k &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory &lt; 400 &gt; 1162 Lys Gly Asp Ser 1 &lt; 210〉 1163 Boxing &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl 太 &lt; 400 &gt; 1163

Gly Ala Val Ser Thr Ala 1 5

&lt; 210> 1164 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400> 1164

Trp Thr Val Pro Thr Ala 1 5 &lt; 210〉 1165 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 22〇 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon 621 200524957 &lt; 400 &gt; 1165 Arg Gly Asp Ser Pro 1 5 &lt; 210〉 1166 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Status &lt; 400〉 1166

Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu

&lt; 210 &gt; 1167 &lt; 211> 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too &400; 1167 Arg Glu Asp Val 1 &lt; 210 &gt; 1168 • &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220 &gt; • &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon too. &Lt; 400 &gt; 1168

Arg Gly Asp Ser Pro Ala Ser Ser Lys Pro 1 5 10 &lt; 210〉 1169 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 622 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tsukitsu Tsuki &lt; 400〉 1169 Arg Gly Asp Thr &lt; 210 &gt; 1170 &lt; 211〉 3

«&Lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1170 • Arg Asp Ser 1 &lt; 210〉 1171 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1171 Ser Asp Gly Arg Gly 1 5

φ &lt; 210 &gt; 1172 &lt; 211〉 4 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 1172

Ser Asp Gly Arg 1 &lt; 210〉 1173 &lt; 211〉 5 200524957 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl 太 &lt; 400 &gt; 1173 Tyr Arg Gly Asp Ser 1 5 &lt; 210 &gt; 1174 &lt; 211 &gt; 42 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; ® &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400 &gt; 1174

Tyr Ala Lys Leu Leu Gly His Gin Asn Leu Lys Gin Lys lie Lys His 15 10 15

Val Val Lys Leu Lys Asp Glu Asn Ser Gin Leu Lys Ser Glu Val Ser 20 25 30

Lys Leu Arg Cys Gin Leu Ala Lys Lys Lys 35 40 &lt; 210 &gt; 1175

&lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 1175

Phe Met Arg Phe &lt; 210> 1176 &lt; 211 &gt; 4 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence 624 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taisei &lt; 400 &gt; 1176 Phe Met Arg Phe &lt; 210 &gt; 1177 &lt; 211 &gt; 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Artificial Sequence Explanations: Synthetic Victory Moon &lt; 400> 1177 • Phe Met Arg Phe 1 &lt; 210 &gt; 1178 &lt; 211〉 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223〉 Artificial sequence description: Synthetic tsukitsutsuki &lt; 400 &gt; 1178 Phe Met Arg Phe 1

• &lt; 210 &gt; 1179 &lt; 211〉 5 &lt; 212 &gt; PRT • &lt; 213 &gt; artificial sequence &lt; 220 &gt; • &lt; 223 &gt; description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1179

Leu Pro Leu Arg Phe 1 5

&lt; 210> 1180 &lt; 211 &gt; 6 &lt; 212> PRT 200524957 &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 1180

Tyr Leu Pro Leu Arg Phe 1 5 &lt; 210 &gt; 1181 &lt; 211〉 3 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon Φ &lt; 400 &gt; 1181 Trp Arg Phe &lt; 210 &gt; 1182 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 1182

Tyr Phe Met Arg Phe

&lt; 210 &gt; 1183 &lt; 211〉 4 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 1183 Tyr Met Arg Phe 1 &lt; 210 &gt; 1184 200524957 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400〉 1184

Ser Asp Arg Asn Phe Leu Arg Phe 1 5

&lt; 210 &gt; 1185 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1185

Ser Asp Arg Asn Phe Leu Arg Phe 1 5 &lt; 210 &gt; 1186 &lt; 211 &gt; 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400> 1186

Asp Pro Phe Leu Arg Phe &lt; 210 &gt; 1187 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400> 1187

Glu lie Leu Glu Val Pro Ser Thr 200524957 &lt; 210 &gt; 1188 &lt; 211〉 30 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400 &gt; 1188

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Val 15 10 15

Gly Asn His Arg Ser Phe Ser Asp Lys Asn Gly Leu Thr Ser 20 25 30

&lt; 210 &gt; 1189 &lt; 211 &gt; 19 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1189

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Val 15 10 15

Gly Asn His

&lt; 210 &gt; 1190 &lt; 211〉 30 • &lt; 212 &gt; PRT &lt; 213> Artificial sequence '&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1190

Met Ala Arg Gly Ser Ala Leu Leu Leu Ala Ser Leu Leu Leu Ala Ala 15 10 15

Ala Leu Ser Ala Ser Ala Gly Leu Trp Ser Pro Ala Lys Glu 20 25 30 628 200524957 &lt; 210 &gt; 1191 &lt; 211 &gt; 24 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Victory Moon <400> 1191

Glu Leu Arg Pro Glu Asp Asp Met Lys Pro Gly Ser Phe Asp Arg Ser 15 10 15 lie Pro Glu Asn Asn lie Met Arg 20

&lt; 210 &gt; 1192 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1192

Thr lie lie Glu Phe Leu Ser Phe Leu His Leu Lys Glu Ala Gly Ala 1 5 10 15

Leu Asp Arg Leu Leu Asp Leu Pro Ala Ala Ala Ser Ser Glu Asp lie

Glu Arg Ser 35 &lt; 210> 1193 &lt; 211 &gt; 29 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb: &lt; 400 &gt; 1193

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala lie 629 200524957 15 10 15

Asp Asn His Arg Ser Phe His Asp Lys Tyr Gly Leu Ala 20 25

&lt; 210 &gt; 1194 &lt; 211 &gt; 16 &lt; 212 &gt; PRT-&lt; 213 &gt; Artificial sequence &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400> 1194

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala lie • 1 5 10 15 &lt; 210〉 1195 &lt; 211〉 29 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 1195

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala He 15 10 15

Asp Asn His Arg Ser Phe Ser Asp Lys His Gly Leu Thr

&lt; 210 &gt; 1196 • &lt; 211〉 40 &lt; 212〉 PRT _ &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 1196

Thr Lys Glu Lys Arg Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu 15 10 15 630 200524957

Gly Pro His Ala lie Asp Asn His Arg Ser Phe Ser Asp Lys His Gly 20 25 30

Leu Thr Gly Lys Arg Glu Leu Pro 35 40 &lt; 210 &gt; 1197 &lt; 211 &gt; 21 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta

&lt; 400 &gt; 1197

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Gly 15 10

Phe Ser Pro Phe Arg 20 &lt; 210 &gt; 1198 &lt; 211 &gt; 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 1198

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Ala 15 10 15

Leu Ala Leu Ala &lt; 210> 1199 &lt; 211 &gt; 24 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 631 200524957 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 1199

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Arg Pro Lys 15 10 15

Pro Gin Gin Trp Phe Trp Leu Leu 20 &lt; 210〉 1200 &lt; 211〉 41 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 _ &lt; 223> Explanation of Artificial Sequences: Synthetic Victory &lt; 400 &gt; 1200

Glu Leu Glu Pro Glu Asp Glu Ala Arg Pro Gly Gly Phe Asp Arg Leu 15 10 15

Gin Ser Glu Asp Lys Ala lie Arg Thr lie Met Glu Phe Leu Ala Phe 20 25 30

Leu His Leu Lys Glu Ala Gly Ala Leu 35 40 &lt; 210 &gt; 1201

&lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 1201

Leu Gin Ser Glu Asp Lys Ala lie Arg Thr lie Met Glu Phe Leu Ala 15 10 15

Phe Leu His Leu Lys Glu Ala Gly Ala Leu 20 25 &lt; 21〇 &gt; 1202 632 200524957 &lt; 211 &gt; 17 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory &lt; 400 &gt; 1202

Thr lie Met Glu Phe Leu Ala Phe Leu His Leu Lys Glu Ala Gly Ala 15 10 15

Leu &lt; 210〉 1203 φ &lt; 211〉 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 1203

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Gin Gin Phe 15 10 15

Phe Gly Leu Met 20

&lt; 210〉 1204 &lt; 211〉 15 Φ &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1204 * Gly Trp Thr Leu Asn Thr Ala Trp Trp Leu Leu Gly Pro His Ala 15 10 15 &lt; 210> 1205 &lt; 211 &gt; 15 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 633 200524957 &lt; 220> &lt; 223 &gt; description of artificial sequence : Satsuki Katsuyuki &lt; 400 &gt; 1205

Gly Trp Thr Leu Asn Thr Ala Trp Trp Leu Leu Gly Pro His Ala 15 10 15 &lt; 210 &gt; 1206 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Artificial Sequence Description: Satsuki Katsuta &lt; 400 &gt; 1206 ® Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Ala 15 10 15

Leu Ala Leu Ala 20 &lt; 210 &gt; 1207 &lt; 211 &gt; 24 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta &lt; 400〉 1207

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Arg Pro Lys 15 10 15

Pro Gin Gin Trp Phe Trp Leu Leu 20 &lt; 210 &gt; 1208 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 〉 1208 634 200524957

Asp Glu Pro Asn Ser Asp Gin Phe He Gly Leu Met 1 5 10 &lt; 210> 1209 &lt; 211 &gt; 120 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Winner: &lt; 400 &gt; 1209

Lys Lys Lys Asp Lys Val Lys Lys Gly Gly Pro Gly Ser Glu Cys Ala 15 10 15

Glu Trp Ala Trp Gly Pro Cys Thr Pro Ser Ser Lys Asp Cys Gly Val 20 25 30

Gly Phe Arg Glu Gly Thr Cys Gly Ala Gin Thr Gin Arg lie Arg Cys 35 40 45

Arg Val Pro Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys Lys Lys 50 55 60

Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr Gly Thr Lys Val Arg 65 70 75 80

Gin Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala Gin Cys Gin Glu Thr 85 90 95 lie Arg Val Thr Lys Pro Cys Thr Pro Lys Thr Lys Ala Lys Ala Lys 100 105 110

Ala Lys Lys Gly Lys Gly Lys Asp 115 120 &lt; 210〉 1210 &lt; 211 &gt; 61 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> 635 200524957 &lt; 223 &gt; Explanation of Artificial Sequence M &lt; 400> 1210

Ala Asp Cys Lys Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr 15 10 15

Gly Thr Lys Val Arg Gin Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala 20 25 30

Gin Cys Gin Glu Thr lie Arg Val Thr Lys Pro Cys Thr Pro Lys Thr 35 40 45

Lys Ala Lys Ala Lys Ala Lys Lys Gly Lys Gly Lys Asp

&lt; 210 &gt; 1211 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400> 1211

Cys His Ser Gly Tyr Val Gly Val Arg Cys 1 5 10 &lt; 210〉 1212 φ &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence 1 &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory 0 too- &400; 1212

Ala Asn Phe Leu Val Trp Glu lie Val Arg Lys Lys Pro 1 5 10

&lt; 210 &gt; 1213 &lt; 211〉 50 &lt; 212〉 PRT 636 200524957 &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Shaotai &lt; 40〇 &gt; 1213

Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gin Phe Cys 15 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gin Glu Asp Lys Pro Ala Cys 20 25 30

Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu 35 40 45

Leu Ala &lt; 210〉 1214 &lt; 211〉 50 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400〉 1214

Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gin Tyr Cys 15 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gin Glu Glu Lys Pro Ala Cys 20 25 30

Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu 35 40 45

Leu Ala 50 &lt; 210〉 1215 &lt; 211 &gt; 10 &lt; 212〉 PRT &lt; 213〉 Artificial sequence 637 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuki Taito &lt; 400 &gt; 1215

Cys His Ser Gly Tyr Val Gly Val Arg Cys 1 5 10 &lt; 210 &gt; 1216 &lt; 211〉 10 • &lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory Moon &lt; 400〉 1216 • Cys His Ser Gly Tyr Val Gly Val Arg Cys 1 5 10 &lt; 210 &gt; 1217 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400> 1217

Pro Pro Gly His Phe Lys 1 5

φ &lt; 210 &gt; 1218 &lt; 211〉 6 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220〉 • &lt; 223〉 Explanation of Artificial Sequence: Katsuyuki Katsuta &lt; 400 &gt; 1218

Arg Thr Gly Gin Tyr Lys 1 5 &lt; 210〉 1219 &lt; 211〉 11 638 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory fl too &lt; 400 &gt; 1219

Phe Asn Leu Pro Leu Gly Asn Tyr Lys Lys Pro v 1 5 10 &lt; 210 &gt; 1220 &lt; 211〉 24 &lt; 212> PRT &lt; 213 &gt; artificial sequence φ &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic Victory &lt; 400> 1220

Pro Ala Leu Pro Glu Asp Gly Gly Ser Gly Ala Phe Pro Pro Gly His 15 10 15

Phe Lys Asp Pro Lys Arg Leu Tyr 20 &lt; 210 &gt; 1221 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence® &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt;; 400〉 1221 • His Ala Glu Lys His Trp Phe Val Gly Leu 1 5 10 &lt; 210 &gt; 1222 &lt; 211 &gt; 12 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation: Synthetic Victory 呔 639 200524957 &lt; 400 &gt; 1222

Cys Met His He Glu Ser Leu Asp Ser Tyr Thr Cys 1 5 10 &lt; 210 &gt; 1223 &lt; 211〉 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory over B &lt; 400> 1223

Asp Val Val Asp Ala Asp Glu Tyr Leu lie Pro Gin 1 5 10

&lt; 210 &gt; 1224 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1224

Cys Tyr Ala Ala Pro Leu Lys Pro Ala Lys Ser Cys 1 5 10

&lt; 210 &gt; 1225 &lt; 211〉 18 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 1225

Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro 15 10 15

Gin Thr &lt; 210 &gt; 1226 640 200524957 &lt; 211〉 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223> Artificial sequence explanation: Synthetic tsukitsuki &lt; 400 &gt; 1226

Ala Leu Leu Glu Thr Tyr Cys Ala Thr Pro Ala Lys Ser Glu 1 5 10 &lt; 210 &gt; 1227 &lt; 211〉 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence • &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 1227

Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gin Thr 1 5 10 &lt; 210 &gt; 1228 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis Katsuyuki

&lt; 400 &gt; 1228

Ser Arg Val Ser Arg Arg Ser Arg &lt; 210〉 1229 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 〉 1229

Tyr Ser Arg Val Ser Arg Arg Ser Arg 1 5 64] 200524957 &lt; 210> 1230 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1230 Gly His Lys 1

&lt; 210 &gt; 1231 &lt; 211〉 22 W &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 1231

Ser Val Arg Val Glu Gin Val Val Lys Pro Pro Gin Asp Lys Thr Glu 15 10 15

Ser Glu Asn Thr Ser Asp 20

&lt; 210 &gt; 1232 &lt; 211 &gt; 24 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400〉 1232

Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly 15 10 15

Glu Trp Gin Trp Ser Val Cys Val 20 &lt; 21〇 &gt; 1233 642 200524957 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Yuetai &lt; 400 &gt; 1233

Ser Phe Leu Pro Ser Ser 1 5 &lt; 210〉 1234 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence φ &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuyuki Katsuta &lt; 400 &gt; 1234

Ser Ala Gin Thr Asn Arg His lie Leu Arg Phe Asn Arg Pro Phe 15 10 15 &lt; 210 &gt; 1235 &lt; 211〉 18 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory over moon too

&lt; 400〉 1235 lie Pro Val Lys Gin Ala Val His Gly Gin Phe Leu Leu Pro Lys Gin 15 10

Glu Lys &lt; 210 &gt; 1236 &lt; 211〉 18 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 3 643 200524957 &lt; 400 &gt; 1236

Leu Ala Gly Glu Thr Gly Gin Glu Ala Ala Pro Leu Asp Gly Val Leu 15 10 15

Ala Asn &lt; 210〉 1237 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too φ &lt; 400 &gt; 1237

Ala Leu Lys Arg Gin Gly Arg Thr Leu Tyr Gly Phe Gly Gly 1 5 10 &lt; 210 &gt; 1238 &lt; 211〉 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 1238

Gly Met Asp Val Leu Gly Arg Pro Lys lie Pro Leu Glu Thr Pro Ala 15 10 15

Tyr Thr Gly Gin Pro Trp His Cys Gin His Cys Phe Leu Leu 20 25 30 &lt; 210 &gt; 1239 &lt; 211〉 43 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400 &gt; 1239

Met Asn Thr lie Thr lie Cys Lys Phe Asp Val Leu Asp Ala Glu Leu 644 200524957 15 10 15

Leu Ser Thr Val Glu Gly Gly Tyr Ser Gly Lys Asp Cys Leu Lys Asp 20 25 30

Met Gly Gly Tyr Ala Leu Ala Gly Ala Gly Ser 35 40 &lt; 210〉 1240 &lt; 211 &gt; 38 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 ® &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner &lt; 400 &gt; 1240

Gly Ala Asp Lys Thr Val Lys Gly Pro Asp Gly Leu Thr Ala Leu Glu 1 5 10 15

Ala Thr Asp Asn Gin Ala lie Asp Tyr Gly Gly Phe Met Glu Val Val 20 25 30

Tyr Val Asp Ala Thr Lys 35

&lt; 210> 1241 &lt; 211 &gt; 16 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1241

Cys Lys Gin Leu Gin Arg Asp Arg Gin Val Tyr Arg Ala Thr His Arg 15 10 15 &lt; 210 &gt; 1242 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; 645 200524957 &lt; 223 &gt; Explanation of the artificial sequence: Satsuki Katsuta synthesis <400> 1242

Cys Glu Gly Asn Val Arg Val Ser Arg Glu Leu Ala Gly His Thr Gly 15 10 15

Tyr &lt; 210〉 1243 &lt; 211 &gt; 16 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory • &lt; 400〉 1243

Cys Gly Ala Gly Glu Ser Gly Lys Ser Thr lie Val Lys Gin Met Lys 15 10 15 &lt; 210〉 1244 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Artificial Sequence Description: Synthetic Tsukiyoshi &lt; 4〇〇 &gt; 1244

Cys Asn Leu Lys Glu Asp Gly He Ser Ala Ala Lys Asp Val Lys 15 10 15

&lt; 210 &gt; 1245 &lt; 211〉 16 • &lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1245

Cys Lys Gin Leu Gin Lys Asp Lys Gin Val Tyr Arg Ala Thr His Arg 15 10 15 &lt; 210 &gt; 1246 646 200524957 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: Satsuki Katsuta &lt; 400 &gt; 1246

Glu Glu Gin Gly Met Leu Pro Glu Asp Leu Ser 1 5 10 &lt; 210 &gt; 1247 &lt; 211 &gt; 15 &lt; 212〉 PRT &lt; 213〉 Artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory fl too &lt; 400 &gt; 1247

Pro Gly Thr Cys Glu lie Cys Ala Tyr Ala Ala Cys Thr Gly Cys 15 10 15 &lt; 210〉 1248 &lt; 211 &gt; 15 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory over moon too

&lt; 400 &gt; 1248

Pro Asn Thr Cys Glu lie Cys Ala Tyr Ala Ala Cys Thr Gly Cys 15 10 15 &lt; 210 &gt; 1249 &lt; 211〉 16 &lt; 212〉 PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 1249

Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu 1 5 10 15 647 200524957 &lt; 210 &gt; 1250 &lt; 211 &gt; 32 &lt; 212> PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 & gt Explanation of artificial sequence: synthetic peptide &lt; 400 &gt; 1250

Ser Thr Pro Leu Met Ser Trp Pro Trp Ser Pro Ser Ala Leu Arg Leu 15 10 15

Leu Gin Arg Pro Pro Glu Glu Pro Ala Ala His Ala Asn Cys His Arg 20 25 30 &lt; 210 &gt; 1251 &lt; 211> 33 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; artificial sequence Explanation: Synthetic Victory &lt; 400〉 1251

Tyr Ser Thr Pro Leu Met Ser Trp Pro Trp Ser Pro Ser Ala Leu Arg 15 10 15

Leu Leu Gin Arg Pro Pro Glu Glu Pro Ala Ala His Ala Asn Cys His

Arg &lt; 210〉 1252 &lt; 211〉 31 鬌 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 1252

His Asn Lys Gin Glu Gly Arg Asp His Asp Lys Ser Lys Gly His Phe 15 10 15 648 200524957

His Arg Val Val He His His Lys Gly Gly Lys Ala His Arg Gly 20 25 30 &lt; 210 &gt; 1253 &lt; 211〉 32 &lt; 212〉 PRT &lt; 213〉 artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation: Synthetic Victory Moon too <400> 1253

Tyr His Asn Lys Gin Glu Gly Arg Asp His Asp Lys Ser Lys Gly His 15 10 15

Phe His Arg Val Val lie His His Lys Gly Gly Lys Ala His Arg Gly 20 25 30 &lt; 210〉 1254 &lt; 211 &gt; 32 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Artificial sequence Description: Synthetic Tsukiyuki &lt; 400 &gt; 1254

Ser Thr Ala Pro Leu Pro Trp Pro Trp Ser Pro Ala Ala Leu Arg Leu 15 10 15

Leu Gin Arg Pro Pro Glu Glu Pro Ala Val His Ala Asp Cys His Arg 20 25 30 &lt; 210 &gt; 1255 • &lt; 211 &gt; 33 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; artificial Explanation of sequence: Synthetic Tsukiyuki &lt; 400 &gt; 1255

Tyr Ser Thr Ala Pro Leu Pro Trp Pro Trp Ser Pro Ala Ala Leu Arg 649 200524957 15 10

Leu Leu Gin Arg Pro Pro Glu Glu Pro Ala Val His Ala Asp Cys His 20 25 30

Arg &lt; 210> 1256 &lt; 211 &gt; 17 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic Katsukitsu # &lt; 400 &gt; 1256

Val Gin Gly Glu Thr Ser Asn Asp Lys lie Pro Val Ala Leu Gly Leu 15 10 15

Lys &lt; 210> 1257 &lt; 211 &gt; 72 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta

&lt; 400 &gt; 1257

Ala Pro Val Ala Asn Glu Leu Arg Cys Gin Cys Leu Gin Thr Val Ala 15 10 15

Gly lie His Phe Lys Asn lie Gin Ser Leu Lys Val Met Pro Pro Gly 20 25 30

Pro His Cys Thr Gin Thr Glu Val He Ala Thr Leu Lys Asn Gly Arg 35 40 45

Glu Ala Cys Leu Asp Pro Glu Ala Pro Met Val Gin Lys lie Val Gin 50 55 60 650 200524957

Lys Met Leu Lys Gly Val Pro Lys 65 70 &lt; 210〉 1258 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon ... &lt; 400〉 1258

Val Gin Gly Glu Glu Ser Asn Asp Lys 1 5 &lt; 210〉 1259 • &lt; 211〉 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon Too <400> 1259 lie Leu Asn Gly He Asn Asn Tyr Lys Asn Pro Lys Leu 1 5 10 &lt; 210> 1260 &lt; 211 &gt; 22 &lt; 212> PRT &lt; 213 &gt; Artificial sequence φ &lt; 220 &gt; &lt; 223〉 Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 1260 • Phe Val Gin Gly Glu Ala lie Pro Met Ser lie Pro Pro Glu Asp Lys 15 10 15 lie Pro Val Ala Leu Gly 20

&lt; 210 &gt; 1261 &lt; 211〉 13 &lt; 212 &gt; PRT 651 200524957 &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1261

Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala 1 5 10 &lt; 210 &gt; 1262-&211; 21

&lt; 212〉 PRT • &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki • &lt; 400〉 1262

Met Val Lys Gin He Glu Ser Lys Thr Ala Phe Gin Glu Ala Leu Asp 15 10 15

Ala Ala Gly Asp Lys 20 &lt; 210 &gt; 1263 &lt; 211 &gt; 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory φ &lt; 400 &gt; 1263

Ala Tyr Val His Asp Ala Pro Val Arg Ser 1 5 10 Lu &lt; 210> 1264 • &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victorious Moon &lt; 400> 1264

Pro Arg Lys Leu Tyr Asp Lys 652 200524957 &lt; 210 &gt; 1265 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 〉 1265

Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Lys 1 5 10 &lt; 210> 1266 ® &lt; 211 &gt; 24 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Peptide &lt; 400 &gt; 1266

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn 15 10 15

Pro Arg Lys Leu Tyr Asp Tyr Lys 20

&lt; 210 &gt; 1267 &lt; 211 &gt; 12 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; w &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400〉 1267

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Lys 1 5 10

&lt; 210> 1268 &lt; 211 &gt; 8 &lt; 212> PRT 653 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1268

Pro Arg Lys Leu Tyr Asp Tyr Lys 1 5 &lt; 210> 1269 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: • &lt; 400〉 1269

Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Lys 1 5 10 &lt; 210 &gt; 1270 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory: &lt; 400 &gt; 1270

Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr 1 5 10 &lt; 210 &gt; 1271 &lt; 211 &gt; 24 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 1271

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn 15 10 15

Pro Arg Lys Leu Tyr Asp Tyr Lys 654 20 200524957 &lt; 210 &gt; 1272 &lt; 211 &gt; 23 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400〉 1272

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn 15 10 15

Pro Arg Lys Leu Tyr Asp Tyr

&lt; 210〉 1273 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 1273

Arg Lys Leu Tyr Asp Tyr Lys 1 5 &lt; 210〉 1274 φ &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence- &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta * &lt; 400〉 1274

Arg Lys Leu Tyr Asp Tyr 1 5

&lt; 210 &gt; 1275 &lt; 211 &gt; 7 &lt; 212 &gt; PRT 655 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1275

Pro Arg Lys Leu Tyr Asp Lys 1 5 &lt; 210〉 1276 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Description of Artificial Sequences: Synthetic Victory 0 too • &lt; 400〉 1276

Pro Arg Lys Leu Tyr Asp 1 5 &lt; 210 &gt; 1277 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 〉 1277

Pro Arg Lys Leu Tyr Asp Tyr Lys

&lt; 210 &gt; 1278

• &lt; 211〉 4 &lt; 212 &gt; PRT • &lt; 213〉 artificial sequence &lt; 220〉 &lt; 223〉 description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1278 Asp Gly Glu Ala 200524957 &lt; 210 &gt; 1279 &lt; 211 &gt; 6 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 1279

Leu Gly Thr lie Pro Gly 1 5

&lt; 210> 1280 &lt; 211 &gt; 23 &lt; 212 &gt; PRT call &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory too &lt; 400 &gt; 1280

Asn He Ser Ser Glu Glu Lys Ala Ser Trp Thr Arg Pro Glu Lys Gin 15 10 15

Glu Thr Leu Asp Gly His Met 20

&lt; 210> 1281 &lt; 211 &gt; 17 &lt; 212 &gt; PRT

&lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1281

Phe Asn Leu Asp Val Arg Phe Leu Val Val Lys Glu Ala Val Asn Pro 15 10 15

Gly &lt; 210> 1282 &lt; 211 &gt; 17 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 657 200524957 &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic Victory: &lt; 400 &gt; 1282

Ala Pro Arg Gin Arg Gin Thr Leu Val Leu Phe Pro Gly Asp Leu Arg 15 10 15

Thr ’&lt; 210〉 1283 &lt; 211〉 24 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 ® &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 1283

Cys Ser Cys Ser Pro Val His Pro Gin Gin Ala Phe Cys Asn Ala Asp 15 10 15

Val Val lie Arg Ala Lys Ala Val 20 &lt; 210 &gt; 1284 &lt; 211> 24 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400〉 1284

Cys Ser Cys Ser Pro Val His Pro Gin Gin Ala Phe Cys Asn Ala Asp 15 10 15

Val Val lie Arg Ala Lys Ala Val 20

&lt; 210 &gt; 1285 &lt; 211〉 13 &lt; 212 &gt; PRT 658 200524957 &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400〉 1285

Asn Val lie Gin lie Ser Asn Asp Leu Glu Asn Leu Arg 1 5 10 &lt; 210 &gt; 1286 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory • &lt; 400〉 1286

Val Pro lie Gin Lys Val Gin Asp Asp Thr Lys Thr Leu lie Lys Thr 15 10 15 lie Val Thr Arg lie Asn Asp He Ser His Thr Gin Ser Val Ser Ser 20 25 30

Lys Gin Lys 35

&lt; 210 &gt; 1287 &lt; 211> 15 &lt; 212 &gt; PRT

&lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1287

Tyr Lys Val Gin Asp Asp Thr Lys Thr Leu lie Lys Thr lie Val 15 10 15 &lt; 210〉 1288 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Artificial Sequences Explanation: Synthetic Victory Moon 659 200524957 &lt; 400 &gt; 1288

Ser Cys Ser Leu Pro Gin Thr Ser Gly Leu Gin Lys Pro Glu Ser 15 10 15 &lt; 210 &gt; 1289 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory fl too &lt; 400 &gt; 1289

Glu Asp Val Asp His Val Phe Leu Arg Phe 1 5 10

&lt; 210〉 1290 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsuta &lt; 400〉 1290

Thr Ser Phe Thr Pro Arg Leu 1 5

&lt; 210 &gt; 1291 &lt; 211 &gt; 8 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 1291

Asp Pro Ala Phe Asn Ser Trp Gly 1 5 &lt; 210 &gt; 1292 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 660 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Synthetic Victory: : &lt; 400 &gt; 1292

Asp Pro Gly Phe Ser Ser Trp Gly 1 5 &lt; 210 &gt; 1293 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl too &lt; 400> 1293 Lu Asp Gin Gly Phe Asn Ser Trp Gly 1 5 &lt; 210> 1294 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory: &lt; 400〉 1294

Asp Ala Ser Phe His Ser Trp Gly 1 5 ® &lt; 210〉 1295 &lt; 211 &gt; 8 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; '&lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 1295

Gly Ser Gly Phe Ser Ser Trp Gly 1 5 &lt; 210 &gt; 1296 &lt; 211 &gt; 8 200524957 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 1296

Asp Pro Ala Phe Ser Ser Trp Gly 1 5 &lt; 210 &gt; 1297 &lt; 211 &gt; 8 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; ® &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Peptide &lt; 400> 1297

Gly Ala Ser Phe Tyr Ser Trp Gly 1 5 &lt; 210〉 1298 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213> Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt;; 400 &gt; 1298

lie lie Gly Gly Arg Glu Ser Arg Pro His 1 5 10 &lt; 210 &gt; 1299 &lt; 211〉 38 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 1299

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 1 5 10 15 662 200524957

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 20 25 30

Gin Arg Val Lys Asn Lys 35 &lt; 210〉 1300 &lt; 211 &gt; 30 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki too &lt; 400 〉 1300

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Arg Gin 15 10 15

Leu Ala Val Arg Arg Tyr Leu Ala Ala Val Leu Gly Lys Arg 20 25 30 &lt; 210〉 1301 &lt; 211〉 21 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence ： Synthetic victory over moon too Φ &lt; 400〉 1301

Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Met Ala Val Lys Lys Tyr 15 10 15

Leu Ala Ala Val Leu ^ 20 &lt; 210> 1302 &lt; 211> 38 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; 663 200524957 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400 &gt; 1302

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 20 25 30

Gin Arg lie Lys Asn Lys 35 &lt; 210 &gt; 1303 &lt; 211〉 27 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400 〉 1303

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu 20 25 &lt; 210 &gt; 1304 &lt; 211〉 22 • &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉-&223; Explanation of Artificial Sequence: Synthesis Victorious limb: &lt; 400〉 1304 &quot; Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin Met Ala Val Lys Lys 15 10 15

Tyr Leu Ala Ala Val Leu 20 &lt; 210〉 1305 &lt; 211〉 38 664 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta &lt; 400〉 1305

His Ser Asp Gly lie Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin 15 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 20 25 30

Gin Arg Val Lys Asn Lys 35

&lt; 210 &gt; 1306 &lt; 211> 33 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1306

Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gin Met Ala Val Lys Lys 15 10 15

Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys Gin Arg Val Lys Asn 20 25 30

Lys &lt; 210> 1307 ‘&lt; 211> 23 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1307

Gin Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr 665 200524957 10 15

Lys Gin Arg Val Lys Asn Lys 20 &lt; 210 &gt; 1308 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1308

Gly Lys Arg Tyr Lys Gin Arg Val Lys Asn Lys 1 5 10 &lt; 210> 1309 &lt; 211> 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Wins: &lt; 400 &gt; 1309

Tyr Lys Gin Arg Val Lys Asn Lys 1 5 • &lt; 210〉 1310 &lt; 211〉 29 &lt; 212〉 PRT. &Lt; 213〉 Artificial sequence &lt; 220 &gt;. &Lt; 223〉 Explanation of artificial sequence: Synthetic victory Tsuki &lt; 400> 1310

Asp Val Ala His Gly lie Leu Asn Glu Ala Tyr Arg Lys Val Leu Asp 15 10 15

Gin Leu Ser Ala Gly Lys His Leu Gin Ser Leu Val Ala 20 25 666 200524957 &lt; 210 &gt; 1311 &lt; 211〉 29 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence ： Synthesis of Fukatsuta &lt; 400 &gt; 1311

Asp Val Ala His Glu He Leu Asn Glu Ala Tyr Arg Lys Val Leu Asp 15 10 15

Gin Leu Ser Ala Arg Lys Tyr Leu Gin Ser Met Val Ala 20 25

&lt; 210 &gt; 1312 &lt; 211 &gt; 20 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic Victory: &lt; 400 &gt; 1312

Ser Asp Glu Asp Ser Asp Gly Asp Arg Pro Gin Ala Ser Pro Gly Leu 15 10 15

Gly Pro Gly Pro 20 &lt; 210 &gt; 1313 &lt; 211 &gt; 52 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 1313

Gly Glu Ser Arg Ser Glu Ala Leu Ala Val Asp Gly Ala Gly Lys Pro 15 10 15

Gly Ala Glu Glu Ala Gin Asp Pro Glu Gly Lys Gly Glu Gin Glu His 667 200524957 20 25 30

Ser Gin Gin Lys Glu Glu Glu Glu Glu Met Ala Val Val Pro Gin Gly 35 40 45

Leu Phe Arg Gly 50 &lt; 210 &gt; 1314 &lt; 211〉 29 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 Spring &lt; 223〉 Rewards of Artificial Sequences ·· Synthesis 臓 &400; 1314

Pro Glu Gly Lys Gly Glu Gin Glu His Ser Gin Gin Lys Glu Glu Glu 15 10 15

Glu Glu Met Ala Val Val Pro Gin Gly Leu Phe Arg Gly 20 25 &lt; 210 &gt; 1315 &lt; 211 &gt; 16 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory flfl &lt; 400 &gt; 1315

Glu Glu Glu Glu Glu Met Ala Val Val Pro Gin Gly Leu Phe Arg Gly 15 10 15 &lt; 210〉 1316 &lt; 211〉 49 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; artificial sequence Description: Synthetic Tsukiyuki &lt; 400 &gt; 1316 668 200524957

Gly Trp Pro Gin Ala Pro Ala Met Asp Gly Ala Gly Lys Thr Gly Ala 15 10 15

Glu Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg 20 25 30

Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg 35 40 45

Gly

&lt; 210 &gt; 1317 &lt; 211〉 48 • &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400> 1317

Gly Trp Pro Gin Ala Pro Ala Asp Gly Ala Gly Lys Thr Gly Ala Glu 15 10 15

Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg Gin 20 25 30

Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg Gly 35 40 45

&lt; 210> 1318 &lt; 211 &gt; 49 • &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence * &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1318

Tyr Gly Trp Pro Gin Ala Pro Ala Asp Gly Ala Gly Lys Thr Gly Ala 15 10 15

Glu Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg 669 200524957 20 25 30

Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg 35 40 45

Gly &lt; 210〉 1319 &lt; 211〉 50 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; $ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 1319

Tyr Gly Trp Pro Gin Ala Pro Ala Met Asp Gly Ala Gly Lys Thr Gly 15 10 15

Ala Glu Glu Ala Gin Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser 20 25 30

Arg Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe 35 40 45

Arg Gly

&lt; 210〉 1320 &lt; 211〉 19 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400> 1320

Leu Ser Phe Arg Ala Pro Ala Tyr Gly Phe Arg Gly Pro Gly Leu Gin 15 10 15

Leu Arg Arg 670 200524957 &lt; 210 &gt; 1321 &lt; 211 &gt; 51 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 1321

Asp Asp Gly Gin Ser Glu Ser Gin Ala Val Asn Gly Lys Thr Gly Ala 15 10 15

Ser Glu Ala Val Pro Ser Glu Gly Lys Gly Glu Leu Glu His Ser Gin

Gin Glu Glu Asp Gly Glu Glu Ala Met Ala Gly Pro Pro Gin Gly Leu 35 40 45

Phe Pro Gly 50 &lt; 210 &gt; 1322 &lt; 211〉 52 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 Call &lt; 223〉 Explanation of artificial sequence · Synthetic peptide &lt; 400> 1322

Tyr Asp Asp Gly Gin Ser Glu Ser Gin Ala Val Asn Gly Lys Thr Gly-15 10 15 'Ala Ser Glu Ala Val Pro Ser Glu Gly Lys Gly Glu Leu Glu His Ser 20 25 30

Gin Gin Glu Glu Asp Gly Glu Glu Ala Met Ala Gly Pro Pro Gin Gly 35 40 45

Leu Phe Pro Gly 671 200524957 50 &lt; 210 &gt; 1323 &lt; 211〉 26 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: • &lt; 400 〉 1323

Gly Glu Leu Glu His Ser Gin Gin Glu Glu Asp Gly Glu Glu Ala Met • 15 10 15

Ala Gly Pro Pro Gin Gly Leu Phe Pro Gly

&lt; 210 &gt; 1324 &lt; 211> 17 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 1324

Gin Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gin Gly Leu Phe Arg 15 10 15

Gly

&lt; 210 &gt; 1325 &lt; 211〉 2 • &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400> 1325 Pro Gly 1 &lt; 210 &gt; 1326 672 200524957 &lt; 211 &gt; 1 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1326

Lys &lt; 210 &gt; 1327 &lt; 211> 4 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence # &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1327 Gly Phe Ala Asp &lt; 210> 1328 &lt; 211 &gt; 6 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory:

&lt; 400 &gt; 1328

Asp Tyr Val Pro Met Leu 5 &lt; 210 &gt; 1329 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1329

Asp Tyr Val Pro Met Leu 200524957 &lt; 210 &gt; 1330 &lt; 211〉 11 &lt; 212 &gt; PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 1330

Gin Lys Arg Pro Ser Gin Arg Ser Lys Tyr Leu 1 5 10

&lt; 210〉 1331 &lt; 211〉 12 • &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1331

Pro Leu Ser Arg Thr Leu Ser Val Ala Ala Lys Lys 1 5 10 &lt; 210 &gt; 1332 &lt; 211 &gt; 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 ® &lt; 223 &gt; Artificial sequence description: Synthetic Victory &lt; 400> 1332

Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gin Pro Gly Tyr • 1 5 10 Dance &lt; 210〉 1333 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Katsuta &lt; 400 &gt; 1333 674 200524957

Arg Gly Tyr Ser Leu Gly 1 5 &lt; 210 &gt; 1334 &lt; 211> 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Satsuki Katsuta &lt; 400 〉 1334

Lys Lys Ala Leu Arg Arg Gin Glu Ala Val Asp Ala Leu 1 5 10 # &lt; 210 &gt; 1335 &lt; 211〉 25 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence : Synthetic Victory Limb: &lt; 400〉 1335 lie Thr Ser Phe Glu Glu Ala Lys Gly Leu Asp Arg lie Asn Glu Arg 15 10 15

Met Pro Pro Arg Arg Asp Ala Met Pro 20 25

&lt; 210〉 1336

&lt; 211〉 20 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Explanation of artificial sequence: Synthetic victory fl too &lt; 400〉 1336

Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala lie Leu Thr 15 10 15

Thr Met Leu Ala 20 675 200524957 &lt; 210 &gt; 1337 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki too &lt; 400 &gt; 1337

Pro Leu Ser Arg Thr Leu Ser Val Ser Ser 1 5 10

&lt; 210 &gt; 1338 &lt; 211 &gt; 10 &lt; 212 &gt; PRT φ &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1338

Pro Leu Arg Arg Thr Leu Ser Val Ala Ala 1 5 10 &lt; 210〉 1339 &lt; 211 &gt; 17 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Status &lt; 400 &gt; 1339

Leu Gin Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Lys Glu Gly Gly 15 10 15

Leu Waki &lt; 210〉 1340 &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic peptide 676 200524957 &lt; 400 &gt; 1340

Cys Leu Arg Arg Ala Ser Leu Gly 1 5

&lt; 210〉 1341 &lt; 211〉 7 &lt; 212〉 PRT-&lt; 213 &gt; Artificial sequence &lt; 220〉 • &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1341

Phe Lys Lys Ser Phe Lys Leu

&lt; 210> 1342 &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 1342

Lys Lys Ala Leu His Arg Gin Glu Thr Val Asp Ala Leu 1 5 10 &lt; 210 &gt; 1343 φ &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220> &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Victory-&lt; 400 &gt; 1343

Lys Arg Thr Leu Arg Arg 1 5 &lt; 210〉 1344 &lt; 211〉 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 677 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 4〇〇 &gt; 1344

Arg Thr Lys Arg Ser Gly Ser Val Tyr Glu Pro Leu Lys lie 1 5 10 &lt; 210〉 1345 &lt; 211> 26 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence : Synthetic Victory 0 Too <400> 1345

Gly He Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 1 5 10 15 lie Ser Trp lie Lys Arg Lys Arg Gin Gin 20 25 &lt; 210 &gt; 1346 &lt; 211〉 9 &lt; 212〉 PRT &lt; 213 〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &400; 1346 • Arg Arg Lys Ala Ser Gly Pro Pro Val 1 5 • &lt; 210 &gt; 1347 &lt; 211〉 17 * &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 1347

Arg Phe Ala Arg Lys Gly Ala Leu Arg Gin Lys Asn Val His Glu Val 1 5 10 15 678 200524957

Lys &lt; 210 &gt; 1348 &lt; 211 &gt; 18 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; '&lt; 223 &gt; description of artificial sequence: synthetic peptide &lt; 400 &gt; 1348

Arg Phe Ala Arg Lys Gly Ala Leu Glu Gin Lys Asn Val His Glu Val 15 10 15 _ Lys Asn &lt; 210〉 1349 &lt; 211〉 14 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 & gt Explanation of artificial sequence: Synthetic victory too <400> 1349

Ser Phe Val Asn Ser Glu Phe Leu Lys Pro Glu Val Lys Ser 1 5 10 Φ &lt; 210〉 1350 &lt; 211〉 11 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220〉 ~ &lt; 223 &gt; Artificial Explanation of sequence: Synthetic Tsukiyuki &lt; 400> 1350

Ser Tyr Thr Asn Pro Glu Phe Val lie Asn Val 1 5 10 &lt; 210 &gt; 1351 &lt; 211〉 15 679 200524957 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223> Explanation of artificial sequence: Katsuyuki Kazuyuki <400> 1351

Ala Gly Asn Lys Val lie Ser Pro Ser Glu Asp Arg Arg Gin Cys 15 10 15 &lt; 210 &gt; 1352 &lt; 211 &gt; 18 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> φ &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Victory &lt; 400〉 1352

Gly Pro Lys Thr Pro Glu Glu Lys Thr Ala Asn Thr lie Ser Lys Phe 15 10 15

Asp Cys &lt; 210〉 1353 &lt; 211〉 29 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory W &lt; 400 &gt; 1353

Leu Leu Tyr Glu Met Leu Ala Gly Gin Ala Pro Phe Glu Gly Glu Asp 15 10 15 Potential

Glu Asp Glu Leu Phe Gin Ser lie Met Glu His Asn Val &quot; 20 25 &lt; 210〉 1354 &lt; 211 &gt; 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 680 200524957 &lt; 223 &gt; Artificial Sequence Explanation: Ichigetsu Ito &lt; 400 &gt; 1354

Asn Tyr Pro Leu Glu Leu Tyr Glu Arg Val Arg Thr Gly Cys 1 5 10 &lt; 210 &gt; 1355 &lt; 211 &gt; 9 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400〉 1355

Val Arg Lys Atr Thr Leu Arg Arg Leu &lt; 210 &gt; 1356 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400〉 1356

Cys Asp Asn Gin lie Lys Lys Met 1 5

&lt; 210〉 1357 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory too &lt; 400> 1357 lie Tyr Gly Glu Phe 1 5

&lt; 210 &gt; 1358 &lt; 211〉 5 &lt; 212 &gt; PRT 681 200524957 &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 1358 lie Tyr Gly Glu Phe 1 5 &lt; 210 &gt; 1359 &lt; 211 &gt; 17 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 Synthetic victory 8

&lt; 223〉 Explanation of artificial sequence &lt; 400〉 1359

Thr Tyr Ala Asp Phe lie Ala Ser Gly Arg Thr Gly Arg Arg Asn Ala 15 10 15 lie &lt; 210 &gt; 1360 &lt; 211 &gt; 11 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223〉 artificial Explanation of the sequence: Synthesis of Katsuki Tsukita φ &lt; 400 &gt; 1360

Gin Lys Arg Pro Ser Gin Arg Ser Lys Tyr Leu 1 5 10 &lt; 210 &gt; 1361 &lt; 211> 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki fl &lt; 400> 1361

Arg Arg Glu Glu Glu Thr Glu Glu Glu 1 5 682 200524957 &lt; 210 &gt; 1362 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Peptide &lt; 400 &gt; 1362

Arg Arg Lys Ala Ser Gly Pro 1 5

&lt; 210 &gt; 1363 &lt; 211> 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 1363

Arg Arg Leu lie Glu Asp Asn Glu Tyr Thr Ala Arg Gly 1 5 10 &lt; 210 &gt; 1364 &lt; 211〉 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; φ &lt; 223 &gt; Explanation of artificial sequence : Synthetic Victory &lt; 400 &gt; 1364

Pro Leu Ala Arg Thr Leu Ser Val Ala Gly Leu Pro Gly Lys Lys ^ 15 10 15 &lt; 210 &gt; 1365 &lt; 211〉 32 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; artificial sequence Explanation: Synthetic Victory &lt; 400 &gt; 1365 683 200524957

Lys Glu Ala Lys Glu Lys Arg Gin Glu Gin lie Ala Lys Arg Arg Arg 15 10 15

Leu Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Gly Gly Ser Gin Lys 20 25 30 &lt; 210〉 1366 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213〉 artificial sequence

&lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Synthesizer Tsukiyuki &lt; 400> 1366

Tyr Ser Phe Val His His Gly Phe Phe Asn Phe Arg Val Ser Trp Arg 15 10 15

Glu Met Leu Ala 20 &lt; 210> 1367 &lt; 211> 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence φ &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 1367 .Val Ala Pro Ser Asp Ser lie Gin Ala Glu Glu Trp Tyr Phe Gly Lys 15 10 15 lie Thr Arg Arg Glu 20 &lt; 210 &gt; 1368 &lt; 211> 6 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 684 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 眈 &lt; 400 &gt; 1368

His Arg His Phe Leu Arg 1 5 &lt; 210 &gt; 1369 &lt; 211 &gt; 25 &lt; 212> PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 〉 1369

Arg Cys Leu Gly Thr Val Gin Gly Gin Phe Pro Leu Cys Tyr His Phe # 1 5 10 15

Leu Ser Ala Pro Gly Arg Phe Gin Glu 20 25 &lt; 210〉 1370 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence &lt; 400〉 1370

Met Tyr Ser Asn Val lie Gly Thr Val Thr Ser Gly Lys Arg 1 5 10 &lt; 210 &gt; 1371 &lt; 211〉 25 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuyuki &lt; 400〉 1371

Phe Tyr Lys Ala Asp Gly Val Val Phe Ser He Tyr Asp Val Pro Gly 15 10 15 685 200524957

Arg Gin Val Pro Leu Ser Ala Arg Gly 20 25 &lt; 210〉 1372 &lt; 211〉 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1372

Trp Ser Pro Gin Glu Glu Asp Arg lie lie Glu Gly Gly lie Tyr Asp 15 10 15

Ala Asp Leu Asn

&lt; 210 &gt; 1373 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: synthetic peptide &lt; 400 &gt; 1373

Val Ser Ser Ala Glu Gly Trp His Gly Asn Val Thr Leu Asn lie Arg 15 10 15

Pro Ser Thr Gly 20 &lt; 210〉 1374 • &lt; 211 &gt; 11 &lt; 212〉 PRT — &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400> 1374

Cys Ser Pro Cys His Ala Met Lys Met Asn He 1 5 10 &lt; 210 &gt; 1375 686 200524957 &lt; 211 &gt; 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Victory of synthesis fl too &lt; 400 &gt; 1375

Glu Val Ser Phe Leu Asn Cys Ser Leu Asp Asn Gly Gly Cys Thr Pro 15 10 15

Leu Leu Pro Arg Gly Gly Gly Gly Leu Ala Ala Leu 20 25 &lt; 210〉 1376 ® &lt; 211 &gt; 33 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400> 1376

Met Ala Pro Glu Glu lie lie Met Asp Arg Pro Phe Leu Phe Val Val 15 10 15

Arg His Asn Pro Thr Gly Thr Val Leu Phe Met Gly Gin Val Met Glu 20 25 30

&lt; 210 &gt; 1377 &lt; 211 &gt; 36 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400> 1377

Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly 15 10 15

Thr Phe Glu Cys lie Cys Gly Pro Asp Ser Ala Leu Val Arg His lie 687 200524957 20 25 30

Gly Thr Asp Cys 35 &lt; 210 &gt; 1378 &lt; 211〉 24 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki Tai &lt; 400 &gt; 1378

His Pro Pro Cys Cys Leu Tyr Gly Lys Cys Arg Arg Tyr Pro Gly Cys φ 1 5 10 15

Ser Ser Ala Ser Cys Cys Gin Leu 20 &lt; 210 &gt; 1379 &lt; 211〉 48 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 1379

Glu Asp Asn Cys lie Ala Glu Asp Tyr Gly Lys Cys Thr Trp Gly Gly 15 10 15

Thr Lys Cys Cys Arg Gly Arg Pro Cys Arg Cys Ser Met lie Gly Thr 20 25 30

Asn Cys Glu Cys Thr Pro Arg Leu lie Met Glu Gly Leu Ser Phe Ala 35 40 45 &lt; 210 &gt; 1380 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence 688 200524957 &lt; 220〉 &lt; 223〉 Explanation of the artificial sequence: Satsuki Katsuta &lt; 400 &gt; 1380

Gly Gly Cys Leu Pro His Asn Arg Phe Cys Asn Ala Leu Ser Gly Pro 15 10 15

Arg Cys Cys Ser Gly Leu Lys Cys Lys Glu Leu Ser lie Trp Asp Ser 20 25 30

Arg Cys Leu 35 &lt; 210〉 1381 • &lt; 211 &gt; 18 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: synthetic tsukitsuta &lt; 400> 1381

Cys Asn Cys Lys Ala Pro Glu Thr Ala Leu Cys Ala Arg Arg Cys Gin 15 10 15

Gin His

&lt; 210 &gt; 1382 &lt; 211 &gt; 60 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 ^ &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1382 &quot; Trp Gin Pro Pro Trp Tyr Cys Lys Glu Pro Val Arg lie Gly Ser Cys 15 10 15

Lys Lys Gin Phe Ser Ser Phe Tyr Phe Lys Trp Thr Ala Lys Lys Cys 20 25 30

Leu Pro Phe Leu Phe Ser Gly Cys Gly Gly Asn Ala Asn Arg Phe Gin 689 200524957 35 40 45

Thr lie Gly Glu Cys Arg Lys Lys Cys Leu Gly Lys 50 55 60

&lt; 210 &gt; 1383 &lt; 211> 60 &lt; 212 &gt; PRT '&lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 1383

Arg lie Cys Tyr He His Lys Ala Ser Leu Pro Arg Ala Thr Lys Thr # 1 5 10 15

Cys Val Glu Asn Thr Cys Tyr Lys Met Phe lie Arg Thr Gin Arg Glu 20 25 30

Tyr lie Ser Glu Arg Gly Cys Gly Cys Pro Thr Ala Met Trp Pro Tyr 35 40 45

Gin Thr Glu Cys Cys Lys Gly Asp Arg Cys Asn Lys 50 55 60

&lt; 210 &gt; 1384 &lt; 211〉 36 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 1384

Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val Cys 15 10 15

Gin Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys Cys 20 25 30 690 200524957

Arg Cys Tyr Ser 35 &lt; 210 &gt; 1385 &lt; 211 &gt; 36 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400 &gt; 1385

Met Cys Met Pro Cys Phe Thr Thr Asp His Gin Met Ala Arg Lys Cys 15 10 15 Lu Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gin 20 25 30

Cys Leu Cys Arg 35 &lt; 210 &gt; 1386 &lt; 211 &gt; 13 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 1386 ^ Glu Cys Cys Asn Pro Ala Cys Gly Arg His Tyr Ser Cys 1 5 10 • &lt; 210 &gt; 1387 &lt; 211 &gt; 31 • &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; of artificial sequence Explanation: Satsuki Katsuyuki &lt; 400 &gt; 1387

Ala Cys Ser Gly Arg Gly Ser Arg Cys Gin Cys Cys Met Gly Leu Arg 15 10 15 691 200524957

Cys Gly Arg Gly Asn Pro Gin Lys Cys He Gly Ala His Asp Val 20 25 30 &lt; 210 &gt; 1388 &lt; 211 &gt; 14 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; of artificial sequence Explanation: Synthetic Victory B too &lt; 400 &gt; 1388

Gly Arg Cys Cys His Pro Ala Cys Gly Lys Asn Tyr Ser Cys

&lt; 210 &gt; 1389 &lt; 211> 17 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 1389

Arg Asp Cys Cys Tyr His Pro Thr Cys Asn Met Ser Asn Pro Gin lie 15 10 15

Cys

&lt; 210 &gt; 1390 &lt; 211 &gt; 13. &lt; 212〉 PRT &lt; 213 &gt; artificial sequence. &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1390

Tyr Cys Cys His Pro Ala Cys Gly Lys Asn Phe Asp Cys 1 5 10 &lt; 210 &gt; 1391 &lt; 211 &gt; 12 692 200524957 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Artificial sequence Explanation: Synthetic Victory Limb: &lt; 400〉 1391

Gly Cys Cys Ser Asp Pro Arg Cys Ala Trp Arg Cys 1 5 10 &lt; 210 &gt; 1392 &lt; 211 &gt; 13 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; φ &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory &lt; 400〉 1392 lie Cys Cys Asn Pro Ala Cys Gly Pro Lys Tyr Ser Cys 1 5 10

&lt; 210 &gt; 1393 &lt; 211 &gt; 19 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory:

&lt; 400〉 1393

Arg Asp Cys Cys Thr Arg Lys Cys Lys Asp Arg Arg Cys Lys Met Lys 15 10 15-Cys Cys Ala * &lt; 210 &gt; 1394 &lt; 211〉 24 &lt; 212 &gt; PRT &lt; 213〉 artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory: &lt; 400〉 1394 693 200524957

Cys Lys Ser Gly Ser Ser Cys Ser Thr Ser Tyr Asn Cys Cys Arg Ser 15 10 15

Cys Asn Tyr Thr Lys Arg Cys Tyr 20 &lt; 210〉 1395 &lt; 211〉 25 • &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 1395 ^ Cys Lys Gly Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys 15 10 15

Thr Gly Ser Cys Arg Ser Gly Lys Cys 20 25 &lt; 210〉 1396 &lt; 211 &gt; 26 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence &lt; 400〉 1396 ^ Cys Lys Gly Lys Gly Ala Pro Cys Arg Lys Thr Met Tyr Asp Cys Cys 15 10 15-Ser Gly Ser Cys Gly Arg Arg Gly Lys Cys 20 25 &lt; 210 &gt; 1397 &lt; 211〉 26 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon 694 200524957 &lt; 400 &gt; 1397

Cys Lys Leu Lys Gly Gin Ser Cys Arg Lys Thr Ser Tyr Asp Cys Cys 15 10 15

Ser Gly Ser Cys Gly Arg Ser Gly Lys Cys 20 25 &lt; 210 &gt; 1398 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory fl Too φ &lt; 400 &gt; 1398

Lys Thr Lys Cys Lys Phe Leu Lys Lys Cys 1 5 10 &lt; 210 &gt; 1399 &lt; 211〉 19 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223> Explanation of Artificial Sequence: Synthetic Victory Yuetai &lt; 400 &gt; 1399

Arg Asp Cys Cys Thr Lys Lys Cys Lys Asp Arg Gin Cys Lys Gin Arg 15 10 15

Cys Cys Ala • &lt; 210 &gt; 1400 &lt; 211 &gt; 37 * &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: synthetic victory: &lt; 400> 1400

Glu Phe Thr Asp Val Asp Cys Ser Val Ser Lys Glu Cys Trp Ser Val 15 10 15 695 200524957

Cys Lys Asp Leu Phe Gly Val Asp Arg Gly Lys Cys Met Gly Lys Lys 20 25 30

Cys Arg Cys Tyr Gin 35 &lt; 210 &gt; 1401 &lt; 211〉 37 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: • &lt; 400〉 1401

Gly Val Glu lie Asn Val Lys Cys Ser Gly Ser Pro Gin Cys Leu Lys 15 10 15

Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys 20 25 30

Cys His Cys Thr Pro 35

&lt; 210 &gt; 1402 &lt; 211〉 37 &lt; 212〉 PRT • &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki • &lt; 400 &gt; 1402

Gly Val Glu lie Asn Val Lys Cys Ser Gly Ser Pro Gin Cys Leu Lys • 15 10 15

Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys 20 25 30

Cys His Cys Thr Pro 35 696 200524957 &lt; 210〉 1403 &lt; 211〉 22 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1403

He Lys Cys Asn Cys Lys Arg His Val lie Lys Pro His lie Cys Arg 15 10 15

Lys lie Cys Gly Lys Asn 20

&lt; 210 &gt; 1404 &lt; 211 &gt; 39 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory I too &lt; 4〇〇 &gt; 1404

Thr He lie Asn Val Lys Cys Thr Ser Pro Lys Gin Cys Leu Pro Pro 15 10 15

Cys Lys Ala Gin Phe Gly Gin Ser Ala Gly Ala Lys Cys Met Asn Gly 20 25 30

Lys Cys Lys Cys Tyr Pro His 35 &lt; 210〉 1405 &lt; 211〉 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 1405

Phe Asp Arg Ala 697 200524957 1 &lt; 210 &gt; 1406 &lt; 211 &gt; 44 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsukita &lt; 400 &gt; 1406

Ala Asp Cys Ser Ala Thr Gly Asp Thr Cys Asp His Thr Lys Lys Cys 1 5 10 15

Cys Asp Asp Cys Tyr Thr Cys Arg Cys Gly Thr Pro Trp Gly Ala Asn 20 25 30

Cys Arg Cys Asp Tyr Tyr Lys Ala Arg Cys Asp Thr 35 40 &lt; 210〉 1407 &lt; 211 &gt; 31 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Description of Artificial Sequence: Synthetic Win 0 too &lt; 400 &gt; 1407

Ala Phe Cys Asn Leu Arg Met Cys Gin Leu Ser Cys Arg Ser Leu Gly

Leu Leu Gly Lys Cys lie Gly Asp Lys Cys Glu Cys Val Lys His 20 25 30 &lt; 210 &gt; 1408 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 1408

Arg Ser Cys lie Asp Thr lie Pro Lys Ser Arg Cys Thr Ala Phe Gin 698 200524957 15 10 15

Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys 20 25 30

Gly Thr Cys 35 &lt; 210〉 1409 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 φ &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Victory &lt; 400〉 1409

Phe Leu Pro Leu lie Leu Gly Lys Leu Val Lys Gly Leu Leu 1 5 10 &lt; 210 &gt; 1410 &lt; 211〉 14 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence : Satsuki Katsuta &lt; 400〉 1410 lie Asn Leu Lys Ala lie Ala Ala Leu Val Lys Lys Val Leu # 1 5 10 &lt; 210 &gt; 1411-&lt; 211〉 14 &lt; 212〉 PRT • &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 1411 lie Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys lie Leu 1 5 10 699 200524957 &lt; 210> 1412 &lt; 211> 14 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic peptide &lt; 400> 1412

He Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Ala Leu Leu 1 5 10

&lt; 210〉 1413 &lt; 211〉 14 &lt; 212 &gt; PRT # &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb: &lt; 400 &gt; 1413 lie Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Arg Leu Leu 1 5 10 &lt; 210 &gt; 1414 &lt; 211 &gt; 14 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthetic Victory B &lt; 4〇〇 &gt; 1414 lie Asn Leu Lys Ala Lys Ala Ala Leu Ala Lys Lys Leu Leu 5 10 &lt; 210〉 1415 &lt; 211 &gt; 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223〉 Description of artificial sequence: Synthetic Victory Moon &lt; 400 &gt; 1415 lie Asn Trp Lys Gly lie Ala Ala Met Ala Lys Lys Leu Leu 700 200524957 1 5 10 &lt; 210> 1416 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 Too &400; 1416

Phe Met Ser Ser His Gin Ser Gin Ala Ser Leu Glu Leu Ala lie Lys 15 10 15

Gin Trp Gly Ser Gin

&lt; 210 &gt; 1417 &lt; 211> 20 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki too &lt; 400 &gt; 1417

Phe Asn Lys He Thr Pro Asn Leu Ala Glu Phe Ala Phe Ser Leu Tyr 15 10 15

Arg Gin Leu Ala

&lt; 210 &gt; 1418 &lt; 211〉 34 Such as &lt; 212〉 PRT &lt; 213 &gt; artificial sequence • &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400 &gt; 1418

Trp Ser Pro Lys Glu Glu Asp Arg lie lie Pro Gly Gly lie Tyr Asn 15 10 15

Ala Asp Leu Asn Asp Glu Trp Val Gin Arg Ala Leu His Phe Ala lie 701 200524957 20 25 30

Ser Glu &lt; 210 &gt; 1419 &lt; 211〉 36 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400〉 1419

Tyr Thr Ser Leu lie His Ser Leu lie Glu Glu Ser Gin Asn Gin Gin φ 1 5 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30

Trp Asn Trp Phe 35 &lt; 210> 1420 &lt; 211 &gt; 38 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; • &lt; 223> Explanation of Artificial Sequences · Synthetic Victory &lt; 400 &gt; 1420

Asn Asn Leu Leu Arg Ala lie Glu Ala Gin Gin His Leu Leu Gin Leu • 15 10 15 ^ Thr Val Trp Gin He Lys Gin Leu Gin Ala Arg He Leu Ala Val Glu 20 25 30

Arg Tyr Leu Lys Asp Gin 35 &lt; 210 &gt; 1421 702 200524957 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400〉 1421

Tyr Thr Asn Thr He Tyr Thr Leu Leu Glu Glu Ser Gin Asn Gin Gin 15 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30

Trp Asn Trp Phe

&lt; 210 &gt; 1422 &lt; 211> 36 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400> 1422

Tyr Thr Gly lie lie Tyr Asn Leu Leu Glu Glu Ser Gin Asn Gin Gin 15 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Asn Leu

Trp Asn Trp Phe • 35 • &lt; 210 &gt; 1423 &lt; 211〉 36 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223〉 artificial sequence description: Katsuta Katsuta synthesis &lt; 4〇 〇 &gt; 1423 703 200524957

Tyr Thr Ser Leu lie Tyr Ser Leu Leu Glu Lys Ser Gin Thr Gin Gin 15 10 15

Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30

Trp Asn Trp Phe 35 &lt; 210 &gt; 1424 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: synthetic peptide &lt; 400> 1424

Leu Glu Ala Asn lie Ser Lys Ser Leu Glu Gin Ala Gin lie Gin Gin 15 10 15

Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp lie Phe 20 25 30

Gly Asn Trp Phe 35

&lt; 210 &gt; 1425 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> ‘&lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400〉 1425

Leu Glu Ala Asn lie Ser Gin Ser Leu Glu Gin Ala Gin lie Gin Gin 15 10 15

Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp Val Phe 20 25 30

Thr Asn Trp Leu 704 200524957 35 &lt; 210〉 1426 &lt; 211〉 41 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223〉 artificial sequence description: synthetic peptide &lt; 400〉 1426

Cys Gly Gly Asn Asn Leu Leu Arg Ala He Glu Ala Gin Gin His Leu 15 10 15

Leu Gin Leu Thr Val Trp Gly lie Lys Gin Leu Gin Ala Arg He Leu

Ala Val Glu Arg Tyr Leu Lys Asp Gin 35 40 &lt; 210 &gt; 1427 &lt; 211〉 38 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400〉 1427

Gin Gin Leu Leu Asp Val Val Lys Arg Gin Gin Glu Met Leu Arg Leu φ 1 5 10 15

Thr Val Trp Gly Thr Lys Asn Leu Gin Ala Arg Val Thr Ala He Glu • 20 25 30 • Lys Tyr Leu Lys Asp Gin 35 &lt; 210> 1428 &lt; 211> 46 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence 705 200524957 &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1428

Tyr Thr Ser Val lie Thr He Glu Leu Ser Asn He Lys Glu Asn Lys 15 10 15

Cys Asn Gly Ala Lys Val Lys Leu lie Lys Gin Glu Leu Asp Lys Tyr 20 25 30

Lys Asn Ala Val Thr Glu Leu Gin Leu Leu Met Gin Ser Thr 35 40 45 &lt; 210 &gt; 1429 Φ &lt; 211 &gt; 54 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223〉 Artificial sequence Explanation: Synthetic Tsukiyuki &lt; 400 &gt; 1429

Ala Ser Gly Val Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val 15 10 15

Asn Lys He Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser 20 25 30

Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr 35 40 45 lie Asp Lys Gin Leu Leu 50 &lt; 210 &gt; 1430 &lt; 211 &gt; 53 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400 &gt; 1430 706 200524957

Gly Glu Pro lie lie Asn Phe Tyr Asp Pro Leu Val Phe Pro Ser Asp 15 10 15

Glu Phe Asp Ala Ser lie Ser Gin Val Asn Glu Lys lie Asn Gin Ser 20 25 30

Leu Ala Phe He Arg Lys Ser Asp Glu Leu Leu His Asn Val Asn Ala 35 40 45

Gly Lys Ser Thr Thr 50 &lt; 210 &gt; 1431 φ &lt; 211〉 48 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequences: Katsuyuki Katsuta &lt; 400〉 1431

Tyr Thr Ser Val lie Thr lie Glu Leu Ser Asn lie Lys Glu Asn Lys 15 10 15

Cys Asn Gly Thr Asp Ala Lys Val Lys Leu lie Lys Gin Glu Leu Asp 20 25 30

Lys Tyr Lys Asn Ala Val Thr Glu Leu Gin Leu Leu Met Gin Ser Thr 35 40 45 &lt; 210〉 1432 &lt; 211〉 34 &lt; 212 &gt; PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Victory Moon <400> 1432

Tyr Thr Ser Val lie Thr lie Glu Leu Ser Asn He Lys Glu Asn Lys 15 10 15 707 200524957

Cys Asn Gly Asp Ala Lys Val Lys Leu He Lys Gin Glu Leu Asp Lys 20 25 30

Tyr Lys &lt; 210〉 1433 &lt; 211〉 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223〉 Description of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1433 • Thr Ser Val lie Thr lie Glu Leu Ser Asn lie Lys Glu Asn Lys Cys 15 10 15

Asn Gly Asp Ala Lys Val Lys Leu lie Lys Gin Glu Leu Asp Lys Tyr 20 25 30

Lys Asn &lt; 210> 1434 &lt; 211 &gt; 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 Lu &223; Artificial Sequence Recitation: Synthetic Dirty &lt; 400〉 1434

Val He Thr lie Glu Leu Ser Asn lie Lys Glu Asn Lys Cys Asn Gly • 15 10 15 'Asp Ala Lys Val Lys Leu He Lys Gin Glu Leu Asp Lys Tyr Lys Asn 20 25 30

Ala Val &lt; 210 &gt; 1435 &lt; 211〉 34 708 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400〉 1435

Val lie Thr lie Glu Leu Ser Asn lie Lys Glu Asn Lys Met Asn Gly 15 10 15

Asp Ala Lys Val Lys Leu lie Lys Gin Glu Leu Asp Lys Tyr Lys Asn 20 25 30

Ala Val • &lt; 210〉 1436 &lt; 211 &gt; 33 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuyuki &lt; 400〉 1436

Val Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys lie 15 10 15

Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val 20 25 30 Lu Ser &lt; 210〉 1437

* &lt; 211〉 33 &lt; 212〉 PRT * &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory: &lt; 400〉 1437

Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys lie Ala 15 10 15 709 200524957

Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser 20 25 30

Val

&lt; 210> 1438 &lt; 211 &gt; 33 &lt; 212 &gt; PRT '&lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1438

Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys lie Ala Leu φ 1 5 10 15

Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val 20 25 30

Leu &lt; 210 &gt; 1439 &lt; 211> 33 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic victory W &lt; 400 &gt; 1439

Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys He Ala Leu Leu 15 10 15 *

Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu ^ 20 25 30

Thr

&lt; 210 &gt; 1440 &lt; 211〉 33 &lt; 212> PRT 710 200524957 &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 4〇〇〉 1440

Lys Val Leu His Leu Glu Gly Glu Val Asn Lys He Ala Leu Leu Ser 15 10 15

Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr 20 25 30

Ser &lt; 210 &gt; 1441 ♦ &lt; 211 &gt; 33 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: synthetic victory &lt; 4〇〇 &gt; 1441

Leu Glu Gly Glu Val Asn Lys lie Ala Leu Leu Ser Thr Asn Lys Ala 15 10 15

Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu 20 25 30

&lt; 210> 1442 &lt; 211> 33 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400 &gt; 1442

Gly Glu Val Asn Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val 15 10 15 711 200524957

Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu 20 25 30

Lys &lt; 210> 1443 &lt; 211> 33 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 4〇〇> 1443

Glu Val Asn Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser 15 10 15

Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys 20 25 30

Asn &lt; 210 &gt; 1444 &lt; 211> 33 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; φ &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 4〇〇 &gt; 1444

Val Asn Lys He Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu ^ 15 10 15 • Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn 20 25 30

Tyr

&lt; 210〉 1445 &lt; 211〉 33 &lt; 212〉 PRT 712 200524957 &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 4〇〇 &gt; 1445

Asn Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser 15 10 15

Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr 20 25 30 lie &lt; 210〉 1446 ® &lt; 211 &gt; 33 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of the artificial sequence: The synthesis of Katsuyuki &lt; 400> 1446

Lys lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn 15 10 15

Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr lie 20 25 30

&lt; 210 &gt; 1447 • &lt; 211 &gt; 33 &lt; 212 &gt; PRT. &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 4〇〇 &gt; 1447 lie Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly 15 10 15

Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr lie Asp 713 200524957 20 25 30

Lys &lt; 210 &gt; 1448 &lt; 211 &gt; 33 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: synthetic peptide &lt; 4〇〇 &gt; 1448

Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val 15 10 15

Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr lie Asp Lys 20 25 30

Gin &lt; 210 &gt; 1449 &lt; 211〉 70 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 4〇〇〉 1449 • Gly Thr lie Ala Leu Gly Val Ala Thr Ser Ala Gin lie Thr Ala Ala 15 10 15-Val Ala Leu Val Glu Ala Lys Gin Ala Arg Ser Asp lie Glu Lys Leu 20 25 30 a

Lys Glu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser 35 40 45

Ser lie Gly Asn Leu lie Val Ala lie Lys Ser Val Gin Asp Tyr Val 50 55 60 714 200524957

Asn Lys Glu lie Val Pro 65 70 &lt; 210〉 1450 &lt; 211〉 56 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 1450

Tyr Thr Pro Asn Asp lie Thr Leu Asn Asn Ser Val Ala Leu Asp Pro 15 10 15 lie Asp He Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu 20 25 30

Ser Lys Glu Trp He Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly 35 40 45

Asn Trp His Gin Ser Ser Thr Thr 50 55

&lt; 210 &gt; 1451 &lt; 211 &gt; 35 &lt; 212> PRT &lt; 213 &gt; artificial sequence

&lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 1451

Thr Leu Asn Asn Ser Val Ala Leu Asp Pro lie Asp He Ser lie Glu 15 10 15

Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp lie Arg 20 25 30

Arg Ser Asn 35 &lt; 210 &gt; 1452 715 200524957 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400〉 1452

Leu Asn Asn Ser Val Ala Leu Asp Pro lie Asp lie Ser lie Glu Leu 15 10 15

Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp He Arg Arg 20 25 30

Ser Asn Gin

&lt; 210> 1453 &lt; 211> 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner: &lt; 400 &gt; 1453

Asn Asn Ser Val Ala Leu Asp Pro lie Asp lie Ser lie Glu Leu Asn 15 10 15

Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser

Asn Gin Lys • 35 • &lt; 210 &gt; 1454 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 4〇〇 &gt; 1454 716 200524957

Asn Ser Val Ala Leu Asp Pro lie Asp lie Ser lie Glu Leu Asn Lys 15 10 15

Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn 20 25 30

Gin Lys Leu 35

&lt; 210 &gt; 1455 &lt; 211〉 35 &lt; 212〉 PRT

&lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1455

Ser Val Ala Leu Asp Pro lie Asp lie Ser lie Glu Leu Asn Lys Ala 15 10 15

Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp He Arg Arg Ser Asn Gin 20 25 30

Lys Leu Asp 35 &lt; 210 &gt; 1456 &lt; 211 &gt; 35 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223〉 Artificial sequence description: Synthetic tsukitsutsuki &lt; 400 &gt; 1456

Val Ala Leu Asp Pro He Asp He Ser lie Glu Leu Asn Lys Ala Lys 15 10 15

Ser Asp Leu Glu Glu Ser Lys Glu Trp He Arg Arg Ser Asn Gin Lys 20 25 30 717 200524957

Leu Asp Ser 35 &lt; 210〉 1457 &lt; 211〉 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400> 1457

Ala Leu Asp Pro lie Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser 15 10 15 ^ Asp Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu ® 20 25 30

Asp Ser lie 35 &lt; 210〉 1458 &lt; 211〉 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu &lt; 400 &gt; 1458 • Leu Asp Pro lie Asp lie Ser He Glu Leu Asn Lys Ala Lys Ser Asp 15 10 15 _ Leu Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp 20 25 30

Ser lie Gly 35 &lt; 210 &gt; 1459 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence 718 200524957 &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic victory fl too &lt; 400> 1459

Asp Pro lie Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu 15 10 15

Glu Glu Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser 20 25 30 lie Gly Asn 35

&lt; 210> 1460 &lt; 211 &gt; 35 &lt; 212> PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400> 1460

Pro lie Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu 15 10 15

Glu Ser Lys Glu Trp He Arg Arg Ser Asn Gin Lys Leu Asp Ser lie 20 25 30 • Gly Asn Trp 35 ^ &lt; 210 &gt; 1461

&lt; 211 &gt; 35 • &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400 &gt; 1461 lie Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu 1 5 10 15 719 200524957

Ser Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly 20 25 30

Asn Trp His 35 &lt; 210〉 1462 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1462 ^ Asp lie Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser 15 10 15

Lys Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser He Gly Asn 20 25 30

Trp His Gin 35 &lt; 210 &gt; 1463 &lt; 211〉 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence_ &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taisei &lt; 400> 1463- He Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys 15 10 15

Glu Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly Asn Trp 20 25 30

His Gin Ser 35 720 200524957 &lt; 210 &gt; 1464 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 1464

Ser lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu 15 10 15

Trp lie Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly Asn Trp His 20 25 30

Gin Ser Ser 35 &lt; 210 &gt; 1465 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory &lt; 400> 1465 lie Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp 15 10 15

lie Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly Asn Trp His Gin 20 25 30

Ser Ser Thr 35 &lt; 210 &gt; 1466 &lt; 211 &gt; 35 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Artificial Sequence Explanation: Synthetic Katsukitsu 721 200524957 &lt; 400 &gt; 1466

Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp He 15 10 15

Arg Arg Ser Asn Gin Lys Leu Asp Ser lie Gly Asn Trp His Gin Ser 20 25 30

Ser Thr Thr 35

&lt; 210 &gt; 1467 &lt; 211> 35 &lt; 212 &gt; PRT # &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1467

Thr Ala Ala Val Ala Leu Val Glu Ala Lys Gin Ala Arg Ser Asp He 15 10 15

Glu Lys Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser 20 25 30

Val Gin Ser 35

&lt; 210 &gt; 1468 &lt; 211> 35 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223> Description of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 1468

Ala Val Ala Leu Val Glu Ala Lys Gin Ala Arg Ser Asp He Glu Lys 15 10 15

Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin 20 25 30 722 200524957

Ser Ser lie 35 &lt; 210〉 1469 &lt; 211〉 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1469

Leu Val Glu Ala Lys Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu 15 10 15 Lu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie 20 25 30

Gly Asn Leu 35 &lt; 210〉 1470 &lt; 211 &gt; 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuki Tsukita &lt; 400 &gt; 1470 ^ Val Glu Ala Lys Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala 15 10 15 • lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie Gly 20 25 30 Etiquette

Asn Leu lie 35

&lt; 210 &gt; 1471 &lt; 211> 35 &lt; 212 &gt; PRT 723 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1471

Glu Ala Lys Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala lie 15 10 15

Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Serlie Gly Asn 20 25 30

Leu lie Val 35 Φ &lt; 210 &gt; 1472 &lt; 211 &gt; 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory JJ too &lt; 400 &gt; 1472

Ala Lys Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala lie Arg 15 10 15

Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu 20 25 30

lie Val Ala 35 &lt; 210 &gt; 1473 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 1473

Lys Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala lie Arg Asp 15 10 15 724 200524957

Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu lie 20 25 30

Val Ala lie 35 &lt; 210 &gt; 1474 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory Moon • &lt; 400〉 1474

Gin Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala lie Arg Asp Thr 15 10 15

Asn Lys Ala Val Gin Ser Val Gin Ser Ser He Gly Asn Leu lie Val 20 25 30

Ala He Lys 35

&lt; 210 &gt; 1475 &lt; 211〉 35 &lt; 212 &gt; PRT _ &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta • &lt; 400 &gt; 1475

Ala Arg Ser Asp lie Glu Lys Leu Lys Glu Ala lie Arg Asp Thr Asn • 15 10 15

Lys Ala Val Gin Ser Val Gin Ser Ser He Gly Asn Leu lie Val Ala 20 25 30 lie Lys Ser 35 725 200524957 &lt; 210 &gt; 1476 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400> 1476

Arg Ser Asp lie Glu Lys Leu Lys Glu Ala He Arg Asp Thr Asn Lys 15 10 15

Ala Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu lie Val Ala lie 20 25 30

Lys Ser Val 35 &lt; 210〉 1477 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1477

Ser Asp lie Glu Lys Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala 15 10 15

Val Gin Ser Val Gin Ser Ser lie Gly Asn Leu lie Val Ala He Lys 20 25 30

Ser Val Gin 35 &lt; 210 &gt; 1478 &lt; 211> 35 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 726 200524957 &lt; 223 &gt; description of artificial sequence: Synthetic Katsukitsu &lt; 400 &gt; 1478

Lys Leu Lys Glu Ala He Arg Asp Thr Asn Lys Ala Val Gin Ser Val 15 10 15

Gin Ser Ser lie Gly Asn Leu lie Val Ala lie Lys Ser Val Gin Asp 20 25 30

Tyr Val Asn 35

&lt; 210 &gt; 1479 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: synthetic peptide &lt; 400> 1479

Leu Lys Glu Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin 15 10 15

Ser Ser lie Gly Asn Leu lie Val Ala lie Lys Ser Val Gin Asp Tyr 20 25 30

Val Asn Lys 35 &lt; 210> 1480 &lt; 211 &gt; 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic victory 0 too &lt; 400> 1480

Ala lie Arg Asp Thr Asn Lys Ala Val Gin Ser Val Gin Ser Ser lie 15 10 15

Gly Asn Leu He Val Ala lie Lys Ser Val Gin Asp Tyr Val Asn Lys 20 25 30 727 200524957

Glu lie Val 35 &lt; 210 &gt; 1481 &lt; 211 &gt; 47 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsu tsukitsu &lt; 400 &gt; 1481

Thr Trp Gin Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn He 15 10 15

Thr Ala Leu Leu Glu Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr 20 25 30

Glu Leu Gin Lys Leu Asn Ser Trp Asp Val Phe Gly Asn Trp Phe 35 40 45 &lt; 210 &gt; 1482 &lt; 211〉 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt;

&lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400> 1482

Trp Gin Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn He Thr 15 10 15

Ala Leu Leu Glu Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu 20 25 30

Leu Gin Lys 35 &lt; 210 &gt; 1483 &lt; 211〉 35 728 200524957 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1483

Gin Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn lie Thr Ala 15 10 15

Leu Leu Glu Glu Ala Gin He Gin Gin Glu Lys Asn Met Tyr Glu Leu 20 25 30

Gin Lys Leu 35

&lt; 210 &gt; 1484 &lt; 211> 35 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 4〇〇 &gt; 1484

Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn lie Thr Ala Leu 1 5 10 15

Leu Glu Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin

Lys Leu Asn 35 &lt; 210 &gt; 1485 &lt; 211 &gt; 35 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 1485

Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn lie Thr Ala Leu Leu 729 200524957 15 10 15

Glu Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys 20 25 30

Leu Asn Ser 35 &lt; 210 &gt; I486 &lt; 211〉 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> φ &lt; 223 &gt; Artificial sequence description: Synthetic victory &lt; 400 &gt; 1486

Glu Arg Lys Val Asp Phe Leu Glu Glu Asn He Thr Ala Leu Leu Glu 15 10 15

Glu Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu 20 25 30

Asn Ser Trp 35

&lt; 210 &gt; 1487 &lt; 211 &gt; 35 φ &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220〉-&223; 223 &gt; Explanation of artificial sequence: Synthetic Katsukitsu &lt; 400 &gt; 1487

Arg Lys Val Asp Phe Leu Glu Glu Asn lie Thr Ala Leu Leu Glu Glu 15 10 15

Ala Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn 20 25 30

Ser Trp Asp 730 200524957 35 &lt; 210 &gt; 1488 &lt; 211 &gt; 35 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 1488

Lys Val Asp Phe Leu Glu Glu Asn He Thr Ala Leu Leu Glu Glu Ala 15 10 15

Gin lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser

Ding Asp Val 35 &lt; 210 &gt; 1489 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1489

Val Asp Phe Leu Glu Glu Asn lie Thr Ala Leu Leu Glu Glu Ala Gin φ 1 5 10 15 lie Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp • 20 25 30 A Asp Val Phe 35 &lt; 210〉 1490 &lt; 211> 35 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence 731 200524957 &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 1490

Asp Phe Leu Glu Glu Asn lie Thr Ala Leu Leu Glu Glu Ala Gin lie 15 10 15

Gin Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp 20 25 30

Val Phe Gly 35

&lt; 210〉 1491 &lt; 211〉 35 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400> 1491

Phe Leu Glu Glu Asn lie Thr Ala Leu Leu Glu Glu Ala Gin lie Gin 15 10 15

Gin Glu Lys Asn Met Tyr Glu Leu Gin Lys Leu Asn Ser Trp Asp Val 20 25 30

Phe Gly Asn 35 &lt; 210 &gt; 1492 &lt; 211 &gt; 35 &lt; 212> PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic victory 8 too &lt; 400 &gt; 1492

Pro Asp Ala Val Tyr Leu His Arg lie Asp Leu Gly Pro Pro lie Ser 15 10 15

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala lie Ala Lys 732 200524957 20 25 30

Leu Glu Asp 35 &lt; 210 &gt; 1493 &lt; 211 &gt; 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1493

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala lie Ala Lys • 1 5 10 15

Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin lie Leu Arg Ser 20 25 30

Met Lys &lt; 210 &gt; 1494 &lt; 211〉 34 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki # &lt; 400> 1494

Leu His Arg lie Asp Leu Gly Pro Pro He Ser Leu Glu Arg Leu Asp 15 10 15

Val Gly Thr Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu * 20 25 30

Leu Leu

&lt; 210> 1495 &lt; 211 &gt; 34 &lt; 212 &gt; PRT 733 200524957 &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic B)) &lt; 400 &gt; 1495

His Arg lie Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val 15 10 15

Gly Thr Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu 20 25 30

Leu Glu &lt; 210 &gt; 1496 • &lt; 211〉 34 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1496

Arg lie Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly 1 5 10 15

Thr Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu Leu 20 25 30

Glu Ser

&lt; 210〉 1497 &lt; 211 &gt; 34 ^ &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence Free &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &400; 1497 lie Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr 15 10 15

Asn Leu Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu 734 200524957 20 25 30

Ser Ser &lt; 210 &gt; 1498 &lt; 211> 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tsutsuki &lt; 400〉 1498

Asp Leu Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr Asn 15 10 15

Leu Gly Asn Ala He Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser 20 25 30

Ser Asp &lt; 210 &gt; 1499 &lt; 211〉 34 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0

&lt; 400〉 1499

Leu Gly Pro Pro He Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu 1 5 10 15

Gly Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser 20 25 30

Asp Gin &lt; 210 &gt; 1500 &lt; 211> 34 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 735 200524957 &lt; 223 &gt; description of artificial sequence: Satsuki Katsuta &lt; 400 &gt; 1500

Gly Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly 15 10 15

Asn Ala lie Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp 20 25 30

Gin lie

&lt; 210〉 1501 &lt; 211〉 34 &lt; 212 &gt; PRT φ &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400〉 1501

Pro Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn 15 10 15

Ala He Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin 20 25 30 lie Leu &lt; 210〉 1502 φ &lt; 211 &gt; 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220〉 &lt; 223 &gt; Explanation of the artificial sequence: Synthesis of Katsuyuki * &lt; 400 &gt; 1502

Pro lie Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala 15 10 15

He Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin He 20 25 30 736 200524957

Leu Arg &lt; 210> 1503 &lt; 211 &gt; 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1503

Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala lie Ala 15 10 15

Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin lie Leu Arg 20 25 30

Ser Met &lt; 210 &gt; 1504 &lt; 211 &gt; 34 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1504

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala lie Ala Lys 15 10 15

Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gin lie Leu Arg Ser 20 25 30

Met Lys &lt; 210 &gt; 1505 &lt; 211 &gt; 22 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; 737 200524957 &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuki &lt; 400〉 1505

Tyr Leu Cys Glu Phe Cys Leu Lys Tyr Gly Arg Ser Leu Lys Cys Leu 15 10 15

Gin Arg His Leu Thr Lys 20 &lt; 210> 1506 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; • &lt; 223> Explanation of artificial sequence ·· Synthetic peptide &lt; 400 &gt; 1506

Ala Ser Thr Thr Thr Asn Tyr Thr 1 5 &lt; 210 &gt; 1507 &lt; 211〉 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence: Synthetic Victory: &lt; 400〉 1507 a Ala Ser Thr Thr Thr Asn Tyr Thr _ 1 5 &lt; 210 &gt; 1508 '&lt; 211 &gt; 8

e &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1508

Ser Gin Asn Tyr Pro lie Val Gin 1 5 738 200524957 &lt; 210 &gt; 1509 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: The victory of synthesis M &lt; 400> 1509

Glu Leu Asp Lys Trp Ala 1 5

&lt; 210 &gt; 1510 &lt; 211〉 11 &lt; 212〉 PRT φ &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400 &gt; 1510

Arg Gly Val Val Asn Ala Ser Ser Arg Leu Ala 1 5 10 &lt; 210〉 1511 &lt; 211〉 10 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Wins: &lt; 400 &gt; 1511 • Arg Gly Arg Arg Gin Pro lie Pro Lys Ala 1 5 10

-&210; 1512 &lt; 211> 23 &lt; &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuta &lt; 400〉 1512

Leu Thr Thr Gly Ser Val Val lie Val Gly Arg lie lie Leu Ser Gly 15 10 15 739 200524957

Arg Pro Ala Val Val Pro Asp 20 &lt; 210〉 1513 &lt; 211〉 14 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 & gt 1513

Gly Ser Val Val He Val Gly Arg lie lie Leu Ser Gly Arg 1 5 10

&lt; 210 &gt; 1514 &lt; 211> 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400> 1514

Pro Leu Gly Phe Phe Pro Asp His Gin Leu Asp Pro Ala Phe Gly Ala 15 10 15

Asn Ser Asn Asn Pro Asp Trp Asp Phe Asn Pro 20 25

&lt; 210 &gt; 1515 &lt; 211> 26-&lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence * &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 1515

Met Gin Trp Asn Ser Thr Thr Phe His Gin Thr Leu Gin Asp Pro Arg 15 10 15

Val Arg Gly Leu Tyr Phe Pro Ala Gly Gly 740 200524957 20 25 &lt; 210 &gt; 1516 &lt; 211〉 11 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1516

Met Gin Trp Asn Ser Thr Ala Phe His Gin Thr 1 5 10 &lt; 210 &gt; 1517 • &lt; 211> 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory fl &lt; 400> 1517

Tyr Gly Ala Val Val Asn Asp Leu 1 5 &lt; 210 &gt; 1518 &lt; 211〉 21 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence φ &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 1518-Cys Thr His Gly lie Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn 15 10 15

Gly Ser Leu Ala Glu 20

&lt; 210 &gt; 1519 &lt; 211〉 7 &lt; 212 &gt; PRT 741 200524957 &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsutsuki &lt; 400 &gt; 1519

Ser Glu Asn Tyr Pro lie Val 1 5 &lt; 210〉 1520 &lt; 211〉 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220>

&lt; 223 &gt; Explanation of the artificial sequence: Synthesis of Katsuyuki &lt; 400〉 1520

Lys Ala Arg Val Phe Glu Ala 1 5 &lt; 210 &gt; 1521 &lt; 211 &gt; 15 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Satsuki Katsuta &lt; 400 &gt; 1521

Arg lie Gin Arg Gly Pro Gly Arg Ala Phe Val Thr He Gly Lys 15 10 15

&lt; 210 &gt; 1522 &lt; 211 &gt; 8 • &lt; 212> PRT &lt; 213 &gt; artificial sequence • &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuki Tsutsuki &lt; 400 &gt; 1522

Ala Ser Thr Thr Thr Asn Tyr Thr 1 5 742 200524957 &lt; 210 &gt; 1523 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence Too &lt; 400 &gt; 1523

Ala Ser Thr Thr Thr Asn Tyr Thr 1 5

&lt; 210> 1524 &lt; 211 &gt; 15 Φ &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki &lt; 400 &gt; 1524

Arg lie Gin Arg Gly Pro Gly Arg Ala Phe Val Thr He Gly Lys 15 10 15

&lt; 210 &gt; 1525 &lt; 211> 38 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence

&lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory: &lt; 400 &gt; 1525

Asn Asn Leu Leu Arg Ala lie Glu Ala Gin Gin His Leu Leu Gin Leu 15 10 15

Thr Val Trp Gly lie Lys Gin Leu Gin Ala Arg lie Leu Ala Val Glu 20 25 30

Arg Tyr Leu Lys Asp Gin 35 &lt; 210 &gt; 1526 743 200524957 &lt; 211 &gt; 10 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 〉 1526

Arg Gly Pro Gly Arg Ala Phe Val Thr He 1 5 10 &lt; 210〉 1527 &lt; 211〉 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence • &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1527 Phe Phe Gly &lt; 210 &gt; 1528 &lt; 211〉 36 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Tai &lt; 400 &gt; 1528 φ Tyr Thr Ser Leu lie His Ser Leu lie Glu Glu Ser Gin Asin Gin Gin 15 10 15 • Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30 «

Trp Asn Trp Phe 35

&lt; 210 &gt; 1529 &lt; 211〉 2 &lt; 212〉 PRT 744 200524957 &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: S Sangyuetai &lt; 400> 1529 Thr Gin &lt; 210 &gt; 1530 &lt; 211> 6 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon • &lt; 400 &gt; 1530

Trp His Trp Leu Gin Leu 1 5 &lt; 210〉 1531 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 & gt 1531

Gly Pro Gly Ala Gly

&lt; 210 &gt; 1532 &lt; 211〉 2 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winning Rib: &lt; 400> 1532 His Gly 1 &lt; 210 &gt; 1533 200524957 &lt; 211〉 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory Moon &lt; 400 &gt; 1533 Phe Val Phe Leu Met 1 5 &lt; 210〉 1534 &lt; 211 &gt; 3 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence • &lt; 220〉 &lt; 223〉 Description of artificial sequence: synthetic peptide &lt; 400 &gt; 1534 Thr Ser Lys 1 &lt; 210 &gt; 1535 &lt; 211〉 3 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400 &gt; 1535 # Lys His Gly 1-&lt; 210 〉 1536 &lt; 211〉 16-&lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 1536

Lys Asn Arg Trp Glu Asp Pro Gly Lys Gin Leu Tyr Asn Val Glu Ala 1 5 10 15 746 200524957 &lt; 210 &gt; 1537 &lt; 211 &gt; 10 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory limb: &lt; 400〉 1537

Leu Arg Ala His Ala Val Asp Val Asn Gly 1 5 10

&lt; 210〉 1538 &lt; 211〉 14 φ &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400〉 1538

Trp Ser Lys Met Asp Gin Leu Ala Lys Glu Leu Thr Ala Glu 1 5 10

&lt; 210> 1539 &lt; 211 &gt; 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki Tai &lt; 400> 1539 Thr Pro Arg Lys &lt; 210 &gt; 1540 &lt; 211 &gt; 12 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki &lt; 400 &gt; 1540 747 200524957

Gly Glu Leu Gin Asn Gin Leu lie Arg Lys Ser Asn 1 5 10 &lt; 210 &gt; 1541 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis I Satsuki &lt; 400> 1541

Gly Glu Tyr Gin Lys Met Leu Asn Leu Arg Ala Glu Val Lys Lys Asn 15 10 15 • Ala &lt; 210 &gt; 1542 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400〉 1542

Pro Phe Cys Asn Ala Phe Thr Gly Cys 1 5 &lt; 210 &gt; 1543 φ &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213〉 Artificial sequence • &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory Yuetai * &lt; 400 &gt; 1543

Glu Lys Ala His Asp Gly Gly Arg 1 5

&lt; 210> 1544 &lt; 211> 14 &lt; 212 &gt; PRT 748 200524957 &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 4〇〇 &gt; 1544

Pro Phe Thr Arg Asn Tyr Tyr Val Arg Ala Val Leu His Leu 1 5 10 &lt; 210〉 1545 &lt; 211〉 39 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence : Satsuki Katsuyuki • &lt; 400 &gt; 1545

Ala Pro Arg Leu Pro Gin Cys Gin Gly Asp Asp Gin Glu Lys Cys Leu 15 10 15

Cys Asn Lys Asp Glu Cys Pro Pro Gly Gin Cys Arg Phe Pro Arg Gly 20 25 30

Asp Ala Asp Pro Tyr Cys Glu 35

&lt; 210 &gt; 1546 &lt; 211 &gt; 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taito &lt; 400> 1546

Lys Gly Asp Glu Glu Ser Leu Ala 1 5 &lt; 210〉 1547 &lt; 211〉 9 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; 749 200524957 &lt; 223 &gt; Explanation of Artificial Sequence Too &lt; 400 &gt; 1547

Trp Ala Gly Gly Asp Ala Ser Gly Glu 1 5 &lt; 210〉 1548 &lt; 211 &gt; 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400 &gt; 1548

Gin Ala Thr Val Gly Asp Val Asn Thr Asp Arg Pro Gly Leu Leu Asp • 1 5 10 15

Leu Lys Tyr Tyr 20 &lt; 210 &gt; 1549 &lt; 211〉 17 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223> Artificial sequence description: Synthetic tsukitsuta &lt; 400 &gt; 1549

Thr Lys Arg Arg Ala lie Gly Phe Lys Lys Leu Ala Glu Ala Val Lys # 1 5 10 15

Cys &lt; 210 &gt; 1550 * &lt; 211〉 8 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; description of artificial sequence: Synthetic victory fl too &lt; 400 &gt; 1550

Ser lie lie Asn Phe Glu Lys Leu 750 200524957 1 5 &lt; 210 &gt; 1551 &lt; 211〉 6 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory : &lt; 400 &gt; 1551

Phe Gin Val Val Cys Gly 1 5 &lt; 210〉 1552

&lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400> 1552

Ala Arg Met Ala Pro Glu 1 5 &lt; 210 &gt; 1553 &lt; 211> 4 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence φ &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Katsuta Katsuta &lt; 400> 1553. Gly Gin Pro Arg &lt; 210 &gt; 1554 &lt; 211 &gt; 3 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 200524957 &lt; 400 &gt; 1554 Thr Val Leu 1 &lt; 210 &gt; 1555 &lt; 211〉 49 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400 &gt; 1555

Leu Leu Ser Lys Arg Gly His Cys Pro Arg lie Leu Phe Arg Cys Pro 15 10 15

Leu Ser Asn Pro Ser Asn Lys Cys Trp Arg Asp Tyr Asp Cys Pro Gly 20 25 30

Val Lys Lys Cys Cys Glu Gly Phe Cys Gly Lys Asp Cys Leu Tyr Pro 35 40 45

Lys &lt; 210 &gt; 1556 &lt; 211 &gt; 10 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic victory 0 too &lt; 400> 1556

Gly Phe Asp Leu Asn Gly Gly Gly Val Gly 1 5 10 &lt; 210 &gt; 1557 &lt; 211 &gt; 18 &lt; 212> PRT &lt; 213 &gt; artificial sequence 752 200524957 &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthesis Victory: &lt; 400〉 1557

Ala Val Gin Ser Lys Pro Pro Ser Lys Arg Asp Pro Pro Lys Met Gin 15 10 15

Thr Asp &lt; 210 &gt; 1558 &lt; 211 &gt; 4 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 1558 Thr Lys Pro Arg 1 &lt; 210 &gt; 1559 &lt; 211 &gt; 11 &lt; 212〉 PRT &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1559

Tyr Leu Asn Phe Thr Pro Asn Trp Gly Thr Tyr 1 5 10 &lt; 210〉 1560 &lt; 211〉 5 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuyuki too &lt; 400 &gt; 1560 Asp Leu Trp Gin Lys 1 5 753 200524957 &lt; 210〉 1561 &lt; 211〉 17 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence : Satsuki Katsuyuki &lt; 400 &gt; 1561

Trp Tyr Glu Pro He Tyr Leu Gly Gly Val Phe Gin Leu Glu Lys Gly 15 10 15

Asp &lt; 210 &gt; 1562 • &lt; 211> 39 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: synthetic β shengyuetai &lt; 400 &gt; 1562

Ala Pro Arg Leu Pro Gin Cys Gin Gly Asp Gin Glu Lys Cys Leu Cys 15 10 15

Asn Lys Asp Glu Cys Pro Pro Gly Gin Cys Arg Phe Pro Arg Gly Asp 20 25 30

Ala Asp Pro Tyr Cys Glu Asp

&lt; 210 &gt; 1563

• &lt; 211〉 4 &lt; 212〉 PRT • &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory 0 too &lt; 400 &gt; 1563 Thr Lys Pro Arg 1 754 200524957 &lt; 210 &gt; 1564 &lt; 211〉 6 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsukitsu &lt; 400 &gt; 1564

Glu Glu Val Val Ala Cys 1 5

&lt; 210 &gt; 1565 &lt; 211〉 4 &lt; 212 &gt; PRT • &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 1565 Ser Asp Lys Pro 1 &lt; 210 &gt; 1566 &lt; 211 &gt; 6 &lt; 212〉 PRT &lt; 213〉 artificial sequence &lt; 220>

&lt; 223 &gt; Explanation of artificial sequence &lt; 400> 1566 Synthetic peptide

Arg Phe Trp lie Asn Lys 1 5 &lt; 210 &gt; 1567 &lt; 211〉 13 &lt; 212〉 PRT &lt; 213〉 Artificial Sequence &lt; 220〉 &lt; 223〉 Explanation of Artificial Sequence: Synthetic Victory &lt; 400> 1567

Cys Gly Tyr Gly Pro Lys Lys Lys Arg Lys Val Gly Gly 755 200524957 1 5 &lt; 210〉 1568 &lt; 211〉 1 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence ： Synthetic tsukiyuki &lt; 400 &gt; 1568 Leu 1 &lt; 210 &gt; 1569 # &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Katsuyuki &lt; 400 &gt; 1569 Asp Asp Asp Asp Asp 1 5

&lt; 210 &gt; 1570 &lt; 211> 6 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Description of artificial sequence: Synthetic tsukitsuki &lt; 400> 1570

Asp Asp Asp Asp Asp Asp Asp 1 5 &lt; 210> 1571 &lt; 211 &gt; 8 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsukitsu 200524957 &lt; 400〉 1571

Asn Pro Asn Ala Asn Pro Asn Ala 1 5 &lt; 210〉 1572 &lt; 211 &gt; 8 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Peptide &lt; 400 &gt; 1572

Val Ala He Thr Val Leu Val Lys

&lt; 210 &gt; 1573 &lt; 211 &gt; 6 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223 &gt; description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1573

Val Gly Val Arg Val Arg 1 5 &lt; 210 &gt; 1574

&lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223> Explanation of artificial sequence: Synthetic victory 呔 &lt; 400 &gt; 1574

Val lie His Ser &lt; 210 &gt; 1575 &lt; 211 &gt; 5 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence 200524957 &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki too &lt; 400> 1575 Val Pro Asp Pro Arg 1 5 &lt; 210 &gt; 1576 &lt; 211 &gt; 4 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400> 1576 φ Val Thr Cys Gly &lt; 210> 1577 &lt; 211> 3 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; &lt; 223 &gt; Description of Artificial Sequences: Synthetic Katsuyuki Tai &lt; 400 &gt; 1577 Arg Ser Arg 1 # &lt; 210 &gt; 1578 &lt; 211 &gt; 11 &lt; 212〉 PRT ^ &lt; 213〉 Artificial sequence &lt; 220〉 &quot; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1578

Ser Ala Lys Leu Cys Pro Gly Gly Asn Cys Val 1 5 10 &lt; 210〉 1579 &lt; 211〉 6 758 200524957 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1579

Asp His Ala Arg Trp Lys 1 5 &lt; 210 &gt; 1580 &lt; 211 &gt; 7 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> φ &lt; 223 &gt; Explanation of artificial sequence: synthetic peptide &lt; 400 &gt; 1580

Pro Gin Asp Pro Gin Asp Leu 1 5 &lt; 210 &gt; 1581 &lt; 211〉 6 &lt; 212〉 PRT &lt; 213〉 Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuyuki &lt; 400〉 1581

Gin His Phe Arg Trp Gly

&lt; 210 &gt; 1582-&lt; 211〉 19 &lt; 212〉 PRT • &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory over moon &lt; 400> 1582

Asn Gin Glu Gin Val Ser Pro Leu Thr Leu Leu Lys Leu Gly Asn Gin 15 10 15 759 200524957

Glu Pro Gly &lt; 210 &gt; 1583 &lt; 211 &gt; 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Artificial sequence description: Synthetic tsukitsutsuki &lt; 400 &gt; 1583

Leu Ser Ala Leu Ser Leu Asp Glu Pro Phe lie Gin Lys Asp Val Glu 15 10 15

Leu Arg lie Met

&lt; 210 &gt; 1584 &lt; 211 &gt; 15 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukitsuta &lt; 400 &gt; 1584

Ala Pro Glu Ala Gin Val Ser Val Gin Pro Asn Phe Gin Gin Asp 15 10 15 &lt; 210 &gt; 1585 # &lt; 211 &gt; 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220〉 &lt; 223 &gt; Artificial Explanation of sequence: Synthesis of Katsuyuki- &400; 1585

Glu Tyr Gly Gly Thr Lys Val Leu Asp Asp Lys Asp Tyr Phe Leu Phe 15 10 15

Arg Asp Gly Asp lie Leu Gly Lys Tyr Val Asp 20 25 760 200524957 &lt; 210 &gt; 1586 &lt; 211〉 16 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory &lt; 400 &gt; 1586

Lys Ala Tyr lie Asn Lys Val Glu Glu Leu Lys Lys Lys Tyr Gly lie 15 10 15

&lt; 210 &gt; 1587 &lt; 211〉 24 &lt; 212〉 PRT φ &lt; 213 &gt; artificial sequence &lt; 220〉 &lt; 223 &gt; Description of artificial sequence: Synthetic victory over moon &lt; 400> 1587

Ser Gin Gin Ser Ser Ser Tyr Gly Gin Gin Ser Glu Lys Pro Tyr Gin 15 10 15

Cys Asp Phe Lys Asp Cys Glu Arg 20

&lt; 210 &gt; 1588 &lt; 211> 15 φ &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; • &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1588 * Ala Thr Glu Ser lie Ala Tyr Leu Ala Pro Pro Tyr Ala Phe Arg 15 10 15 &lt; 210 &gt; 1589 &lt; 211 &gt; 16 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence 761 200524957 &lt; 220> &lt; 223〉 Explanation of artificial sequence : Satsuki Katsuyuki &lt; 400 &gt; 1589

Lys Arg Lys Arg Ser Glu Met Leu Phe Arg Gly Arg Arg Ala Ser Gin 15 10 15 &lt; 210 &gt; 1590 &lt; 211〉 13 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Artificial Sequence Explanation: Synthetic victory: &lt; 400〉 1590 ® Val Ser His Pro Tyr Ser Gin His Leu Glu Gly Lys Gly 1 5 10 &lt; 210〉 1591 &lt; 211〉 7 &lt; 212〉 PRT &lt; 213 &gt; Sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400> 1591

Ala Leu Thr Asp Phe Phe Arg 1 5 ^ &lt; 210 &gt; 1592 &lt; 211〉 20 &lt; 212 &gt; PRT. &Lt; 213 &gt; Artificial Sequence ^ &lt; 220 &gt; &lt; 223> Explanation of Artificial Sequence Too &lt; 400 &gt; 1592

Gin Ala lie Gly Leu Met Gly Tyr Arg Leu Ser Pro Gin Thr Leu Thr 15 10 15

Thr lie Val Lys 20 762 200524957 &lt; 210〉 1593 &lt; 211〉 17 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequences &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Victory fl too &400; 1593

Met Gly Phe Asn Ala Phe Lys Glu Leu Trp Ala Ala Leu Asn Ala Trp 15 10 15

Lys ® &lt; 210 &gt; 1594 &lt; 211〉 16 &lt; 212〉 PRT &lt; 213〉 Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic winning rib: &lt; 400 &gt; 1594

Glu Val Gin Leu Val Glu Ser Gly Val Gly Leu Val Gin Pro Gly Asp 15 10 15

&lt; 210 &gt; 1595 &lt; 211>

Glu Leu Asp Ala Lys lie Pro Ser Thr Gly Asp Ala Thr Glu Trp Arg 15 10 15

Asn

&lt; 210〉 1596 &lt; 211 &gt; 20 &lt; 212〉 PRT 763 200524957 &lt; 213〉 Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400> 1596

Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly 15 10 15

Val Thr Ser Ala 20

&lt; 210 &gt; 1597 &lt; 211〉 20 &lt; 212 &gt; PRT φ &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; Explanation of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 1597

Gly Lys Glu lie Leu Val Gly Asp Val Gly Gin Thr Val Asp Asp Pro 15 10 15

Tyr Ala Thr Phe 20

&lt; 210 &gt; 1598 &lt; 211〉 15 φ &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220〉 • &lt; 223 &gt; Description of artificial sequence: Synthetic victory 0 too &lt; 400 &gt; 1598 ** Glu Leu Ser Leu Ala Gly Asn Glu Leu Gly Asp Glu Gly Ala Arg 15 10 15 &lt; 210> 1599 &lt; 211 &gt; 22 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence 764 200524957 &lt; 220 &gt; &lt; 223 &gt; Artificial sequence Explanation: Synthetic Victory Moon <400> 1599

Met Phe He Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro Asp Gly 15 10 15

Phe Leu Ser Glu Leu Thr 20 &lt; 210〉 1600 &lt; 211〉 35 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence φ &lt; 220 &gt; &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Katsuki Taisho &lt; 400 〉 1600

Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe lie Gly lie lie lie Asp 15 10 15

Asn Phe Trp Gin Gin Lys Lys Lys Leu Gly Gly Lys Asp lie Phe Met 20 25 30

Thr Glu Glu 35 &lt; 210> 1601 Φ &lt; 211 &gt; 27 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence- &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory Moon ^ &lt; 400 &gt; 1601

Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg Glu Gly Phe Arg Gly 15 10 15

Glu Glu Gly Asp Pro Gly Leu Pro Gly Ala Ala 20 25 765 200524957 &lt; 210 &gt; 1602 &lt; 211 &gt; 21 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthesis Victory &lt; 400> 1602

Cys Lys Thr Cys Gin Arg Lys Phe Ser Arg Ser Gly His Leu Lys Thr 15 10 15

His Thr Arg Thr His 20 • &lt; 210> 1603 &lt; 211 &gt; 15 &lt; 212> PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; &lt; 223> description of artificial sequence: Synthetic Katsuyuki &lt; 400 &gt; 1603

His Val Ser Ser Glu Ala Phe Arg Met Cys Asp Val Cys Leu Glu 15 10 15

&lt; 210 &gt; 1604 &lt; 211〉 5 &lt; 212 &gt; PRT call &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic Katsuyuki-&lt; 400 &gt; 1604

Pro His Ser Arg Asn # 1 5 &lt; 210> 1605 &lt; 211> 5 &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220 &gt; 766 200524957 &lt; 223 &gt; description of artificial sequence: synthetic victory: ; 400 &gt; 1605 Pro His Ser Cys Asn 1 5 &lt; 210 &gt; 1606 &lt; 211 &gt; 28 &lt; 212 &gt; PRT &lt; 213> Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Katsuta Katsuta &lt; 400 &gt; 1606

Met Gly Pro Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu # 1 5 10 15

Leu Val Val Met Ala Gly Val Ala Pro Val Trp Ala 20 25 &lt; 210〉 1607 &lt; 211〉 15 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Winner &lt; 400 &gt; 1607Met Val Lys Ser His lie Gly Ser Trp lie Leu Val Leu Phe Val 15 10 15 &lt; 210 &gt; 1608 • &lt; 211〉 9

^ &lt; 212 &gt; PRT ^ &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory: &lt; 400 &gt; 1608

Cys Ser Leu Pro Gly Ser Ala Ala Ala 1 5 767 200524957 &lt; 21〇 &gt; 1609 &lt; 211〉 15 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Tokiyuki &lt; 400 &gt; 1609

Arg Gly Leu Lys Arg Gin Ser Asp Glu Arg Lys Arg Asp Arg Glu 15 10 15

&lt; 210〉 1610 &lt; 211〉 57 &lt; 212〉 PRT φ &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation of Artificial Sequence: Synthetic Victory &lt; 400 &gt; 1610

Gly Arg Ser His Met Val Leu Asn Ser Ala Leu Glu Gly Ala Arg Gly 15 10 15

Gly Pro Gly Gly Glu Glu lie Pro Glu Arg Phe Ser lie Pro Glu Leu 20 25 30

Gin Trp Met Leu Ser Asn Ala Glu Leu Ala Pro Val Gin Ala Asp Glu 35 40 45 • Pro Pro Gin Ser Arg Met Asp Leu Val 50 55

• &lt; 210 &gt; 1611 &lt; 211〉 35 ^ &lt; 212 &gt; PRT &lt; 213 &gt; artificial sequence &lt; 220> &lt; 223 &gt; description of artificial sequence: Synthesis of Katsuyuki &lt; 400 &gt; 1611

Gin Ala Arg Ala Val Gly Leu Ala Gly Thr Ser Arg Ala Phe Leu Ser 15 10 15 768 200524957

Ser Arg Leu Gin Asp Leu Tyr Ser lie Val Arg Arg Ala Asp Arg Ala 20 25 30

Ala Val Met 35 &lt; 210〉 1612 &lt; 211 &gt; 15 &lt; 212〉 PRT &lt; 213 &gt; Artificial sequence &lt; 220〉 &lt; 223 &gt; Explanation of artificial sequence: Synthetic victory fl too φ &lt; 400 &gt; 1612

Met Val Lys Ser His lie Gly Ser Trp lie Leu Val Leu Phe Val 15 10 15 &lt; 210〉 1613 &lt; 211 &gt; 29 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequence &lt; 220〉 &lt; 223 &gt; Explanation: Satsuki Katsuta &lt; 400 &gt; 1613

Leu Arg Asp Leu Val Ser Tyr Cys Arg Ala Arg Gly Lys Gly Arg Glu 15 10 15

Arg Met Asn Gly Thr Arg Lys Gly His Leu Leu Tyr Met 20 25 &lt; 210> 1614 &lt; 211> 33 &lt; 212> PRT &lt; 213 &gt; Artificial Sequence &lt; 220> &lt; 223 &gt; Explanation of Artificial Sequence: Synthesis Victory Limb: &lt; 400〉 1614

Gly Lys Arg Ser Ser Pro Glu Thr Leu lie Ser Asp Leu Leu Met Arg 769 200524957 15 10 15

Glu Ser Thr Glu Asn Val Pro Arg Thr Arg Leu Glu Asp Pro Ala Met 20 25 30

Trp &lt; 210 &gt; 1615 &lt; 211〉 30 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence: Synthetic tsukiyuki • &lt; 400〉 1615

Asp Val Glu Pro Leu Leu Gly Phe Leu Ser Pro Lys Ser Gly Gin Glu 15 10 15

Asn Glu Val Asp Asp Phe Pro Tyr Lys Gly Gin Gly Glu Leu 20 25 30 &lt; 210〉 1616 &lt; 211〉 20 &lt; 212 &gt; PRT &lt; 213 &gt; Artificial sequence &lt; 220 &gt; &lt; 223 &gt; Explanation of artificial sequence : Synthetic Victory • &lt; 400〉 1616

Phe Cys Lys Cys Arg Leu Glu Pro Met Lys Ala Thr Cys Asp lie Ser 15 10 15

Glu Cys Pro Glu ^ 20 &lt; 210 &gt; 1617 &lt; 211〉 20 &lt; 212〉 PRT &lt; 213 &gt; Artificial Sequences &lt; 220 &gt; 770 200524957 &lt; 223 &gt; Explanation of Artificial Sequences: Synthetic Katsuki Tsukita &lt; 400 & gt 1617

Lys Ser His Gly Arg Thr Gin Asn Pro Val Val His Phe Phe Lys Asn 15 10 15

He Val Thr Pro 20

771

Claims (1)

200524957 10. Scope of patent application: 1. A modified therapeutic peptide capable of forming a peptidase-stable therapeutic peptide conjugate, the peptide having a carboxyl terminal amino acid, a monoamine terminal amino acid, A therapeutically active region and a poorer therapeutically active region. The therapeutically active region is identified by structural activity relationship analysis. The peptide is characterized in that it comprises SEQ ID NO: 397, 398, 399, or 400, or The 'derivative' allows a reactive group to be attached to an amino acid position of an amino acid located in a poorly therapeutically active region, and the reactive group can interact with an amino group located on albumin , Hydroxyl groups, or thiol groups react to form a stable covalent bond, thereby forming the peptidase-stabilizing therapeutic peptide conjugate, and the reactive group is selected from the group consisting of peroxamine And cis-butyl diimide group, in which SEQ ID NO .: 397 Tyr Pro lie Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 1 5 10 15 Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 2〇25 30 Arg Gin Arg Tyr 35, SEQ ID DN: 398 He Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn 15 l〇is Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gin 20 25 30 Arg Tyr 200524957 SEQ ID NO.:399 Tyr Pro Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 15 10 15 Leu Ser Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr 20 25 30 Arg Gin Arg Tyr 35 SEQ ID NO .: 400 Tyr Pro lie Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu 1 5 i〇 15 Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Leu Thr 20 25 30 Arg Pro Arg Tyr 35. 2. The peptide according to item 1 of the patent application range, wherein the poor therapeutically active region includes the carboxyl terminal amino acid, and the reactive group is attached to the carboxyl terminal amino acid. 3. The peptide according to item 1 of the patent application scope, wherein the poor therapeutically active region includes the amino terminal amino acid, and the reactive group is attached to the amino terminal amino acid. 4. The peptide according to any one of claims 1 to 3, wherein the reactive group is coupled to the therapeutic peptide via an lysine and / or a linking group. 5. The peptide according to any one of claims 1 to 3, wherein the reactive group comprises maleimide. 6. The peptide according to any one of claims 1 to 3, wherein the peptide is SEQ ID NO: 397 or 398, or a derivative thereof. 2 200524957 7. The peptide according to any one of claims 1 to 3, wherein the peptide is SEQ ID NO: 398, or a peptide derived from the peptide. 8. The peptide according to any one of claims 1 to 3, wherein the peptide is a peptide of SEQ ID NO: 398. 9. A peptidase stabilized therapeutic peptide conjugate comprising: an albumin and a modified therapeutic peptide comprising a reactive group covalently bound to an amine group located on albumin Group, a weilyl group, or # is a thiol group, the modified therapeutic peptide has a weiryl terminal amino acid, a amino terminal amino acid, a therapeutically active region, and a poorly therapeutically active region The therapeutically active region is identified by a structure-activity relationship analysis, and the modified therapeutic peptide is characterized in that it contains SEQ ID NO: 397, 398, 399, or 400 as mentioned in item 1 of the patent application scope, or Is a derivative thereof, which attaches the reactive group to an amino acid position of an amino acid located in a poorly therapeutically active region, the reactive group being selected from the group consisting of H succinylamino and cis In the group consisting of butene dihydrazine groups. 10. The conjugate according to item 9 of the patent application scope, wherein the poor therapeutic activity region includes the carboxyl-terminal amino acid, and the reactive group is attached to the carboxyl-terminal amino acid. 11. The conjugate according to item 9 of the application, wherein the poorly treated region includes the amino terminal amino group and the reactive group is attached to the amino terminal amino acid. 12. If the conjugate of any of claims 9 to 11 of the scope of the patent application, its anti-3 200524957 responsive group is coupled to the therapeutic peptide through an lysine and / or a linking group . 13. The conjugate according to any one of claims 9 to 11, wherein the reactive group comprises maleimide. 14. The conjugate according to any one of claims 9 to 11, wherein the peptide is a peptide of SEQ ID NO: 397 or 398, or a derivative thereof. 15. The conjugate according to any one of claims 9 to 11, wherein the peptide is a peptide of SEQ ID NO: 398, or a derivative thereof. 16. The conjugate according to any one of claims 9 to 11, wherein the month is SEQ ID NO: 398. 17. A method for synthesizing a modified therapeutic peptide capable of forming a peptidase-stable therapeutic peptide conjugate, the peptide comprising SEQ ID NO: 397 as mentioned in item 1 of the scope of patent application , 398, 399, or 400, or a derivative thereof, the peptide has a carboxyl-terminated amino acid, a monoamino-terminated amino acid, a therapeutically active region, and a poorer therapeutically active region. Identifying by structural activity relationship analysis, the method includes the following steps: a) selecting at least one position in the poor therapeutically active area, and b) 1) if the therapeutic peptide does not contain cysteine, then The carboxy-terminal amino acid synthesizes the peptide and couples a reactive group to an amino acid located in the poor therapeutically active region, or 2) if the therapeutic peptide contains only one cysteine, Then the peptide is synthesized from carboxyl 4 200524957 base amino acid; the protecting group is protected with a cysteine; the reactive group is coupled to the amino acid located in the poor therapeutically active region, and Deprotection of the protected cysteine; or 3) If the therapeutic peptide contains two cysteine, the peptide is synthesized from a carboxyl-terminal amino acid; the two cysteines are oxidized to form a disulfide bridge; the reactive group Is coupled to the amino acid located in one of the less therapeutically active regions; or 4) if the therapeutic peptide contains more than two cysteine amino acids as disulfide bridges, synthesizing the amino acid from the carboxyl terminal amino acid Peptide; sequential oxidation of the cysteine acids to form a disulfide bridge; purification of the peptide; and coupling the reactive group to at least one of the (or) positions of the poorly therapeutically active region; c) A stable covalent bond is formed between the reactive group and an amine group, a hydroxyl group or a thiol group on an albumin in vivo or in vitro, thereby providing a peptide-albumin conjugate To produce a peptidase to stabilize the therapeutic peptide while retaining the therapeutic activity of the therapeutic peptide; the peptide-albumin conjugate has higher stability to the degradation of the peptidase than the therapeutic peptide, And d) analysis of the therapeutic activity of the peptide-albumin conjugate with the peptide-albumin conjugate The stability of the peptide on the degradation of peptidase confirms that the peptide-albumin conjugate has higher stability than the therapeutic peptide; it is confirmed that 5 200524957 4 the peptide-albumin conjugate retains the therapeutic peptide The treatment is effective, and the selected position is located in the poor therapeutically active area. 18. The method of claim 17 in which the reactive group is coupled to the therapeutic group via an lysine and / or a linking group. 19. The conjugate of claim 18, wherein the reactive group comprises maleimide. 20. The method according to any one of claims 17 to 19, wherein the peptide is a peptide of SEQ ID NO: 397 or 398, or a derivative thereof. 21. The method according to any one of claims 17 to 19 of the scope of application for a patent, wherein the wink is a peptide of SEQ ID NO: 398 'or a derivative thereof. 22. The method according to any one of claims π to 19, wherein the peptide is SEQ ID NO: 398. 23. · A method for protecting a therapeutic peptide from peptidase degradation in vitro, the peptide comprising SEq ID NO: 397, 398, 399, or 400 as mentioned in the first patent application scope, or Is a derivative thereof. The peptide has a carboxyl-terminated amino acid, a amino-terminated amino acid, a therapeutically active region, and a poorly therapeutically active region. The method includes: (a) by coupling a reactivity Group to the carboxy-terminated amino acid, the amino-terminated amino acid, or an amino acid bounded between the carboxy-terminated amino acid and the amino-terminated amino acid to modify the peptide, the reaction The reactive group may form a covalent bond with a reactive functional group located on the albumin; (b) a covalent bond is formed between the reactive group and the reactive functional group located on the albumin to form a trivalent peptide -Albumin conjugate 200524957 conjugate, thereby protecting the peptide from degradation of the peptide while retaining the therapeutic activity of the therapeutic peptide; and (c) analyzing the therapeutic activity of the peptide-albumin conjugate, and The stability of the peptide-albumin conjugate to peptidase degradation confirmed the peptide-albumin White conjugate having the therapeutic peptide relatively high stability, and confirmed that the peptide - albumin conjugate retains the therapeutic activity of the therapeutic peptide. 24. The method of claim 23, wherein the reactive group comprises maleimide. 25. The method of claim 24, wherein the reactive group is coupled to the peptide via an lysine and / or a linking group. 26. The method of claim 23, wherein one or more of the amino acids are synthesized. 27. The method according to any one of claims 23 to 26, wherein the peptide is a peptide of SEQ ID NO. · 397 or 398, or a derivative thereof. 28. The method according to any one of claims 23 to 26, wherein the peptide is SEQ IDNCX 398, or a peptide derived from the peptide. 29. The method according to any one of claims 23 to 26, wherein the peptide is SEQ ID NO: 398. 30 · —A method for protecting a therapeutic peptide from peptide degradation in vitro, the peptide contains ID NO: 397, 398, 399, or 400 as mentioned in the first patent application scope, or Derivative, the peptide has a therapeutically active region of an amino acid, and a poorer therapeutically active region of the amino acid 'The method includes · 200524957 (a) Identification of the therapeutic activity of the amino acid by structural activity relationship analysis Region; (b) modifying the peptide by combining a reactive group directed to an amino acid contained in a poorly therapeutically active region to the amino acid to form a modified peptide, so that the The modified peptide has therapeutic activity, and the reactive group can form a covalent bond with a reactive functional group on albumin; (c) forming a covalent bond between the reactive group and the functional group located on the albumin to form a peptide-albumin conjugate, thereby protecting the peptide from degradation of the peptide while retaining The therapeutic activity of the therapeutic peptide; and (d) analyzing the therapeutic activity of the peptide-albumin conjugate and the stability of the peptide-albumin conjugate to peptidase degradation to confirm the peptide- The albumin conjugate has higher stability than the therapeutic peptide, and it was confirmed that the peptide-albumin conjugate retains the therapeutic activity of the therapeutic peptide. 31. The method of claim 30, wherein the peptide has a carboxyl terminal, an amino terminal, a carboxyl terminal amino acid, and a monoamino terminal amino acid, and wherein (b) step further comprises : (A) if the poor therapeutically active region is located at the carboxyl terminus of the peptide, then coupling the reactive region to the carboxyl terminal amino acid; (b) if the poorer therapeutically active region is located at the viable When the amine end is coupled, the reactive region is coupled to the amine end amino acid; 200524957 (C) if the poor therapeutically active site is not located on the amine end of the peptide or on the carboxyl group of the peptide At the end, the reactive region is coupled to an amino acid located between the carboxyl end and the amine end. 32. The method of claim 30, wherein the reactive group is a cis-butene diimide group. ► 33. The method as claimed in claim 31, wherein the reactive group is a cis-butene diimide group. 34. The method of claim 32, wherein the reactive group is coupled to the peptide by a linking group. 35. The method of claim 33, wherein the reactive group is coupled to the peptide by a linking group. 36. The method of claim 30, wherein one or more of the amino acids are synthetic. 37. The method according to any one of claims 30 to 36, wherein the peptide is a peptide of SEQ ID NO: 397 or 398, or a derivative thereof. &gt;, The method according to any one of claims 30 to 36, wherein the peptide is a peptide of SEQ ID NO: 398, or a derivative thereof. 3. The method according to any one of items 30 to 36 in the scope of patent application, wherein the victory k is SEQ ID NO: 398. 200524957 7. Designated representative map: (1) The designated representative map in this case is: (none) . (2) Brief description of the component symbols in this representative figure: None 8. If there is a chemical formula in this case, please disclose the chemical formula that can best show the characteristics of the invention: